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Scientific Abstract  
 
Cancer cells, unlike normal tissue, frequently rely on glycolysis for the production of energy 
and the metabolic intermediates required for their growth regardless of cellular oxygenation 
levels. This metabolic reconfiguration, termed the Warburg effect, provides a potential 
strategy to preferentially target tumours from a therapeutic perspective. The present study 
sought to investigate the glycolytic phenotype of breast and ovarian cancer, and assess the 
possibility of exploiting several glycolytic targets therapeutically. Initially the growth 
dependency of breast and ovarian cancer cells on the availability of glucose was established. 
An array of 10 compounds reported to inhibit key enzymes of the glycolytic pathway were 
investigated and compared against an extended panel of breast and ovarian cancer cell line 
models. All inhibitors investigated, targeted against multiple points of the pathway, were 
shown to block the glycolytic pathway as demonstrated by glucose accumulation in the 
culture media combined with decreased lactate secretion, and attenuated breast and ovarian 
cancer cell proliferation in a concentration dependent manner. Furthermore their mechanism 
of action was investigated by flow cytometric analysis and their antiproliferative effect was 
associated with induction of apoptosis and G0/G1 cell cycle arrest. The glycolytic inhibitors 
were further assessed in combination strategies with established chemotherapeutic and 
targeted agents and several synergistic interactions, characterised by low combination index 
values, were revealed. Among them, 3PO  (a novel PFKFB3 inhibitor) enhanced the effect of 
cisplatin in both platinum sensitive and platinum resistant ovarian cancer cells suggesting a 
strategy for treatment of platinum resistant disease. Furthermore robust synergy was 
identified between IOM-1190 (a novel GLUT1 inhibitor) and metformin, an antidiabetic 
inhibitor of oxidative phosphorylation, resulting in strong inhibition of breast cancer cell 
growth. This combination is proposed for the treatment of highly aggressive triple negative 
breast tumours. An additional objective of this research was to investigate the effect of the 
oxygen level on sensitivity to glycolysis inhibition. Breast cancer cells were found to be 
more sensitive to glycolysis inhibition in high oxygen conditions. This enhanced resistance 
at low oxygen levels was associated with upregulation of the targeted glycolytic enzymes as 
demonstrated at both the mRNA (by gene expression microarray profiling, Illumina 
BeadArrays) and protein level (by Western blotting). Manipulation of LDHA (Lactate 
Dehydrogenase A) by siRNA knockdown provided further evidence that downregulation of 
this target was sufficient to significantly suppress breast cancer cell proliferation. Finally, the 
expression of selected glycolytic targets was examined in a clinical tissue microarray set of a 




The role of the glycolytic phenotype in ovarian cancer was suggested and interesting 
associations between the glycolytic profile and clear cell and endometrioid ovarian cancers 
revealed. Increased PKM2 (Pyruvate kinase isozyme M2) and LDHA expression were 
demonstrated in clear cell tumours and also low expression of these enzymes was 
significantly correlated with improved survival of endometrioid ovarian cancer patients. 
Taken together the findings of this study support the glycolytic pathway as a legitimate 








Breast and ovarian cancer are two malignancies that present a major concern in public health 
care. Therefore there is an urgent need for novel targeted effective therapies. It is now well 
established that many cancer cells, unlike normal tissue, reduce their dependence on 
mitochondrial oxidative phosphorylation as their primary energy source and favour 
glycolysis. This altered metabolism, a defining feature of cancer, is expected to offer a 
strategy to preferentially kill cancer cells. The present study set out to investigate the 
glycolytic metabolism of breast and ovarian cancer, and assess the possibility of exploiting 
this alternative metabolic route for the development of novel cancer drug therapies. Initially 
it was established that proliferative growth of breast and ovarian cancer cells was dependent 
on glucose availability. The effects of a series of pharmacological tool compounds inhibiting 
key molecules of the pathway along with their mechanism of action were then examined. All 
compounds tested blocked the pathway and were shown to effectively target proliferation 
and growth of various breast and ovarian cancer cell line models. An additional objective of 
this research was to assess the metabolic inhibitors in combination strategies with common 
chemotherapeutic and targeted agents. Two novel promising strategies have been identified 
and are proposed for further evaluation. Glycolytic inhibitors were found to enhance the 
potency of platinum chemotherapy and sensitise resistant ovarian cancer cells to it. Also in 
combination with the antidiabetic drug metformin they produced robust synergistic effects 
on cell growth of relatively aggressive breast cancer cells. This study examined the impact of 
the oxygen level on the antiproliferative efficacy of the metabolic inhibitors and greater 
resistance to the compounds was demonstrated at low oxygen conditions. This was 
interpreted as due to the elevated expression of the target enzymes in these conditions. 
Finally, the expression of glycolytic targets of interest was evaluated in clinical tissue 
ovarian cancer samples. The importance of the glycolytic pathway in ovarian cancer was 
ascertained and furthermore, subgroups of tumours from which glycolytic enzymes could be 
used as survival markers or that could be more susceptible to glycolysis inhibition, were 
identified. Overall, this research makes a further contribution to our knowledge of the role of 
the glycolytic metabolism in breast and ovarian tumours and provides evidence that the 
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Chapter 1: Introduction 
 
 
1.1 Breast & Ovarian Cancer 
Examining the glycolytic profile of breast and ovarian cancer cell line models as well as 
exploiting several glycolytic targets therapeutically were the main objectives of this study. A 
brief introduction regarding these two malignancies is given below. 
 
 
1.1.1 Epidemiology of female malignancies  
Breast cancer is undeniably the most frequently diagnosed female malignancy accounting for 
30% of all new female cases each year in the UK. The ovary is the fifth most common 
female cancer site with ovarian cancer accounting for 4% of all female cancer cases. 
According to Cancer Research UK, as presented in Figure 1.1, in 2012 nearly 51,000 women 
were diagnosed with breast cancer in the UK and approximately 7,000 with ovarian cancer 
[1].   
Breast cancer is the second most common cause of female cancer deaths, following lung 
cancer, accounting for approximately 15% of all cancer related deaths among women each 
year in the UK. Ovarian cancer, being the most lethal among all gynaecological 
malignancies, is the fifth most common cause of cancer deaths in women, responsible for 
nearly 6% of female cancer mortality (Figure 1.2). The survival rates for both types of cancer 
have been improving over the last few years; this is attributed to better awareness, earlier 
diagnosis and treatment advances. Nevertheless in 2012 nearly 12,000 women died from 
breast cancer and 4,300 from ovarian cancer in the UK [1]. The American Cancer Society 
estimates that this year (2016) more than 40,000 women in the US will succumb to breast 
cancer and more than 14,000 to ovarian cancer [2]. 
 
Both breast and ovarian cancer present a major concern in public health care and further 
research to enhance our understanding and develop further treatment opportunities is 



















































1.1.2 Breast Cancer 
1.1.2.1 Risk factors 
A single cause for breast cancer has not been described but several factors have been linked 
to the disease. The best-documented risk factors are gender and increasing age.  A woman in 
the UK is estimated to have a 1 in 8 chance of being diagnosed with breast cancer during her 
lifetime. Men are rarely affected with around 400 cases diagnosed in the UK in 2012 [1]. 
The malignancy is more frequent in women around menopause with 80% of cases occurring 
in women aged 50 and over [1]. Natural hormonal changes are considered to play an 
important role in breast cancer development. Early menarche, late menopause as well as 
nulliparity are associated with an elevated risk of occurrence. In contrast prolonged 
breastfeeding and young age at childbearing are described to have protective value. 
Extensive exogenous hormone intake during hormone replacement therapy is a well-defined 
risk factor contributing to a higher incidence of breast carcinogenesis. Among further factors 
that have been suggested to increase the risk of breast cancer are obesity for postmenopausal 
women, alcohol consumption and exposure to radiation [2-5]. 
Individuals with a first-degree relative diagnosed with breast cancer have an elevated risk of 
developing the disease. Approximately 10% of breast cancer incidences in the Western 
world are attributed to familial predisposition. The most important and best characterised 
susceptibility genes are the tumour suppressor genes BRCA1 and BRCA2. Germline 
mutations in these DNA repair genes are associated with up to 80% cumulative lifetime risk 
of breast cancer occurrence. Several polymorphisms in additional genes have also been 
identified along with rare familial predisposing syndromes including the Li-Fraumeni (TP53 
germline mutations) and the Cowden syndrome (PTEN germline mutations) [6, 7]. Women 
with prior history of benign breast lesions like atypical hyperplasia have significantly 
elevated risk of developing malignant breast carcinomas [3-5]. 
1.1.2.2 Diagnosis 
The U.K. NHS breast screening programme offers an X-ray mammogram test to women 
aged between 50 and 70 every three years [8].  Women with symptoms, most frequently a 
palpable lump in the breast, or with suspicious screening results are referred to a specialist 
breast clinic for triple assessment. This involves clinical examination, a mammography and 





Following pathological examination of the biopsy material, tumours are graded and staged. 
Breast tumours are graded based on the Bloom-Richardson histological grading system with 
a scoring scale ranging from 1 to 3. This system provides an indication of ‘the degree of 
potential malignancy’ with grade 1 tumours being well differentiated while grade 3 tumours 
are poorly differentiated [11]. The most broadly used staging system for breast cancer is the 
American Joint Committee on Cancer (AJCC) TNM staging system. Tumours are classified 
based on their size, their lymph node status and the presence of distant metastasis. A five-
year relative survival rate is statistically predicted for patients with similarly staged disease 
[12].  
 
1.1.2.3 Histopathological classification  
The vast majority of breast malignancies are adenocarcinomas, at a percentage greater than 
95%, originating from the same segment of the mammary gland terminal duct lobular unit 
[13]. However, breast cancer is a very heterogeneous group of diseases that exhibit great 
diversity not only clinically but histologically and genetically as well. Pathologists have 
developed a classification system based on the morphological and cytological characteristics 
of tumours. Breast cancer is broadly categorised as either in situ or invasive carcinoma. In 
situ carcinoma is non-invasive, confined to the breast epithelium and is classified as either 
ductal or lobular [14, 15]. Ductal carcinoma in situ (DCIS) is considerably more frequent 
accounting for almost one quarter of all breast cancer cases diagnosed each year. It is 
considered a precursor lesion that could potentially evolve into invasive malignancy but it is 
currently debatable as to how aggressively it should be treated. In many cases DCIS would 
not develop further and therefore a considerable issue of overdiagnosis undoubtedly exists. 
DCIS is classically subdivided into five subtypes according to the architectural 
characteristics of the tumour (comedo, cribriform, micropapillary, papillary and solid) [16]. 
Invasive (infiltrating) carcinomas constitute a group of heterogeneous highly proliferative 
malignancies that have penetrated the stroma through the basement membrane. Multiple 
histological subtypes of invasive carcinomas are recognised accounting for up to 25% of all 
breast cancer cases. The most common specific subtypes include invasive lobular, tubular, 
cribriform, medullary, mucinous, papillary, micropapillary, apocrine and metaplastic. 
However almost 80% of all invasive tumours cannot be classified as a special histological 
type and are collectively designated as invasive carcinoma of no special type (NST), 




1.1.2.4 Molecular classification  
Routine use of molecular markers has been incorporated into everyday clinical practice. The 
expression levels of the oestrogen receptor (ER), progesterone receptor (PR) and the human 
epidermal growth factor 2 (HER2) are examined through immunohistochemistry (IHC) and 
fluorescence in situ hybridisation (FISH). Determination of the status of these biomarkers 
enables stratification of breast cancer patients predicting their clinical outcome and their 
response to targeted therapies [17, 18].  
In the last decade novel high-throughput gene expression microarray technology has 
enhanced our understanding of breast cancer heterogeneity. In their seminal study, Perou et 
al classified breast tumours into distinct molecular subgroups based on their gene expression 
profile [19].  The intrinsic subtypes identified have been further confirmed from a number of 
studies and are broadly recognised and associated with distinct clinical outcomes and 
survival predictions. Breast tumours are clustered into two main groups; the ER positive 
luminal group, subdivided into luminal A and luminal B subgroups and the ER negative 
group subdivided into HER2 positive, basal-like and normal breast-like carcinomas [14, 15, 
18]. Luminal tumours are the most common group accounting for around 60% of all breast 
cancer cases. They have a similar expression pattern with mammary luminal epithelial cells 














) tumours demonstrate increased expression of proliferation-related 







comprises up to 20% of all breast cancers. These tumours overexpress the HER2 gene along 
with several other genes related to the pathway and are associated with poor prognostic 






) subtype contains 15% of all breast cancer 
patients including the vast majority of BRCA1 cases. These tumours have a similar 
expression pattern with mammary myoepithelial cells and normal basal epithelial cells and 
they also express basal cytokeratins 5, 6 and 17. They are mostly aggressive tumours of high 
histological grade. Normal breast-like cancers have a gene-expression profile similar to 
adipose tissue of normal breasts and they account for 5% of all diagnoses [15, 18, 20, 21]. 







) tumours have a genetic profile similar to that of mammary stem cells and are 









) subtype is characterised by the expression of androgen receptors and an active 




1.1.2.5 Treatment  
There are five main modalities currently available in clinical practice for breast cancer 
treatment. These include surgery, chemotherapy, radiotherapy, endocrine therapy and 
targeted therapies. Most frequently two or more types of therapy are combined to achieve the 
optimal result. The treatment strategy is decided based on the stage and grade of the disease, 
the general health of the patient as well as the nodal status and the molecular characteristics 
of the tumour [2, 8-10].   
Surgery is considered the most effective treatment for breast cancer and is used as first-line 
management for the vast majority of patients excluding those presenting with advanced 
metastatic disease or weak elderly patients. Two different clinical approaches are currently in 
use; breast conserving surgery and mastectomy. In breast conserving surgery, also called 
lumpectomy, only the tumour is removed along with a margin of the surrounding healthy 
tissue. Breast conserving surgery is followed by post-operative radiotherapy meaning high-
energy x-ray ionizing irradiation. Adjuvant radiation therapy destroys any residual cancer 
cells and reduces the possibility of local recurrence [23]. Mastectomy ranges from simple 
mastectomy to modified radical mastectomy and radical mastectomy depending on whether 
the axillary lymph nodes and the pectoral muscles respectively are removed along with the 
entire breast. Less disfiguring operations include skin sparing and nipple sparing 
mastectomy. Many women choose to undergo reconstructive surgery following a 
mastectomy. This can be an immediate or delayed procedure and usually saline or silicone 
implants are used or even tissue from a different part of the patient’s body (autologous 
reconstruction). Recent studies based on a twenty-year randomised trial demonstrate that 
women offered breast conserving surgery followed by adjuvant radiotherapy had equivalent 
outcome and survival rates to women who underwent mastectomy [24]. Axillary lymph node 
dissection for further histological examination is a crucial procedure for staging and dictates 
patient further management. To avoid highly invasive techniques like axillary node clearance 
and the possible risk of lymphoedema in patients with clinically negative axilla, sentinel 
node biopsy is frequently performed. Using a radioactive isotope and a blue dye, surgeons 
identify the sentinel nodes to which lymph fluid drains from the tumour and which have the 
highest probability of metastasis [25]. Systemic therapy is usually offered after surgery 
regardless of the nodal status and significantly reduces the risk of metastasis and regional 
recurrence [2, 8-10]. 
Chemotherapy involves the cyclical co-administration of multiple cytotoxic agents. The most 




taxanes (paclitaxel, docetaxel), antimetabolites (fluorouracil) and alkylating agents 
(cyclophosphamide, carboplatin). Chemotherapy is most commonly used in the adjuvant 
setting for patients with increased risk of recurrence [26]. However in cases with inoperable 
tumours it may be offered preoperatively (neoadjuvant setting) to shrink the tumours and 
make them resectable or allow breast conserving surgery in cases where tumour size exceeds 
recommendations [2, 8-10, 27].  
Around two-thirds of all breast tumours express hormone receptors and are highly dependent 
on oestrogen and/or progesterone to stimulate their growth. Endocrine therapy blocks 
hormone action and plays a critical role in the treatment of luminal cancers; it is used both in 
adjuvant and neoadjuvant settings [5, 8-10]. Tamoxifen is a selective estrogen receptor 
modulator (SERM), acts as an ER antagonist and is used for the treatment of pre-menopausal 
women. It has been shown that tamoxifen adjuvant therapy with a 5 year duration reduces 
the recurrence probability and the mortality rate [28].  Aromatase inhibitors block the 
synthesis of oestrogen from androgens through inhibition of the aromatase enzyme in 
peripheral fatty tissues. Letrozole, anastrozole and exemestane are currently used for the 
treatment of postmenopausal women with hormone-receptive tumours [29].  
Molecular targeted therapies involve inhibitors targeting specific pathways crucial for the 
growth and recurrence of tumours. Trastuzumab is a humanised monoclonal antibody that 
binds to the extracellular domain of the HER2 receptor inhibiting the activation of 
downstream signalling pathways. Twelve months of adjuvant trastuzumab significantly 
increases survival rate and is the standard treatment for HER2 positive breast cancer patients 
combined with chemotherapy or as monotherapy [30-32]. Trastuzumab emtansine, 
previously referred as T-DM1, is an antibody- drug conjugate of Trastuzumab with the 
cytotoxic agent emtansine. It allows targeted delivery of chemotherapy to HER2 positive 
cancer cells and is approved as a single-agent for the treatment of advanced, metastatic 
HER2 positive tumours pre-treated with trastuzumab and a taxane [33]. Lapatinib is a dual 
EGFR/HER2 tyrosine kinase inhibitor. It is approved for the treatment of advanced stage 
tumours and can be effective in trastuzumab resistant disease. Pertuzumab is a humanised 
monoclonal HER2 antibody that inhibits the receptor’s heterodimerisation. It is used in 
combination with trastuzumab and chemotherapy for neoadjuvant treatment of early stage 
HER2 positive tumours or for adjuvant treatment of advanced metastatic HER2 tumours [31, 
34, 35]. Everolimus targets the mTOR complex 1 (mammalian target of rapamycin) 
inhibiting the mTOR signalling pathway. It is approved in combination with exemestane for 




resistant to nonsteroidal aromatase inhibitors [36]. Palbociclib inhibits cyclin-dependent 
kinases 4 and 6 (CDK4 and CDK6) and it has recently been approved for the treatment of 
postmenopausal women with hormone receptor positive metastatic tumours in combination 
with letrozole [2, 37]. Multiple targeted agents inhibiting different pathways have been 
developed and are currently undergoing clinical trials to assess their efficacy and potential 
benefit in advanced breast cancer [38].  
 
1.1.3 Ovarian Cancer 
1.1.3.1 Risk factors 
The specific aetiology of ovarian cancer has not been identified yet, but several risk factors 
have been described. The predominant risk factor for ovarian cancer is age. Every woman in 
the UK is considered to have a 1 in 52 chance of being diagnosed with ovarian cancer during 
her lifetime. However nearly three-quarters of ovarian cancer cases are diagnosed in 
postmenopausal women aged 55 and over [1]. The number of a woman’s lifetime ovulation 
cycles is correlated with the risk of ovarian cancer occurrence. Oral contraception, multiple 
pregnancies and prolonged breastfeeding are considered of protective value. Hormonal 
factors have also been linked to development of the disease.  Hormone replacement therapy 
as well as ovarian stimulation treatment and infertility itself have been associated with an 
elevated risk of ovarian carcinogenesis. Women who suffered from endometriosis or 
polycystic ovarian syndrome may also face an elevated risk. Several lifestyle factors 
including genital use of talcum powder, obesity and tobacco smoking have also been 
suggested to increase ovarian cancer risk but studies are inconclusive [39-43]. 
A strong family history of ovarian or breast cancer is a well-established risk factor for 
ovarian cancer. It is estimated that up to 10% of ovarian cancer incidences are attributable to 
hereditary genetic predisposition [39-43]. Germ-line mutations in the high-penetrance 
susceptibility genes BRCA1 and BRCA2 are associated with up to 50% and 30% 
respectively lifetime risk of developing ovarian cancer [7, 44-46]. Women with such 
mutations are frequently offered prophylactic bilateral salpingo-oophorectomy after 
childbearing to eliminate the risk of ovarian cancer occurrence [44, 46]. The hereditary 
nonpolyposis colon cancer syndrome (HNPCC/ formerly known as Lynch syndrome) caused 
by germline mutations in the DNA mismatch repair genes (predominantly MSH2 and 





Ovarian cancer has a high mortality rate and this is attributed to the fact that almost 80% of 
cases are diagnosed at an advanced stage which is correlated with poor survival. Disease is 
mainly asymptomatic at early stages and even advanced disease symptoms are difficult to 
recognise. Clinical indications including abdominal distension, pelvic or abdominal pain, and 
changes in urinary or bowel habits are atypical and are usually misinterpreted as non-
malignant aetiology. A palpable ovarian mass, ascites or pleural effusions mostly present 
when disease has already metastasised beyond the ovaries [39, 43, 48].  A screening 
programme for ovarian cancer is not currently in use.  Diagnosis is based on a transvaginal 
ultrasonography and detection of high serum CA125 levels and is confirmed by surgical 
biopsy. The glycoprotein CA125 has been investigated as an ovarian cancer biomarker but it 
lacks the required specificity and sensitivity to be used as a screening tool. Several benign 
conditions including endometriosis, menstruation or pregnancy can elevate CA125 blood 
levels [39, 43, 48]. Research trials show that it has no value in being implemented in the 
general population as a screening tool, as it did not reduce mortality rates for ovarian cancer. 
However recent studies indicate that sequential CA125 measurements interpreted by a 
mathematical algorithm (ROCA- Risk of Ovarian Cancer Algorithm) may offer a promising 
strategy to calculate ovarian cancer risk [49, 50].     
 
Women with suspected ovarian cancer usually undergo laparotomy surgery. Diagnosis is 
confirmed through histopathological examination of the biopsy material and tumours are 
graded and staged. A histological grading system is followed classifying well differentiated 
tumours as grade 1, moderately differentiated as grade 2 whereas poorly differentiated 
tumours are classified as grade 3 [1]. The FIGO staging classification system (established 
from the International Federation of Gynaecology and Obstetrics) based on the tumour size 
and the presence of lymph node and distant metastasis is typically used. Stage I tumours are 
confined to the ovaries, stage II tumours have spread into the pelvis, stage III tumours have 
spread into the peritoneal cavity and may have lymph node involvement while final stage IV 
tumours have metastasised into distant organs [2, 39, 43, 46]. The most common sites of 
ovarian cancer metastasis include the liver, spleen, stomach and lungs. Survival rate is highly 
dependent on the stage classification with stage I tumours typically having a 90% five year 
relative survival rate as opposed to only 5% of stage IV tumours [1].    




1.1.3.3 Histopathological classification  
Over 90% of ovarian tumours are of epithelial origin traditionally considered to arise from 
malignant transformation of the epithelium lining the ovaries or cortical inclusion cysts [51].  
Epithelial ovarian tumours constitute a greatly heterogeneous group of diseases. The World 
Health Organisation (WHO) classifies epithelial ovarian tumours based on their 
histopathological and morphological features into four major histotypes exhibiting 
substantial heterogeneity. These are serous, endometrioid, clear cell and mucinous 
carcinomas. Less common histotypes include mixed, transitional cell (Brenner tumours) and 
undifferentiated tumours [52-57]. Serous is the most common histological subtype 
accounting for approximately 70% of all diagnosed ovarian cancer cases. Serous carcinomas 
are commonly diagnosed at advanced stage (III and IV).  They usually present a combination 
of architectural patterns including papillary, glandular and solid and frequently contain 
calcified structures called psammoma bodies [52-54]. Two different types of serous 
carcinomas having distinct pathogeneses and molecular profiles are characterised; low grade 
and high grade serous tumours. High grade serous tumours present great resemblance to the 
fimbrial epithelium of the fallopian tubes and it is proposed that they may have fallopian 
origin [52, 55-59]. They are also associated with BRCA1 and BRCA2 abnormalities.  
Endometrioid adenocarcinomas account for 10% of ovarian tumours and are usually 
diagnosed at an early stage. They have glandular or papillary morphology resembling the 
normal endometrial epithelium and are often associated with endometriosis. Clear cell 
carcinomas have similar frequency to endometrioid tumours and are also frequently 
diagnosed at an early stage. They are characterised by typical hobnail shaped cells with clear 
cytoplasm. Clear cell tumours may be associated with endometriosis and exhibit 
chemoresistance correlated with poor outcome. Mucinous tumours are rare and constitute 
less than 3% of ovarian cancers. They usually have glandular architecture with typical cells 
containing mucin-filled cytoplasm. Mucinous cancer cells resemble those of the 
gastrointestinal epithelium [52-54]. Recent evidence strongly challenges the notion of 
universal origin from the ovarian epithelium and suggests that a substantial proportion of the 
tumours traditionally considered of exclusive ovarian origin only relate to the ovary 
secondarily [57, 60]. The histotypes exhibit distinctive gene expression signatures and 
interestingly a correlation has been demonstrated between the gene expression profile of 
normal differentiated fallopian tube epithelium and serous carcinomas, endometrial 
epithelium and endometrioid and clear cell tumours as well as colonic mucosa and mucinous 
tumours [51, 61]. Mixed ovarian tumours are often diagnosed when two histologically 




occurring combination is that of endometriosis associated histotypes, endometrioid with 
clear cell. An epithelial ovarian tumour is diagnosed as undifferentiated when it lacks 
histological differentiation and cannot be classified in another way. It is a group of clinically 
aggressive heterogeneous tumours usually associated with poor prognosis [52-54, 56]. 
1.1.3.4 Molecular classification  
Based on distinctive carcinogenetic pathways and molecular profiles, Kurman et al. 
classified ovarian tumours into two major groups named type I and type II. Type I tumours 
account for roughly a quarter of all diagnosed cases; low grade serous, endometrioid, clear 
cell and mucinous carcinomas are included. Type II mainly involves high grade serous and 
undifferentiated carcinomas. Type I tumours are slow growing, confined to the ovaries at 
diagnosis, well differentiated and have gradually progressed from established benign 
precursor lesions (e.g. endometriosis and borderline tumours). In contrast, type II tumours 
are aggressive, poorly differentiated and are considered to develop de novo since no 
precursor lesion has been identified. The molecular signatures of the two types are distinct 
and differ greatly. Type I tumours are characterised by genetic stability and mutations at 
KRAS, KRAF, PTEN are frequently detected. In contrast type II tumours are genetically 
remarkably unstable and are defined by TP53 mutations [59, 62-64]. 
1.1.3.5 Treatment 
The standard treatment of ovarian cancer is debulking surgery followed by systemic 
platinum and taxol-based chemotherapy. Cytoreductive surgery involves abdominal 
hysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy and omentectomy 
aiming to eradicate disease. It has been shown that lower residual tumour volume is of 
crucial importance for improved clinical outcome. Adjuvant chemotherapy is offered to 
high-risk patients both at early and advanced stages. Intraperitoneal chemotherapy 
administration has been studied and proved more effective compared to the standard 
intravenous delivery route in certain situations. However, it has not been universally adopted 
because of several toxicity and practical implications [65-68]. The gold standard first-line 
treatment is a combination of platinum analogues (cisplatin or carboplatin which cause DNA 
crosslinking) and taxanes (paclitaxel or docetaxel which inhibit microtubule 
depolymerisation). It has been shown that optimally debulked women with low grade and 
early stage disease (FIGO stages IA and IB) do not benefit from chemotherapy [39, 65, 67]. 
Complete remission is observed in up to 80% of early stage patients and 50% of patients 
with advanced disease [67, 69]. Following treatment patients are frequently monitored 




relapse. Second line treatment of recurrent disease depends on the disease free interval 
following completion of initial therapy. Platinum sensitive disease (relapse after at least 6 
months) is likely to respond to a subsequent carboplatin – paclitaxel combination. In contrast 
for platinum insensitive (relapse within 6 months) and platinum refractory disease (progress 
even during platinum treatment) different cytotoxic agents usually as monotherapy are 
employed including the pegylated liposomal doxorubicin, topotecan and gemcitabine. 
Because of the low response rates these patients are preferred candidates for clinical trials 
and investigational studies of novel therapeutic strategies [65, 67, 70]. Radiation therapy and 
hormonal therapy are rarely used for ovarian cancer treatment. 
Several novel targeted molecular therapies hold promise for improved outlook of ovarian 
cancer patients. Olaparib is a small molecule PARP (poly (ADP)-ribose polymerase) 
inhibitor used for the treatment of ovarian cancer patients who are carriers of BRCA 
germline mutations and have advanced disease. Based on a synthetic lethality strategy, 
PARP inhibitors cause the accumulation of DNA single strand breaks and if the homologous 
recombination DNA repair pathway is impaired due to loss of function of the BRCA tumour 
suppressor genes, cell cycle arrest and cell death are induced. It is now realised that BRCA 
deficiency also occurs in many sporadic ovarian cancers, especially high grade serous 
carcinomas, and these patients can potentially benefit from PARP inhibition [71, 72]. 
Bevacizumab is a recombinant humanised monoclonal antibody targeting the vascular 
endothelial growth factor A (VEGFA). Clinical trials showed promising results of the use of 
this angiogenesis inhibitor as monotherapy or in combination with traditional chemotherapy 
even for advanced platinum resistance disease [67, 69, 73-75].      
                                                                                                                                            
1.1.4 Limitations of current treatment approaches of breast & ovarian cancer 
Substantial progress has been made for the treatment of breast and ovarian cancer 
documented by the significant improvement of the survival rates of both diseases in the last 
few decades. Nevertheless major challenges still remain to be faced.   
An issue of vital importance is the side effect profiles of conventional chemotherapeutic 
agents which are usually very distressing. Unfortunately, chemotherapy can have a serious 
impact on the patient’s quality of life, without always guaranteeing a beneficial response. 
Common side effects include gastrointestinal complications (nausea, vomiting, constipation 
or diarrhoea), myelosuppression (increased infection risk, bleeding and fatigue), loss of 




well tolerated with limited symptoms however there are still significant challenges. For 
example tamoxifen causes menopausal symptoms (hot flushes, irregular menstrual periods), 
trastuzumab causes cardiotoxicity and bevacizumab has been associated with gastrointestinal 
perforation, hypertension and thrombosis [32, 69, 73]. 
Endocrine and HER2 targeted therapies present great advances in the treatment of breast 
cancer improving greatly the disease free survival and the clinical outcome for the benefiting 
subgroups. However disease recurrence following endocrine therapy and clinical resistance 
to trastuzumab present major clinical issues. Furthermore treatment of triple negative 
tumours remains challenging because of the limited treatment options and the consequent 
poor survival rates [76]. 
Quantitation of protein expression levels of ER and HER2 receptors determines the use of 
endocrine and HER2 targeted therapy. Gene expression analysis and molecular classification 
of breast cancers could improve prediction of therapeutic response and also identify specific 
key regulators of each molecular subtype to enable development of novel targeted therapies 
[77].                         
Regarding ovarian cancer, even though platinum based chemotherapy has high response 
rates, it is estimated that approximately 70% of patients will relapse with resistant disease. 
The median progression free survival is calculated equal to 18 months [67, 69]. Recurrent 
disease is generally untreatable and current treatment is only palliative [39, 68]. Even 
platinum sensitive recurrent disease is retreated with the same agent again and again until 
eventually resistance develops and patients succumb to their disease.     
It should be realised that under the umbrella term ovarian cancer several diseases are 
included with distinct morphological and molecular characteristics and different aetiology. 
Ovarian cancer histotypes should not be regarded as a single homogenous disease and 
separate therapeutic approaches for each of them should be developed [78]. For example 
clear cell tumours exhibit chemoresistance and cytotoxic chemotherapy may be 
inappropriate since there is little proven benefit [67, 79, 80]. Specific treatment modalities 
should be developed for these tumours using different cytotoxic regimens and targeted 
agents. Novel high-throughput technologies and large-scale gene expression profiling studies 
should be used to identify novel molecular targets for drug development.  
It is apparent that there is an urgent need for the development of novel less-toxic treatments 




1.2 Tumour Metabolism 
 
1.2.1 Warburg Effect 
It would be irrational to commence an analysis of cancer cell metabolism without first 
mentioning the renowned biochemist Otto Heinrich Warburg (Figure 1.3). In the 1920s, 
almost a century ago he made an outstanding observation showing that cancer cells exhibit 
increased production of lactic acid from glucose [81]. In his seminal study On the origin of 
cancer cells he identified a metabolic alteration as the sole pivotal cause responsible for the 
loss of cell differentiation and carcinogenesis. Warburg demonstrated that because of an 
irreversible ‘injury of respiration’ cancer cells rely on lactic fermentation for energy 
production [82-85].  
                                                    [86]                            
Non-malignant differentiated cells in the presence of oxygen (O2) metabolise glucose to 
carbon dioxide (CO2) in their mitochondrial tricarboxylic acid cycle (TCA) and generate 
their required energy through oxidative phosphorylation. Only under low oxygen conditions 
are they forced to utilise breakdown of glucose to lactate in the cytoplasm. However most 
cancer cells rely on glycolysis as their primary source of energy regardless of oxygen 
availability (Figure 1.4) [87, 88]. The persistence of glycolysis even under aerobic conditions 
is termed aerobic glycolysis or the Warburg effect; as it was first called by Racker in 1972 
[89]. The metabolic alteration of tumours is nowadays well substantiated, extensively 
demonstrated in a wide variety of cancers and considered a ‘hallmark’ of advanced 
malignancy [90, 91].  Hanahan and Weinberg in their key review Hallmarks of Cancer: The 
Next Generation were the first to recognise the metabolic reprogramming of tumours as a 
hallmark of tumourigenesis [92]. The exact contribution of the glycolytic pathway to energy 
production is highly dependent on the cell type and the oxygenation level. Nevertheless it 
has been estimated that many tumour cells under aerobic conditions produce up to 60% of 
their ATP requirement through glycolysis [93, 94].   
Figure 1.3: Nobel Laureate Otto Heinrich 
Warburg (1883-1970) 
He was awarded the Nobel Prize in 
Physiology or Medicine in 1931 "for his 
discovery of the nature and mode of 












Figure 1.4: Simplistic schematic emphasising the alteration in cancer cell metabolism in the presence of oxygen. 
The avid uptake of glucose by tumours has been exploited clinically with the use of 2-
[
18
F]fluoro-2-deoxyglucose positron emission tomography (FdG-PET) [95, 96]. This 
imaging technique was first developed in the late 1980s and approved in 1998 for detection, 
staging and monitoring of treatment response and relapse of most human cancers [97]. This 
traceable glucose analogue is administered to the patient and follows the metabolic route of 
glucose. It enters the cells through glucose transporters, gets phosphorylated by hexokinase 
and subsequently undergoes isomerisation. However it cannot be further catabolised and 
accumulates inside cells where it can be visualised and quantified reflecting the rate of 
glucose uptake which is enhanced in malignant tissues [95-97]. This non-invasive, sensitive 
technique is a valuable, universal tool in oncology and presents a direct translation of the 
Warburg effect into clinical practice.  
The metabolic deregulation is evidently not a unique feature of malignancy [87, 88, 98]. A 
similar metabolic switch is also observed in unicellular organisms exhibiting exponential 
growth in an abundant nutrient environment and also in differentiated cells engaged in 
proliferative metabolism such as stimulated lymphocytes and proliferating fibroblasts [87, 
98, 99]. It has been suggested that the glycolytic pathway has been selected by evolution to 
fulfil the special needs of rapidly proliferating cells [87, 98, 99].           
In his day Warburg’s theory was profoundly disregarded but recently it has regained a lot of 
interest and Warburg’s contribution is universally recognised. In the last two decades, 
tumour metabolism has played a leading role in cancer research with tremendous therapeutic 
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1.2.2 The reason behind aerobic glycolysis 
According to Warburg’s hypothesis the reason behind the high rate of glycolysis in cancer 
cells is a defect in their mitochondria that impairs aerobic respiration. However it is now 
recognised that mitochondrial function is retained intact in most cancer cells and oxidative 
phosphorylation contributes significantly to ATP generation depending on O2 availability 
[90, 99]. In Warburg’s day using Warburg’s own data, Weinhouse resolutely contradicted 
the idea of a respiratory defect in cancer cells, but he did confirm the unquestionable 
elevated rate of glycolysis found by Warburg [84, 106]. 
Many factors contribute to the metabolic alteration of tumours including oncogenic 
transformation, the tumour microenvironment and mitochondrial DNA mutations. 
Aberrations in oncogenes and tumour suppressor genes can dictate and strictly regulate the 
metabolic alterations of tumours [83, 90, 91, 96, 107].  Akt, the serine-threonine kinase, 
downstream signalling effector of the phosphatidylinositol 3-kinase (PI3K), plays a critical 
role in the regulation of glucose metabolism [104, 108]. Akt activation promotes the 
metabolic switch to the glycolytic pathway and induces translocation of the Glucose 
transporter 4 (GLUT4) to the plasma membrane [104, 109, 110]. Further downstream in the 
same signalling pathway, Akt-mediated mTORC1 activation leads to increased GLUT1 
levels through upregulation of mRNA translation [111]. It has also been proposed that Akt 
regulates the translocation of specific hexokinase isoforms (HKI and HKII) to the outer 
mitochondrial membrane and their interaction with the mitochondrial voltage-dependent 
anion channel (VDAC) enabling access to the mitochondrial ATP and promoting an 
advanced glycolytic rate. Through a mechanism that is not completely understood, Akt 
mediated hexokinase mitochondrial association prevents cytochrome c release and induction 
of apoptosis [112]. Constitutively active transformed c-Myc stimulates glycolysis and drives 
the overexpression of multiple glycolytic targets including GLUT1, GLUT4, Hexokinase, 
Pyruvate kinase and LDHA [104, 113, 114]. TIGAR (TP53-induced glycolysis and apoptosis 
regulator), a well characterised p53 regulator, attenuates glycolysis reducing the level of 
fructose-2,6-bisphosphate in the presence of a functional tumour suppressor p53 [104, 115]. 
It has also been demonstrated that p53 stimulates mitochondrial respiration by directly 
upregulating synthesis of cytochrome c oxidase-2, essential for the formation of the 
cytochrome c oxidase complex [116]. Another crucial factor is that the primary role of 
mitochondria is switched from energy generation to anabolic biosynthesis through aberrant 
oncogenic signalling [90]. The TCA cycle generates intermediates used for the biosynthesis 




Preferential expression of specific isoforms of glycolytic enzymes is also crucial for the 
glycolytic phenotype of tumours [96]. The most extensively studied is the M2 pyruvate 
kinase isoform. Furthermore amplification of glycolytic enzymes has also been described. 
Rempel et al demonstrated a five-fold amplification of Hexokinase II in a hepatoma cell line 
compared to normal hepatocytes [117].  
The tumour microenvironment selects for cells adapted in hypoxic conditions. Stabilization 
of the transcription factor HIF-1α (Hypoxia Inducible Factor) stimulates glycolysis and 
upregulates the majority of enzymes related to the glycolytic pathway. It has been 
demonstrated through certain mechanisms that the HIF-1α subunit can be stabilised even in 
the presence of oxygen [107, 118]. Activation of mTOR as well as several oncogenes 
including Src, H-Ras and PI3K has been linked to HIF induction. The β domain of the von 
Hippel–Lindau (VHL) gene product binds the HIF-1α subunits leading to their oxygen 
dependent polyubiquitylation and proteasomal degradation. Subsequently, the inactivation of 
the VHL tumour suppressor gene, which is strongly associated with renal-cell carcinomas, 
inhibits HIF-1α degradation [119]. Moreover Lu et al suggested that the glycolytic pathway 
itself, through its final product pyruvate, promotes HIF-1α stability independently of the 
oxygenation level [120]. Recently it has also been shown that accumulation of succinate due 
to loss-of-function of succinate dehydrogenase results in prolyl hydroxylase inhibition and 
HIF-1α stabilisation irrespective of O2 availability [83, 118, 121]. HIF regulation is 
described in greater detail in section 1.3.1. 
Even though it is well established that mitochondrial function in tumours is in general not 
impaired, it has been demonstrated that mitochondrial DNA mutations contribute in certain 
cases to the glycolytic phenotype of tumours [83, 94, 96, 100, 107]. Moreover somatic or 
germline mutations in nuclear genes encoding TCA cycle enzymes might partially 
compromise mitochondrial respiration. It has been shown that succinate dehydrogenase and 
fumarate hydratase act as tumour suppressor genes in certain tumour types [88, 121].  
1.2.3 The advantages of aerobic glycolysis 
The metabolic switch of cancer cells involves an apparent paradox taking into consideration 
that glycolysis is a much less efficient pathway stoichiometrically for the production of ATP. 
Indeed the glycolytic pathway generates two ATP molecules per glucose molecule as 
opposed to 36 molecules generated through complete mitochondrial oxidation of glucose 
[87, 107, 122]. The abundant energy production of oxidative phosphorylation (OXPHOS) is 
the basis of the Pasteur Effect which describes the inhibition of glycolysis when O2 is 




But what could be the reason behind this unprofitable, in terms of ATP generation, metabolic 
selection within tumours? First of all it has been suggested that for cancer cells nutrients are 
in many cases abundant. It is likely that malignant tissues maintain a constant affluent 
nutrient supply through blood circulation that enables a high rate of ATP production through 
the glycolytic pathway [87]. It has been shown that regardless of the high proliferation rate, 
cancer cells typically demonstrate high ATP/ADP and NADH/ NAD
+
 ratios proving that 
resources are usually not scarce [87].  
The ‘metabolic reprogramming’ is an adaptation to fulfil the immense anabolic requirements 
of highly proliferative malignant tissues, providing the precursors needed to support 
biosynthesis. Glycolysis and biosynthetic pathways provide the cells with energy and the 
metabolic intermediates needed for cell growth and biosynthesis of macromolecules [87, 88, 
91, 98, 122]. Amino acid, fatty acid and nucleotide biosynthesis demands consumption of a 
large amount of carbon precursors in the form of α-ketoacids, acetyl-CoA or ribose in 
addition to ATP. Mitochondrial enzymes play a leading role in anabolic reactions. On the 
other hand vast ATP production through oxidative phosphorylation would compromise 
biosynthesis because of the lack of reducing equivalents and also jeopardise constant glucose 
uptake because of an elevated ATP/ADP ratio. Highly elevated ATP levels suppress 
glycolysis inhibiting allosterically phosphofructokinase (PFK) [98, 123, 124]. 
The metabolic alteration of cancer cells is proposed to provide them with a selective 
advantage for survival and growth in the low O2 tumour microenvironment. As tumours 
grow and expand away from a functional blood supply, glycolysis is an evolutionary 
adaptation of cells to survive and thrive in a hypoxic environment [91, 102, 125]. 
Furthermore the acidic microenvironment from the vast amount of released lactate, offers 
cancer cells a selective growth advantage promoting motility and invasion (discussed in 
greater detail in section 1.3.2)  [125, 126].  
Another important aspect is that the metabolic switch offers a survival advantage protecting 
tumours from intracellular reactive oxygen species (ROS). An elevated level of oxidative 
phosphorylation in aerobic conditions would result in extensive ROS production that would 
induce oxidative stress and ROS-associated apoptosis. It has been repeatedly suggested that 








Glutamine is the most abundant amino acid in blood circulation and a nutrient of major 
importance to proliferating tumour cells. Glutaminolysis is an alternative metabolic pathway 
playing a crucial role in many tumours [127-130]. In 1979 Reitzer et al demonstrated that 
HeLa cells are highly dependent on glutamine for the production of energy. They reported 
that glutamine was the exclusive energy source when cells were cultured in fructose or 
galactose while contributing to energy generation at a level exceeding 65% in the presence 
of glucose [131]. More recently DeBerardinis et al examined the metabolism of glioblastoma 
cells using nuclear magnetic resonance spectroscopy. They documented that highly 
glycolytic tumour cells maintained a functional TCA cycle and engaged in glutamine 
metabolism to generate intermediates (anaplerosis) as well as reducing equivalents 
(NADPH) [132]. Although glutamine is a non-essential amino acid that can be synthesised 
from glutamate and ammonia by glutamine synthetase, it has been observed that many 
cancer cells require elevated amounts of glutamine for survival and growth [127-130].  
Glutamine is transported into the cell by specific glutamine transporters. Once inside the cell 
glutamine is hydrolysed to glutamate by glutaminase. Subsequently glutamate is converted 
to α-ketoglutarate either through oxidative deamination by glutamate dehydrogenase or 
through a transamination reaction catalysed by aminotransferases. α-ketoglutarate is then 
directed to the TCA cycle for oxidation. It should also be mentioned that glutamate is a 
precursor of the redox regulator and major antioxidant glutathione [98, 130].  
Cancer cell addiction to glutamine can be interpreted in several ways. First of all, glutamine 
provides nitrogen for amino acid synthesis as well as for the synthesis of purines and 
pyrimidines supporting the anabolic growth of tumours. Furthermore glutamine along with 
amino acid abundance activates mTORC1 and downstream signalling pathways promoting 
protein synthesis and tumour growth. Finally glutamine is a primary substrate of the 
mitochondrial TCA cycle contributing to biosynthetic precursors and NADPH generation 
and subsequently to macromolecular synthesis as well as energy production [98, 127-129]. It 
is well substantiated that c-Myc oncogenic transformation promotes glutamine addiction 
upregulating glutamine transporters and enzymes involved in glutamine catabolism 





1.2.4.1 Targeting Glutaminolysis 
The dependency of many tumours on glutamine can be exploited for preferential targeting of 
glutamine ‘addicted’ cancer cells. Several approaches to target glutamine metabolism for 
cancer therapy have been suggested and are currently under investigation [128, 129]. 
Glutaminase catalyses the conversion of glutamine to glutamate. Hydrolytic cleavage of 
glutamine generates glutamate along with an ammonium ion. BPTES (Figure 1.5) [Bis-2-(5-
phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulphide] is a small molecule, identified as a 
glutaminase inhibitor through a library screen in 2002. Five years later, Robinson et al 
performed extensive kinetic analyses and characterised the compound as a selective non-
competitive inhibitor of the kidney glutaminase isoform. BPTES presents no structural 
similarity to either glutamine or glutamate and binds with high affinity to both the free 
enzyme as well as the enzyme-substrate complex. The authors suggested that the mechanism 
of inhibition involves restriction of phosphate-mediated allosteric activation and formation 
of inactive stable tetramers [135]. 
 
                                                                                        [135, 136] 
Le et al performed isotope-resolved metabolomic studies and investigated the metabolism of 
Myc-activated P493 human Burkitt lymphoma cells. They reported that Myc induced both 
glucose and glutamine metabolism. However a functional glutamine-dependent TCA cycle 
under low O2 or glucose-deprived conditions was substantiated. Glutaminase inhibition 
confirmed the crucial role of glutamine metabolism for tumour survival and growth. BPTES 
inhibited cell proliferation and impaired ATP production, elevating ROS levels, in P493 cells 
under both normoxic and hypoxic conditions. Attenuation of tumour growth in xenograft in 
vivo models was also demonstrated [137]. Isocitrate dehydrogenase 1 (IDH1) catalyses the 
oxidative decarboxylation of isocitrate to α-ketoglutarate. This enzyme is frequently mutated 
in gliomas and acute myelogenous leukemia. The mutants perform a different distinct 
reaction generating 2-hydroxyglutarate from α-ketoglutarate. Seltzer et al demonstrated that 
BPTES can preferentially suppress the growth of glioma cancer cells bearing IDH1 
mutations by attenuating glutaminase activity and eliminating α-ketoglutarate levels [138]. 
These findings were further verified by Emadi et al who documented that primary acute 
myelogenous leukemia cells expressing mutant IDH were highly dependent on glutamine 
Figure 1.5: 
BPTES 
Linear Formula: C24H24N6O2S3 
Molecular Weight: 524.68 







metabolism and selectively sensitive to glutaminase BPTES-mediated inhibition [139]. A 
very interesting recent study conducted by Hudson and colleagues associated ovarian cancer 
platinum resistance with c-Myc upregulated glutamine metabolism. Platinum resistant 
ovarian cancer cells proved highly dependent on glutamine availability and upregulation of 
glutamine transporters and glutaminase was observed. Interestingly, analysis of three 
publicly available ovarian cancer patient microarray datasets revealed a significant 
correlation between elevated glutaminase expression and poor survival. A synergistic 
interaction between BPTES and cisplatin was reported and indicated by induction of 
apoptosis. Furthermore, BPTES was able to sensitise platinum resistant ovarian cancer cells 
to cisplatin treatment [140].  
A novel selective glutaminase inhibitor named CB-839 (Calithera BioSciences) 
demonstrated preclinical antitumour activity across a range of tumour types. Phase I dose 
escalation trials in solid and haematological tumours are currently conducted [141]. 
 
1.3 Hypoxia 
As mentioned earlier, hypoxia is a well substantiated characteristic of the microenvironment 
of advanced solid tumours. Several previous studies have documented that at least 50% of 
locally advanced solid tumours contain hypoxic and anoxic areas; a typical feature that does 
not correlate with the histological grade, the pathological stage nor any other clinical 
parameter. Substantial heterogeneity in the oxygenation status of individual tumours as well 
as among separate tumours has been extensively described [142-144]. Vaupel et al reported 
that at least 40% of examined breast carcinomas exhibited hypoxic tissue regions with O2 
tensions ranging from 0 to 2.5mmHg [144, 145]. They also revealed considerable variability 
in oxygenation even between breast tumours sharing identical histology, stage and grade 
[145].  Variability among separate tumours has proved greater than heterogeneity among 
areas of the same tumour [142, 143, 145]. Furthermore, it has been shown that relapsed 
lesions are more hypoxic compared to their primary counterparts [142-144].  
Hypoxia in tumours, defined as O2 tension lower than 2.5mmHg, develops because of a 
disturbed balance between O2 availability and consumption [142-144]. Heterogeneously 
distributed alternating normoxic, hypoxic, anoxic necrotic as well as re-oxygenated areas are 
a common pattern of solid malignancies. This phenomenon results from the chaotic 
architecture of tumour microvessels and is termed ‘Cycling hypoxia’ [146]. Perfusion-




delivery due to a functionally or structurally damaged microvasculature network and 
abnormalities of microcirculation. Additionally diffusion limited hypoxia, referred as chronic 
hypoxia, emerges due to extended diffusion distances as growing tumours expand further 
than 100 to 200μm away from blood capillaries [146, 147] [142-144]. Marked variability in 
blood flow of tumours has been reported ranging from zero and in some cases even 
exceeding that of surrounding healthy tissue. However O2 extraction is typically deficient 
leading to reduced O2 tensions [148]. Interestingly abnormal tumour microvasculature has 
been shown to stimulate the extraction of glucose as opposed to O2 thus promoting the 
Warburg phenotype [148]. Other aetiologies of tumour oxygen deficiency include treatment-
related anaemia or plasma-perfused microvessels [142-144].  
Hypoxia disrupts cellular homeostasis and suppresses proliferation. In response to hypoxia, 
cells reduce their protein synthesis rate and frequently undergo p53-dependent or BCL2-
regulated apoptotic cell death or even necrosis [142, 143]. The minimum O2 requirement for 
normal cellular function is estimated at 1mmHg. Bellow this threshold, cell cycle arrest at 
the G1/S phase is induced [143].  However, oxygen deficiency plays a pivotal role in tumour 
progression through critical hypoxia-induced genome and proteome changes. Hypoxia has 
been associated with a clinically aggressive phenotype, resistance to radiation therapy and 
limited response to several chemotherapeutic agents (e.g. anthracyclines, carboplatin) [142-
144]. Moreover, a considerable amount of literature confirms that hypoxic areas in tumours 
correlate with adverse clinical outcome and poor survival in a wide range of malignancies 
[142-144]. In line with this it has been suggested that pre-treatment oxygenation status could 
serve as a useful survival prognostic marker [144].   
1.3.1 Hypoxia Inducible Factor 1 
Cellular response to conditions of low oxygen availability is mainly coordinated by the 
transcription factor HIF-1 which plays a major role in tumour progression. HIF-1 was first 
described through the identification of a hypoxia-response element in the erythropoietin gene 
[149, 150]. It is a heterodimer of constitutively and ubiquitously expressed HIF-1α and HIF-
1β subunits and has a basic–helix-loop-helix structure [147, 151]. The HIF-1β subunit, also 
named the aryl hydrocarbon-receptor nuclear translocator, is a typical subunit of several 
transcription factors [149]. HIF-1α, even though continually synthesised, undergoes rapid 
ubiquitination and proteasomal degradation in the presence of O2 [152, 153]. In high O2 
tensions, HIF-1α gets hydroxylated by highly-conserved prolyl hydroxylases [153, 154]. 
Hydroxylated HIF-1α is recognised by the von Hippel-Lindau (VHL) tumour suppressor 




subunit and attracts the E3 ubiquitin-protein ligase complex [119, 153, 155, 156]. The factor 
inhibiting HIF-1 (FIH-1), utilising molecular O2, hydroxylates an asparagine residue of HIF 
blocking its transactivation and suppressing its transcriptional activity [153, 157, 158]. In 
hypoxic conditions, hydroxylation and subsequent degradation is inhibited due to O2 
deprivation, leading to HIF-1α accumulation. In addition to substrate depletion, 
mitochondrial ROS inactivate the hydroxylases through oxidation of the ferrous ions in their 
catalytic centre [118, 159]. Stabilised HIF-1α is then translocated to the nucleus where it 
dimerises with the HIF-1β subunit to form the transcriptionally active complex [150].  HIF-1 
induction is tightly regulated in response to O2 tension; it is degraded promptly when O2 
availability is restored in hypoxic cells having a half-life lower than 5 min [149, 150].    
Activated HIF-1 coordinates oxygen homeostasis and mediates adaptive responses to 
hypoxia via transcriptional activation of target genes [151, 153]. These responses include 
angiogenesis and erythropoiesis, promoting enhanced O2 delivery, as well as metabolic 
reprogramming eliminating O2 utilisation [149, 153]. HIF-1 induces the expression of 
SLC2A1 and SLC2A3 genes, encoding glucose transporters GLUT1 and GLUT3; and 
upregulates virtually all enzymes involved in the glycolytic pathway [118]. Indeed nine out 
of the ten glycolytic enzymes are known to be HIF-1 inducible. PDHK1 (pyruvate 
dehydrogenase kinase) is a HIF-1 target that suppresses mitochondrial respiration redirecting 
ATP synthesis to glycolysis through inhibition of the mitochondrial enzyme PDH (pyruvate 
dehydrogenase) [118, 160, 161]. Furthermore HIF-1 induces the expression of BNIP3 
leading to selective mitochondrial autophagy [118].    
Activation of HIF-1 resulting either from the hypoxic tumour microenvironment or 
uncoupled from changes in cellular oxygenation levels plays a critical role in carcinogenesis 
and tumour progression. A tight cooperation has been revealed between HIF-1 and 
deregulated oncogenic transcription factor c-Myc stimulating the glycolytic phenotype of 
tumours through upregulation of glycolytic enzymes [159, 162].  
1.3.2 Lactate  
Lactate generated by the glycolytic pathway was long considered merely a waste metabolic 
product however it is now well established that it plays a crucial role in carcinogenesis and 
tumour progression [163]. Lactate is transported in and out of cells via four monocarboxylate 
transporters MCT1-MCT4; members of a large solute carrier family. These are proton-linked 
proteins containing 12 transmembrane helices, intracellular terminal regions and a distinct 
cytosolic loop in-between the 6
th
 and the 7
th
 domain [164, 165]. The principal lactate 




Highly glycolytic tumours export large amounts of lactate into the extracellular milieu. 
Lactate tumour levels have been extensively associated with treatment resistance and adverse 
clinical outcome [163]. Specifically secreted lactate has been shown to induce the expression 
of proinflammatory cytokines IL-23 and IL-17 in macrophages or monocytes and stimulated 
tumour-infiltrating immune cells. The proinflammatory response is well associated with 
tumour progression and distant metastases [166]. Furthermore it has been demonstrated that                                        
the lactate efflux impairs the tumour specific adaptive immune response. The acidic tumour 
microenvironment hinders the glycolytic metabolism of activated cytotoxic T cell 
lymphocytes as due to the lack of a concentration gradient, the lactic acid produced by 
tumour infiltrating immune cells cannot be efficiently removed. As a result their function is 
undermined as evidenced by reduced cytokine production [167]. An additional proposed role 
for lactate is that of a signalling molecule. It has been demonstrated that lactate released 
from tumour cells can be taken up by endothelial cells and can initiate a proangiogenic 
response through activation of the NFκB and IL-8 autocrine pathway, stimulating cell 
migration [168].      
Lactate shuttling between tumour cells has been described. It has recently been realised that 
lactate may fuel the oxidative metabolism of tumour cells growing in an oxygenated 
microenvironment. Use of lactate as an alternative metabolic fuel has been observed in 
several non-malignant tissues including the liver and skeletal muscles. Sonveaux et al 
identified a metabolic symbiosis between hypoxic tumour cells that produce lactate which is 
then oxidised and used as an energy source from the subpopulation of tumour cells growing 
under high O2 tensions. In this way glucose is spared for the highly glycolytic hypoxic 
tumour cell compartment located in great distance from a functional blood supply [122, 165, 
169, 170]. MCT1 is considered the premier regulator of this symbiotic relationship and has 
been proposed as an attractive antitumour target [122, 169, 170].     
 
1.4 The glycolytic pathway and the major targets 
The glycolytic pathway comprises a series of ten enzymatic cytoplasmic reactions (Figure 
1.6). One molecule of glucose is catabolised in the cytoplasm to two molecules of pyruvate 
generating two ATP and two NADH molecules [93, 100, 105, 122].  
Glucose is transported into the cell by glucose transporters and gets phosphorylated to 
glucose-6-phosphate by hexokinase. Glucose-6-phosphate can be redirected to the pentose 




Alternatively glucose-6-phosphate is converted to fructose-6-phosphate by isomerase and 
then a second phosphate group is added by 6-phosphofructo-1-kinase generating fructose-
1,6-bisphosphate. In a series of consecutive steps in the second energy-yielding phase of the 
pathway, fructose-1,6-bisphosphate is metabolized to phosphoenolpyruvate through the 
intermediate products glyceradehyde-3-phosphate, 1,3-diphosphoglycerate, 3-
phosphoglycerate and 2-phosphoglycerate. The enzymes catalysing these reactions are: 
aldolase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, 
phosphoglycerate mutase and enolase. Subsequently, pyruvate kinase transforms 
phosphoenolpyruvate to pyruvate. Differentiated tissues under aerobic conditions direct 
pyruvate into the mitochondrial TCA cycle for oxidative phosphorylation. In contrast tumour 
cells mainly convert pyruvate to lactate by lactate dehydrogenase, which is released through 
monocarboxylate transporters [93, 100]. 
The glycolytic pathway can be summarised in the following reaction: Glucose+2ADP → 
2ATP+2 Lactate+2H
+
+2H2O (Figure 1.6). The glycolytic components of particular interest 
to this study will be presented below. 
 
 
Figure 1.6: Representation of the glycolytic metabolic pathway and the enzymes catalysing its reactions. Figure 
adapted from Porporato et al [122]. PPP and TCA indicate the pentose phosphate pathway and the tricarboxylic 




1.4.1 Glucose Transporters 
Proliferative cells demand a constant supply of nutrients to support biosynthesis and growth. 
This requirement is usually met by increased expression of nutrient transporters. Membrane 
glucose import into the cytosol is a key rate-limiting step for glycolysis and cellular 
proliferation. Glucose transporters (GLUTs) mediate the facilitated (energy independent) 
bidirectional diffusion of glucose and other hexone molecules across the plasma membrane 
in favour of the concentration gradient [171-176]. The GLUTs are members of the SLC2A 
gene family of transporters – solute carrier family 2A. The family comprises 14 isoforms 
each one of them containing 12 highly conserved transmembrane alpha helices and a N-
linked glycosylation site. Three different classes of transporters are distinguished based on 
their sequence similarities. Class I comprises the extensively studied GLUT1-GLUT4; also 
known as classical transporters, as well as GLUT14, which is considered a gene duplication 
of GLUT3. The different isoforms display distinct tissue-specific expression patterns and 
substrate affinity [172-177]. GLUT1/ SLC2A1 is ubiquitously expressed, highly abundant in 
erythrocytes, and facilitates basal glucose transport in most tissues. The transport of glucose 
across the blood brain barrier is exclusively mediated by this transporter. GLUT1 plays an 
important role in tumourigenesis and is found overexpressed in the vast majority of 
transformed cells [171, 173-177]. GLUT2/ SLC2A2 shows low affinity for glucose and is 
expressed primarily in pancreatic islet cells, the intestinal epithelium and hepatocytes. It has 
also been associated with some neoplasms [172, 173, 175-177]. GLUT3/ SLC2A3 is a high- 
affinity transporter predominantly found in neurons and the testes. Abnormal expression has 
been described in several tumour types [171, 175-177]. GLUT4/ SLC2A4 is an insulin 
responsive transporter abundantly expressed in adipose tissue as well as skeletal and cardiac 
muscles. Even though its role is best characterised in insulin related disorders, including 
obesity and type II diabetes, upregulation in some tumours has been documented [171, 175-
177]. GLUT5/ SLC2A5 belongs in Class II and presents high specificity for fructose. It is 
primarily expressed in the kidneys and small intestine but is also induced in some cancers 
[172, 173, 176, 177].     
Among the transporters GLUT1 has the most universal and pivotal role in tumourigenesis. 
GLUT1 upregulation has been described in many different tumour types and is typically 
associated with tumour progression and poor prognosis [174-176]. In a study conducted by 
Carvalho et al IHC staining of tissue microarray (TMA) slides comprising 1955 samples of 
different tumour types revealed variable GLUT1 expression in the different neoplasms. 
Sarcomas, lymphomas, melanomas and hepatoblastomas were the only exceptions suggested 




A considerable amount of literature indicates the crucial role of GLUT1 in breast tumours. 
Grover-McKay et al performed a comparative study of GLUT isoform protein expression 
against breast cancer cell line invasiveness. The non-invasive MCF7, the moderately 
invasive MDA-MB-435 and the highly invasive MDA-MB-231 cell lines were used and 
Western blot analysis was conducted. Interestingly, GLUT1 expression was correlated with 
breast cancer cell invasive potential while in contrast GLUT2 and GLUT5 presented an 
inverse correlation. GLUT3 expression was higher in MDA-MB-435 cells and GLUT4 was 
not detected in any of the cell lines [179]. In a more recent in vitro study the expression of 
GLUTs was compared between MCF7 and MDA-MB-231 cells based on Northern blot 
analysis. Xu et al reported that both cell lines express GLUT1, with the triple negative cell 
line exhibiting significantly higher levels, as well as the fructose transporter GLUT5, which 
is undetectable in healthy breast tissue. GLUT3 was found specifically expressed only in 
MDA-MB-231. The authors correlated the elevated GLUT1 and GLUT3 expression with the 
invasive and aggressive phenotype of the multidrug resistant MDA-MB-231 line [180]. In an 
IHC study conducted by Brown and Wahl contradicting the previous in vitro results GLUT3 
and GLUT5 were not detected in any of the 12 breast cancer samples and 8 lymph node 
metastases examined. GLUT2 was mildly expressed in all tissues and GLUT4 was only 
detected in a subgroup of them. In contrast GLUT1 was overexpressed in all primary 
tumours and metastases. Membranous as well as cytoplasmic expression along with 
remarkable intratumoral and intertumoral staining variability were reported [181]. Unlike 
Brown, Younes et al assessed GLUT1 expression in 118 breast tumours and reported that 
less than half of them (42%) were positive for GLUT1. The discrepancy with Brown’s 
results was attributed other than population variability to the staining technique and antibody 
specificity. Nevertheless GLUT1 expression was correlated with high proliferative index, as 
determined by ki-67 positivity, and higher nuclear grade [182]. In a subsequent study Brown 
et al showed that GLUT1 was expressed in 61% of 27 untreated breast cancer tissue 
sections. GLUT1 immunostaining was both membranous and cytoplasmic and was described 
as heterogeneous with higher expression observed in advanced stage tumours. Interestingly 
FDG uptake was associated with GLUT1 expression and not HKII [183]. Following IHC 
staining of 100 invasive ductal carcinoma samples Kang et al reported positive GLUT1 
staining in 47% of the samples and correlated GLUT1 overexpression with negative ER and 
PR status and higher nuclear grade. Notably GLUT1 expression was significantly correlated 
with disease-free survival along with tumour size and lymph node involvement [184]. A 
more recent study conducted by Jang et al confirms that GLUT1 expression correlates with 




GLUT1 immunoreactivity in 38% of 276 invasive ductal tumours and 43% of 58 lymph 
node metastases. GLUT1 was also proposed as an independent prognostic marker as the 
transporter’s expression was significantly correlated with poor disease-free and overall 
survival [185]. Pinheiro et al examined GLUT1 expression in 124 invasive breast tumours 
and reported immunoreactivity in 46% of the samples. GLUT1 expression was correlated 
with the expression of the hypoxia marker CAIX as well as MCT1 but not MCT4. 
Significant associations between GLUT1 upregulation and advanced tumour grade, absence 
of PR, basal-like subtype as well as high proliferative activity (ki-67) were further 
confirmed. However no association with the survival outcome was identified [186]. Krzeslak 
et al followed a slightly different approach and assessed GLUT1 mRNA and protein 
expression in 70 breast cancers using Q-PCR and Western blotting. GLUT1 was expressed 
in 50% of the samples at both the mRNA and protein level and the expression was higher in 
poorly differentiated tumours. Elevated GLUT3 expression in high grade tumours was also 
observed [187]. However in the literature there is substantial controversy regarding GLUT1 
expression in normal mammary epithelium. In both his studies Brown along with Krzeslak 
and Jang described GLUT1 expression in normal and hyperplastic benign breast tissue [181, 
183, 185, 187]. However, others, including Younes and Kang, failed to detect GLUT1 
expression in normal breast epithelial cells [182, 184, 186]. Kang et al attributed the 
contradictory findings to the sensitivity of the various immunostaining protocols as well as to 
differential GLUT1 expression during the various phases of the menstrual cycle [184]. 
Another study by Alo et al documented GLUT1 expression in 31% (out of 48 samples) of 
normal breast tissues adjacent to in situ breast carcinomas and 36% (out of 28) of adjacent 
typical/atypical hyperplastic tissues. It should be noted that this is an additional study 
correlating GLUT1 expression with invasive phenotype and advanced tumour grade based 
on immunostaining of 66 breast carcinomas [188].  
In reviewing the literature the pivotal role of GLUT1 in ovarian tumourigenesis is also 
revealed. Cantuaria et al argued that GLUT1 is critical for the malignant transformation of 
ovarian epithelia. The authors evaluated GLUT1 expression following an IHC streptavidin 
labelled biotin protocol in 21 borderline and 82 malignant epithelial ovarian tumours. 
GLUT1 was observed in 95 and 99% of the lesions respectively, while normal ovarian 
epithelium was mostly negative. GLUT1 expression was gradually elevated from borderline 
to high-grade malignant tumours and was correlated with the grade and histology of the 
tumours; serous carcinomas were found to express higher GLUT1 levels compared to other 
histotypes [189]. In a follow-up study the authors examined GLUT1 expression in 113 




subgroup of advanced stage tumours GLUT1 overexpression was correlated significantly 
with clinical response to chemotherapy and poor disease free survival [190]. An interesting 
study conducted by Kalir et al corroborated the previous findings and demonstrated negative 
GLUT1 staining in normal and benign ovarian epithelial tissue, moderate expression in 
borderline tumours and strong expression in malignant tumours (54 out of 56 ovarian 
adenocarcinomas were stained positively) [191]. Rudlowski et al further confirmed previous 
findings of progressive GLUT1 expression from benign ovarian tissue (n=16) and borderline 
tumours (n=16) to malignant ovarian adenocarcinoma (n=78) as demonstrated by IHC, 
Western blotting analysis as well as in situ hybridisation. However in this study GLUT1 
expression was not correlated with either the tumour grade, nor the histological subtype or 
the survival outcome. Weak GLUT3 expression was observed in both benign and tumour 
lesions while none of the GLUT2 and GLUT4 were found [192]. Contradictory findings 
were published by Tsukioka and colleagues who demonstrated strong GLUT1, GLUT3 and 
GLUT4 expression in ovarian adenocarcinomas. The authors examined 154 ovarian tumours 
using IHC and found the transporters expressed in 99, 93 and 84% respectively and their 
expression was correlated with angiogenesis and VEGF. GLUT1 along with GLUT4 were 
significantly higher in serous carcinomas compared to clear cell tumours and their 
expression was correlated with tumour stage [193]. In a more recent study Semaan et al 
examined GLUT1 expression in 213 primary ovarian tumours by IHC and correlated 
GLUT1 expression with tumour proliferation and microvessel density but not angiogenesis. 
Furthermore based on a univariate survival analysis elevated GLUT1, ki-67 and CD34 levels 
were significantly associated with poor clinical outcome. Also overexpression of GLUT1 in 
highly proliferative advanced stage tumours was shown to have a significant impact on 
optimal cytoreduction  [194].  Cho et al performed genome wide microarray analysis and 
compared the gene expression profiles of developed ovarian cancer cell lines against benign 
ovarian tissue. GLUT1 was among the differentially expressed genes that were found 
remarkably overexpressed in ovarian malignancy. Subsequently the authors detected GLUT1 
expression in each of the 50 examined ovarian tumour tissues and reported overexpression in 
serous carcinomas as well as a significant association with the survival outcome [195]. 
Lamkin et al adopted a totally different perspective and proved that glucose may have 
prognostic value in ovarian carcinogenesis. They examined the pre-surgical plasma glucose 
levels of ovarian cancer patients and demonstrated that high glucose levels were correlated 





Overexpression of GLUTs in tumours is attributed to aberrant oncogenic growth factor 
signalling. As previously described hypoxia and HIF-1 induce GLUT1 and GLUT3 
expression [118]. The PI3K/ Akt/ mTOR signalling pathway upon cytokine activation is 
highly associated with GLUT1 upregulation at the transcriptional and post-translational 
levels [197]. Activation of the serine/ threonine kinase Akt has been shown to induce 
GLUT1 gene transcription [198]. Several signals including insulin as well as ras and src 
oncogenic transformation have been described to stimulate the transporter’s expression [197-
199]. Insulin has been shown to induce both GLUT1 mRNA transcription and translation 
while an opposite effect has been observed for GLUT4 [111]. KRAS and BRAF 
transformation have also been associated with GLUT1 upregulation. Interestingly, Yun et al 
demonstrated that glucose deprivation can induce KRAS pathway mutations in colorectal 
cancer cells [200]. Another study conducted by Chen et al revealed that elevated GLUT1 
expression upon HRAS transformation is mediated by HIF-1α upregulation and subsequent 
transactivation of the glut1 promoter [201]. Other than aberrant growth factor signalling 
nutrient starvation is also described to contribute to GLUT upregulation. Impaired tumour 
blood supply may also trigger the overexpression of nutrient transporters [171]. On the other 
hand the tumour suppressor p53 is evidenced to repress the expression of the GLUT1 and 
GLUT4 transporters [202].   
GLUT1 is considered a very attractive target for cancer therapy. A study conducted by 
Young et al demonstrated that GLUT1 knockdown suppressed mammary tumour growth in 
athymic nude mice. On the other hand GLUT1 overexpression stimulated tumour growth in 
the same in vivo model [203]. Several compounds inhibiting glucose transport have been 
identified and novel specific GLUT1 inhibitors have been recently synthesised attracting 
great interest [102]. Finally it should be mentioned that the GLUT1 deficiency syndrome is a 
treatable disorder transmitted through autosomal dominant inheritance. Impaired glucose 
transport into the brain is typically associated with infantile seizures, developmental delay 
and movement disorders. Various different mutations have been identified in the SLC2A1 
gene combined with extended phenotypic diversity. It should be highlighted that the 
syndrome is somewhat treatable with a ketogenic diet (high fat, low carbohydrate diet) as 
ketone bodies can enter the central nervous system and provide an alternative energy source 





1.4.2 Hexokinase (HK) 
Hexokinase catalyses the first rate-controlling irreversible reaction of the glycolytic 
pathway; phosphorylating glucose to glucose-6-phosphate coupled with ATP de-
phosphorylation [205-207]. This phosphorylation traps glucose inside the plasma membrane 
and determines its fate to follow the glycolytic pathway [205]. Four different mammalian 
isoforms have been identified; referred to as HKI, HKII, HKIII and HKIV. The first three of 
these present high affinity for glucose and their kinase activity is subjected to strong 
inhibition by the phosphorylation product [206, 208]. They have evolved through duplication 
of an ancestral glucokinase gene resembling that encoding HKIV [205, 206, 208]. Among 
the different isoforms, HKII is considered to play a pivotal role in carcinogenesis [205, 206]. 
Rapidly produced glucose-6-phosphate from cancer cells follows the glycolytic pathway for 
ATP production or is directed to the pentose phosphate pathway for NADPH and 
biosynthetic precursor generation [205, 206].     
HKII is bound to the outer mitochondrial membrane anchored to the voltage-dependent 
anion channel (VDAC) via a binding domain at the amino-terminus. HKII preferentially 
utilises the ATP synthesised by the mitochondrial ATP synthase transferred by the adenine 
nucleotide translocator, and avoids strong inhibition from the generated glucose-6-phosphate 
[112, 205, 207, 209]. Due to its position in the mitochondrial membrane HKII plays a critical 
anti-apoptotic role promoting cancer cell survival [112, 205-207, 209]. Pastorino et al 
revealed that HKII prevents mitochondrial interaction of the proapoptotic protein Bax thus 
inhibiting Bax-induced apoptosis [112, 209, 210]. Furthermore Azoulay-Zohar et al showed 
that mitochondrial-bound hexokinase suppresses the formation of the mitochondrial 
permeability transition pore thereby inhibiting the release of cytochrome c [205, 211]. 
According to Roberts et al, HKII also regulates a protective glucose sensing mechanism 
mediated by mTORC1 inhibition and subsequent autophagy induction in glucose deprivation 
conditions. They recently demonstrated that the phosphorylation product, glucose-6-
phosphate, not only suppresses the kinase activity of the enzyme and its mitochondrial 
localisation but also inhibits mTORC1 binding and autophagy activation [212, 213].    
HKII is not expressed in most healthy mammalian tissues excluding insulin-responsive 
tissues such as skeletal muscle and the heart [205, 206]. Nevertheless it is overexpressed in 
many tumours [206]. The overexpression of HKII can be explained through both genetic and 
transcriptional events. Firstly, as previously mentioned, Rempel et al have demonstrated a 
five-fold amplification of the HKII gene in a hepatoma cell line [117, 214]. Furthermore it 




inhibited at the epigenetic level because of extensive methylation. Nonetheless in 
hepatocellular carcinomas HKIV is silenced and HKII expression is activated by 
demethylating agents [205, 207, 215]. Enhanced transcription has been extensively 
demonstrated in tumours and is attributed to cis-element promoter activation by protein 
kinase-A, protein kinase-C, HIF-1, p53 as well as glucose, glucagon and insulin [205, 207, 
214].  
Several studies have examined the role of HKII in breast and ovarian cancer. Brown et al 
examined HKII expression in a cohort of 27 untreated primary breast tumours by IHC. They 
found HKII cytoplasmic expression in 79% of the samples, not always correlating with 
GLUT1 expression. No association was observed between HKII expression and FDG uptake 
[183]. In a recent study Sato-Tadano et al identified HKII as a HIF-1α induced gene 
associated with breast cancer recurrence based on microarray gene expression analysis. 
Examining 118 breast tumours using IHC they detected HKII expression in 44% of them 
while expression in normal and benign tissues was considerably lower. The authors reported 
an association between HKII expression and the histological grade as well as expression of 
the proliferation marker Ki-67 and disease recurrence. HKII was proposed as a useful 
independent prognostic factor of disease-free survival in breast cancer patients [216]. 
Palmieri et al performed a small scale gene expression analysis examining differentially 
expressed genes between primary breast tumours and metastatic disease in the brain and 
observed a trend of HK overexpression in metastatic lesions. Indeed following IHC staining 
in a cohort of 123 resected brain metastases of breast cancer, HKII was found expressed in 
77% of the samples and a significant association between HKII overexpression and poor 
clinical outcome was revealed [217].   
Regarding the role of HKII in ovarian cancer a search of the existing literature revealed 
several studies. Suh et al examined HKII expression in 111 ovarian cancer samples 
following an IHC protocol. They reported a correlation between HKII overexpression and 
chemoresistance, defined as disease recurrence within 6 months of treatment completion. 
HKII overexpression was demonstrated as a prognostic factor for early disease recurrence 
and was significantly associated with reduced progression-free survival [218]. In 2014 Jin et 
al investigated HKII expression in ovarian tumour samples using IHC and qRT-PCR. 
Significantly elevated HKII expression was observed in malignant tissues compared to 
healthy and benign ones, as well as poorly-differentiated compared to well-differentiated 
lesions. HKII overexpression was associated with serous histogenesis, an association 




1.4.3 Phosphofructokinase (PFK) 
PFK1 (6-phosphofructo-1-kinase) catalyses the transfer of a phosphate group from ATP to 
fructose-6-phosphate. This irreversible reaction yields one molecule of ADP along with one 
fructose-1,6-bisphosphate (F1,6BP) molecule. It is the first committed step of glycolysis 
regulating the rate of the whole pathway. Elevated PFK1 activity is detected in many 
tumours as a result of oncogenic transformation [220, 221]. PFK1 is a complex tetramer 
composed of three different subunits in a tissue dependent manner. The three subunits, each 
encoded by a separate gene, are PFKM, PFKL and PFKP predominantly found in muscles, 
the liver and platelets respectively. PFK1 being a critical control point of the glycolytic 
pathway is tightly regulated. The enzyme is inhibited by lactate and citrate as well as fatty 
acids. However the most powerful PFK1 inhibitor is ATP. Likewise AMP activates PFK1 
since both molecules reflect the cellular energy state [220, 221]. Nonetheless the most potent 
allosteric activator of PFK1 is fructose-2,6-bisphospate (F2,6BP) which promotes high 
glycolytic flux regardless of the ATP content. F2,6BP is both  synthesised (fructose-6-
phospate phosphorylation) and degraded (F2,6BP dephosphorylation) by a family of 
bifunctional enzymes called 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases 
(PFKFB) [220-222]. The kinase catalytic domain (PFK2 activity) is in the amino-terminus of 
a single polypeptide within a homodimeric protein complex while the bisphosphatase 
domain is in the carboxyl-terminus. Four different mammalian isozymes have been 
identified, encoded by separate genes and referred to as PFKFB1-4. As opposed to the other 
three isozymes, PFKFB3 presents a significant bias towards kinase enzymatic activity 
favouring F2,6BP synthesis (actual kinase: phosphatase activity ratio 740:1) [220-222].  
PFKFB3 is hypoxia inducible, frequently overexpressed in tumours and considered to play a 
critical role in tumourigenesis [220-222]. Atsumi et al examined PFKFB3 mRNA and 
protein expression in situ in 60 human tumour samples. They reported that PFKFB3 was 
overexpressed in neoplastic cells; including lung, breast, colon and ovarian carcinomas, 
compared to their corresponding healthy tissues [223]. The upregulation of PFKFB3 during 
neoplastic transformation has been justified in many ways.  Firstly, multiple repeat copies of 
the AUUUA instability motif have been observed in the 3’ untranslated region (3’UTR) of 
the PFKFB3 mRNA stimulating transcriptional activity [224]. Novellasdemunt et al 
identified a progesterone response element in the PFKFB3 promoter and showed that 
binding of the progesterone receptor following progestin hormonal treatment induced 
transactivation of PFKFB3 transcription in breast cancer cells [225]. Moreover, it has been 
shown that AMPK-mediated extensive phosphorylation of a serine residue in the carboxyl-




[226]. Telang et al identified PFKFB3 as a key metabolic mediator of ras oncogenic 
transformation. Paradoxically they observed reduced F2,6BP cellular levels in immortalised 
or ras transformed cells in spite of PFKFB3 overexpression. The authors attributed the 
reduction to a compensation feedback mechanism or increased glycolytic utilisation [227]. 
Almeida et al demonstrated that under physiological conditions PFKFB3 is constantly 
degraded in neurons via ubiquitination by the E3 ubiquitin ligase anaphase-promoting 
complex/cyclosome (APC/C)- Cdh1. Inactivation of the ligase activator Cdh1 at the 
restriction point of G1 phase is required for transition to S phase and induction of 
proliferation and glycolysis [228]. Interestingly, Garcia-Cao et al indicated that the tumour-
suppressor PTEN downregulates PFKFB3 by promoting APC/C-Cdh1 complex activity and 
subsequently PFKFB3 degradation [229].   
An additional role in regulation of cellular proliferation and cell cycle progression in a 
glycolysis-independent manner has been attributed to PFKFB3. Several PFKFB3 splice 
variants with distinct carboxyl-terminal domains have been noted in tumours. A key study 
conducted by Yalcin et al revealed nuclear localisation of the most prevalent PFKFB3 splice 
variant in tumours and demonstrated that nuclear F2,6BP activated Cdk1 resulting in 
phosphorylation and degradation of the cell cycle inhibitor p27 [230]. In a recent follow-up 
study the authors verified that PFKFB3 knockdown suppressed Cdk1 activity while elevating 
p27 levels and induced apoptosis via cell cycle arrest at G1/S phase [231]. De Bock et al 
revealed new insight into the roles of PFKFB3 as an angiogenesis regulator. They observed 
that PFKFB3 promoted vessel sprouting of highly glycolytic endothelial cells as well as 
lamellipodia formation and migration, a function mediated by an association between the 
enzyme and F-actin [232]. Additionally, Seo et al recently described PFKFB3 as a protective 
regulator of redox homeostasis. They reported that elevated ROS levels lead to S-
glutathionylation of PFKFB3 attenuating its enzymatic activity and reducing F2,6BP 
generation. Subsequently the impaired glycolytic rate stimulated the pentose phosphate 
pathway influx and reduced glutathione production contributing to ROS detoxification [233].      
1.4.4 Pyruvate Kinase (PK) 
Pyruvate kinase catalyses the irreversible conversion of phosphoenolpyruvate (PEP) to 
pyruvate coupled with ADP phosphorylation which is the final rate-limiting step of the 
glycolytic pathway. Four different mammalian isoforms have been identified encoded by 
two separate genes. The L and R isoforms, found mainly in liver and erythrocytes 
respectively, are encoded by the Pklr gene using different promoters [234, 235]. M1 and M2 




in the M1 isoform comprising exon 9, whereas M2 isoform comprises exon 10. The two 
isoforms differ in 23 amino acids encoding the inter-subunit contact domain associated with 
tetrameric formation [234-236]. PKM1 is constitutively active and present in many 
differentiated tissues including skeletal muscles and the brain while PKM2 is the 
predominant isoform of highly proliferative cells and embryonic tissues as well as cancer 
cells [234, 235]. Aberrant activation of the oncogenic transcription factor c-Myc has been 
shown to upregulate the transcription of heterogeneous nuclear ribonucleoproteins 
responsible for PKM2 specific splicing, i.e. exon 9 exclusion, resulting in preferential PKM2 
overexpression in tumours [236].  
PKM2 is found overexpressed in various tumour types and plays a pivotal role in 
carcinogenesis [234, 237]. Two different PKM2 forms have been described. The tetrameric 
form presents high affinity to PEP and is catalytically active while the dimeric form has low 
affinity to the enzyme’s substrate and is virtually inactive. The interconversion is regulated 
by the upstream glycolytic metabolite fructose-1,6-bisphosphate (FBP) which acts as an 
allosteric activator inducing the formation of tetramers [234, 235, 237]. The low enzymatic 
activity isoform regulates the rate of the glycolytic pathway and leads to the accumulation of 
glycolytic intermediates stimulating the biosynthetic pathways. In this way, PKM2 balances 
energy production with channelling carbon sources for the biosynthesis of nucleic acids, 
proteins and lipids [235, 237, 238].  
The dimeric:tetrameric ratio determines PKM2 activity and is tightly regulated [234, 237]. 
Evidence of oncogenic growth factor regulation was first provided by Christofk et al. In 
2008 they demonstrated that PKM2 binds directly to phosphotyrosine peptides provoking the 
release of the bound allosteric activator FBP thereby suppressing PKM2 catalytic activity 
[239]. A year later Hitosugi et al reported that aberrant growth factor receptor tyrosine 
kinase signalling causes PKM2 phosphorylation resulting in interruption of FBP binding. 
Inhibiting the formation of highly active PKM2 tetramers favours anabolic pathways and the 
glycolytic tumour phenotype promoting tumour growth [240]. 
Other than fulfilling the tumour metabolic requirements, additional roles have been 
attributed to PKM2 [234, 237]. In 2012, Gao et al demonstrated that while tetrameric PKM2 
is a pyruvate kinase, PKM2 dimer acts as an active protein kinase regulating gene 
transcription and promoting cancer cell proliferation. They provided evidence that dimeric 
PKM2 locates in the nucleus and phosphorylates stat3 stimulating the transcription of a 
number of stat3 target genes [241]. In parallel Yang et al revealed that PKM2 regulates cell 




They showed that EGFR growth stimulation promotes PKM2 nuclear translocation where it 
binds and transactivates the c-Src-phosphorylated β-catenin. The interaction of the two 
proteins enhances cyclin-D1 expression through histone H3 acetylation and dissociation of 
histone deacetylase 3 from the CCND1gene promoter [242].  In a follow-up study conducted 
by the same group, it was reported that PKM2 binds directly to and phosphorylates histone 
H3 following EGFR activation; a modification essential for the induction of cyclin-D1 and c-
Myc expression and consequently tumour progression [243]. Another key study by Luo et al 
revealed a feedback-loop interaction between PKM2 and HIF-1, mediating tumour metabolic 
transformation and transactivation of HIF-1 target genes. PKM2 being a HIF-1 induced gene 
itself, containing a hypoxia response element within the first intron, was found to coactivate 
HIF-1 enhancing its transcriptional activity. Hydroxylation of nuclear PKM2 by prolyl 
hydroxylase 3 (in the PKM2-specific domain in exon 10) promotes PKM2- HIF-1α 
interaction which stimulates HIF-1 binding to hypoxia response elements, recruitment of 
coactivators (p300) and therefore expression of HIF-1 target genes [244, 245]. 
Solid evidence of the fundamental role of PKM2 in tumourigenesis came firstly from 
Christofk et al in 2008. PKM2 proved essential for the glycolytic phenotype of tumours and 
it was shown that replacing the M2 isoform with M1 increased oxygen consumption and 
reduced tumour growth of human lung cancer cells in nude mouse xenografts [246]. In the 
same vein, in 2012 Anastasiou et al demonstrated that small molecule activation of PKM2, 
similarly to expression of the constitutively active PKM1 isoform, attenuated tumour growth 
in xenograft mouse models. The identified compounds bind specifically to PKM2, at a 
distinct site from that of FBP binding, and stimulate tetramer formation [238, 247]. Vander 
Heiden et al followed a different approach and through a library screening assay they 
identified a small-molecule selective PKM2 inhibitor that inhibited glycolysis and caused 
cytotoxicity to H1299 human lung cancer cells [248]. Both approaches, activation and 
inhibition, have been considered legitimate antitumour strategies [102, 104, 105]. Even 
though PKM2 emerges as an attractive target for cancer therapy some recent studies have 
challenged the notion of a switch from PKM1 to PKM2 expression during malignant 
transformation [249, 250]. Evidence of PKM2 expression in several normal differentiated 
tissues has been demonstrated and PKM2 isoform specificity in proliferating tissues has been 
questioned [234, 249, 250]. Along the same lines Cortes-Cros et al documented that dual 
knockdown of both PKM1 and PKM2 isoforms was required to attenuate colorectal cancer 
cell proliferation in vitro while PKM2 knockdown or total depletion of PK activity had no 




1.4.5 Pyruvate Dehydrogenase Kinase 
Pyruvate Dehydrogenase Complex (PDC) is composed of three enzymatic components; 
pyruvate dehydrogenase (E1-PDH), dihydrolipoamide acetyltransferase (E2) and 
dihydrolipoamide dehydrogenase. Mitochondrial PDC catalyses the irreversible oxidative 
decarboxylation of pyruvate generating acetyl-CoA and CO2 with a concomitant reduction of 
NAD+ to NADH. It is a tightly regulated link of cytosolic glycolysis with the mitochondrial 
TCA cycle, determining the fate of pyruvate between glycolytic lactate secretion and 
oxidative phosphorylation [252-254]. PDC is inhibited through PDH phosphorylation by a 
family of enzymes named Pyruvate Dehydrogenase Kinases (PDHKs). Phosphorylated PDH 
gets reactivated via dephosphorylation mediated by pyruvate dehydrogenase phosphatases. 
PDHKs regulate glucose homeostasis and are considered to be involved in several metabolic 
diseases including cancer [252, 254]. Four different PDHK isozymes with tissue specific 
distribution have been identified in humans. Acetyl-CoA and NADH act as allosteric 
activators of these enzymes while in contrast coenzyme A, NAD+, ADP and pyruvate inhibit 
their function  [252-254].  
PDHK1 is a direct HIF-1 target and plays a critical role in neoplastic transformation 
promoting the glycolytic phenotype of tumours. Inactivation of PDC, following PDHK1-
mediated PDH phosphorylation, suppresses mitochondrial respiration and pro-apoptotic 
signals and eliminates ROS production favouring tumour progression [160, 252, 255]. 
PDHK1 is upregulated in tumours by HIF-1 and c-Myc. Additional activation has recently 
been demonstrated by Hitosugi et al through oncogenic tyrosine kinase signalling. They 
reported that tyrosine kinases, including Fibroblast growth factor receptor 1 (FGFR1) 
localised to the mitochondria phosphorylate PDHK1 stimulating glycolysis and tumour 
development [256].         
   
1.4.6 Lactate Dehydrogenase (LDH) 
LDH catalyses the interconversion of pyruvate to lactate along with concomitant oxidation 
of NADH to NAD
+
. The final reversible reaction of the glycolytic pathway is a critical rate 
limiting step as regeneration of NAD
+
 is essential to maintain the glycolytic flux. Human 
LDH belongs to the family of L-specific enzymes that use NAD
+
 as a cofactor. LDH is a 
homo- or hetero-tetrameric enzyme composed from two different subunits, LDHA and 
LDHB. The two subunits are highly conserved, characterised by great sequence homology 
(reaching 75%) and are encoded by two separate genes ldha and ldhb respectively [257-259]. 




such as skeletal muscle and liver while LDHB (also known as LDHH-heart) is the 
predominant subunit of tissues with aerobic metabolism including cardiac muscle, brain and 
kidneys. Five different isozymes have been identified depending on the subunit synthesis- 
LDH1 (H4 or LDHB), LDH2 (M1H3), LDH3 (M2H2), LDH4 (M3H1) and LDH5 (M4 or 
LDHA as it is herein referred). LDH5 along with isozymes with an excess of LDHA chains 
are mostly detected in anaerobic tissues favouring lactate generation whereas LDH1 and 
isozymes enriched in LDHB chains are kinetically more efficient in catalysing the 
conversion of lactate to pyruvate. The different isozymes have distinct electrophoretic 
mobility and kinetic features; with LDHA being the slowest moving and having the highest 
affinity to pyruvate [257-259]. An additional subunit named LDHC encoded by a separate 
ldhc gene, exhibiting high homology to the other two LDH genes, has been identified. The 
relevant LDHX (LDHC4) sixth isozyme is expressed exclusively in the testes and to a lesser 
extent in oocytes. LDHX is the predominant isozyme of spermatozoa and has been 
associated with male fertility [260, 261].  
LDH is a well characterised and extensively studied enzyme family since it was first isolated 
back in the early 1930s. Elevated LDH serum level is used as an indication of tissue damage 
and is an important biomarker of several acute medical conditions that cause a rapid release 
of the enzyme into the blood; including myocardial, liver, skeletal muscle as well as 
neoplastic disorders [257, 258, 262]. Besides that, LDHA overexpression has been observed 
in various tumour types and is considered to have a crucial role in tumourigenesis. It is 
broadly associated with poor clinical outcome and resistance to therapy [257-259, 262]. 
Regarding breast and gynaecological malignancies Koukourakis et al demonstrated that 
LDHA expression was upregulated in 60% of breast, endometrial and ovarian 
adenocarcinomas compared to healthy control tissues. LDHA exhibited a cytoplasmic and 
nuclear expression pattern and was associated with HIF1α expression. In the same study 
LDH serum levels were found to be significantly increased only in endometrial and ovarian 
cancer patients suggesting that LDHA upregulation may not be the only factor contributing 
to elevated LDH activity in the bloodstream [263]. A recent study conducted by Dennison et 
al revealed that even though LDHA is widely overexpressed in breast tumours, LDHB 
exhibits differential expression. mRNA microarray data analysis of a panel of breast cancer 
cell lines identified LDHB as a bimodal expressed gene. In patient datasets LDHB was found 
expressed specifically in glycolytic basal-like tumours and overexpression was associated 
with response to neoadjuvant chemotherapy and disease relapse in triple-negative tumours 
[264]. Conversely, LDHB silencing due to promoter hypermethylation has been observed in 




by Wang et al. In this study the authors correlated LDHA expression with tumour size but no 
other clinicopathological features using 49 breast cancer tissue samples. Additionally LDHA 
shRNA knockdown was shown to attenuate tumour growth in both in vitro and in vivo breast 
cancer models and induce oxidative stress and mitochondrial- mediated apoptosis [266].     
Upregulation of LDHA in tumours is mainly attributed to HIF1 and Myc transcription 
factors [262]. Additionally, activation through oncogenic receptor tyrosine kinases has been 
described. FGFR1 (Fibroblast growth factor receptor 1) directly phosphorylates LDHA and 
enhances its enzymatic activity; promoting tetrameric formation and NADH- cofactor 
binding [267]. LDHA is mainly cytoplasmic, engaging in the glycolytic pathway. However it 
has been demonstrated that LDH localises also in the nucleus where it acts as a single-
stranded DNA binding protein regulating gene transcription through interaction with the 
DNA polymerase α primase complex [268]. Further evidence has been provided by Luo and 
colleagues who showed that LDH is involved in the transcriptional activator complex of the 
histone 2B (H2B) gene and is essential for the attachment of the complex to the gene 





cellular redox status which plays a critical role in H2B optimal 
transcription and S-phase progression [269, 270].  
LDHA constitutes a promising anticancer target and has recently attracted a lot of interest. 
Conversion of pyruvate to lactate at the very bottom of the glycolytic pathway is specific to 
cancer cells and is expected to have very limited effect on normal cells that primarily oxidise 
pyruvate in their mitochondrial TCA cycle. It should be mentioned that individuals 
genetically deficient for LDHA are viable, relatively healthy and face only minor symptoms 
especially following intense physical activity [257, 258]. LDH knockdown has proved to 
have a major impact on tumour physiology; reduced LDHA activity promoted mitochondrial 
respiration, decreased mitochondrial membrane potential and suppressed tumour growth 
[271]. To date several LDH inhibitors have been identified and some of them have shown 
promising antitumour activity [102, 257, 258]. Additionally, LDH has been suggested as an 
attractive antimalarial target and inhibition of the LDH isozyme of the protozoan of the 






1.5 Targeting Glycolysis 
The deregulated cellular metabolism of tumour cells and their preferential reliance on 
glycolysis opens a promising therapeutic window. The propensity of cancer cells to favour a 
glycolytic metabolism has been characterised as their Achilles’ heel and signifies a viable 
vulnerability option promising to preferentially target tumours highly dependent on the 
pathway sparing normal differentiated cells. The array of enzymes comprising the glycolytic 
pathway can be exploited as potential targets for selective cancer treatment [93, 94, 100-105, 
272].        
Several glycolytic inhibitors have recently emerged exhibiting promising anticancer activity 
both in vitro and in vivo; nevertheless very few have reached clinical trials to date [94, 100-
102, 105, 122]. The effect of glycolysis inhibition on breast cancer and even more on ovarian 
cancer remains to be thoroughly investigated. In the present study ten glycolytic inhibitors 
(Figure 1.7) targeting five prime components of the pathway were selected and compared 
against a panel of breast and ovarian cancer cell lines. The inhibitors are presented in detail 
below. 
 










Figure 1.7: Representation of selected components of the glycolysis pathway and the glycolytic inhibitors used in 































1.5.1 Targeting Glucose Transport 
 
1.5.1.1 Flavonoids – Phloretin & Quercetin 
Flavonoids represent a substantial group of over 4,000 natural polyphenolic substances 
ubiquitously distributed in the plant kingdom. They are secondary metabolites; benzo-γ-
pirone derivatives synthesised from the aromatic amino acids phenylalanine and tyrosine 
along with acetate units, and fulfil numerous diverse biological roles in plant physiology. 
They act as the coloured pigments of crops and flowers, contribute to developmental and 
defence mechanisms of plants and are generally involved in several processes including  
photosensitisation, morphogenesis and photosynthesis [274, 275].  Flavonoids are essential 
constituents of the human daily diet as they abundantly occur in fruits, vegetables, seeds, 
herbs as well as olive oil and red wine. It has been estimated that on average we consume 
roughly 1g of flavonoids on a daily basis [274, 275].  
Various remarkable pharmacological responses have been linked with these ‘natural 
therapeutic drugs’ as they are also referred to. Antioxidant, anti-inflammatory, anti-allergic, 
anti-hyperglycaemic, oestrogenic as well as hepato-protective and cardio-protective 
properties, among many others, have all been attributed to them [274-276]. Of particular 
interest to this study, flavonoids have been shown to inhibit glucose transmembrane transport 
and have demonstrated notable preclinical antiproliferative effects [274-277]. The inhibition 
of glucose transport has been reported to be sensitive to pH variation since maximal effect 
has been observed at low pH that causes the dissociation of the molecules [277]. Phloretin 
and Quercetin are representative members of the large family of flavonoids.  
 
Phloretin (Figure 1.8) [2 ,́4 ,́6΄-trihydroxy-3-(4-hydroxyphenyl)-propiophenone], the 
aglucone of phloridzin, is mainly found in plants of the Rosaceae family, including pears and 
apples. This phytochemical is considered a natural nonsteroidal estrogen and has been 
described as a protein kinase C inhibitor [278, 279]. The reversible binding of Phloretin to 
the erythrocyte membrane and the selective inhibition of glucose efflux have been well 
documented [277, 280]. Chalcone Phloretin has been described as the most potent flavonoid 




 [136, 277] 
Phloretin-mediated antitumour effects have been demonstrated in several models both in 
vitro and in vivo. More than two decades ago Nelson et al reported that phloridzin and 
phloretin inhibited the growth of Fisher bladder carcinoma and rat mammary 
adenocarcinoma cells in vivo [281]. In a follow up study the authors attributed the 
antiproliferative effect to inhibition of glucose transmembrane transport [282]. Kobori et al 
documented induction of apoptosis in B16 mouse melanoma 4A5 cells following Phloretin 
treatment. Apoptotic cell death was linked with inhibition of glucose transport as 
extracellular glucose was shown to prevent Phloretin action. The authors suggested that 
glucose transport inhibition is mainly responsible for the antitumour effect of Phloretin 
[278]. In a following study the authors reported that induction of apoptosis in B16 cells was 
mediated by Bax and caspase activation while a different mechanism was found responsible 
for the apoptotic cell death of HL60 human leukemia cells that was associated with protein 
kinase C inhibition [283]. Wu et al demonstrated induction of apoptosis in a human 
hepatocellular carcinoma cell line while cells could be rescued by glucose pretreatment. 
Additionally Phloretin attenuated the growth of HepG2 xenograft bearing mice suppressing 
FdG uptake. GLUT2 upregulation was evidenced in hepatoma cells as well as patient 
samples and the Phloretin effect was correlated with GLUT2 glucose transport inhibition 
[284]. Regarding breast cancer Kim et al presented induction of apoptosis in H-Ras 
transformed MCF10A mammary cells upon Phloretin treatment. Activation of MAPKs 
(Mitogen-Activated Protein Kinases – JNK and p38) and caspase-3 were documented 
followed by upregulation of p53 and Bax as well as Bcl-xl downregulation [279]. The same 
molecular mechanisms underlying Phloretin-mediated apoptotic cell death were verified in a 
very recent study conducted by Min and colleagues. Inhibition of proliferation and migration 
of non-small cell lung carcinoma A549 cells as well as attenuation of tumour growth of 
xenograft models were demonstrated [285]. Gonzalez-Menendez et al compared the effect of 
different flavonoids on androgen sensitive and insensitive prostate cancer cells. With respect 
to Phloretin they reported that it exhibits a potent antiproliferative effect regardless of 
androgen receptor signalling. They observed that Phloretin treatment suppressed glucose 
uptake leading to GLUT1 and GLUT4 upregulation without affecting the localisation of the 
transporters. Furthermore, based on docking simulation studies with a bacterial GLUT 
Figure 1.8: 
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homolog they predicted that Phloretin interacts with a conserved area near the active site 
centre of GLUT1 and GLUT4 blocking glucose binding [286].  
Combinatorial interaction between Phloretin and common chemotherapeutic agents has also 
been evidenced. In a key study Cao et al examined GLUT1 expression in primary colon and 
breast tumours and noticed that GLUT1 was overexpressed especially in hypoxic regions 
with extensive necrosis. Phloretin was shown to reduce glucose uptake to 60% in SW620 
colon cancer cells and proved able to resensitise both hypoxia-induced resistant as well as 
multi-drug resistant colon cancer and leukemia cells to daunorubicin, exclusively under 
hypoxic conditions [287]. Similarly, Yang et al documented that Phloretin enhanced the 
antitumour effect of Paclitaxel on in vitro and in vivo hepatocellular carcinoma models. The 
combination of the agents induced apoptotic cell death mediated by caspases 3,8 and 9 
activation [288].   
 
Quercetin (Figure 1.9) (3,3 ,́4 ,́5,7-pentahydroxyflavone) has been referred to as the most 
frequently consumed flavonoid [275, 289]. It is abundant in the form of glycosides in several 
components of the human diet including caper, chili peppers, cocoa beans, red onions, dill 
and fennel. A wide range of physiological actions have been attributed to this phytochemical 
however the underlying molecular mechanisms are not completely understood yet [289-291]. 
It is worth mentioning that the U.S. National Institutes of Health clinical trials website lists 
45 different Quercetin related trials referring to an impressive range of conditions including 
Alzheimer’s disease, anaemia, asthma, diabetes, hypertension, inflammation and obesity; 
emphasising the fascinating pleiotropic nature of this natural compound. Relative to 
carcinomas 4 studies were found. Isoquercetin (hydrolysed in vivo to Quercetin) as adjunct 
therapy for renal cell carcinoma patients treated with first-line sunitinib (ClinicalTrials.gov 
Identifier: NCT02446795), effect of Quercetin on green tea polyphenol uptake in prostate 
tissue of prostate cancer patients undergoing radical prostatectomy (ClinicalTrials.gov 
Identifier: NCT01912820), cancer associated thrombosis and isoquercetin 
(ClinicalTrials.gov Identifier: NCT02195232) and a pilot study evaluating broccoli sprouts 
in patients with advanced pancreatic ductal adenocarcinoma that receive palliative 
chemotherapy (ClinicalTrials.gov Identifier: NCT01879878). All these trials are currently 




   [136, 277] 
Quercetin is considered a phytoestrogen with antioxidant properties at low concentrations 
while potent oxidative apoptotic action is presented at high concentrations. Potent 
chemopreventive action is attributed to this phytochemical. Multiple intracellular targets 
including heat shock proteins, protein kinases and topoisomerases as well as inhibition of 
certain signalling pathways have been described. Antitumour activity has been demonstrated 
in several types of cancer including breast, colon, lung, bladder and melanoma [289-291, 
293]. Of particular interest to this study competitive binding of Quercetin to GLUT1 has 
been documented [294]. Moreover Quercetin has been shown to inhibit glucose uptake by 
isolated rat adipocytes and direct inhibition of GLUT4 has been suggested [295].  Inhibition 
of glucose uptake by MCF7 as well as MDA-MB-231 breast cancer cells in a concentration 
dependent manner has also been evidenced by Moreira et al [296].    
Selected recent publications regarding breast and ovarian cancer will be discussed here. In 
2013 Deng et al examined the effect of Quercetin on MCF7 breast cancer cells. Quercetin 
treatment attenuated breast cancer cell proliferation, induced apoptosis and G0/G1 phase cell 
cycle arrest. The apoptotic effect was linked with a reduction in mRNA and protein of the 
apoptotic inhibitor survivin [297]. The exact same antiproliferative observations regarding 
apoptotic cell death and G0/G1 cell cycle arrest characterised by survivin suppression were 
also documented for the ovarian cancer cell SKOV3 by Ren et al [298]. In another very 
recent study Ranganathan et al verified the apoptotic effect of Quercetin on MCF7 cells and 
reported selectivity over the triple negative MDA-MB-231 breast cancer cell line. Treatment 
with the flavonoid was shown to reduce the levels of the Twist oncogene and also suppress 
cyclin D1 and phospho-p38MAPK expression [299]. In contrast Tao et al presented similar 
sensitivity from the two breast lines. Caspase-3 dependent apoptotic cell death was linked 
with miR-146a upregulation and was also confirmed in vivo [300]. Seo et al examined the 
effect of Quercetin on the HER2-overexpressing BT-474 breast cancer cell line. Induction of 
caspase dependent apoptosis corroborating previous findings was demonstrated along with 
suppression of the STAT3 signalling pathway [301]. Zhang et al compared the effect of 
Quercetin with that of its sulphated derivative QS (quercetin-50,8-di-sulfonate) on MCF7 
cells. QS proved more potent in attenuating cell proliferation, blocking cell cycle at the S 
Figure 1.9: 
Quercetin 
Linear Formula: C15H10O7 
Molecular Weight: 302.24 




phase and inducing apoptotic cell death in a ROS dependent manner [302]. Very recently 
Liao et al synthesised two novel alkylated derivatives of Quercetin, 7-O-butylquercetin and 
7-O-geranylquercetin. Both agents exhibited greater cytotoxicity to MCF7 cells compared to 
the parental compound. They were associated with induction of caspase-independent 
apoptosis [303]. Zhao et al demonstrated great antitumour activity in vivo using a MCF7 
xenograft nude mouse model. Quercetin treatment attenuated tumour growth, reduced Ki-67 
expression and promoted tumour necrosis without any side-effects being reported. 
Additionally the phytochemical exhibited potent antiangiogenic action compromising 
microvessel density, downregulating VEGF and VEGFR2 and inhibiting calcineurin [304].  
Several studies have demonstrated a synergistic effect between Quercetin and common 
therapeutic modalities. Wang et al reported that Quercetin reversed tamoxifen resistance in 
breast cancer cells. The authors established a tamoxifen resistant cell line and observed that 
Quercetin significantly enhanced the cytotoxic effect of tamoxifen. The combination 
promoted induction of apoptosis and resulted in reduced HER2 and upregulated ERα levels 
[305]. Minaei et al provided evidence that nanoparticle-conjugated Quercetin (to achieve 
enhanced bioavailability) sensitised MCF7 cells to doxorubicin, augmenting apoptosis 
induction [306]. As regards combinations in ovarian cancer models, Maciejczyk et al 
demonstrated that Quercetin sensitised ovarian cancer cells to paclitaxel and cisplatin [307]. 
This finding was verified by Yang et al who showed that Quercetin pre-treatment sensitised 
ovarian cancer cells to cisplatin both in vitro and in vivo and alleviated cisplatin 
nephrotoxicity. Quercetin provoked endoplasmic reticulum stress and suppressed STAT3 
signalling downregulating its target genes including Bcl-2 [308]. Yi et al documented that 
Quercetin enhanced TRAIL-induced (tumor necrosis factor-related apoptosis-inducing 
ligand) cytotoxicity in ovarian cancer cells in vitro (SKOV3, OVCAR3 and TOV21G cell 
lines) as well as in SKOV3 mouse xenografts. Synergistic apoptotic cell death was 
associated with caspase activation, enhanced ROS generation and DR5 (TRAIL binding – 
death receptor 5) upregulation [309]. Twenty years ago a first in class phase I clinical trial 
was published. A patient with cisplatin resistant disease reported a remarkable decline in 
serum CA125 levels following Quercetin intravenous treatment. Similarly α-fetoprotein 
serum concentration was diminished in a hepatoma patient. Quercetin was generally well 
tolerated and was correlated with tyrosine kinase inhibition [310]. An interesting very recent 
case report study revealed that oral Quercetin (up to 2g per day) along with 
cyclophosphamide resulted in complete radiological response with minimal adverse effects 





In 2011 Chan et al performed a high-throughput chemical synthetic lethal screen to discover 
agents that specifically target VHL deficient renal cell carcinomas. STF31 (Figure1.10) [4-
[[[[4-(1,1-Dimethylethyl)phenyl]sulfonyl]amino]methyl]-N-3-pyridinylbenzamide] is a 
pyridyl-anilino-thiazole that belongs to the second class of the 3-series small-molecules 
identified to exhibit selective cytotoxicity in cells that have lost a functional VHL tumour 
suppressor gene. In their characterisation study the authors argued that STF31 impairs the 
glycolytic metabolism of VHL deficient tumours by binding specifically to the GLUT1 
transporter. Based on molecular modelling STF31 was predicted to interact directly with the 
central pore of the transporter and was shown to inhibit glucose uptake and induce necrotic 
cell death selectively in glycolytic cancer cells harbouring a VHL mutation. Interestingly 
elevated GLUT2 expression proved able to prevent the STF31 cytotoxic effect in renal cell 
cancer cells.  In vivo efficacy of the compound was also demonstrated. A soluble STF31 
analogue impaired glucose uptake, as monitored by FDG-PET, and attenuated tumour 
growth of mice with VHL-defective renal cell carcinoma xenografts without any apparent 
toxicity to normal tissue including the brain  [312].          
  [313] 
In a very recent study Matsumoto et al reported the effectiveness of STF31 against myeloma 
cell lines. The authors examined the glucose uptake and the expression of glucose 
transporters in multiple myeloma cell lines and demonstrated a cytotoxic effect specifically 
on cell lines with upregulated GLUT1 expression. STF31 was shown to impair glucose 
uptake of these cell lines and was associated with induction of caspase-8 dependent apoptotic 
cell death. A very interesting finding of this study was that STF31 enhanced the cytotoxic 
effect of first-line anti-myeloma regimens including doxorubicin, bortezomib and melphalan 
[314]. 
However three years after the first identification of the compound, in 2014, Adams et al 
claimed that the main cellular target of STF31 is nicotinamide phosphoribosyl-transferase 
(NAMPT), an enzyme involved in NAD
+ 
regeneration. They performed a large-scale cancer 
cell line sensitivity profiling study and observed that the response pattern to STF31 was 
highly correlated to that of established NAMPT inhibitors. Based on whole genome next-
Figure 1.10: 
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generation sequencing data of clones resistant to a more potent STF31 analogue (referred to 
as compound 146) they attributed the resistance to a recurrent mutation in the NAMPT gene. 
It was also demonstrated that STF31 inhibits the enzymatic activity of recombinant NAMPT 
and cells can be rescued from the cytotoxic effects of the small molecule by co-treatment 
with nicotinic acid, a substrate for NAMPT independent NAD
+
 recycling (providing a 
functional nicotinate phosphoribosyl-transferase isoform 1 NAPRT1, an enzyme involved in 
the NAD
+
 recycling pathway, is expressed) [315]. In agreement with these, a small molecule 
with identical structure was among the compounds characterised as potent direct NAMPT 
inhibitors in a fragment-based identification study conducted by Dragovich and colleagues 
[316]. Along the same line Kropp et al recognised STF31 as a NAMPT inhibitor attributing 
its metabolic effects on NAD
+
 depletion. This study demonstrated that the compound was 
effective in eliminating the undifferentiated human pluripotent stem cells under several 
culture conditions with minimal toxicity to differentiated cells [317].     
 
1.5.1.3 WZB117 
In 2010 Liu et al reported the identification of a group of novel synthetic small molecules 
inhibiting basal glucose transport. Among these compounds WZB27 and WZB115 were 
presented as potent growth inhibitors of breast and lung cancer cell lines while exhibiting 
minimal toxicity on normal cells. Induction of caspase-3 dependent and p53 independent 
apoptotic cell death as well as a synergistic interaction with cisplatin and paclitaxel were also 
demonstrated [318]. In a follow-up study, two years later, the representative structural 
analogue WZB117 (Figure 1.11) [3-Fluoro-1,2-phenylene-bis(3-hydroxybenzoate)] was 
characterised as a novel selective GLUT1 inhibitor. The compound exhibited potent 
antiproliferative activity in lung and breast cancer cell line models and proved more effective 
under hypoxic conditions. Remarkable antitumour efficacy was also demonstrated in vivo in 
A549 lung tumour bearing nude mice with limited side-effects. Glucose transport inhibition 
in human red blood cells that are exclusively dependent on GLUT1 indicated that WZB117 
is a specific GLUT1 inhibitor. Ligand docking studies revealed that inhibitor-transporter 
binding comprises 3 hydrogen bonds in the central channel of GLUT1. WZB117 treatment 
suppressed glucose uptake and lactate production and decreased intracellular ATP levels 
leading to AMPK phosphorylation. The mechanism of action of the effective GLUT1 
inhibitor was also examined; G1 cell cycle arrest along with senescence were observed and 




  [320] 
In 2014 Liu et al investigated 5-fluorouracil (5-FU) resistance in colon cancer. They 
generated a 5-FU resistant colon cancer cell line and observed that resistance was associated 
with increased GLUT1 expression and elevated glucose uptake. WZB117 was used to 
overcome 5-FU resistance in colon cancer cells and a synergistic interaction between the two 
agents was demonstrated [321]. Along the same lines Zhao et al very recently reported a link 
between glycolysis and radiation therapy resistance (radioresistance) in breast cancer. 
GLUT1 upregulation accompanied with a stimulated glycolytic metabolism were 
documented in radioresistant breast cancer cells as well as radioresistant patient tumour 
samples. Interestingly GLUT1 overexpression reduced sensitivity to radiation therapy while 
GLUT1 knockdown conferred the opposite effect. A synergistic inhibitory interaction was 
presented between WZB117 and radiation and furthermore the GLUT1 inhibitor proved able 
to resensitise radioresistant breast cancer cells to treatment. The synergism was attributed to 
the decreased GLUT1 levels (both mRNA and protein) and the suppression of glucose 
metabolism following WZB117 treatment [322]. Another study by Shibuya et al examined 
the role of GLUT1 in the self-renewal capacity of cancer stem cells. They documented that 
WZB117 treatment attenuated the self-renewal and tumour initiating ability of highly 
glycolytic cancer stem cells in both in vitro and in vivo models [323]. 
       
1.5.1.4 IOM-1190 
In 2014 IOmet Pharma patented the identification of a series of novel best-in-class specific 
GLUT1 inhibitors [324]. One of the lead molecules, IOM-1190 (Figure 1.12), was provided 
for this study to complement the array of glycolytic inhibitors used. Official characterisation 
of the compound has not been published yet; however Dr Alan Wise presented initial 
information in the 26th EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer 
Therapeutics’ in November 2014.  
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The compound, possessing an imidazo[1,2-a]pyrazine core, was identified through a small 
molecule diversity study and was presented as a potent (low nM potency) and selective 
GLUT1 inhibitor. Suppression of 2-DG uptake and lactate production were demonstrated in 
A549 lung cancer cells along with evidence of induction of rapid apoptotic cell death. 
Competitive action against 2-DG for GLUT1 binding was reported and high affinity GLUT1 
binding of radiolabelled compound was documented. Furthermore, a synergistic interaction 
was demonstrated between an optimised analogue and metformin in lung, melanoma and 
glioma cancer cell lines promoting ATP depletion and cell death.    
 
1.5.2 Targeting Hexokinase 
3-bromopyruvate (3BP) (Figure 1.13) (3-Bromo-2-oxopropionic acid) is a small molecule 
and a synthetic analogue of pyruvate and lactate that directly inhibits mitochondrial bound 
HKII. It has consistently demonstrated potent anticancer activity in both in vitro and in vivo 
model systems [325, 326]. 3BP is a strong alkylating agent that exerts its antitumour activity 
mainly through inhibition of glycolysis and cellular ATP depletion [325, 326]. Furthermore 
it has been shown that 3BP through a covalent modification of cysteine residues of HKII 
causes dissociation of the enzyme from the mitochondrial membrane and promotes the 
release of apoptosis inducing factor into the cytoplasm [327]. It has also been suggested that 
through HKII inhibition, low 3BP concentrations cause shortage of biosynthetic precursors 
hindering anabolic reactions [326, 328]. Potent inhibitory action has been described in 
various cancer cell line models including pancreatic, hepatocellular, melanoma, glioblastoma 
and mammary [325].  
   [136]                        
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Majkowska-Skrobek et al demonstrated a cytotoxic inhibitory effect in a human myeloma 
cell line induced by intracellular ATP depletion. The authors described increased tumour 
specificity of 3BP action compared to normal peripheral blood cells which correlated with 
increased uptake due to MCT1 overexpression  [329]. Along the same line Queiros et al in 
their study presented induction of apoptosis in breast cancer cell lines following 3BP 
treatment. Interestingly, they observed that pre-treatment with the carboxylic acid butyrate 
enhanced 3BP cytotoxicity particularly in the most resistant ER-negative cell line. The 
authors attributed the butyrate effect to MCT4 upregulation and increased membrane 
localisation of MCT1 [330]. Xu et al documented that leukaemia and colon cancer cells with 
impaired mitochondrial function due to hypoxic conditions or mitochondrial defects, as well 
as cells with a multidrug resistant phenotype, were found to be particularly sensitive to 3BP. 
3BP induced ATP-depletion related apoptotic cell death associated with Bad 
dephosphorylation, and Bax translocation to the mitochondria and enhanced the cytotoxic 
effect of doxorubicin, vincristine and cytarabine. 3BP treatment was proposed as a promising 
strategy to overcome multidrug resistance [331]. In their study Icard et al reported that 3BP 
treatment induced cell death even in platinum-resistant mesothelioma cells as well as 
improved the survival of nude mice bearing mesothelioma tumours [332]. Recently Zou et al 
showed induction of apoptosis in nasopharyngeal carcinoma cell lines following 3BP 
treatment [333]. Another study by Wintzell et al provided evidence that a multi-resistant 
ovarian cancer cell population resembling cancer stem cells, developed from the SKOV3 cell 
line through repeated treatment with increasing concentrations of cisplatin, was sensitive to 
3BP [334].  
The first in vivo system in which the anti-tumour effect of 3BP was examined in was the 
VX2 tumour implanted into a rabbit liver. In 2001 Ko et al described the VX2 tumour as 
highly glycolytic and sensitive to 3BP treatment delivered via the hepatic artery, with no 
marked side-effects reported [335]. In a following study, three years later the same author 
using a hepatocellular carcinoma model in the rat, demonstrated that 3BP eradicated the 
tumours that had developed in all 19 animals studied, exhibiting 100% efficacy; while no 
toxicity or recurrence were observed [336]. Another study conducted by Buijs et al reported 
that 3BP treatment selectively reduced FDG uptake in breast tumours in a rat model 
suggesting that 3BP did not affect the glucose metabolism of healthy tissues [337]. Three 
years ago Ko et al published a case study of the first human patient treated with a specially 
formulated 3BP. It was a young Caucasian male suffering from advanced stage fibrolamellar 
hepatocellular carcinoma. 3BP treatment was not associated with any major toxicities and 




second case was reported by El Sayed et al. A male patient with metastatic stage IV 
melanoma received 3BP intravenous infusions. The authors described minimal adverse 
effects; nevertheless the antitumour activity was modest. This was attributed to the elevated 
tumour glutathione level and co-administration of a glutathione depletor was suggested  
[339].   
3BP as a potent alkylating agent inhibits other metabolic enzymes as well [326, 328]. 
Among 3BP targets another glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as well as the mitochondrial succinate dehydrogenase have been described [326, 
328, 340, 341]. In a recent study Kwiatkowska et al showed that 3BP inhibits several 
enzymes in glutathione metabolism and causes an imbalance in the cellular redox state 
increasing ROS production. They illustrated increased sensitivity of MDA-MB-231 breast 
cancer cells through induction of oxidative stress compared to the non-invasive MCF7 cell 
line [342].  Overall, it has been claimed that because of targeting key metabolic enzymes 
impairing both the glycolytic pathway and mitochondrial respiration, and taking into 
consideration the demonstrations of tumour specificity and low toxicity profile, 3BP could 
play a leading role in cancer treatment in the near future [102, 328]. Because of its structural 
similarity to lactate, 3BP is taken up specifically by tumour cells through MCTs and exerts 
potent antitumour activity [102].      
1.5.3 Targeting PFKFB3 
In 2008 Clem et al identified a competitive inhibitor of PFKFB3 using computational 
modelling and virtual database in silico screening. 3PO (Figure 1.14) [3-(3-Pyridinyl)-1-(4-
pyridinyl)-2-propen-1-one] is a novel small molecule, dipyridinyl-propenone based 
compound. In their characterisation study, the authors demonstrated that 3PO reduced 
intracellular F2,6BP levels, glucose uptake and lactate production followed by an induction 
of G2-M phase cell cycle arrest in Jurkat T cell leukemia cells. Selective sensitivity of ras-
transformed bronchial epithelial cells along with a cytostatic effect in several tumour cell 
line models, including MDA-MB-231 breast cancer cells, was demonstrated. PFKFB3 
overexpression was shown to induce resistance to 3PO while the enzyme’s deletion 
enhanced the sensitivity of Jurkat cells, suggesting that PFKFB3 is critical for the observed 
tumour growth inhibition. Finally, 3PO treatment suppressed tumour growth in vivo in mice 
bearing leukaemia, lung and breast adenocarcinoma xenografts with no adverse effects 
documented. The authors mentioned that even though 3PO was identified as a specific 
PFKFB3 inhibitor; due to the high homology between the different PFKFB isozymes 




reported that the metabolic stress induced by PFKFB3 inhibition activates autophagy as a 
protective pro-survival mechanism in response to glucose starvation. 3PO treatment of HCT-
116 colon adenocarcinoma cells increased ROS production and induced autophagy, as 
demonstrated by increased levels of the autophagy marker LC3-II, reduced p62 levels and 
detection of autophagosomal structures. It was shown that co-treatment with autophagy 
inhibitors can enhance 3PO antitumour efficacy both in vivo and in vitro  [344]. 
 [320, 343] 
Several very recent studies have revealed supplementary effects of 3PO treatment other than 
glycolysis inhibition. Trefely et al performed a global human genome kinase screening 
combined with siRNA knockdown and among others they identified PFKFB3 as a kinase 
involved in the insulin growth factor (IGF) signalling pathway. Indeed they showed that 3PO 
treatment of 3T3-L1 adipocytes impaired insulin-dependent GLUT-4 membrane localisation 
and Akt kinase activity as demonstrated through decreased phosphorylation of downstream 
substrates [345]. An antiangiogenic effect of 3PO was revealed in another recent study by 
Schoors et al. The authors reported that the PFKFB3 inhibitor impaired vessel sprouting in 
both in vivo and in vitro models. Even though 3PO treatment had only a partial and 
temporary effect on glycolysis decrement, it attenuated pathological angiogenesis and 
enhanced the antivascular activity of VEGFR inhibitors in ocular and inflammatory mouse 
models [346]. Furthermore Telang et al suggested 3PO as a T cell immunosuppressive agent. 
3PO treatment was shown to suppress glycolytic metabolism and activation of T cells and 
also impaired T cell dependent immunity of in vivo mouse models [347].  
In 2011 Seo et al published the structure based development of another novel small molecule 
competitive PFKFB3 inhibitor named N4A and its potent derivative YNI. The authors 
reported reduced F2,6BP levels, glycolysis inhibition and cell death in HeLa cells validating 
PFKFB3 inhibition as a promising strategy for cancer treatment [348].  
Two years later, in 2013, Clem et al published the identification of an optimised derivative 
of 3PO, 100 times more active against enzymatic PFKFB3. PFK15 [1-(4-pyridinyl)-3-(2-
quinolinyl)-2-propen-1-one] has a quinolinyl ring substituted for a pyridinyl ring. The 
second generation compound presented markedly enhanced potency and pharmacokinetic 
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properties and induced apoptosis in tumour cells both in vitro and in vivo. PFK15 suppressed 
glucose uptake and attenuated tumour growth in several tumour xenograft models [349]. A 
related compound termed PFK158 is currently undergoing a phase I safety clinical trial in 
patients with advanced solid malignancies (ClinicalTrials.gov Identifier: NCT02044861) 
[350]. The study was initiated in January 2014 and initial results are expected soon [102, 
350, 351].  
 
1.5.4 Targeting Pyruvate Dehydrogenase Kinase 
Dichloroacetate (DCA) is a pyruvate analogue (Figure 1.15), a small molecule that inhibits 
PDHK. PDHK inhibition restrains PDH phosphorylation and subsequent PDC activation. 
Hence pyruvate metabolism is redirected from glycolysis and lactate production to oxidative 
phosphorylation. DCA is a generic drug with great oral bioavailability that was described 
almost fifty years ago in 1969. DCA has been used clinically for decades to alleviate the 
symptoms of lactic acidosis and ketoacidosis of several inherited mitochondrial diseases 
[352, 353]. Nonetheless DCA has been associated with nerve toxicity and because of its 
potency in high millimolar concentrations off-target effects cannot be excluded. A 
randomised placebo-controlled trial in 30 patients suffering from MELAS (mitochondrial 
myopathy, encephalopathy, lactic acidosis and stroke-like episodes) syndrome was 
discontinued because of peripheral neuropathy [354]. However another randomised double-
blinded trial in 21 children with congenital lactic acidosis reported that DCA was well 
tolerated [355]. Actually it has been shown that DCA plasma clearance and consequently 
toxicity are inversely associated with age as well as haplotype genetic variability in the 
glutathione transferase zeta 1 gene (GSTZ1). GSTZ1 catalyses DCA biotransformation and 
dehalogenates it to glyoxylate [353, 356].  
  [136]                        
Antitumour activity of DCA has been extensively demonstrated in a wide spectrum of cancer 
types in vitro (including pancreatic, prostate, colon, lung, leukaemia, neuroblastoma, 
endometrial) as well as several in vivo tumour models [255, 352, 353]. Of particular interest 
to this study Saed et al provided evidence that DCA induced apoptosis via oxidative stress in 
Figure 1.15: 
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epithelial ovarian cancer cell lines. It was shown that DCA reduced the expression of key 
redox regulator enzymes (myeloperoxidase and inducible nitric oxide synthase) as well as 
HIF-1α, upregulated superoxide dismutase and subsequently increased caspase 3 activity 
[357]. Regarding breast cancer, Sun et al demonstrated that DCA treatment attenuated 
proliferation in a panel of breast cancer cell lines; sensitivity ranged from 20 to 80% after a 4 
day treatment, without affecting the growth of a control non-cancerous line (MCF-10A). 
Even though an increase in caspase 3/7 activity was observed, induction of apoptosis was not 
detected, differing from several studies showing apoptotic cell death in various cancer types. 
Furthermore an antitumour effect was presented in vivo in a highly metastatic breast 
adenocarcinoma rat model [358]. In a follow up study the authors demonstrated that DCA 
upregulated the ATP synthase β subunit leading to increased ATP and ROS production and 
inhibited HIF-1α in breast cancer cells. Moreover DCA was shown to enhance the cytotoxic 
effect of arsenic trioxide, an anti-mitochondrial agent used for the treatment of acute 
promyeloid leukaemia, and this combination profoundly suppressed c-Myc and HIF-1α 
expression [359]. Similarly DCA was found unable to induce apoptosis in a panel of breast 
cancer cell lines by Gang et al; however DCA treatment reinforced the apoptotic effect of 
PENAO [4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid] another mitochondrial 
inhibitor targeting the adenine nucleotide translocase, by an oxidative stress-related 
mechanism due to enhanced ROS generation [360].   
In a key study conducted by Bonnet and co-workers it was shown that DCA reverses the 
function of mitochondria in tumours and induces apoptosis selectively in cancer cells. DCA 
stimulates glucose oxidation, decreases the membrane potential of hyperpolarised 
mitochondria and promotes mitochondria-induced apoptosis through the release of pro-
apoptotic signals, ROS production and activation of K
+
 channels [361]. Sutendra et al 
revealed an antiangiogenic role of DCA. They demonstrated that PDHK inhibition elevated 
H2O2 levels and induced p53 activation and nuclear localisation resulting in decreased HIF-
1α transcriptional activity. HIF-1α inhibition reduced the expression of HIF-1α target genes 
and suppressed angiogenesis in cancer cells both in vitro and in vivo [362]. Although the 
DCA antitumour effect is generally associated with ROS mediated mitochondrial apoptosis 
some recent indications of autophagy have been reported. In 2014 Lin et al documented 
increased expression of the autophagy marker LC3B II, cell cycle arrest and induction of 
autophagy following DCA treatment of colorectal and prostate cancer cell lines and in vivo 
HT29 colorectal tumour xenografts. Autophagy was associated with mTOR inhibition and 




was also observed and the authors suggested that DCA may also act as a potential 
competitive MCT1 inhibitor [363].       
Aiming to enhance the potency and specificity of PDK inhibition, several attempts to 
develop a DCA structural analogue have been described [353]. Among them mitaplatin 
[c,t,c-[Pt(NH3)2(O2CHCl2)2Cl2]] has gained a lot of interest. It is a fusion compound that 
upon reduction from the negative intracellular redox potential releases cisplatin and two 
DCA units. A dual killing mechanism is accomplished through cisplatin-mediated DNA 
crosslinks as well as DCA mitochondrial targeting. Mitaplatin reduces mitochondrial 
membrane potential and induces apoptosis and nuclear degradation specifically in cancer 
cells [364].  
Early phase trials using DCA in cancer patients have been reported. The first-in-human DCA 
study was conducted in 2010 by Michelakis and colleagues in five patients with glioblastoma 
multiforme. Peripheral neuropathy was the only clinically significant toxicity noted; 
nevertheless it was reversible and mitigated with a lower, yet clinically relevant dosage. 
Three of the patients (one with recurrent disease and the other two with newly diagnosed 
tumours receiving DCA in combination with chemotherapy and radiotherapy) presented 
radiologic regression and four patients in total were stable upon completion of a 15 month 
DCA treatment and alive 3 months afterwards. Additionally, the authors treated ex vivo, 49 
tissue specimens collected from patients with glioblastoma, and reported that DCA treatment 
normalised mitochondrial hyperpolarisation, induced ROS production and p53 activation 
leading to apoptosis and suppressed HIF-1α and tumour angiogenesis [365]. Dunbar et al 
conducted a phase I trial in 15 patients with advanced recurrent gliomas or brain metastasis 
from primary tumours outside the central nervous system. Dosing was effectively adjusted 
according to GSTZ1 genotype and no clinically significant adverse effects were observed. 
Eight patients received DCA treatment for at least 1 four-week cycle and they were reported 
as clinically stable  [356]. Another open-label phase II study in patients with advanced stage 
non-small cell lung cancer and metastatic breast cancer was designed by Garon et al and was 
terminated prematurely in 2014 due to limited participation and lack of clinical benefit [366]. 
Finally Strum et al published a noteworthy case report of a 46 year old male individual with 
relapsed non-Hodgkin’s lymphoma after standard chemotherapy. The authors documented 
complete remission over 4 years following DCA monotherapy without any toxicity [367]. A 
considerable amount of evidence suggests that DCA warrants further investigation and may 




1.5.5 Targeting Lactate Dehydrogenase 
1.5.5.1 Oxamic acid 
Oxamic acid (Figure 1.16) is an established pyruvate analogue (a structural isostere of 
pyruvic acid) described as a well characterised substrate-like competitive inhibitor of LDH. 
It is a non-selective inhibitor demonstrating an inhibitory effect on both LDHA and LDHB 
isoforms. Additionally inhibition of the Plasmodium LDH isoform has been reported and 
Oxamic acid has gained a lot of interest as a potential antimalarial agent [368]. Several N-
substituted derivatives have been synthesised [368].   
 [136, 369] 
Promising antiproliferative effect of Oxamic acid has been extensively reported mainly in 
vitro using various types of cancer cell line models. Fiume et al demonstrated that Oxamic 
acid supressed lactic acid production and attenuated the proliferation of two hepatocellular 
carcinoma cell lines. Treatment with the LDH inhibitor was associated with elevated PUMA 
levels indicating increased cell death [370]. In a follow-up study the authors confirmed the 
Oxamic acid-mediated glycolysis inhibition through reduced lactate production in a 
hepatocellular carcinoma cell line. Additionally they demonstrated that Oxamic acid 
enhanced the antiproliferative effect of kinase inhibitors. This was attributed to reduced ATP 
levels following LDH inhibition, competing with the kinase inhibitors for binding to the 
same site of oncogenic protein kinases [371]. A key study by Zhao et al demonstrated that 
Oxamic acid attenuated tumour growth of several HER2-positive and trastuzumab-resistant 
breast cancer cell lines as well as xenograft nude mice models of trastuzumab sensitive and 
resistant breast cancer. Interestingly Oxamic acid enhanced the antitumour effect of 
trastuzumab and helped overcome trastuzumab resistance in both in vitro and in vivo breast 
cancer models [372]. Similarly, Zhou et al published a synergistic interaction between 
Oxamic acid and taxol in breast cancer cell lines. Oxamic acid was found to be effective in 
inhibiting proliferation of MDA-MB-435 breast cancer cells as well as a taxol resistant 
derivative line, which exhibited even greater sensitivity to the combination of taxol with 
Oxamic acid. The LDH inhibitor was able to resensitise taxol resistant breast cancer cells to 
taxol, triggering apoptotic cell death [373]. Another recent study conducted by Miskimins 
and collaborators demonstrated a very modest antitumour effect of Oxamic acid against a 
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tonsil cancer cell line (E6E7Ras) and a CT26 colon cancer mouse model. Nonetheless, a 
synergistic effect was revealed between the LDH inhibitor and phenformin, a biguanide, 
shown to be a more potent inhibitor of mitochondrial respiratory chain complex I than 
metformin. The combination proved effective in various cancer cell lines as well as in vivo in 
immune competent syngeneic mice. Reduced lactate production, increased ROS generation, 
ATP depletion and induction of apoptotic and PARP-dependent cell death were reported 
[374].       
Regarding the mechanism of action of Oxamic acid, Zhai et al reported that treatment with 
the LDH inhibitor induced mitochondrial oxidative stress-mediated apoptosis in 
nasopharyngeal carcinoma cells. Cell cycle arrest at G2/M phase was demonstrated and 
correlated with downregulation of the CDK1/ cyclin B1 kinase complex. Additionally, 
Oxamic acid was shown to suppress tumour growth in nasopharyngeal cancer cell lines and 
enhance the antitumour effect of ionising radiation in both in vitro and in vivo 
nasopharyngeal tumour models. The radio-sensitising effect of the LDH inhibitor was 
associated with increased ROS generation augmenting the DNA damage [375]. In 2014 
Yang et al published that non-small cell lung cancer cells presented a differential response to 
Oxamic acid treatment. They reported that Oxamic acid induced apoptosis in H1395 cells 
along with G2/M cell cycle arrest. However, a protective autophagic response was recorded 
for the more resistant A549 cell line coupled with G0/G1 quiescence. Autophagy was 
associated with activation of glycogen synthase kinase-3β and subsequent inhibition of the 
Akt/mTOR signalling pathway, a known negative regulator of autophagy. It was suggested 
that autophagy inhibition could be a promising strategy to overcome LDH inhibition 
resistance. Another noteworthy observation of this study was that HBE normal lung 
epithelial cells were found considerably less sensitive to Oxamic acid treatment [376]. In the 
same vein a very recent study conducted by Zhao and colleagues confirmed induction of 
protective autophagy following Oxamic acid treatment in gastric cancer cells. It was 
demonstrated that Oxamic acid attenuated proliferation of gastric cancer cell lines and 
promoted autophagy which was correlated with elevated ROS production and inhibition of 
the Akt/mTOR signalling pathway. Interestingly, autophagy inhibition by chloroquine was 
shown to enhance the antiproliferative effect of Oxamic acid as well as apoptotic cell death 
[377].      
Oxamic acid is a rather non-specific LDH inhibitor as inhibition of aspartate 
aminotransferase (AAT), an enzyme involved in the malate-aspartate NADH shuttle, has 




compound inhibits both LDHA and AAT recombinant enzymes. It was shown that Oxamic 
acid only modestly affected glucose uptake and lactate production of breast cancer cells 
while inhibition of the TCA mitochondrial cycle and reduced O2 consumption were reported. 
However, evidence was provided that Oxamic acid treatment selectively inhibited the 
proliferation of MDA-MB-231 breast cancer cells compared with normal mammary 
epithelial cells and also suppressed the growth of established breast tumour xenografts in 
athymic mice [369]. Besides multiple confirmed metabolic targets the compound is also 
characterised by low potency as high concentrations in the millimolar range are demanded to 
exert antitumour activity and membrane permeability is limited due to its polar nature. 
Unfortunately such high concentration levels have proved challenging for in vivo 
experiments [368, 371].     
1.5.5.2 NHI-1 
In 2011 Granchi et al published the identification of a series of N-hydroxy-2-carboxy-
substituted indoles synthesised specifically as LDHA inhibitors. NHI-1 (Figure 1.17) [1-
Hydroxy-6-phenyl-4-(trifluoromethyl)-1Hindol-2-carboxylic acid] is the most promising of 
these N-hydroxyindole-based (NHI) inhibitors, also referred as compound 1j, competitive for 
both the substrate-pyruvate as well as the cofactor-NADH. In their characterisation study the 
authors showed that NHI-1 reduced lactate production of HeLa cells and attenuated tumour 
growth, inducing apoptotic cell death, of various cancer cell lines including ovarian, 
mesothelioma and pancreatic. Specificity for the LDHA isoform over LDHB as well as 
enhanced efficacy under hypoxic conditions has also been demonstrated [378].  
  [368, 378] 
In a follow-up study the authors confirmed the antiproliferative activity of NHI compounds 
in two pancreatic carcinoma cell lines particularly under hypoxic conditions. Several 
analogues modifying the aryl-substituents of the standard NHI scaffold were synthesised and 
characterised as potent and selective LDHA inhibitors [379]. Two years later, in 2013, the 
authors performed a comparative study between NHI compounds and novel malonic 
derivatised LDHA inhibitors synthesised by AstraZeneca UK. In this analysis the methyl 
ester NHI-2 [methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indole-2-carboxylate] was 
identified as a very potent LDHA inhibitor exhibiting great antiproliferative activity and 
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enhanced cell-membrane permeability [380]. Many derivatives of the original NHI scaffold 
have been synthesised in subsequent studies [368]. In 2014 Maftouh et al described a 
synergistic interaction between NHI-1 (as well as NHI-2) and gemcitabine; a 
chemotherapeutic nucleoside analogue, in pancreatic ductal adenocarcinoma. The LDHA 
inhibitor was particularly effective in attenuating proliferation of the pancreatic cancer cell 
lines PANC-1 and LPC006 in low O2 conditions, inducing apoptosis and inhibiting growth 
and invasion of 3D spheroid culture models. It was also shown that NHI-1 treatment resulted 
in reduced expression of metalloproteinases as well as cancer-stem-like cell markers. The 
synergism with gemcitabine was evidenced by impaired cellular proliferation and migration, 
induction of apoptosis and S phase cell cycle arrest; and was attributed to elevated levels of 
phosphorylated active gemcitabine metabolites (deoxy-nucleotides) [381].     
1.6 Combinatorial Therapeutic Approaches 
Inhibition of the glycolytic pathway is recognised as a promising therapeutic strategy 
especially for tumours with impaired mitochondrial function. Tumours harbouring 
mitochondrial defects or hypoxic ones are expected to be preferentially sensitive to 
glycolysis inhibition. It should be mentioned that these conditions are associated with 
increased resistance to common therapies [100, 103, 104, 331]. However even though it is 
widely accepted that many tumours are more reliant on the glycolytic pathway it is 
undeniable that ATP generation through oxidative phosphorylation, to a certain extent, also 
occurs [100, 103, 104].  
Combinatorial treatments of glycolytic inhibitors with traditional therapeutics are considered 
the best way to achieve optimal therapeutic efficacy and complete ATP depletion. Indeed 
combination regimes have always attracted considerable attention and are a major area of 
growing interest. Several successful combinations have recently been identified and 
glycolytic inhibitors have proved able to resensitise resistant cells to conventional regimens 
[100, 103, 104, 382, 383]. Other than enhanced antitumour effect and an optimal therapeutic 
index an additional benefit of combinational strategies is reduced adverse effects since the 
doses used for both agents are considerably lower than monotherapy.    
Some combinatorial studies involving inhibitors of particular interest were mentioned earlier. 
Even though exploiting glycolysis inhibition to enhance the effect of traditional agents has 
recently emerged as a powerful strategy, so far only a few studies have been conclusive and 
such combinations have not progressed into clinical practice to date. The main purpose of 
this part of the research was to investigate novel combinations of glycolytic inhibitors with 




1.6.1 Cytotoxic drugs – Cisplatin & Paclitaxel 
Cisplatin is a platinum based chemotherapeutic agent widely used for the treatment of 
several tumours among them bladder, testicular, brain as well as lung cancers. Its main 
mechanism of action involves DNA cross-links, preferentially binding to purine bases on the 
DNA, causing DNA damage. In this way cell division is inhibited, DNA repair mechanisms 
are activated and eventually apoptotic cell death is induced. Cisplatin is associated with 
severe side effects including nephrotoxicity, neurotoxicity, cardiotoxicity and 
myelosuppression. Cisplatin-refractory disease frequently develops and hence combinatorial 
treatments with other antitumour agents are currently under investigation, aiming to alleviate 
adverse effects and overcome resistance  [384, 385]. As previously mentioned cisplatin or its 
analogue carboplatin along with paclitaxel is the first line treatment for ovarian cancer [39].  
Paclitaxel belongs to the taxane family; it is a natural compound derived from the pacific 
yew tree Taxus brevifolia. It exhibits potent antitumour activity and is extensively used for 
the treatment of breast, ovarian, pancreatic and lung tumours as well as Kaposi’s sarcoma. It 
is an important agent of chemotherapeutic regimens in combination with other drugs. 
Paclitaxel is a mitotic agent that binds specifically to polymerised tubulin. It stabilises 
microtubule formation, inhibiting depolymerisation and cell division and leads to cell cycle 
arrest and cell death. Paclitaxel is associated with the common side effects of cytotoxic 
agents such as hair loss, sickness, diarrhoea and limb numbness [386-388].  
1.6.2 Targeted agent – Trastuzumab 
Trastuzumab is a humanised monoclonal antibody that binds to the extracellular domain of 
the HER2 receptor inhibiting the activation of downstream signalling pathways. It is used for 
the treatment of HER2 positive breast cancer tumours (as described in section 1.1.2.5) [32]. 
1.6.3 Metabolic targeted agent – Metformin 
Metformin is a biguanide used for first-line treatment of type 2 diabetes mellitus. It is the 
most widely prescribed antidiabetic medication based on its established anti-hyperglycaemic 
efficacy (reducing hepatic gluconeogenesis) coupled with low toxicity profile and low cost. 
Metformin reduces insulin resistance and blood glucose levels through inhibition of 
mitochondrial respiratory chain complex 1 leading to reduced ATP production and 
subsequent AMPK activation [389, 390].   
A considerable amount of epidemiologic meta-analysis studies have associated metformin 
with a decreased incidence of several malignancies as well as with improved clinical 




recent years, a large and growing body of literature has revealed potent antitumour activity. 
Antiproliferative action has been extensively demonstrated in preclinical studies in several 
types of cancer. Furthermore great attention has been focused in combinatorial studies with 
other antitumour agents. Evidence has been provided that metformin enhanced the cytotoxic 
effect of several agents including cisplatin, paclitaxel and doxorubicin [389, 391]. A number 
of clinical trials have recently been conducted or are currently underway investigating the 
effect of metformin on various cancer types as monotherapy or combined with 
chemotherapeutic drugs [389-392]. The antitumour effect of metformin is mainly attributed 
to AMPK activation and mTOR inhibition along with activation of T cell tumour immune 
response [389-392].         
1.7 Aims & Objectives 
The ultimate aim of this project was to explore the role of aerobic glycolysis in two major 
female malignancies, breast and ovarian cancer. Furthermore this study set out to identify a 
translatable glycolytic target as well as a legitimate combinatorial strategy for the 
development of novel metabolic cancer drug therapies. 
An overview of the aims and objectives of each results chapter of this thesis is presented 
below in Table 1.1. 
Thesis 
Chapters  
Overview of Aims & Objectives 
Chapter 3  
Assess the growth dependency of breast and ovarian cancer cell line models on 
glucose and glutamine availability. 
Examine the growth inhibitory effect of several compounds reported to inhibit key 
enzymes of the glycolytic pathway against panels of breast and ovarian cancer cell 
lines. 
Chapter 4  
Investigate the mechanism of action of these agents using Annexin V and cell cycle 
flow cytometric analysis. 
Examine the effect of each compound on glucose uptake and lactate production. 
Evaluate two major glycolytic targets, GLUT1 and LDHA, using siRNA knockdown. 
Chapter 5 
Examine the efficacy of novel combinatorial strategies among glycolytic inhibitors and 
established cytotoxic and targeted therapies. 
Chapter 6 
Investigate the effect of the oxygen level on sensitivity to glycolysis inhibition. 
Investigate the effect of the oxygen level on the expression of the glycolytic enzymes 
at both the mRNA and protein level. 
Chapter 7   
Examine the expression of four selected glycolytic targets (GLUT1, HKII, PKM2 and 
LDHA) on a clinical tissue microarray set of ovarian cancers using quantitative 
immunofluorescence technology. 
Correlate the expression of the targets with the histological subtype, the stage of the 
disease and the survival outcome. 
 




To date there hasn’t been a detailed comparative study of multiple metabolic inhibitors in 
these tumour types. To address this, a panel of breast and ovarian cancer cell lines were 
cultured under varying concentrations of glucose and glutamine with the aim of developing 
an understanding of the growth dependency of these cancer models on availability of these 
two major nutrients. Ten commercially available pharmacological tool compounds reported 
to inhibit five main components of the glycolytic pathway (GLUT1, HKII, PFKFB3, PDH1 
and LDHA) were selected. These included both established inhibitors (Phloretin, Quercetin, 
3BP, DCA and Oxamic acid) as well as novel agents (STF31, WZB117, IOM-1190, 3PO 
and NHI-1) (Figure 1.7). The array of glycolytic inhibitors were compared against a panel of 
four breast and four ovarian cancer cell line models as well as a panel of two pairs of 
chemosensitive and chemoresistant ovarian cancer cell lines using a cell proliferation assay. 
The differential effects of the compounds as growth inhibitors on these cell lines were 
investigated. Comparisons were made between the sensitivity of the two cancer types and a 
hypothesised association between chemoresistance and resistance to glycolysis inhibition 
was examined. Correlations between the sensitivity of the cell lines to different inhibitors as 
well as with the expression of the glycolytic targets and cellular growth rate were explored. 
A glutaminase inhibitor (BPTES) was employed to examine sensitivity to the glutaminolytic 
pathway and give a comprehensive view of the metabolic phenotype of breast and ovarian 
cancer. (Chapter 3)    
Secondly, the mechanism of action of the agents targeted against multiple points of the 
pathway was assessed using Annexin V and cell cycle flow cytometric analysis. Additionally 
in vitro cell-based biochemical glucose uptake and lactate assays were developed to assess 
the effect of each compound on the glycolytic pathway. Two major targets of interest at the 
very top and bottom of the glycolytic pathway, GLUT1 and LDHA, were selected for further 
evaluation using siRNA knockdown. (Chapter 4) 
Thirdly, the main aim of this study was to explore interactions between glycolytic inhibitors 
and established cytotoxic and targeted therapies. Based on previously published data it was 
hypothesised that glycolytic inhibitors may sensitise cancer cells to established therapies. 
Novel combinations between cisplatin, paclitaxel or trastuzumab with inhibitors of the 
glycolytic pathway were investigated and evaluated quantitatively by their combination 
index values. The antidiabetic drug metformin, an inhibitor of mitochondrial oxidative 
phosphorylation was employed for a combinatorial strategy aiming for complete ATP 
depletion and subsequent induction of cell death. The mechanism of action as regards 




examined using flow cytometry. The purpose of this work was to identify successful 
synergistic combinations of glycolytic inhibitors and traditional agents and propose them for 
further in vivo assessment. (Chapter 5) 
Fourthly, this study sought to explore the effect of the oxygen level on the expression of the 
glycolytic enzymes and sensitivity to their inhibition. The effect of the array of glycolytic 
inhibitors was investigated across a range of oxygenation levels (21%, 7%, 2% and 0.5% 
O2), since most experimental studies in the field have only focused on normoxic conditions 
which are less relevant to the tumour microenvironment. The response to glycolysis 
inhibition under varying oxygen levels was interpreted through examination of the protein 
expression of the drug targets in the exact same conditions. The modulation of the relevant 
glycolytic targets was examined under the selected range of oxygen levels by Western 
blotting. Additionally the mRNA levels of the enzymes of the glycolytic pathway were 
analysed in breast cancer cells cultured in hypoxia for different periods of time using gene 
expression microarray profiling. This study intended to investigate the effect of glycolysis 
inhibition under varying oxygenation levels and attempt to interpret the results based on the 
expression of the glycolytic enzymes at both the mRNA and protein level. (Chapter 6)  
Fifthly, in the final chapter of this thesis the expression of four selected glycolytic targets 
(GLUT1, HKII, PKM2 and LDHA) were examined on a clinical tissue microarray of 469 
human ovarian cancers using quantitative immunofluorescence technology. The expression 
of the targets was correlated with the histological subtype, the stage of the disease and the 
survival outcome. Far too little is known regarding the clinical value of the glycolytic 
pathway in ovarian cancer and these experiments sought to enhance our current 
understanding and reveal subtypes of tumours in which glycolysis inhibition might be more 
beneficial. (Chapter 7) 
Overall this study aimed to elucidate further the role of aerobic glycolysis in breast and 
ovarian cancer and to evaluate the possibilities of therapeutic exploitation of the Warburg 


























Chapter 2: Materials & Methods 
 
All laboratory experiments in this study, unless otherwise stated, were carried out in the 
Division of Pathology Laboratories, Western General Hospital, University of Edinburgh. 
2.1 Mammalian Cell Culture 
2.1.1 Cell lines 
A panel of four breast and four ovarian cancer cell lines were used in the majority of the 
experiments in this study.  MCF7, MDA-MB-231, HBL100 and BT549 are human breast 
adenocarcinoma cell lines. The MCF7 cell line was isolated in 1970 from a pleural effusion 
of a 69-year old Caucasian female with invasive ductal carcinoma. It has a luminal 
transcription profile and expresses oestrogen and progesterone receptors [393]. MDA-MB-
231 was derived from a pleural effusion of a 51-year old Caucasian woman [394, 395]. It has 
an invasive basal B phenotype and is a triple negative cell line. HBL100 was isolated from 
the milk of a 27-year old Caucasian nursing mother. It has an epithelial basal B morphology 
and does not express oestrogen or progesterone receptors [396]. BT549 was established from 
an invasive ductal tumour of a 72-year old Caucasian woman in 1978. It has basal B 
epithelial morphology and does not express oestrogen or progesterone receptors [394, 395]. 
MCF7-HER2 (originally named MCF-7/HER2–18) is a HER2 overexpressing MCF7 cell 
line. It was a kind gift from the Osborne/Schiff laboratory, Baylor College of Medicine, USA 
and was available in the laboratory [397]. This cell line was included in the gene expression 
experiment presented in Chapter 6, section 6.4. MDA-MB-361 is a human breast 
adenocarcinoma cell line originating from a metastatic site in the brain of a 40-year old 
Caucasian woman suffering from breast adenocarcinoma. It has luminal epithelial phenotype 
and expresses oestrogen and HER2 receptors [394, 395]. This cell line was used for 
combinatorial studies of glycolytic inhibitors with a monoclonal HER2 antibody (Chapter 5, 
section 5.2). 
OVCAR5, TOV112D, OVCAR3 and CAOV3 are human ovarian adenocarcinoma cell lines 
with epithelial morphology. OVCAR5 was isolated in 1982 from the ascitic fluid of a 67-
year old Caucasian female with progressive ovarian adenocarcinoma who had not received 
any cytotoxic treatment. TOV112D was established in 1992 from a 42-year old woman of 
French- Canadian origin with early onset, stage III, endometrioid carcinoma [395]. 
OVCAR3 was derived in 1982 from the malignant ascites of a 60-year old Caucasian female 




chemotherapy [398].  CAOV3 was established from the primary tumour of a 54-year old 
Caucasian woman [395]. 
PEA1-PEA2 and PEO1-PEO4 are two ovarian cancer cell line pairs derived from two 
patients with ovarian adenocarcinoma at different stages of platinum-based chemotherapy. 
The first cell line pair was derived from a patient with poorly-differentiated ovarian 
adenocarcinoma. The PEA1 cell line was established from a pleural effusion prior to 
treatment while PEA2 was established 6 months later from peritoneal ascites of platinum-
resistant, relapsed disease. The second cell line pair was derived from malignant peritoneal 
ascites of a patient with poorly- differentiated serous adenocarcinoma. PEO1 was derived 
from relapsed disease 22 months after combined chemotherapy and was shown to be 
sensitive to platinum-based agents. PEO4 was established 10 months later from resistant 
progressive disease. These two paired cell lines, each of them derived from a single patient at 
different times during treatment; provide an excellent model for studying differences 
between platinum sensitive and platinum resistant disease (Figure 2.1) [399, 400].   
 
     
 
Figure 2.1: Timeline explaining how the ovarian cancer cell line pairs, PEA1-PEA2 and PEO1-PEO4, have been 
established from two patients with poorly-differentiated ovarian adenocarcinoma at different stages of platinum-
based chemotherapy. Figure adapted from Cooke et al., 2010 [400]. 
All cell lines used in this study were authenticated using Short Tandem Repeat profiling 
(STR) and had been subjected to mycoplasma testing. 
2.1.2 Cell culture conditions 
All cell line experimental work was conducted in aseptic sterile conditions in a class II 
Laminar Air Flow hood at room temperature. Cells were incubated in a humidified 
atmosphere of 5% CO2 at 37
o
C.  
The panel of four breast and four ovarian cancer cell lines (MCF7, MDA-MB-231, HBL100, 
BT549, OVCAR5, TOV112D, OVCAR3 and CAOV3) as well as the MCF7-HER2 and the 
MDA-MB-361 cell lines were all maintained in Dulbecco's Modified Eagle Medium without 
HEPES modification (DMEM, 31885/ Thermo Fisher Scientific), containing low glucose 
(5.56mM), Sodium Pyruvate (1mM) and L-glutamine (3.97mM). The two ovarian cancer 
cell line pairs (PEA1-PEA2, PEO1-PEO4) were maintained in Roswell Park Memorial 
PEA1   PEA2 
PEO1               PEO4 




Institute Medium 1640 (RPMI 1640, 21875/ Thermo Fisher Scientific) containing 11.11mM 
glucose and 2mM L-glutamine. In both cases the media contained phenol red and were 
supplemented with 10% heat inactivated fetal bovine serum FBS (Fetal Bovine Serum, South 
America origin, 10270106/ Thermo Fisher Scientific) and 1% Penicillin-Streptomycin 
(Penicillin-Streptomycin 10,000 U/mL, 15140122/ Thermo Fisher Scientific). For the 
MCF7-HER2 cell line, the medium was supplemented with 800μg/mL of Geneticin (G418 
Geneticin, 10131035/ Thermo Fisher Scientific). 
In the deprivation experiments presented in Chapter 3 section 3.1 where the effect of glucose 
and glutamine availability on cell growth of different cell lines was examined; medium 
without glucose or glutamine was used (DMEM, A14430/ Thermo Fisher Scientific). Phenol 
red free media were supplemented with 10% heat inactivated dialysed fetal bovine serum 
(26400036/ Thermo Fisher Scientific) and 1% Penicillin-Streptomycin. In the glucose and 
glutamine depleted medium the desired concentration of nutrients, D-Glucose (G8270/ 
Sigma Aldrich) and L-Glutamine (G7513/ Sigma Aldrich) was added, respectively. For the 
glucose treatments a standard 4mM glutamine concentration was added while for glutamine 
treatments a constant 5.56mM glucose concentration was used. These concentrations were 
selected to be consistent with the content of DMEM medium used for the rest of the 
experiments.  
2.1.3 Routine cell culture 
Cells were routinely maintained in T175cm
3
 tissue culture flasks and were sub-cultured at 
least once a week, when reaching 70-80% confluence as described below. Medium was 
discarded and cells were washed with preheated phosphate buffered saline (PBS tablets 
Dulbecco A, BR0014G/ Oxoid™). Cells were then incubated for a few minutes with a 
trypsin/EDTA solution (Trypsin-EDTA 0.05%, 25300062/ Thermo Fisher Scientific) at 37
o
C 
to cause cell detachment. The enzyme was neutralised by addition of serum-containing 
medium and cell suspension was centrifuged at 1,200rpm for 5min. Pelleted cells were 
resuspended in fresh media and passaged into new flasks at a ratio of 1:10. When setting up 
an experiment cells were counted using a Neubauer hemocytometer and were seeded in cell 
culture plates or dishes at the desired dilution.  
2.1.4 Hypoxic cell culture  
Hypoxia experiments presented in Chapter 6, were conducted at 37
o
C with 5% CO2 using the 
H35 Hypoxystation (Don Whitley Scientific, Shipley, UK). The oxygen level was set at 7, 2 




adapt to each oxygen level for at least 6h. Cells were preadapted to the oxygen level for 
different periods of time depending on the specific requirements of each experiment.  
2.1.5 Cell cryopreservation in liquid nitrogen and recovery  
For long term storage cells were preserved in liquid nitrogen tanks at -196
o
C. To prepare 
cells for cryopreservation they were detached and pelleted as described above (section 2.1.3). 
Then the pellet was resuspended in a solution containing 10% Dimethylsulphoxide (DMSO) 
in serum. The suspension was aliquoted in cryovials that were kept in a -70
o
C freezer 
overnight before being transferred to the liquid nitrogen tank (Institute of Genetics and 
Molecular Medicine, University of Edinburgh). 
To recover cells from liquid nitrogen, cryovials were defrosted rapidly and their content was 
transferred into preheated medium. Cell suspension was centrifuged at 1,200rpm for 5min to 
remove DMSO. Finally, cell pellet was resuspended into fresh medium and transferred into 
flasks for culture. Cells were only used for experiments two weeks after recovery from liquid 
nitrogen. 
2.1.6 Pharmacological tool compounds 
The pharmacological tool compounds used in the present study are listed in the table below 
(Table 2.1). The solvent used to prepare stock solutions as well as the supplier company and 
the catalogue number of each of the compounds is indicated. 
Compounds  Solvent Catalogue No/Supplier company 
Phloretin  DMSO P7912/ Sigma Aldrich 
Quercetin  DMSO Q4951/ Sigma Aldrich 
STF31  DMSO 4484/ Tocris Bioscience 
WZB117  Ethanol 400036/ Merck Millipore 
IOM-1190 DMSO provided by IOmet Pharma 
3-bromopyruvate  PBS 16490/ Sigma Aldrich 
3PO  DMSO 525330/ Merck Millipore 
Dichloroacetate  PBS 347795/ Sigma Aldrich 
Oxamic acid  PBS O2751/ Sigma Aldrich 
NHI-1  DMSO provided by IOmet Pharma 
BPTES DMSO SML0601/ Sigma Aldrich 
Metformin PBS 2864/ Tocris Bioscience 
 
Table 2.1: Pharmacological tool compounds used in the present study. The solvent as well as the supplier 




Cisplatin (Teva UK Limited), Paclitaxel (Actavis) and Trastuzumab (Roche 
Pharmaceuticals) were kindly provided from Western General Hospital Pharmacy, 
Edinburgh.  
2.2 Sulphorhodamine B assay (SRB) 
The SRB assay is a colorimetric cell density assay based on the quantification of cellular 
protein content [401]. It was used in this study to examine the efficacy of glycolytic 
inhibitors as growth inhibitors and to measure compound-induced cytotoxicity. 
Cells were seeded in flat-bottom 96-well plates at the appropriate density based on the 
proliferation rate of each cell line and the duration of the treatment. After a 48h incubation 
cells were treated with or without the relevant treatment as indicated (final volume 200μl). A 
series of 10 dilutions with 1:2 steps of each inhibitor in six replicates was applied. Once the 
treatment period was completed cell monolayers were fixed on the day of treatment (Day 0 
control) and on selected time points thereafter with cold 25% trichloroacetic acid (TCA, 
Sigma Aldrich - 50μl per well). After a 60min incubation at 4
o
C TCA was discarded and 
plates were thoroughly washed under running tap water to remove any residuals and left to 
dry. Then cell monolayers were stained with 0.4% SRB dye solution (Sigma Aldrich - 50μl 
per well) and after 30min at room temperature unbound excess dye was removed by 1% 
glacial acetic acid (VWR International) washes. Once plates dried, the protein bound stain 
was solubilised in 10mM Tris buffer solution pH 10.5 (Sigma Aldrich - 150μl per well). 
Finally after 60min at room temperature absorbance was measured at 540nm with a 
spectrophotometer microplate reader (BP800, Biohit Health Care). 
Analysis: Measurements were corrected for background absorbance and values are presented 
as percentage of absorbance of untreated control.  The half maximal inhibitory concentration 
(IC50), indicating the concentration needed to reduce cell viability by half, was used as a 
quantitative indication of the effectiveness of each compound as a cancer cell growth 
inhibitor. IC50 values were generated through sigmoidal concentration response curves fitted 
using the XL fit tool within Microsoft Excel. 
2.2.1 Combinatorial treatments 
In Chapter 5 glycolytic inhibitors were assessed in interaction studies with traditional drugs. 
For these treatments a range of different concentrations of a glycolytic inhibitor were 
combined with a constant fixed concentration, around the IC20 or less, of the other drug. Both 
drugs were delivered at the same time. Concentration response curves of each examined 




the Calcusyn Software. To quantitatively evaluate the effectiveness of each combination 
index values were generated for each combination point indicating synergism, additivity or 
antagonism. Indication of the CI values is presented in Table 2.2 [402]. 
CI value Indication 
<0.1 very strong synergism 
0.1 – 0.3 strong synergism 
0.3 – 0.7 synergism 
0.7 – 0.85 moderate synergism 
0.85 – 0.9 slight synergism 
0.9 – 1.1 nearly additive 
1.1 – 1.2 slight antagonism 
1.2 – 1.45 moderate antagonism 
1.45 – 3.3 antagonism 
3.3 – 10 strong antagonism 
>10 very strong antagonism 
 
Table 2.2: Indication of combination index values generated through Calcusyn Software. Figure adapted from 
Ian A. Cree, Cancer Cell Culture, 2011 [402]. 
2.3 Glucose uptake assay 
The effect of glycolytic inhibitors on glucose uptake was examined using the Amplex Red 
Glucose/Glucose Oxidase Assay Kit (A22189/ Thermo Fisher Scientific). MCF7 and 
HBL100 breast cancer cells were seeded in 12-well plates at a density of 2x10
5
 cells per 
well. After a 24h incubation cells were treated or not with a glycolytic inhibitor as indicated. 
A range of three different concentrations of each of the inhibitors was used; selected by 
taking into consideration the corresponding IC50 concentration determined from the SRB 
assays (Chapter 3). Culture media was collected after a 24h treatment and the concentration 
of glucose was determined using the kit based on the following principle.  
The Amplex Red Glucose/Glucose Oxidase Assay Kit provides a sensitive colorimetric 
method for detecting glucose through two coupled enzymatic reactions depicted in Figure 
2.2. Glucose oxidase reacts with D-glucose and generates D-gluconolactone and H2O2. The 
H2O2 produced then reacts stoichiometrically with the Amplex Red reagent; reaction 
catalysed by Horseradish Peroxidase (HRP), and forms the fluorescent product resorufin. 





The concentration of glucose in the culture media was measured using the kit according to 
the manufacturer’s instructions. A 96-well plate format with triplicates was applied. Samples 
were diluted 1:50 with the provided reaction buffer (50mM sodium phosphate buffer pH 7.4) 
in a final volume of 50μl and were incubated with 50μl of the glucose reagent solution. This 
was prepared in reaction buffer containing 100μM Amplex Red reagent, 0.2 U/ml HRP and 
2U/ml glucose oxidase. Reactions were incubated for 30min at room temperature, protected 
from light. Finally absorbance was measured at 540nm with a spectrophotometer microplate 
reader. The glucose standard curve generated through the assay is presented in Figure 2.3. 
Analysis: Measurements were corrected for background absorbance subtracting the value of 
the no-glucose control. Data are presented as mean optical density of 3 replicates. To 
evaluate the statistical significance of differences between treated samples and untreated 




Figure 2.2: Principle of coupled enzymatic reactions used for the detection of glucose [403]. 
 
Figure 2.3: Glucose standard curve generated through the Amplex Red Glucose/Glucose Oxidase Assay for 
glucose concentrations of 0 to 100μΜ. 
2.4 Lactate assay 
The effect of glycolytic inhibitors on lactate production was examined using the Lactate 
Assay Kit (735-10/ Trinity Biotech). Lactate concentration was measured in the same 
samples used for the glucose assay; culture media collected after a 24h treatment with the 
glycolytic inhibitors as described above. The concentration of lactate was determined using 
the kit based on the following principle.  
y = 0.0041x - 0.0056 
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The Lactate Assay Kit provides a sensitive colorimetric method for detecting lactate through 
two coupled enzymatic reactions depicted in Figure 2.4. Lactate oxidase reacts with L-lactic 
acid and generates pyruvate and H2O2. The produced H2O2 then reacts stoichiometrically 
with chromogen precursors; reaction catalysed by Horseradish Peroxidase (HRP), and forms 
a coloured dye. This oxidation product can be detected spectrophotometrically [404]. 
The amount of lactate in the culture media was measured using the kit according to the 
manufacturer’s instructions. A 96-well plate format with triplicates was applied. 2μl of 
sample were incubated with 200μl of the lactate reagent solution. This was reconstituted by 
the addition of 20ml dH2O to the solid reagent provided. Reactions were incubated for 7min 
at room temperature, protected from light. Finally absorbance was measured at 540nm with a 
spectrophotometer microplate reader. The lactate standard curve generated through the assay 
is presented in Figure 2.5. 
Analysis: Measurements were corrected for background absorbance subtracting the value of 
a no-lactate control. Data are presented as mean optical density of 3 replicates. To evaluate 
the statistical significance of differences between treated samples and untreated controls one-




Figure 2.4: Principle of coupled enzymatic reactions used for the detection of lactate [404]. 
 
 
Figure 2.5: Lactate standard curve generated through the Lactate Assay for lactate levels of 0 to 4.8μg. 
y = 0.3692x - 0.0134 
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2.5 Annexin V apoptosis assay 
To quantitatively determine the percentage of cells undergoing apoptosis following treatment 
with glycolytic inhibitors; dual staining with annexin V, conjugated with the fluorochrome 
FITC, and propidium iodide (PI) was conducted along with flow cytometric analysis. 
Detection of compound-induced cell death was performed using the FITC Annexin V 
Apoptosis Detection Kit I (556547/ BD Pharmingen). The kit was used according to the 
manufacturer’s instructions [405]. 
MCF7 or MDA-MB-231 (for combinatorial treatments in Chapter 5, section 5.4) breast 
cancer cells were seeded in 6-well plates at a density of 3x10
5
 cells per well. After a 24h 
incubation cells were treated with or without a glycolytic inhibitor as indicated. Culture 
media was collected after a 24 or 48h treatment and cells were washed twice with ice-cold 
PBS. Culture media along with PBS used for washes were all collected in a universal 30ml 
tube labelled for each sample to ensure collection of floating apoptotic cells. Adherent cells 
were then incubated for a few minutes with an Accutase solution (A6964/ Sigma Aldrich) at 
37
o
C to cause cell detachment. The Accutase enzymes were neutralised by addition of 
serum-containing medium and the suspension of all cells collected was centrifuged at 
1,200rpm for 5min. Pelleted cells were resuspended in the provided binding buffer (diluted 
in dH2O - 600μl). 100μl of the solution was transferred in a microcentrifuge tube and 10μl 
FITC annexin V along with 10μl PI was added. Samples were gently vortexed and incubated 
for 15min at room temperature, protected from light before 400μl binding buffer was added 
in each tube. Finally measurements of PI and FITC-conjugated annexin V fluorescence of 
30,000 events for each sample were taken using the BD Accuri C6 (BD Biosciences) flow 
cytometer (Institute of Genetics and Molecular Medicine, University of Edinburgh) within 
1h after staining.  
Analysis: Analysis of measurements was performed using the BD Accuri C6 flow cytometer. 
Annexin V versus PI (FL1 versus FL2) two-dimensional scatter plots of single cell gated 
populations were generated. Controls of unstained and single stained cells with either FITC-
annexin or PI were used to determine the required compensation of the cytometer and the 
proper position of the quadrant markers. Annexin V and PI negative cells were identified as 
live intact cells. Double positive cells were identified as end stage apoptotic cells. Annexin V 
single positive cells were considered early apoptotic while PI single positive cells as 
necrotic. The proportion of cells in each subpopulation was determined.    
FACs analysis was conducted with the assistance of Elisabeth Freyer, Institute of Genetics 




2.6 Cell cycle flow cytometric analysis 
To assess whether treatment with glycolytic inhibitors had an impact on cell cycle 
progression staining with the red fluorescent propidium iodide (PI) was conducted along 
with flow cytometric analysis. The FxCycle PI/RNase Staining Solution (F10797/ Thermo 
Fisher Scientific) was used according to the manufacturer’s instructions [406]. The 
percentage of cells in various stages of the cell cycle following treatment with glycolytic 
inhibitors was determined through measurement of the DNA content. 
MCF7 or MDA-MB-231 (for combinatorial treatments in Chapter 5, section 5.5) breast 
cancer cells were seeded in 6-well plates at a density of 1x10
6
 cells per well. After a 24h 
incubation cells were treated or not with a glycolytic inhibitor as indicated. Adherent cells 
were harvested using trypsin/EDTA solution as described in section 2.1.3. Floating apoptotic 
cells were not used for cell cycle analysis experiments. After centrifugation the supernatant 
was discarded and the cell pellet was collected in a microcentrifuge tube. Pelleted cells were 
resuspended in 300μl 50% FBS in PBS. Cells were fixed adding dropwise 700μl ice-cold 
70% ethanol in dH2O while gently vortexing. Fixed samples were stored overnight at 4
o
C. 
The following day samples were centrifuged at 1,200rpm for 10min and the supernatant was 
discarded gently. To ensure that all fixative was removed cells were washed twice by re-
suspension in 1,000µl PBS, centrifugation at 1,200 rpm for 10 minutes, and supernatant 
discarded. Following washes the cell pellet was resuspended in 500µl of FxCycle PI/RNase 
Staining Solution. DNase-free Ribonuclease A was included in the staining solution to 
enable DNA specific binding of PI. Samples were gently vortexed and incubated for 30min 
at room temperature, protected from light and finally were analysed using the BD 
LSRFORTESSA (BD Biosciences) flow cytometer (Institute of Genetics and Molecular 
Medicine, University of Edinburgh). 
Analysis: Analysis of measurements was performed using the BD FACSDIVA Software 
(BD Biosciences). Forward scatter versus side scatter (FS versus SS) two-dimensional 
scatter plots of single cell populations were gated and PI histograms were generated 
indicating the DNA content in X-axis against the number of cells in the Y-axis. Cells during 
G0/G1 phase, prior to DNA synthesis, have one set of paired chromosomes. During S phase 
cells replicate their DNA and have variable DNA content, increased compared to the diploid 
chromosomal amount. While during G2/M phase cells have already doubled their DNA 
content containing two sets of paired chromosomes. The proportion of cells in various stages 




FACs analysis was conducted with the assistance of Elisabeth Freyer, Institute of Genetics 
and Molecular Medicine, Western General Hospital, University of Edinburgh. 
2.7 Immunoblotting 
2.7.1 Protein Extraction  
Cells were seeded in cell culture dishes and were incubated until reaching approximately 70-
80% confluence. Then dishes were transferred on ice, medium was discarded and cells were 
washed with ice cold PBS before being lysed in 400μl ice-cold isotonic lysis buffer (50mM 
Tris pH7.5, 5mM EGTA pH8.5, 150mM NaCl supplemented as presented in Table 2.3). 
Cells were then scraped and left for 15min for lysis to occur. Subsequently lysates were 
collected in a microcentrifuge tube and centrifuged at 13,000g for 6min at 4ºC. Pelleted cell 
debris was discarded and lysate supernatant was collected and stored at -70ºC. 
For experiments in Chapter 6, section 6.2 cells were seeded in cell culture dishes and were 
incubated in the Hypoxystation under the indicated O2 conditions for the indicated period of 
time (24, 48 or 72h). Dishes were removed from the Hypoxystation only after cells were 
washed with ice cold PBS preadapted to the respective oxygen level and then were lysed as 
previously described.  
Component Quantity in 10ml Catalogue No/Supplier company 
Complete Protease Inhibitor Tablet 1 tablet 11836153001/ Roche 
Phosphatase Inhibitor Cocktail 2 100μl P5726/ Sigma Aldrich 
Phosphatase Inhibitor Cocktail 3 100μl P0044/ Sigma Aldrich 
Aprotinin  50μl A6279/ Sigma Aldrich 
Triton-X 100 100μl X100/ Sigma Aldrich 
 
Table 2.3: Additional contents of isotonic lysis buffer -50mM Tris pH7.5, 5mM EGTA pH8.5, 150mM NaCl. 
2.7.2 Bicinchoninic Acid Assay (BCA) 
To quantify the protein concentration of the lysates the BCA assay was used. Protein 
samples were diluted 1:10 in dH2O in a final volume of 50μl. The BCA reagent was prepared 
containing 1 volume of copper sulphate (C2284/ Sigma Aldrich) in 50 volumes of BCA 
solution (B9643/ Sigma Aldrich). 1ml of the reagent was added to each sample and then they 
were incubated at 60
o
C for 15 min. Finally, 200μl of each sample was loaded in 96-well 
plates and absorbance was measured at 540nm with a spectrophotometer microplate reader. 




curve as presented in Figure 2.6 and through this the protein concentration of samples was 
determined. 
 
Figure 2.6: Protein standard curve generated through the BCA Assay for protein concentrations of 0 to 1mg/ml. 
2.7.3 Western Blotting 
Samples were prepared containing 40μg of protein diluted in 4x Laemmli Sample Buffer 
(1610747/ Bio-Rad Laboratories). Complete lysis buffer was used to equalise the volume of 
each protein sample. Sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE) were 
constructed as presented in Table 2.4 using the mini-Protean equipment (Bio-Rad 
Laboratories). Protein samples were denatured at 90
o
C for 5 min and loaded onto the 
polyacrylamide gel along with two markers the Spectra Multicolor High Range Protein 
Ladder (26625/ Thermo Fisher Scientific) and the Prestained Protein Marker, Broad Range 
(P7708L/ New England Biolabs). Electrophoresis was conducted in Tris-Glycine, SDS 
buffer at 80V for 15min and subsequently at 180V for 45-60min depending on the molecular 
weight of the target protein. 
Component 10% Resolving Gel 6% Stacking Gel 
30% Acrylamide 6.75 1.8 
1M Tris pH 8.85 7.5 - 
0.375M Tris pH 6.8 - 5 
dH2O 5.55 8 








Table 2.4: Contents of SDS-PAGE gels, quantities indicated are ml required for 2 gels. 
y = 0.9153x + 0.0399 



































When electrophoresis was completed separated proteins were transferred onto a methanol-
activated Immobilon-P polyvinylidene difluoride (PVDF) membrane (Merck Millipore) 
using the Protean Transfer Cell equipment (Bio-Rad Laboratories). Transfer was conducted 
at 100V for 90min at 4
o
C in ice-cold Tris-Glycine transfer buffer. Following transfer the 
membrane was blocked in 1:1 Odyssey Blocking Buffer (LI-COR Biosciences) / PBS for 
60min at room temperature. The membrane was then washed with PBS-0.1% Tween 20 
(PBS-T, Sigma Aldrich) three times for 5min each before an overnight incubation in primary 
antibody solution at 4
o
C was performed. The antibodies used in the present study along with 
their host, the dilution factor used as well as the supplier company and the catalogue number 
are listed in Table 2.5. Odyssey Blocking Buffer/ PBS or 5%w/v bovine serum albumin 
(BSA, Sigma Aldrich) in PBS-0.1% Tween 20 (for GLUT1 and PDHK1) were used as 
primary antibody diluent.   
Antibody Host WB Dilution Catalogue No/Supplier company 
GLUT1 rabbit 1:15,000 07-1401/ Merck Millipore 
HKII rabbit 1:3,000 2867/ Cell Signaling Technology 
PFKFB3 rabbit 1:800 13123/ Cell Signaling Technology 
PDHK1 rabbit 1:1,500 3820/ Cell Signaling Technology 
LDHA rabbit 1:3,000 3582/ Cell Signaling Technology 
LDHB mouse 1:5,000 ab85319 / Abcam 
α tubulin mouse 1:10,000 ab7291/ Abcam 
β actin rabbit 1:10,000 ab8227/ Abcam 
 
Table 2.5: Primary antibodies used for WB in the present study. Antibodies’ host, used dilution as well as the 
supplier company and the catalogue number are indicated. 
The following day the membrane was washed with PBS-T three times for 5min each before 
secondary fluorescent antibodies raised against the species of the primary antibody were 
applied (Table 2.6). Secondary antibodies were diluted in Odyssey Blocking Buffer/ PBS 
supplemented with 0.001% SDS and incubation lasted for 45min at room temperature, 
protected from light. Three final 5min PBS-T washes were performed and then the 
membrane was left to dry remaining always in the dark. Finally it was scanned on the 
Odyssey scanner (LI-COR Biosciences) using two infrared channels at wavelengths of 





Antibody Host WB Dilution Catalogue No/Supplier company 
Anti-rabbit 
IR Dye 800CW 
goat 1:10,000 926-32211/ LI-COR Biosciences 
Anti-mouse 
IR Dye 680LT 
goat 1:10,000 926-68020/ LI-COR Biosciences 
 
Table 2.6: Secondary antibodies used for WB in the present study. Antibodies’ host, used dilution as well as the 
supplier company and the catalogue number are indicated. 
Analysis: Densitometry analysis was conducted using the Odyssey Infrared Imaging System 
software (LI-COR Biosciences) and target protein’s expression was normalised to the 
respective expression of a loading control (either α tubulin or β actin). 
2.8 siRNA Knockdown 
Four individual predesigned siRNA oligos and a pool with a mixture of the four sequences 
targeting two glycolytic enzymes, GLUT1 (/SLC2A1) and LDHA, were acquired from the 
ON-TARGETplus series of GE Healthcare Dharmacon. Specifications of the siRNA 
sequences are presented in Table 2.7. The siRNA oligos were resuspended in RNase-free 
siRNA Buffer (B-002000-UB/ Dharmacon) to generate a 20µM stock which was aliquoted 
and stored at -70ºC. The standard transfection protocol suggested by the manufacturer was 
followed.  









































Table 2.7: ON-TARGETplus siRNAs used in the present study. The targeted region as well as the catalogue 




MCF7 and MDA-MB-231 breast cancer cells were seeded in 6-well plates at a density of 
3x10
5
 cells per well using DMEM medium as described in section 2.1.2 supplemented with 
FBS but containing no antibiotics. Cells were incubated for 24h before being transfected. 
Two separate microcentrifuge tubes were prepared one containing the desired amount from 
the 20µM siRNA stock solution and the other 4µl of DharmaFECT 1 Transfection Reagent 
(T-2001/ Dharmacon), both in a final volume of 200μl FBS and antibiotic-free medium.  The 
contents of each tube were mixed gently and incubated for 5min at room temperature. 
Subsequently, the two tubes were combined in a total volume of 400μl, mixed carefully and 
incubated for 20min at room temperature. Meanwhile, medium was discarded from cells and 
after a PBS wash 1ml antibiotic-free medium was added. When the 20min incubation was 
completed 600μl antibiotic-free medium was added to the transfection mix before this was 
added to the cells dropwise and while shaking the plate gently. Transfected cells were then 
incubated for the indicated period of time.  
Each experiment included the following; untreated cells, mock cells treated only with 
transfection reagent (but no siRNA sequence) as well as a negative control- cells transfected 
with a non-targeting siRNA sequence (D-001810-01/ Dharmacon). Lysates of transfected 
samples were collected and efficiency of knockdown was assessed at the protein level 
through Western blotting; comparing the expression of the targeted protein between 
transfected and mock treated cells. 
2.9 Immunofluorescence of clinical ovarian cancer tissues  
2.9.1 Tissue Microarrays (TMAs) 
The TMAs used in the present study were obtained from the Division of Pathology 
Laboratories, Western General Hospital, University of Edinburgh. Primary tissue of 469 
ovarian carcinomas had been collected from patients treated in the Edinburgh Cancer Centre 
the period between 1991 and 2006 prior to treatment. Tissues were formalin-fixed and 
paraffin-embedded and using a microtome sections were cut and cores were mounted onto 
TMA slides. Three separate TMA replicates containing cores of 469 ovarian tumours had 
been constructed. The study was approved by the Lothian Research Ethics Committee 
(08/S1101/41). No informed consent (written or verbal) was obtained for use of retrospective 
tissue samples from the patients within this study, most of whom were deceased, since this 
was not deemed necessary by the Ethics Committee. The TMA material was provided by the 
Edinburgh Experimental Cancer Medicine Centre (ECMC ID: SR319). The cohort 




2.9.2 Immunofluorescence  
TMA slides were deparaffinised in xylene (twice for 5min each time) and then rehydrated in 
graded ethanol solutions (99%, 99%, 80% and 50% for 2min each). Following a wash in 
running tap water, heat-induced antigen retrieval was performed by pressure cooking in 
sodium citrate buffer at pH6 (18ml 0.1M citric acid, 82ml 0.1M sodium citrate, 900μl 
dH2O). Slides were then left to cool and after a 5min wash in 0.05% PBS Tween 20 (PBS-T) 
were incubated in a 3% hydrogen peroxide solution for 10min to block any endogenous 
peroxidase activity. Following an additional PBS-T 5min wash non-specific binding was 
blocked by a 10min incubation in serum-free protein block (X0909/ DAKO). Primary 
antibodies were diluted in antibody diluent (S0809/ DAKO) and were applied for an 
overnight incubation at 4ºC (Table 2.8). The selected primary rabbit antibodies had been 





Table 2.8: Antibodies used for IF in the present study. Antibodies’ host, used dilution as well as the supplier 
company and the catalogue number are indicated. 
The following day the tissue sections were washed with PBS-T, three times for 5min each, 
and then were incubated with the second primary mouse anti-cytokeratin antibody (M3515/ 
DAKO) diluted 1:25 in the same antibody diluent in order to mask the tumour areas. This 
incubation was performed at room temperature, lasted 1h and was followed by three 
additional PBS-T washes. To enable epithelial mask visualisation slides were then incubated 
with the secondary goat anti-mouse antibody conjugated with Alexa Fluor 555 (A21422/ 
Thermo Fisher Scientific) diluted 1:25 in the goat anti-rabbit peroxidase-conjugated 
Envision reagent (K4003/ DAKO). The duration of this incubation was 90min, it was 
conducted at room temperature protected from light and was followed by three PBS-T 
washes. Target visualisation was implemented by a 10min incubation with Cyanine 5 (Cy5) 
Tyramide, diluted at 1:50 in amplification diluent (SAT705A001KT/ PerkinElmer), at room 
temperature protected from light. Subsequently, tissue sections were washed three times with 
PBS-T as previously and dehydrated in 80% ethanol for 1min. Finally, slides were 
counterstained with 45μl Prolong Gold Antifade Mountant with DAPI (4', 6-diamidino-2-
Antibody Host IF Dilution Catalogue No/Supplier company 
GLUT1 rabbit 1:300 07-1401/ Merck Millipore 
HKII rabbit 1:50 2867/ Cell Signaling Technology 
LDHA rabbit 1:400 3582/ Cell Signaling Technology 




phenylindole) (P-36931/ Thermo Fisher Scientific) to visualise the nuclei and a coverslip 
was mounted.  
2.9.3 AQUA Image Analysis 
The expression of glycolytic targets in clinical ovarian tumours was quantitatively evaluated 
by Automated Quantitative Analysis (AQUA). High resolution monochromatic images of 
each TMA core were captured at 20x objective using an Olympus AX-51 epifluorescence 
microscope and were analysed by the AQUAnalysis software. DAPI, Cy-3 and Cy-5 filters 
were applied to visualise the nuclei, the cytokeratin tumour mask and the target protein 
respectively. The Cy-5 fluorescent signal intensity of the target antigen was quantified in 
each image pixel. A quantitative score was attributed in each histospot based on the average 
Cy5 signal in the cytoplasmic compartment within the epithelial tumour mask, as this was 
identified from the cytokeratin Cy3 stain. Damaged cores or cores containing imaging errors 
as well as those consisting of less than 5% epithelium were excluded from further analysis. 
 
Analysis: Target expression in the cytoplasmic compartment of each core was quantified and 
assigned an AQUA score. Data were filtered and only samples that had at least two replicate 
values were considered. Expression values were averaged from either two or three replicates. 
The expression of examined glycolytic targets was compared across the different 
pathological stages and histological types of ovarian tumours using one-way ANOVA and 
statistical significance was determined by the Tukey's multiple comparisons test. 
Furthermore, the expression of the glycolytic enzymes was correlated with expression of 
several proliferation, apoptosis and signalling markers described previously for the same 
cohort. Spearman nonparametric correlation and network analysis were conducted using 
TMA Navigator. Correlation heatmaps were generated using the same server 
(http://www.tmanavigator.org/). Expression data of different markers had been log2 
transformed, mean-centred and quantile-normalised to compensate for differences in the 
staining. Association of glycolytic targets expression with clinical outcome was assessed 
using Kaplan-Meier analysis. The X-Tile tool was used to define optimised cut-off values. 
Miller–Siegmund P-value correction was applied and the Log-Rank survival analysis test 
was performed to determine statistical significance. 
Data analysis was conducted with the assistance of Dr Arran Turnbull, Edinburgh Breast 
Cancer Now Research Team, Division of Pathology Laboratories, Western General Hospital, 




2.10 Gene Expression Analysis 
Gene expression experiment was conducted in collaboration with James Meehan and Ed 
Jarman.  
 2.10.1 Sample collection 
Gene expression analysis was performed using MCF7, MCF7-HER2, MDA-MB-231 and 
HBL100 breast cancer cell lines. Gene expression changes were examined under four 
different conditions: normoxic cells cultured at 21% O2, acute hypoxic cells cultured at 0.5% 
O2 for 24h, chronic hypoxic cells cultured at 0.5% O2 for 10 weeks and cells treated with 
400μM CoCl2 (Cobalt Chloride) for 24h to chemically mimic hypoxia.  
Breast cancer cells were seeded in cell culture dishes and incubated accordingly in the 
conditions mentioned above. Cells were then trypsinised as described in section 2.1.3 and the 
cell suspension was centrifuged at 1,200rpm for 5min. 3x10
6
 pelleted cells were collected in 
microcentrifuge tubes and kept at -70
o
C. Samples were prepared in 3 biological replicates.        
2.10.2 RNA Extraction 
Total RNA was extracted and purified using the miRNeasy Mini Kit (217004/ Qiagen) 
according to the manufacturer’s instructions [407]. 1ml of QIAzol lysis reagent (phenol and 
guanidine thiocyanate solution included in the kit) along with one steel ball was added in 
each sample tube. Cells were homogenised in the lysis reagent using the TissueLyser 
(Qiagen) for 5min at 50Hz at room temperature. Subsequently, 240µl of Chloroform was 
added and following a centrifugation for 15 min at 13000rpm at 4°C the homogenates were 
separated into aqueous and organic phases. 500µl of the upper aqueous phase was carefully 
extracted and 750µl of 100% ethanol was added to provide a suitable binding environment 
for RNA molecules. Samples were then applied onto RNeasy Mini columns and after a 
centrifugation at 13000rpm for 15 sec at room temperature RNA was attached to the 
membranes and the filtrates were discarded. Columns were washed with 350µl RWT buffer 
followed by an additional centrifugation and discarding of the flow-through. Contaminating 
DNA was removed by incubating with 80µl of DNAse mix (1:8 DNAse in RDD buffer, 
Qiagen) for 15min at room temperature. Further washing steps with 350µl RWT buffer and 
500µl RPE buffer (twice) followed by additional centrifugations ensured removal of other 
contaminants. Finally RNA was eluted in 30µl of RNase-free water. The concentration as 
well as the quality of the RNA was assessed using the spectrophotometer Nanodrop 2000c 




2.10.3 RNA Amplification  
The RNA was biotinylated and amplified using the Illumina TotalPrep RNA Amplification 
Kit (AMIL1791/ Thermo Fisher Scientific) according to the manufacturer’s instructions 
[408]. Samples were prepared containing 500ng RNA in a final volume of 11μl Nuclease-
free H2O and were incubated with 9μL of Reverse Transcription Master Mix, containing the 
T7 Oligo(dT) Primer, for 2h at 42°C. Through the reactions the first strand cDNA with a T7 
promoter sequence was synthesised. From the single stranded cDNA a double stranded 
dsDNA was then synthesised through incubating with 80μl of Second Strand Master Mix for 
2h at 16°C. DNA polymerase and RNase H were included in the master mix to enable 
simultaneous synthesis of the second strand cDNA and RNA degradation. Subsequently the 
synthesised cDNA was purified; 250μl of cDNA Binding Buffer were added to each sample 
and the mixture was filtered through a cDNA Filter Cartridge, 500μl of Wash Buffer was 
then applied and the cDNA was eluted in 20μl 55°C Nuclease-free H2O. Once purification 
was completed 7.5μl of IVT Master Mix was added to each cDNA sample and they were 
incubated for 14h at 37°C for the synthesis of cRNA. The following day the in vitro 
transcription was ceased by adding 75μl Nuclease-free H2O and then the synthesised cRNA 
was purified. 350μl of cRNA Binding Buffer was added to each cRNA sample followed by 
250μl 100% ethanol and then the mixture was filtered through a cRNA Filter Cartridge. 
Finally 650μl Wash Buffer was applied to each sample and the cRNA was eluted in 200μl 
55°C Nuclease-free H2O. The concentration as well as the quality of the cRNA was assessed 
using the spectrophotometer Nanodrop 2000c. 
2.10.4 Concentration of Nucleic acids 
In some cases the concentration of the amplified RNA was not adequate for hybridization 
and it was necessary to concentrate particular samples by precipitation with NH4OAc 
(ammonium acetate). 20μl of 7.5M NH4OAc along with 550μl 100% ethanol was added to 
the eluted cRNA sample and the mixture was incubated for 30 min at -20°C. Following a 
centrifugation for 15min at top speed at 4°C, the pellet was washed with 500μl 70% ice-cold 
ethanol. Finally an additional centrifugation was performed, residual ethanol was removed 
and the pelleted RNA was resuspended in 50μl Nuclease-free H2O. 
2.10.5 Northern Blotting 
Ten cRNA samples were randomly selected to test biotin incorporation following 
amplification through northern blotting. Samples were prepared containing 2µl 1M NaOH, 
0.25µl 200mM EDTA pH8.2 and 2.75µl cRNA. After being heated at 100
o
C for 10min 




Scientific). The membrane was then rinsed in Saline-Sodium Citrate buffer (Sigma Aldrich) 
and then incubated in 1:1 Odyssey Blocking Buffer/ PBS supplemented with 1% SDS for 
60min at room temperature. Finally the IR Dye 800CW Streptavidin (925-32230/ LI-COR 
Biosciences) at 1:10,000 dilution was used as a secondary detection reagent and the 
membrane was scanned on the Odyssey scanner as described in section 2.7.3. All cRNA 
samples examined were properly biotinylated (Figure 2.7). 
 
Figure 2.7: Biotin incorporated into the labelled cRNA samples was detected by fluorophore labelled 
streptavidin through Northern blotting.  
2.10.6 Whole-Genome Direct Hybridisation and Data Normalisation  
Labelled RNA was hybridised to HumanHT-12 v4 whole-genome expression BeadChip 
(BD-103-0204/ Illumina). Each array on the chip targets 47,000 probes derived from the 
National Centre for Biotechnology Information Reference Sequence (NCBI) Release 38 
(2009). Samples were carefully distributed over 4 chips, each one containing 12 samples. 
The Direct Hybridisation Assay along with scanning of the hybridised chips on the Illumina 
iScan System was performed at the Hologic healthcare and diagnostics company 
(Manchester). Image data were processed with the Illumina GenomeStudio Software and a 
raw dataset was generated containing a quantitative level of expression intensity for each 
probe sequence. Data were filtered using the Illumina probe detection P-value and 
undetected probes were excluded (P>0.05 in at least n-3 samples). Probe profiles were log2 
transformed and quantile normalised using the lumi Bioconductor package within the 
statistical software package R. Data were re-annotated to Ensembl gene identifiers mapping 
the probe sequences to Ensembl genes.   
Analysis: Data were subjected to paired and unpaired Rank Products analysis. Hierarchical 
clustering was performed on mean-centred data using Cluster. Functional gene analysis was 
performed using the online pathway annotation tool DAVID Bioinformatics Resources 6.7 
(https://david.ncifcrf.gov/). Gene Ontology (GO) enrichment analysis was conducted in the 
Revigo server (http://revigo.irb.hr/). Heatmaps of differentially expressed genes were 
generated using TM4 microarray software suite’s Multiple Experiment Viewer. Log2 fold 
change expression values calculated between hypoxic and normoxic conditions for each cell 




significance of expression differences of specific genes of interest under different conditions 
one-way ANOVA and the Dunnett’s multiple comparisons test were used.    
Data analysis was conducted with the assistance of Dr Arran Turnbull, Edinburgh Breast 
Cancer Now Research Team, Division of Pathology Laboratories, Western General Hospital, 
University of Edinburgh.  
2.11 Statistical Analysis 
Unless otherwise mentioned statistical tests were undertaken using the GraphPad Prism 



























Chapter 3: The effect of metabolic inhibitors on cell proliferation 
 
Glycolysis and glutaminolysis both play a pivotal role in the metabolism of tumours and 
targeting of these pathways is considered an exploitable promising anticancer strategy [88, 
272]. The primary aim of this chapter was to investigate the growth inhibitory effects of 
several compounds targeting the glycolytic and glutaminolytic pathways in a panel of breast 
and ovarian cancer cell lines. Initially the growth dependency of these cancer cell line 
models on the availability of the basic metabolic substrates (glucose and glutamine) was 
examined.      
 
 
3.1 The effect of glucose and glutamine availability on cell growth of a panel of 
four breast and four ovarian cancer cell lines 
The aim of these experiments was to develop an understanding of the metabolic profile of 
breast and ovarian cancer cell lines by investigating their growth dependency on glucose and 
glutamine availability. The effect of varying concentrations of the main nutrient sources on 
cancer cell growth was examined. A panel of four breast and four ovarian cancer cell lines 
was cultured in the presence of variable glucose and glutamine concentrations and cancer 
cell proliferation was examined by SRB assay after a 5-day incubation period. Growth was 
compared with controls completely deprived of glucose or glutamine. These experiments 
were conducted in glucose and glutamine depleted medium. For the glucose treatments a 
standard 4mM glutamine concentration was applied while for glutamine treatments a 
constant 5.56mM glucose concentration was used. These concentrations were selected based 
on the content of the standard medium used for the majority of experiments of this study.  
The following graphs illustrate the average optical density value generated through an SRB 
assay against increasing concentration of glucose or glutamine. A duplicate control for 
complete glucose or glutamine depletion conditions (the first two columns of each graph) 
was used to establish a baseline of growth under complete deprivation. The statistical 
significance of differences with the depleted controls was determined by one-way ANOVA 
and the Tukey-Kramer multiple comparisons test. Experiments were conducted at least twice 





Figures 3.1 & 3.2: Optical density values of MCF7 breast cancer cells treated with glucose concentrations 
between 0-25.6mΜ and glutamine concentrations between 0-12.8mΜ for a five day period. Optical density was 
determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Faint coloration at the bottom of the columns represents OD value on the day of treatment (Day 0).  
Statistical significance indications: * P<0.05, *** P<0.001 compared with the average of no glucose/ no 
glutamine controls (one-way ANOVA followed by Tukey-Kramer multiple comparisons test). Representative 
data of 3 independent experiments are presented. 
Figure 3.1 presents the effect of different glucose concentrations on MCF7 breast cancer cell 
growth in the presence of a constant 4mM glutamine concentration. MCF7 cells were able to 
grow in the absence of glucose increasing their cell number six fold compared to the number 
of cells on day 0. Maximal optimal growth was observed at glucose concentrations of 
1.6mM or more. In contrast MCF7 cell growth proved highly dependent on glutamine 
concentration. Figure 3.2 presents the effect of different glutamine concentrations on MCF7 
breast cancer cell growth in the presence of 5.56mM glucose. It can be observed that MCF7 
cells were unable to proliferate at zero glutamine concentration. They required a minimum 
concentration of 0.1mM glutamine to proliferate.   
  
Figures 3.3 & 3.4: Optical density of MDA-MB-231 breast cancer cells treated with glucose concentrations 
between 0-25.6mΜ and glutamine concentrations between 0-12.8mΜ for a five day period. Optical density was 
determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Faint coloration at the bottom of the columns represents OD value on the day of treatment (Day 0). 
Statistical significance indications: ns not significant P>0.05, *** P<0.001 compared with the average of no 
glucose/ no glutamine controls (one-way ANOVA followed by Tukey-Kramer multiple comparisons test). 
Representative data of 3 independent experiments are presented. 
As demonstrated in Figures 3.3 and 3.4 MDA-MB-231 cells were unable to proliferate when 
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A significant increase in cell proliferation was only observed at a concentration of 0.4mM 
glucose compared to the no-glucose control. In contrast, 0.1mM glutamine was adequate to 
significantly increase the cell number compared to the no glutamine samples.    
  
Figures 3.5 & 3.6: Optical density of HBL100 breast cancer cells treated with glucose concentrations between 0-
25.6mΜ and glutamine concentrations between 0-12.8mΜ for a five day period. Optical density was determined 
by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard deviations. Faint 
coloration at the bottom of the columns represents OD value on the day of treatment (Day 0). Statistical 
significance indications: ns not significant P>0.05, * P<0.05, *** P<0.001 compared with the average of no 
glucose/ no glutamine controls (one-way ANOVA followed by Tukey-Kramer multiple comparisons test). 
Representative data of 3 independent experiments are presented. 
HBL100 cells also demonstrated strong reliance on both glucose and glutamine for cell 
growth. As can be observed in Figures 3.5 and 3.6, HBL100 cells could not proliferate if 
lacking glucose or glutamine. A significant induction in cell proliferation was only observed 
after addition of 0.4mM glucose and 0.4mM glutamine compared to the depleted controls. 
  
Figures 3.7 & 3.8: Optical density of BT549 breast cancer cells treated with glucose concentrations between           
0-25.6mΜ and glutamine concentrations between 0-12.8mΜ for a five day period. Optical density was 
determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Faint coloration at the bottom of the columns represents OD value on the day of treatment (Day 0). 
Statistical significance indication: *** P<0.001 compared with the average of no glucose/ no glutamine controls 
(one-way ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 3 independent 
experiments are presented. 
Figures 3.7 and 3.8 present the response of BT549 cells to variable concentrations of these 
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found completely unable to proliferate when glutamine was depleted. A glutamine 
concentration equal to 0.1mM was sufficient to significantly induce growth compared to the 
zero glutamine control. In contrast, BT549 cells were able to double their cell number even 
in a completely glucose free environment.    
  
Figures 3.9 & 3.10: Optical density of OVCAR5 ovarian cancer cells treated with glucose concentrations 
between 0-25.6mΜ and glutamine concentrations between 0-12.8mΜ for a five day period. Optical density was 
determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Faint coloration at the bottom of the columns represents OD value on the day of treatment (Day 0). 
Statistical significance indications: ns not significant P>0.05, *** P<0.001 compared with the average of no 
glucose/ no glutamine controls (one-way ANOVA followed by Tukey-Kramer multiple comparisons test). 
Representative data of 2 independent experiments are presented. 
Figures 3.9 and 3.10 show that OVCAR5 cells were not able to proliferate when cultured in 
a no glucose or no glutamine environment for five days, and were strongly reliant on both 
substrates for proliferation. 0.2mM of glucose or glutamine was essential for significant 
growth then higher concentration led to higher growth rate until a plateau was reached with a 
maximal cell number at a concentration of 1.6mM glucose and 0.8mM glutamine.    
  
Figures 3.11 & 3.12: Optical density of TOV112D ovarian cancer cells treated with glucose concentrations 
between 0-25.6mΜ and glutamine concentrations between 0-12.8mΜ for a five day period. Optical density was 
determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Faint coloration at the bottom of the columns represents OD value on the day of treatment (Day 0). 
Statistical significance indications: ns not significant P>0.05, ** P<0.01, *** P<0.001 compared with the average 
of no glucose/ no glutamine controls (one-way ANOVA followed by Tukey-Kramer multiple comparisons test). 
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Figures 3.11 and 3.12 depict the response of TOV112D ovarian cancer cells to different 
glucose and glutamine concentrations. These cells showed a threefold increase in their cell 
number in the absence of glucose while in contrast no proliferation was observed in 
glutamine depleted conditions. They demonstrated a minimum glutamine requirement of 
0.2mM for statistically significant proliferation. 
 
  
Figures 3.13 & 3.14: Optical density of OVCAR3 ovarian cancer cells treated with glucose concentrations 
between 0-25.6mΜ and glutamine concentrations between 0-12.8mΜ for a five day period. Optical density was 
determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Faint coloration at the bottom of the columns represents OD value on the day of treatment (Day 0). 
Statistical significance indications: ns not significant P>0.05, * P<0.05, ** P<0.01, *** P<0.001 compared with 
the average of no glucose/ no glutamine controls (one-way ANOVA followed by Tukey-Kramer multiple 
comparisons test). Representative data of 2 independent experiments are presented. 
 
OVCAR3 cells were able to proliferate and increase their cell number up to 2.5 times despite 
a 5-day glucose depletion as presented in Figure 3.13. An interesting observation is that 
OVCAR3 cells were found unable to maintain proliferation at 0.2mM glucose and their cell 
number was significantly reduced while maximal growth was observed at 0.8mM. In 
contrast Figure 3.14 suggests that they rely strongly on glutamine. OVCAR3 cells could not 
proliferate in the absence of glutamine. A concentration of 0.1mM glutamine was essential 
for growth resulting in a statistically significant higher cell number in comparison to the zero 
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Figures 3.15 & 3.16: Optical density of CAOV3 ovarian cancer cells treated with glucose concentrations 
between 0-25.6mΜ and glutamine concentrations between 0-12.8mΜ for a five day period. Optical density was 
determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Faint coloration at the bottom of the columns represents OD value on the day of treatment (Day 0). 
Statistical significance indications: ns not significant P>0.05, ** P<0.01, *** P<0.001 compared with the average 
of no glucose/ no glutamine controls (one-way ANOVA followed by Tukey-Kramer multiple comparisons test). 
Representative data of 2 independent experiments are presented. 
 
In Figures 3.15 and 3.16 evidence is provided of a strong reliance on both glucose and 
glutamine for CAOV3 ovarian cancer cell proliferation. CAOV3 cells were unable to grow 
when glucose or glutamine were not present in the culture medium. In comparison to the 
control samples, cells demonstrated significant growth when cultured with a minimum of 




Interestingly, marked variation was observed in the growth requirements of these key 
nutrients among the different breast and ovarian cancer cell lines. The table below 
demonstrates the minimum glucose and glutamine concentration required by each cell line 
for significant growth compared to growth on the day of treatment (day 0). It should be noted 
that statistical significance indications in the above figures refer to growth comparison with 
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Concentration required for 
significant growth 
Minimum Glutamine 
Concentration required for 
significant growth 
MCF7 0mM  0.1mM  
MDA-MB-231 0.2mM 0.1mM  
HBL100 0.2mM  0.2mM  
BT549 0mM 0.1mM 
OVCAR5 0.2mM 0.2mM 
TOV112D 0mM 0.2mM 
OVCAR3 0mM 0.1mM 
CAOV3 0.4mM 0.1mM 
 
Table 3.1: Minimum glucose or glutamine concentration required by a panel of breast and ovarian cancer cell 
lines to achieve significant growth following a five day treatment under a range of glucose and glutamine 
concentrations respectively. All values are significant at the P<0.001 level. 
3.2 The effect of glycolytic inhibitors on cell growth of a panel of four breast 
and four ovarian cancer cell lines 
An array of glycolytic inhibitors, targeted against multiple points of the glycolytic pathway, 
were selected and compared against a panel of four breast and four ovarian cancer cell lines. 
Cancer cell proliferation was examined by the SRB assay after a 5-day treatment period. 
Experiments were conducted at least twice and representative results are presented. 
3.2.1 Targeting Glucose Transport 
GLUT1 is a member of the SLC transporter family that enables glucose to enter the cells. It 
is abundantly expressed in most human tissues and found overexpressed in many cancers 
[171, 173-177]. Several compounds reported to inhibit glucose transmembrane transport 
were compared in this study. 
3.2.1.1 Phloretin & Quercetin 
Phloretin and Quercetin are flavonoids described to inhibit glucose transmembrane transport 
[277]. Figures 3.17 and 3.18 present the concentration response curves of these compounds 
for a panel of four breast cancer cell lines generated through an SRB assay. They depict the 
percentage of cell number remaining after a 5-day treatment with increasing concentrations 





Figures 3.17 & 3.18: Concentration response curves of breast cancer cells treated with Phloretin (3.17) and 
Quercetin (3.18) concentrations between 0.6-300μΜ for a five day period. Cell viability was determined by an 
SRB assay. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are 
shown as a percentage of control. A constant 0.3% DMSO concentration was used across the whole curve in both 
cases. Representative data of 5 independent experiments are presented. 
Both compounds inhibited the cell proliferation of all four breast cancer cell lines in a 
concentration dependent manner. The IC50 values ranged from 36 to 135μΜ for Phloretin 
and from 44 to 105μΜ for Quercetin, as shown in Table 3.2. Both compounds shared the 
same pattern of sensitivity between the different cell lines. BT549 cells were found to be 
more sensitive to both compounds while MDA-MB-231 cells were less sensitive.  
  
Figures 3.19 & 3.20: Concentration response curves of ovarian cancer cells treated with Phloretin (3.19) and 
Quercetin (3.20) concentrations between 0.6-300μΜ for a five day period. Cell viability was determined by an 
SRB assay. Mean results of 6 replicates are reported and error bars represent standard deviations.  Values are 
shown as a percentage of control. A constant 0.3% DMSO concentration was used across the whole curve in both 
cases. Representative data of 5 independent experiments are presented. 
Figures 3.19 and 3.20 present the concentration response curves of Phloretin and Quercetin 
for a panel of four ovarian cancer cell lines. All four cell lines were sensitive to both 
compounds and presented IC50 values that ranged between 51 and 197μΜ for Phloretin and 
21 to 240μΜ for Quercetin. TOV112D presented greater sensitivity to Phloretin and 












































































































3.2.1.2 STF31 & WZB117 
STF31 and WZB117 are both recently identified compounds described as specific GLUT1 
inhibitors [312, 319].  
  
Figures 3.21 & 3.22: Concentration response curves of breast cancer cells treated with STF31 (3.21) and 
WZB117 (3.22) concentrations between 0.06-30μΜ for a five day period. Cell viability was determined by an 
SRB assay. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are 
shown as a percentage of control. A constant 0.3% DMSO concentration was used across the whole STF31 curve 
and a constant 0.3% Ethanol concentration was used across the whole WZB117 curve. Representative data of 3 
independent experiments are presented. 
Figures 3.21 and 3.22 present the effect of STF31 and WZB117 on cell proliferation of the 
breast cancer cell panel. STF31 exhibited an interesting differential effect between the cell 
lines. Three of them were very sensitive to this compound, presenting IC50 values in the 
range of 173 (HBL100) to 813nM (MDA-MB-231), while BT549 cells were almost resistant 
to the compound with an IC50 value of 18μΜ. Regarding WZB117 all four breast cancer cell 
lines presented similar sensitivities with an IC50 value of around 6μΜ. 
  
Figures 3.23 & 3.24: Concentration response curves of ovarian cancer cells treated with STF31 (3.23) and 
WZB117 (3.24) concentrations between 0.06-30μΜ for a five day period. Cell viability was determined by an 
SRB assay. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are 










































































































and a constant 0.3% Ethanol concentration was used across the whole WZB117 curve. Representative data of 3 
independent experiments are presented. 
Figures 3.23 and 3.24 depict the effect of STF31 and WZB117 on the selected ovarian 
cancer cell lines. The four cell lines presented great differences in their response to these 
compounds. Regarding STF31, TOV112D was very sensitive with an IC50 value equal to 
154nM while OVCAR3 was completely resistant to the range of the concentrations used. 
Similar differences were also observed for WZB117. OVCAR3 cells were very sensitive 
presenting an IC50 value of 1.4μΜ while in contrast OVCAR5 cells proved resistant to this 
compound. The other two cell lines had similar sensitivity to the examined breast cancer 
cells.   
 
3.2.2 Targeting Hexokinase 
Hexokinase catalyses the first rate-limiting reaction of the glycolytic pathway and 
phosphorylates glucose to glucose-6-phosphate. 3-Bromopyruvate (3BP) inhibits the 
mitochondrial bound hexokinase II [325, 326].  
 3-Bromopyruvate 
  
Figures 3.25 & 3.26: Concentration response curves of breast (3.25) and ovarian (3.26) cancer cells treated with 
3-bromopyruvate concentrations between 0.6-300μΜ for a five day period. Cell viability was determined by an 
SRB assay. Mean results of 6 replicates are reported and error bars represent standard deviations.  Values are 
shown as a percentage of control. Representative data of 3 independent experiments are presented. 
Figures 3.25 and 3.26 indicate the effects of 3BP on cell viability of the panels of breast and 
ovarian cancer cell lines respectively. Both groups of cancer cells presented similar 
sensitivities to this agent. Among breast cancer cell lines, BT549 was more sensitive with an 
IC50 value of 10μΜ whereas MDA-MB-231 was the least sensitive, having an IC50 value 
equal to 84μΜ. Between the ovarian cancer cell lines TOV11D was the most sensitive and 






















































3.2.3 Targeting Phosphofructokinase 
PFK1 catalyses the second rate-limiting reaction of the glycolytic pathway adding a second 
phosphate group to glucose-6-phosphate. PFKFB3 is a component of Fru-2,6-BP which is an 




Figures 3.27 & 3.28: Concentration response curves of breast (3.27) and ovarian (3.28) cancer cells treated with 
3PO concentrations between 0.005-100μΜ (3.27) and between 0.06-30μΜ (3.28) for a five day period. Cell 
viability was determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent 
standard deviations. Values are shown as a percentage of control. A constant 1% and 0.3% DMSO concentration 
was used respectively across the curves. Representative data of 2 independent experiments are presented. 
 
Figures 3.27 and 3.28 demonstrate the response of the breast and ovarian cell panel to 3PO 
treatment. Breast cancer cell lines had a similar response to this compound with an IC50 
value around 2μΜ. MDA-MB-231 cells were found slightly more resistant (IC50 4μΜ). 
Between the ovarian cancer cell lines TOV112D was the most sensitive with an IC50 value as 
low as 1μΜ and CAOV3 the most resistant with an IC50 value almost six fold higher. 
 
3.2.4 Targeting Pyruvate Dehydrogenase Kinase 
PDHK1 phosphorylates and inactivates PDH. Dichloroacetate (DCA) is a well-established 
PDHK1 inhibitor leading to redirection of ATP synthesis through mitochondrial oxidative 
























































Figures 3.29 & 3.30: Concentration response curves of breast (3.29) and ovarian (3.30) cancer cells treated with 
Dichloroacetate concentrations between 0.4-100mΜ for a five day period. Cell viability was determined by an 
SRB assay. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are 
shown as a percentage of control. Representative data of 5 independent experiments are presented. 
DCA was effective in inhibiting breast and ovarian cancer cell proliferation in the millimolar 
concentration range (Figures 3.29 and 3.30). HBL100 was the most resistant breast cancer 
cell line (IC50 19mΜ) and MCF7 the most sensitive one (IC50 7mΜ). Having similar IC50 
values CAOV3 and TOV112D were the least and most sensitive ovarian cancer cell lines 
respectively.  
3.2.5 Targeting Lactate Dehydrogenase 
LDHA catalyses the final step of the glycolytic pathway converting pyruvate to lactate.  
3.2.5.1 Oxamic acid 
Oxamic acid is an established LDH inhibitor [368].  
  
Figures 3.31 & 3.32: Concentration response curves of breast (3.31) and ovarian (3.32) cancer cells treated with 
Oxamic acid concentrations between 0.4-100mΜ for a five day period. Cell viability was determined by an SRB 
assay. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are shown as 









































































































The above graphs present the effect of Oxamic acid on cell proliferation of the panel of 
breast and ovarian cancer cells respectively (Figures 3.31&3.32). Oxamic acid attenuated 
cell proliferation of both panels in the millimolar concentration range. MDA-MD-231 was 
the most resistant breast cancer cell line with an IC50 value of 60mM while MCF7 and 
HBL100 were the most sensitive cell lines having an IC50 value of 30mM. Among the 
ovarian cancer cell lines CAOV3 was the most resistant and TOV112D the most sensitive. 
Their IC50 values were analogous to the respective breast lines. 
 
3.2.5.2 NHI-1 
NHI-1 was described recently by Granchi et al as a specific LDHA inhibitor [378]. 
 
  
Figures 3.33 & 3.34: Concentration response curves of breast (3.33) and ovarian (3.34) cancer cells treated with 
NHI-1concentrations between 0.6-300μΜ for a five day period. Cell viability was determined by an SRB assay. 
Mean results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a 
percentage of control. A constant 0.3% DMSO concentration was used across the whole curve in both cases.  
Representative data of 2 independent experiments are presented. 
 
NHI-1 was more effective than Oxamic acid in inhibiting cancer cell proliferation, requiring 
much lower concentrations (Figures 3.33&3.34). MCF7 was the most sensitive breast cancer 
cell line to this compound among those examined, presenting an IC50 value of 8μΜ. In 
contrast, the ovarian CAOV3 was certainly the most resistant of all examined cell lines with 
an IC50 value of 90μΜ. Among the breast cancer cell lines, HBL100 presented the greatest 





























































MCF-7 MDA-MB-231 HBL100 BT549 
Phloretin (μΜ) GLUT1 122 135 69 36 
Quercetin (μΜ) GLUT1 44 105 76 44 
STF31 (μΜ) GLUT1 0.31 0.81 0.17 18 
WZB117 (μΜ) GLUT1 6.4 6.3 5.2 6.6 
3-bromopyruvate (μΜ) HKII 18 84 15 10 
3PO (μΜ) PFKFB3 2.1 3.8 2.7 2.3 
Dichloroacetate (mM) PDHK1 6.8 13 19 9.1 
Oxamic acid (mM) LDH 28 58 27 39 
NHI-1 (μΜ) LDHA 8 20 53 22 
 
Table 3.2: Summary of the IC50 concentrations generated for four breast cancer cell lines after a five day 





OVCAR5 TOV112D OVCAR3 CAOV3 
Phloretin (μΜ) GLUT1 119 51 54 197 
Quercetin (μΜ) GLUT1 154 94 21 240 
STF31 (μΜ) GLUT1 7.4 0.15 >30 4.9 
WZB117 (μΜ) GLUT1 >30 5.9 1.4 4.3 
3-bromopyruvate (μΜ) HKII 20 16 20 84 
3PO (μΜ) PFKFB3 3.9 1.2 2.8 5.8 
Dichloroacetate (mM) PDHK1 14 5.5 13 20 
Oxamic acid (mM) LDH 38 24 34 59 
NHI-1 (μΜ) LDHA 45 28 35 91 
 
Table 3.3: Summary of the IC50 concentrations generated for four ovarian cancer cell lines after a five day 







3.3 Exploration of the differential sensitivity of breast and ovarian cancer cell 
lines to glycolytic inhibitors  
 
To explore the reasons for the differential effects of the glycolytic inhibitors on the panel of 
cell lines, the expression of the glycolytic targets of interest was first examined in whole cell 
lysates of the panel of breast and ovarian cancer cell lines. Figure 3.35 shows the Western 
blotting results for GLUT1, HKII, PFKFB3 and LDHA protein expression in the various cell 
lines. The four glycolytic enzymes were found present in all eight cell lines. Figures 3.36, 
3.37 and 3.38 present the results of the quantitative densitometric analysis of the 
immunoblots. Data were normalised to α tubulin expression. GLUT1, HKII and LDHA 
expression was comparable among the different breast and ovarian cell lines. Based on the 
loading control data MCF7 and OVCAR5 cells had increased GLUT1 level compared to the 
other cell lines. OVCAR3 cells presented higher HKII expression. Regarding PFKFB3, 
OVCAR3 and CAOV3 ovarian cancer cells expressed higher levels of this target. For the 
other cell lines the expression was low and difficult to quantify. OVCAR5 and OVCAR3 
cells had slightly higher LDHA expression compared to the other cell lines.  
It was hypothesised that the differences observed in the sensitivity of the cell lines to the 
various glycolytic inhibitors (Tables 3.2&3.3) could possibly be explained by differential 
expression of the glycolytic enzymes. The IC50 values obtained for the panel of eight cell 
lines when treated with different glycolytic inhibitors were correlated with the protein 
expression level of the respective glycolytic target. Spearman r nonparametric correlation 
values are summarised in Τable 3.4. No significant correlation was found between sensitivity 
to any of the inhibitors and expression of the inhibitor target (two-tailed P values> 0.05).   
It was next investigated whether the rate of proliferation of each cell line could have an 
impact on cellular response to glycolytic inhibitors. As illustrated in Figures 3.39 and 3.40, 
sensitivity to two of the glycolytic inhibitors was revealed to correlate significantly with the 
proliferation rate of the different cell lines. Sensitivity to STF31 was found to correlate with 
the cell growth rate at p=0.0368 level, as well as sensitivity to Oxamic acid at the p=0.0046 
level. Cell lines with the fastest growth rates presented increased sensitivity to these 
inhibitors while in contrast the slowest proliferating ones were found more resistant to both 












                      
 
 
Figure 3.35: GLUT1, HKII, PFKFB3 and LDHA protein expression detected through Western blotting in a panel 
of 4 breast and 4 ovarian cancer cell lines. Alpha tubulin was used as a loading control (n=1). 
 
   
    
 
Figures 3.36 & 3.37: GLUT1, HKII and LDHA protein expression detected through Western blotting in a panel 
of 4 breast and 4 ovarian cancer cell lines. Densitometry analysis was conducted using the Odyssey Infrared 













































































Figure 3.38: LDHA protein expression detected through Western blotting in a panel of 4 breast and 4 ovarian 
cancer cell lines. Densitometry analysis was conducted using the Odyssey Infrared Imaging System software 









Spearman r two-tailed 
P value 
Phloretin 0.1667 0.7033 
Quercetin 0.2381 0.5821 
STF31 -0.3571 0.3894 
WZB117 0.2381 0.5821 
3-bromopyruvate 0.6347 0.0962 
Oxamic acid 0.2431 0.2431 
NHI-1 0.5952 0.1323 
 
 
Table 3.4: Spearman nonparametric correlation of the IC50 concentrations generated for 4 breast and 4 ovarian 
cancer cell lines when treated with the indicated glycolytic inhibitors for a five-day period with the protein 




































Figures 3.39 & 3.40: IC50 concentrations generated for 4 breast and 4 ovarian cancer cell lines when treated with 
STF31 and Oxamic acid for a five-day period plotted against growth fold change of the respective cell line. For 
STF31: Spearman nonparametric correlation r=-0.7619 and two-tailed P value 0.0368; characterised significant. 





























































Phloretin  0.018 0.53 0.93 0.017 0.010 0.22 0.049 0.19 
Quercetin 0.018  0.88 0.94 0.07 0.015 0.14 0.097 0.019 
STF31 0.53 0.88  0.63 0.62 0.88 0.89 0.71 0.99 
WZB117 0.93 0.94 0.63  0.99 0.58 0.38 0.98 0.38 
3-BP 0.017 0.07 0.62 0.99  0.024 0.24 0.002 0.29 
3PO 0.010 0.015 0.88 0.58 0.024  0.021 0.009 0.03 
DCA 0.22 0.14 0.89 0.38 0.24 0.021  0.21 0.011 
Oxamic acid 0.049 0.097 0.71 0.98 0.002 0.009 0.21  0.30 
NHI-1 0.19 0.019 0.99 0.38 0.29 0.03 0.011 0.30  
 
 
Table 3.5: Pearson correlation of each pair of IC50 concentrations of nine glycolytic inhibitors generated for 4 
breast and 4 ovarian cancer cell lines treated for a five-day period. Statistically significant Person P-values (P < 



















































































Figure 3.41: Correlation heatmap of pairs of IC50 concentrations of nine glycolytic inhibitors generated for 4 
breast and 4 ovarian cancer cell lines treated for a five-day period. Positive Person R correlation values are 
displayed in bright white colours while negative Pearson R correlation values in dark red colours.  
 
 
It was observed that two particular cell lines presented greater resistance to the majority of 
glycolytic inhibitors; MDA-MB-231 among the breast cancer cell lines and CAOV3 among 
the ovarian cancer cell lines (Tables 3.2&3.3). In order to develop a better understanding of 
the differential sensitivity of the cell lines to glycolysis inhibition the generated IC50 
concentrations were correlated with each other. Table 3.5 presents the Pearson correlation P 
values of pairs of IC50 concentrations obtained for the panel of breast and ovarian cancer cell 
lines when treated with the nine glycolytic inhibitors. In Figure 3.41 is shown a correlation 
heatmap that illustrates the Pearson R correlation values. Positive R correlation values are 
displayed in bright white colours while negative R values are displayed in dark red colours. 
Seven of the inhibitors (Phloretin, Quercetin, 3BP, 3PO, DCA, Oxamic acid and NHI-1) had 
IC50 values that generated positive R values when compared to each other; visualised in the 
bright yellow square of the heatmap. Only two of the array of compounds, STF31 and 
WZB117 in the first branch of the dendrogram, gave IC50 values that did not correlate 
significantly with any of the other inhibitors. Negative R values are visualised in the dark red 
border of the bottom and left side of the heatmap.   
 





3.4 The effect of glycolytic inhibitors on cell growth of two pairs of 
chemosensitive - chemoresistant ovarian cancer cell lines 
 
PEA1-PEA2 and PEO1-PEO4 are two ovarian cancer cell line pairs established from two 
patients with ovarian adenocarcinoma. The first cell line of each pair is platinum sensitive 
while the second one was acquired after platinum resistance had been established [399, 400]. 
The effect of three selected glycolytic inhibitors on these cell lines was examined. 
 
3.4.1 STF31 
Figures 3.42 and 3.43 show the response of the two ovarian cancer cell line pairs to STF31 
treatment. In both cases the two cell lines of each pair responded similarly to the GLUT1 
inhibitor. The PEA2 cell line was found to be slightly more resistant compared to its paired 
platinum naïve line PEA1, with an IC50 value of 1.3μΜ against 0.9μΜ. In contrast the 
platinum-resistant line PEO4, having an IC50 value of 1.3μΜ, showed increased sensitivity to 
the inhibitor compared to its paired platinum-sensitive line PEO1, with an IC50 value of 





Figures 3.42 & 3.43: Concentration response curves of ovarian cancer cell line pairs treated with STF31 
concentrations between 0.06-30μΜ for a four day period. Cell viability was determined by an SRB assay. Mean 
results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a percentage 
of control. A constant 0.3% DMSO concentration was used across the whole curve in both cases. Representative 





















































Results of 3PO treatment for the two ovarian cancer cell line pairs are shown in Figures 3.44 
and 3.45. In both cases sensitivity to the PFKFB3 inhibitor coincided with platinum 
sensitivity. Both platinum resistant cell lines presented greater resistance to 3PO compared to 
their platinum sensitive paired cell lines. Both of them had a twofold higher IC50 value 
compared to the corresponding values of the platinum sensitive cell lines (Table 3.6).       
  
Figures 3.44 & 3.45: Concentration response curves of ovarian cancer cell line pairs treated with 3PO 
concentrations between 0.06-30μΜ for a four day period. Cell viability was determined by an SRB assay. Mean 
results of 6 replicates are reported and error bars represent standard deviations. Constant 0.3% DMSO 
concentration was used across the whole curve in both cases. Representative data of 3 independent experiments 
are presented. 
3.4.3 Oxamic acid 
The figures below present the results of the two ovarian cancer cell line pairs when treated 
with Oxamic acid (Figures 3.46&3.47). The first pair responded similarly to the LDH 
inhibitor with an almost identical IC50 value of 16mM. Regarding the second pair, the PEO4 
platinum resistant cell line proved to be more resistant to Oxamic acid, having an IC50 value 
threefold higher than the corresponding value of PEO1 (Table 3.6).        
  
Figures 3.46 & 3.47: Concentration response curves of ovarian cancer cell line pairs treated with Oxamic acid 
concentrations between 0.4-100mΜ for a four day period. Cell viability was determined by an SRB assay. Mean 
results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a percentage 






































































































PEA1 PEA2 PEO1 PEO4 
STF31 (μM) 0.86 1.3 1.5 0.88 
3PO (μM) 6.3 11.9 3 6.8 
Oxamic acid (mM) 16 17.6 3.8 10.1 
 
Table 3.6: Summary of the IC50 concentrations generated for two ovarian cancer cell line pairs after a four day 
treatment with three glycolytic inhibitors. 
 
3.5 The effect of the novel GLUT1 inhibitor IOM-1190 
 
3.5.1 The effect of IOM-1190 on cell growth of selected breast and ovarian 
cancer cell lines 
IOM-1190 is a novel selective GLUT1 inhibitor [324]. The effect of this inhibitor on cell 
proliferation of two breast cancer cell lines (MCF7 and MDA-MB-231) as well as the two 
pairs of chemosensitive - chemoresistant ovarian cancer cell lines (PEA1-PEA2 and PE01-
PE04) described above was examined. Cancer cell proliferation was examined by the SRB 
assay. 
 
Figure 3.48: Concentration response curves of two breast cancer cell lines treated with IOM-1190 concentrations 
between 0.06-30μΜ for a three day period. Cell viability was determined by an SRB assay. Mean results of 6 
replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control. 
A constant 0.3% DMSO concentration was used across the whole curve. Representative data of 3 independent 
experiments are presented. 
Figure 3.48 depicts the concentration response curves of two breast cancer cell lines, the ER 
positive MCF7 and the triple negative MDA-MB-231, when treated with IOM-1190 for three 
days. As shown in Table 3.7 MDA-MB-231 cells, with an IC50 value of 2μΜ, appeared to be 
























IC50 values MCF-7 MDA-MB-231 
IOM-1190 (μΜ) 8.6 2.4 
Table 3.7: Summary of the IC50 
concentrations generated for two breast 
cancer cell lines after a three day treatment 






Figures 3.49 & 3.50: Concentration response curves of ovarian cancer cell line pairs treated with IOM-1190 
concentrations between 0.2-100μΜ for a four day period. Cell viability was determined by an SRB assay. Mean 
results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a percentage 
of control. A constant 1% DMSO concentration was used across the whole curve in both cases. Representative 









PEA1 PEA2 PEO1 PEO4 
IOM-1190 (μM) 0.28 0.46 4.8 1.6 
 
Table 3.8: Summary of the IC50 concentrations generated for two ovarian cancer cell line pairs after a four day 
treatment with IOM-1190. 
 
 
Figures 3.49 and 3.50 demonstrate the effect of IOM-1190 on cell proliferation of two 
ovarian cancer cell line pairs. The compound effectively attenuated cell proliferation of both 
chemosensitive and chemoresistant cell lines. The first pair of cell lines responded in a 
similar way and presented similar sensitivity to the inhibitor. PEA1 had an IC50 value equal 
to 280nM and PEA2 equal to 460nM. In contrast, the PEO4 platinum-resistant cell line 
presented greater sensitivity having a threefold lower IC50 value (equal to 1.6μΜ) compared 


















































3.5.2 The effect of IOM-1190 under different glucose concentrations 
The effect of IOM-1190 on MCF7 and MDA-MB-231 cell lines was examined under two 
different conditions; low glucose 5.56mM (as used in every experiment of this study) and 
high glucose 25mM.  
  
Figures 3.51 & 3.52: Concentration response curves of two breast cancer cell lines treated with IOM-1190 
concentrations between 0.06-30μΜ under two different conditions of low and high glucose. Cell viability was 
determined by an SRB assay after a three day treatment. Mean results of 6 replicates are reported and error bars 
represent standard deviations. Values are shown as a percentage of control. A constant 0.3% DMSO 
concentration was used across the whole curve in both cases. Statistical significance indications: ns not 
significant P>0.05, * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 (two-tailed P value generated from 












IOM-1190 (μM) 7.8 10.3 0.78 2.34 
 
Table 3.9: Summary of the IC50 concentrations generated for two breast cancer cell lines after a three day 
treatment with IOM-1190 under two different conditions of low and high glucose. 
 
Figures 3.51 and 3.52 indicate the response of MCF7 and MDA-MB-231 cells to IOM-1190 
treatment in the presence of a low or high glucose environment. Both cell lines presented 
greater resistance to the compound under high glucose conditions. The data demonstrated 
that MDA-MB-231 cells had a threefold increase in their IC50 value in the presence of high 
concentration of glucose compared to low glucose conditions. MCF7 cells presented a 
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3.6 The effect of a glutaminolysis inhibitor on cell growth of a panel of four 
breast and four ovarian cancer cell lines 
 BPTES 
It is well established that many tumours have elevated glutamine metabolism [127-130]. 
Glutaminase catalyses the conversion of glutamine to glutamate which is the first reaction of 
the glutaminolytic pathway. BPTES, a selective glutaminase inhibitor, was used in this study 
and compared against the panel of four breast and four ovarian cancer cell lines described 
above [135]. Cancer cell proliferation was examined by the SRB assay after a 5-day 
treatment period.  
 
  
Figures 3.53 & 3.54: Concentration response curves of breast (3.53) and ovarian (3.54) cancer cells treated with 
BPTES concentrations between 0.02-10μΜ for a five day period. Cell viability was determined by an SRB assay. 
Mean results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a 
percentage of control. A constant 0.1% DMSO concentration was used across the whole curve in both cases. 
Representative data of 2 independent experiments are presented. 
 
 
Figures 3.53 and 3.54 present the results of the breast and ovarian cancer cell lines treated 
with BPTES. Great variation is demonstrated in the response of the different cell lines to this 
inhibitor. Regarding the breast cancer cell lines, MDA-MB-231 was very sensitive to 
BPTES, with an IC50 value equal to 80nM, while MCF7 and BT549 were found to be highly 
resistant to it in the range of the concentrations used. Between the ovarian cancer cell lines 
OVCAR5 and OVCAR3 cells were also found to be very sensitive, with IC50 values a little 
higher than 100nM, while in contrast CAOV3 cells demonstrated resistance to the compound 






















































IC50 values MCF-7 MDA-MB-231 HBL100 BT549 
BPTES (μΜ) N/A 0.08 0.66 N/A 
 
IC50 values OVCAR5 TOV112D OVCAR3 CAOV3 
BPTES (μΜ) 0.18 0.8 0.12 N/A 
 
Table 3.10: Summary of the IC50 concentrations generated for four breast and four ovarian cancer cell lines after 
a five day treatment with BPTES. N/A stands for not achieved in the range of tested concentrations. 
 
3.7 Discussion  
3.7.1 Growth dependency of breast and ovarian cancer cell lines on nutrient 
availability 
The initial aim of this study was to develop an understanding of how the growth of breast 
and ovarian cancer cell lines were influenced by varying the concentrations of glucose and 
glutamine. The mean physiological level of glucose in the plasma is approximately 5mM; 
with a maximum concentration of 9mM after eating and a minimum of 3mM following 
physical exercise or moderate fasting [409]. Nevertheless the concentration of glucose in 
malignant tissues is significantly lower than their normal counterparts (up to 10 fold) in 
consequence of augmented glucose consumption and abnormal tumour microvasculature 
[410]. The majority of in vitro cell culture studies are typically conducted at a 
supraphysiological 25mM D-glucose concentration (the concentration present in DMEM 
medium 4500mg/L) to allow  sufficient energy and maximal growth; however in the present 
metabolic study a lower glucose environment (5.56mM), closer to the physiological glucose 
level, was selected for the experiments. Glutamine is the most abundant free amino acid with 
a concentration reaching 0.7-0.9mM in the plasma [411, 412]. All the experiments in this 
study, similar to the majority of cancer research literature, were conducted with 4mM L-
glutamine. The first question in this study sought to determine the growth of a panel of 
selected breast and ovarian cancer cell lines under a range of glucose and glutamine 
concentrations as well as in conditions of complete deprivation of each metabolic substrate. 
The most interesting observation from the breast cancer data is that MDA-MB-231 and 
HBL100 cells were completely unable to proliferate in the absence of glucose. For both cell 
lines a significant induction in cell proliferation was only observed after addition of 0.4mM 




cell lines behaved in a different way. MCF7 cells were able to proliferate and increase their 
cell number by an impressive six fold when glucose was depleted; compared to the number 
of cells on the day of treatment (day 0). In the same conditions, BT549 cells doubled their 
cell number (Figures 3.1&3.7). All four examined breast cancer cell lines demonstrated 
maximal growth when cultured at 1.6mM glucose and above that concentration a plateau of 
growth was reached. The ovarian cancer cell lines demonstrated similar differences in the 
ability to grow in the absence of glucose. TOV112D and OVCAR3 were both able to 
increase their cell number up to threefold in glucose depleted conditions while in contrast 
OVCAR5 and CAOV3 were unable to grow when glucose was not present in the culture 
medium (Figures 3.9, 3.11, 3.13&3.15). Particularly for CAOV3 cells, a relatively high 
concentration equal to 0.4mM was essential for significant growth. Interestingly OVCAR5, 
TOV112D and CAOV3 cells reached a plateau of maximal growth at 1.6mM glucose, 
similar to the breast lines. In contrast OVCAR3 cells demonstrated optimal growth when 
cultured in a low glucose environment of 0.4mM. The observed differential sensitivity to 
glucose limitation corroborates the findings of Birsoy et al. In their study the authors 
developed a novel cell culture system ensuring constant low glucose availability and 
reported that cancer cells respond differently to glucose limitation. Based on RNAi pool 
screen data of metabolic genes, they identified that oxidative phosphorylation upregulation 
was of major importance for adaptation to a low glucose environment and correlated 
sensitivity to low glucose with mitochondrial mutations or deficient glucose utilisation [410].    
As regards glutamine growth requirements, three out of four breast cancer cell lines (MCF7, 
MDA-MB-231 and BT549) were found unable to proliferate under zero glutamine 
availability. For these cell lines a minimum concentration of 0.1mM glutamine was required 
to achieve significant proliferation while optimal growth was observed between 0.4 and 
0.8mM with no significant difference in growth under higher glutamine concentrations 
(Figures 3.2, 3.4&3.8). In contrast HBL100 cells required a minimum concentration of 
0.4mM glutamine to significantly induce growth compared to the glutamine depleted control 
while higher glutamine concentration led to higher growth rate with the maximal cell number 
observed at the highest tested concentration of 12.8mM (Figure 3.6). With respect to the 
ovarian cancer cell lines an interesting finding is that none of the examined lines was able to 
show any sign of growth when glutamine was not present in the culture medium (Figures 
3.10, 3.12, 3.14&3.16). Another finding of note is that OVCAR3 and CAOV3 cells 
demonstrated maximal growth at a low glutamine concentration, equal to 0.4 and 0.2mM 
respectively, whereas OVCAR5 and TOV112D demanded a concentration higher than 




glutamine dependency with invasive capability. Nonetheless the current study has been 
unable to support this association as proliferative growth of OVCAR3 cells, considered of 
low invasive potential was not found independent of glutamine as previously described 
[413]. This discrepancy could possibly be attributed to the prolonged incubation of 5 days 
under glutamine depleted conditions whereas previous findings do not exceed a 3 day 
‘treatment’.   
Results from this set of experiments are consistent with those of Mathews et al who 
demonstrated that glucose and glutamine deprivation had a significant effect on HeLa cell 
survival. They documented that low glucose and glutamine availability and especially 
complete depletion impaired cancer cell viability and induced morphological changes even 
after a rapid 2h exposure [414]. Glucose deprivation has been extensively associated with 
oxidative stress [414, 415]. Aykin-Burns et al attributed the increased sensitivity of breast 
cancer cells to glucose withdrawal (and subsequently to glucose inhibition) compared to 
normal mammary epithelial cells, to the pro-oxidant status mediated by elevated ROS 
production [415]. In line with these findings Graham et al also confirmed the association 
between the metabolic reconfiguration of tumours and increased sensitivity to glucose 
deprivation. They linked glucose depletion with elevated tyrosine kinase signalling and ROS 
mediated cell death [416]. Regarding glutamine dependency Yuneva et al associated 
glutamine withdrawal with apoptotic cell death in cells bearing an activated Myc oncogene. 
Apoptosis was not related to DNA damage nor ATP depletion but only to deficiency of 
Krebs cycle intermediates [417].  
Taken together these findings highlight that both breast and ovarian cancer cell growth is 
highly dependent on the availability of the major metabolic substrates, glucose and 
glutamine. The most striking observation is that none of the examined cell lines was able to 
proliferate in glutamine depleted conditions. Furthermore only four of the cell lines, two 
breast (MCF7 and BT549) and two ovarian (TOV112D and OVCAR3) achieved minimal 
growth when deprived of glucose (Table 3.1). The evidence of strong reliance on both 
glucose and glutamine for breast and ovarian cancer cell proliferation indicates that targeting 
of these metabolic pathways could potentially be therapeutically exploited and provide a 
promising strategy for the treatment of these female malignancies. Nevertheless it could be 
argued that the cell lines might have adapted metabolically to prolonged culture in a nutrient-
rich in vitro environment and this might compromise the present findings. Further research is 




3.7.2 Growth inhibitory effect of glycolytic inhibitors on breast and ovarian 
cancer cell lines 
The effect of several inhibitors targeting key enzymes of the glycolytic pathway was then 
investigated in this study. Upstream components of the pathway (GLUT1, HKII and 
PFKFB3), the downstream target LDH along with PDHK1, an important regulator of the 
mitochondrial PDH complex, were selected and targeted with pharmacological tool 
compounds (Figure 1.7). Initially the growth inhibitory effect of these agents against a panel 
of breast and ovarian cancer cell lines was examined by the SRB assay after a 5-day 
treatment period. 
Even though the tetrazolium-based MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide] assay has been considered the ‘gold-standard’ of in vitro cytotoxicity 
assays several concerns have recently been raised and its accuracy has been questioned [418, 
419]. The MTT assay, as well as other tetrazolium-based assays including the XTT and 
MTS, is based on the enzymatic reduction of a tetrazolium salt to the water insoluble 
formazan by metabolically active cells [420]. Recent evidence suggests that the MTT assay 
may interfere with several compounds containing oxido-reductive properties, including the 
glycolytic inhibitors 3BP, 2-deoxyglucose and lonidamine; generating false positive results 
thus indicating enhanced cellular viability [418, 419]. In contrast, the SRB assay is 
independent of metabolic function and exclusively based on the cellular protein content. 
Therefore it was selected here as more suitable for the study of metabolic inhibitors. Indeed 
this assay has gained a lot of ground in preclinical compound screening and is now the assay 
of choice in the Developmental Therapeutics Programme of the USA National Cancer 
Institute (NCI-60 Human Tumor Cell Lines Screen) [418, 421].     
The most important finding of this set of experiments is that every single inhibitor tested 
attenuated breast and ovarian cancer cell proliferation in a concentration-dependent manner. 
Each of the examined compounds exhibited distinct inhibitory potency while each cell line 
demonstrated differential sensitivity to the same inhibitor. Recently developed agents, 
including STF31, WZB117 and 3PO were considerably more effective in inhibiting cancer 
cell proliferation compared to more established compounds like DCA and Oxamic acid that 
required higher concentrations (Tables 3.2&3.3).  
A limitation of these experiments lies in the absence of a non-malignant control cell line that 
would allow a comparison of the effect of glycolysis inhibition between benign and 
malignant cells. Nevertheless selectivity towards cancers cells has already been 




[312, 329, 358, 369]. Through metabolic plasticity normal cells are expected to tolerate 
glycolytic inhibition more readily and be able to generate ATP through mitochondrial 
respiration using alternative energy sources (fatty acids and amino acid) [100].  
GLUT1 plays a critical role in breast and ovarian tumourigenesis and has been validated as a 
promising therapeutic target. GLUT1 overexpression has been extensively associated with 
poor clinical outcome and adverse prognosis [174-176]. Two flavonoids, reported to inhibit 
glucose transmembrane transport were compared with two novel GLUT1 inhibitors. STF31 
and WZB117 proved more potent compared to the phytochemicals Phloretin and Quercetin 
(Figures 3.17 to 3.24). A striking observation is the differential effect of the novel inhibitors 
among the cell lines. STF31 was associated with remarkable cytotoxicity against HBL100 
breast and TOV112D ovarian cancer cells with an IC50 concentration lower than 0.2μM. In 
contrast BT549 breast and OVCAR3 ovarian cancer cells presented great resistance in the 
examined range of concentrations (Figures 3.21&3.23). Likewise, while the four breast 
cancer cell lines along with two ovarian lines (TOV112D and CAOV3) responded to 
WZB117 treatment in a similar manner, with IC50 values between 5 and 6μM; OVCAR3 
cells were considerably more sensitive (IC50 value equal to 1.4μM) whereas OVCAR5 cells 
were found absolutely resistant to the compound (Figures 3.22&3.24).  
Based on previously presented growth dependency data it was anticipated that cell lines able 
to grow in glucose depleted conditions would be less sensitive to GLUT1 inhibition 
compared to cell lines that proved unable to proliferate in the absence of glucose. However 
this does not appear to be the case. BT549 as well as TOV112D and OVCAR3 were the 
most Phloretin sensitive breast and ovarian cancer cell lines respectively. Nevertheless all 
these cell lines had proved able to proliferate when deprived of glucose (Table 3.1). 
Similarly for MCF7 and BT549 among the breast lines as well as OVCAR3 among the 
ovarian lines that were the most sensitive to Quercetin. This discrepancy might be attributed 
to the pleiotropic nature of these phytochemicals as both have a wide range of biological 
effects beyond inhibition of glucose transport [274, 275]. Indeed the growth inhibitory effect 
of the next-generation GLUT1 inhibitor STF31 seems more consistent with the glucose 
growth reliance of the cell lines. BT549 and OVCAR3 cells, both demonstrating the ability 
to grow in glucose depleted conditions, showed resistance to the compound. Furthermore 
since all four compounds are considered to target the same molecule they would be expected 
to have a more comparable effect among the cell lines.  A possible explanation for this is that 
some of these compounds are likely to have additional off-target effects, for example they 




Regarding previous research a thorough literature review did not reveal any information for 
antiproliferative action of the traditional phytochemical Phloretin against the breast nor the 
ovarian cancer cell line models used in this study; similarly for STF31. With respect to 
Quercetin and WZB117, data for only one of the cell lines (MCF7) was identified. 
Sensitivity of MCF7 breast cancer cells to Quercetin and WZB177 is consistent with 
findings from previous studies. The IC50 values detected here for MCF7 cells when treated 
with Quercetin and WZB117 are 44 and 6.4μM respectively as opposed to 37 and 10μM 
(approximate figure from supplementary data) that were previously reported [299, 319].   
HKII is the mitochondrial-associated isoform upregulated in many types of cancer [206]. 
Specifically for breast and ovarian tumours HKII upregulation has been linked with disease 
recurrence [216, 218]. The synthetic pyruvate analogue, 3BP, effectively inhibited tumour 
cell growth of breast and ovarian cancer cell lines (Figures 3.25&3.26). The two cancer types 
responded in a similar way to HKII inhibition with all examined cell lines demonstrating 
IC50 values between 10 and 20μM. Only two of the lines, the MDA-MB-231 breast and the 
CAOV3 ovarian, were at least fourfold less sensitive (IC50 values higher than 80μM). The 
similar response to this inhibitor demonstrated by the majority of examined cell lines might 
be an indication that they all express similar levels of this target or have comparable 
activities. This remains to be further investigated.   
PFKFB3 catalyses the synthesis of F2,6BP the allosteric activator of PFK1. PFKFB3 
overexpression has been documented in several tumour types including breast and ovarian 
cancers [223]. 3PO was confirmed as a potent growth inhibitor of both breast and ovarian 
cancer cell lines generating low IC50 values (Figures 3.27&3.28). Sensitivity of MDA-MB-
231 cells corroborates previous findings of Clem et al [343]. In the same study 3PO was 
shown to inhibit MDA-MB-231 xenograft tumour growth. It is therefore likely that the other 
breast and ovarian lines demonstrating similar or even enhanced sensitivity to PFKFB3 
inhibition compared to MDA-MB-231 cells may also have in vivo potential.  
DCA targets PDHK1 preventing PDH phosphorylation and therefore stimulating 
mitochondrial glucose oxidation [352]. DCA was effective in attenuating breast and ovarian 
cancer cell proliferation in a concentration dependent manner (Figures 3.29&3.30). However 
this compound required higher concentrations in the millimolar range. Sensitivity of MCF7 
cells to PDHK1 inhibition corroborated previous published data by Sun et al [358]. The low 
potency of the compound renders it challenging to achieve relevant therapeutic levels 
clinically. Nevertheless the high bioavailability and impressive in vivo and preclinical data of 




LDHA, the enzyme catalysing the reduction of pyruvate at the bottom of the glycolytic 
pathway, is the final target of interest in this study. LDHA upregulation has been reported in 
breast and ovarian cancers compared to normal tissues [263]. Two inhibitors, an established 
pyruvate analogue along with a novel LDHA selective inhibitor were compared here. Both 
compounds induced a concentration-dependent decline of viable cancer cell number (Figures 
3.31 to 3.34). Nevertheless NHI-1 demonstrated significantly greater growth inhibitory 
potency compared to Oxamic acid.  
These experiments provide evidence that nine compounds targeting key components of the 
glycolytic pathway inhibited breast and ovarian cancer cell proliferation in a concentration- 
dependent way. Interestingly both cancer types presented similar sensitivities to these 
inhibitors. It should be mentioned that Phloretin, 3BP, 3PO, DCA and NHI-1 presented a 
clear cytotoxic effect in the majority of cell lines whereas Quercetin, WZB117 and Oxamic 
acid suppressed cancer cell proliferation in a cytostatic way, since for the latter compounds 
the optical density measurements at the final day of treatment were higher than the 
corresponding values on the day of treatment (day 0) thus indicating that at least the initial 
number of treated cells was viable even following treatment with the highest concentration 
of these compounds for 5 days. 
On searching the literature, this work appears to be the first comparative study of an 
extended array of glycolytic inhibitors against breast and ovarian cancer cell line panels. 
There is little published data on the effect of the majority of these compounds on breast 
cancer and particularly on ovarian cancer lines. Taken together these results provide 
evidence that breast and ovarian cancer cell proliferative growth is dependent on the 
glycolytic pathway which may have therapeutic implications. The glycolytic pathway was 
validated as a legitimate target for cancer treatment.  
3.7.3 Sensitivity to glycolytic inhibitors varies among cell lines  
The noteworthy variation in IC50 concentrations indicates that the different breast and 
ovarian cancer cell lines exhibit diverse responses to the glycolytic inhibitors (Tables 
3.2&3.3). The protein expression of the targeted glycolytic enzymes was examined in the 
panel of breast and ovarian cancer cell lines through Western blotting. GLUT1, HKII and 
LDHA expression did not differ markedly between these cell lines (Figures 3.36 to 3.38). 
Furthermore no association was identified between the expression of the targeted glycolytic 




Nevertheless an interesting correlation between inhibitor response and proliferation rate was 
detected. It was revealed that sensitivity to two of the inhibitors targeting the top and bottom 
of the glycolytic pathway, STF31 and Oxamic acid, correlated significantly with the growth 
rate of the cell lines (Figures 3.39&3.40). Thus the differential response of cancer cells to 
these compounds could be attributed to growth rate differences. The fastest growing cell 
lines appeared more sensitive to these agents (lower IC50 values) compared to the slower 
growing ones that presented greater resistance to glycolysis inhibition (higher IC50 values). It 
could conceivably be hypothesised that faster growing cells are likely to be more dependent 
on the glycolytic pathway for biosynthetic precursor and energy generation in order to 
sustain their rapid proliferation and hence are more sensitive to inhibition of the pathway.    
Another interesting observation was that two of the cell lines demonstrated remarkable 
resistance to the majority of the tested inhibitors; MDA-MB-231 breast cancer cells and 
CAOV3 ovarian cancer cells (Tables 3.2&3.3). MDA-MB-231 is a triple negative cell line 
characterised as highly invasive; elevated resistance to several antitumour agents including 
tumour necrosis factor-α (TNFα) and taxol has previously been documented [422]. 
Furthermore Gaglio et al reported that MDA-MB-231 cells, harbouring an oncogenic K-Ras, 
exhibit enhanced glycolytic activity and upregulation of several glycolytic enzymes [423]. It 
is possible therefore that upregulation of the glycolytic targets is responsible for the 
decreased sensitivity to glycolytic inhibitors, as higher concentration of a compound could 
be required to target higher level of an enzyme. For further support it should also be 
mentioned that it has been reported that the Warburg is the dominant metabolic phenotype of 
triple negative tumours [424]. As regards CAOV3, this is a primary ovarian cancer cell line 
that carries a nonsense mutation in the p53 gene and multiple copies of  the PIK3CA 
oncogene [425, 426]. P53 is a well-established metabolic regulator promoting the glycolytic 
switch when it is inactivated [116]. Another relevant aspect is that CAOV3 is the slowest 
growing cell line among the ones tested here (Figures 3.39&3.40). Hence, it seems likely 
that the observed increased resistance to glycolysis inhibition could be related to the slow 
proliferation rate.   
A very significant finding to emerge from the analysis of these experiments is that sensitivity 
of the panel of breast and ovarian cancer cell lines to the vast majority of the glycolytic 
inhibitors (7 out of 9 compounds) appeared correlated with each other. Phloretin, Quercetin, 
3-BP, 3PO, DCA, Oxamic acid and NHI-1 generated IC50 concentrations that gave high 
Pearson R correlation values when compared in pairs (Figure 3.41). This association of 




compounds have a similar mode of action sharing a common target, i.e. the glycolytic 
pathway. STF31 and WZB117 formed an exception and did not correlate with sensitivity to 
any of the other agents. This could possibly be attributed to off-target effects. Indeed, 
regarding STF31 inhibition of NAMPT has been evidenced [315-317]. 
Finally, for the above analyses, breast and ovarian cancer cell lines were collectively 
considered as cancer cells and analysed together. Even though it is far from homogenous the 
panel of eight cancer cell lines was essential to get statistically significant correlations.   
3.7.4 Comparing sensitivity to glycolysis inhibition with platinum sensitivity in 
ovarian cancer cell lines 
PEA1-PEA2 and PEO1-PEO4 are two ovarian cancer cell line pairs each derived from a 
single patient with ovarian adenocarcinoma at different stages of platinum treatment. The 
first cell line of each pair is responsive to platinum therapy while the second one exhibits 
resistance to it [399, 400]. These two pairs represent a valuable model to study platinum 
sensitive and resistant ovarian cancer. Recent evidence associated drug resistance with an 
elevated dependency on the glycolytic phenotype however much less is known as to whether 
glycolysis inhibition could be exploited against resistant disease [427]. This set of 
experiments investigated the sensitivity of platinum sensitive and resistant ovarian cancer 
cells to glycolytic inhibitors. Three compounds were selected targeted against three major 
components of the glycolytic pathway; the upstream transporter GLUT1, the downstream 
target LDHA and the intermediate regulator PFKFB3.  
Targeting all three major components of glycolysis proved effective in attenuating ovarian 
cancer cell proliferation in a concentration dependent manner regardless of platinum 
sensitivity (Figures 3.42 to 3.47). These findings provide evidence that inhibition of the 
glycolytic pathway could be a promising strategy for the treatment of platinum resistant 
disease.  
The PEO1-PEO4 pair appeared considerably more sensitive to the glycolytic inhibitors 
compared to the PEA1 and PEA2 lines. Interestingly, PEA1 and PEA2 cells responded in a 
very similar way to STF31 and Oxamic acid. In contrast the platinum resistant cell line of 
both pairs appeared more resistant to PFKFB3 inhibition, demonstrating a twofold increase 
in the IC50 value. Likewise the platinum resistant PEO4 line had reduced sensitivity to 
Oxamic acid. In contrast the same cell line presented more sensitivity to STF31 compared to 




3.7.5 Investigating the antiproliferative effect of the novel GLUT1 inhibitor 
IOM-1190  
Several compounds reported to inhibit glucose transport have been used in this study. 
However concerns have been raised and their specificity has been questioned. The two 
flavonoids, Phloretin and Quercetin, are pleiotropic in nature and as discussed in the 
Introduction (section 1.5.1.1) have been associated with a wide range of biological effects 
[274, 275]. Moreover recent evidence has linked the STF31-mediated antiproliferative effect 
with NAMPT inhibition [59-61]. For that reason a novel compound specifically inhibiting 
GLUT1 was sought and investigated.      
IOM-1190 is the lead compound of a series of specific GLUT1 inhibitors identified very 
recently by IOmet Pharma [324]. The effect of this novel inhibitor on cell proliferation of a 
pair of breast cancer cell lines as well as the previously mentioned chemosensitive and 
chemoresistant ovarian cancer cell line pairs was investigated. IOM-1190 demonstrated 
remarkable antiproliferative action against breast as well as ovarian cancer cell lines both 
resistant and sensitive to platinum therapy generating low IC50 values (Figures 3.48 to 3.50).  
The most striking finding was the enhanced sensitivity of the MDA-MB-231 triple negative 
breast cancer cells compared to MCF7 cells (Table 3.7). This contradicts earlier findings 
showing that MDA-MB-231 cells were more resistant to a collection of 9 glycolytic 
inhibitors compared to the ER positive cell line (Table 3.2). Nevertheless it is in agreement 
with the nutrient growth dependency experiments presented in section 3.1. MDA-MB-231 
cellular growth proved highly dependent on glucose availability as cells were unable to 
proliferate when glucose was depleted. This strong reliance could possibly be interpreted as 
an indication of enhanced sensitivity to inhibition of glucose transport. Triple negative 
tumours are highly aggressive and with limited treatment options thus the observed 
sensitivity to a novel agent is a very important and encouraging finding [428]. 
As regards the ovarian cancer cell line pairs, an interesting observation was the elevated 
sensitivity of the PEA1 and PEA2 lines, compared to the other ovarian cancer cell pair, a 
finding that is in contrast with the results from the previously examined glycolytic inhibitors 
(Table 3.6). The PEA1 line appeared remarkably sensitive to the GLUT1 inhibitor with an 
IC50 value as low as 280nM, 17 times lower than the corresponding value of the other 
platinum sensitive line PEO1. Another noteworthy observation is that this platinum sensitive 
line PEO1 was considerably more resistant to IOM-1190 compared to its paired platinum 




Overall IOM-1190 proved a very potent inhibitor with a strong antiproliferative effect on 
widely considered resistant lines, including the triple negative MDA-MB-231 and the 
platinum resistant PEO4 cell lines. 
The next question addressed was whether sensitivity to this novel GLUT1 inhibitor would be 
affected by the concentration of glucose in the culture medium. Therefore MCF7 and MDA-
MB-231 cells were treated with IOM-1190 under low glucose (5.56mM) and high glucose 
conditions (25mM). Interestingly the effect on both cell lines proved dependent on glucose 
availability and both of them appeared more sensitive to the agent in a low glucose 
environment (Table 3.9). Even though especially for MCF7 the effect was only marginal this 
finding is in agreement with data presented by Dr Alan Wise in the 26th EORTC-NCI-
AACR Symposium given that the molecule was reported to have a substrate competitive 
mechanism of action [429]. These data indicated that A549 lung cancer cells were eightfold 
more sensitive to IOM-1190 when treated in 5mM glucose medium compared to a high 
glucose 17mM environment. Glucose sensitive cytotoxicity is also in agreement with 
findings from Liu et al on another GLUT1 inhibitor. They reported that high glucose 
concentration was able to alleviate the growth inhibitory effect of WZB115 on H1299 non-
small cell lung cancer cells suggesting this as an indication of basal glucose transport 
inhibition [318].           
3.7.6 Growth inhibitory effect of a glutaminolytic inhibitor on breast and 
ovarian cancer cell lines 
Previously it was demonstrated that breast and ovarian cancer cell growth was highly 
dependent on glutamine availability (section 3.1). The effect of glutaminolysis inhibition was 
therefore examined in the previously mentioned panel of four breast and four ovarian cancer 
cell lines. BPTES is as a selective non-competitive glutaminase inhibitor. This agent induced 
a concentration dependent reduction in the number of both breast and ovarian viable cancer 
cells (Figures 3.53&3.54). The compound demonstrated a cytostatic mechanism of action 
since the maximal growth inhibitory effect observed for any of the cell lines was around 80% 
following a 5-day incubation with the highest concentrations used in the present study. 
Antiproliferative action against the selected cell line models has not been previously 
reported.  
BPTES exhibited an interesting differential effect among the various cell lines. MDA-MB-
231 was by far the most sensitive breast cancer cell line with an IC50 value as low as 80nM. 
This sensitivity confirms the association between oncogenic K-ras transformation and 




Moreover HBL100 cells proved considerably more sensitive compared to MCF7 and BT549 
cells. This seems in agreement with glutamine growth requirements presented above. 
HBL100 cancer cells proved highly reliant on glutamine as they required high glutamine 
availability (equal to 0.4mM) to achieve significant growth compared to the glutamine 
depleted control and also they were responsive to high glutamine concentrations by 
increasing cellular proliferation (Figure 3.6).     
Among ovarian cancer cell lines OVCAR3, OVCAR5 and TOV112D presented a similar 
response to glutaminase inhibition with the latter being around fourfold less sensitive. An 
interesting observation was that CAOV3 cells demonstrated resistance to BPTES. This result 
is consistent with findings from the glutamine growth dependency experiments. CAOV3 
cells were unresponsive to high glutamine availability. Maximal growth was achieved with 
concentrations as low as 0.2mM glutamine and remained unaffected even with a 
concentration as high as 12.8mM. It is also worth mentioning that in glutamine depleted 
conditions CAOV3 cells were not able to proliferate nevertheless they were able to sustain 
their cell number as the average OD value of the no glutamine controls was comparable to 
the respective value on the day of treatment (Figure 3.16). It is possible that if the duration of 
glutamine ‘treatments’ was shorter than 5 days CAOV3 cells might be able to proliferate 
even in the absence of glutamine and prove completely independent of glutamine as 
resistance to glutaminase inhibition indicates. 
Taken together BPTES proved a potent inhibitor of breast and ovarian cancer cell 
proliferation. Inhibition of glutamine catabolism therefore also seems a promising 



























Chapter 4: The effect of glycolytic inhibitors on breast cancer cellular 
function 
 
4.1 The effect of glycolytic inhibitors on induction of apoptosis 
 
The mechanism by which the glycolytic inhibitors attenuate cancer cell proliferation was 
next examined. Flow cytometric analysis of cells double stained with annexin V conjugated 
with the fluorochrome FITC, and propidium iodide, was conducted. Annexin V is a calcium-
dependent phospholipid binding protein that binds with high affinity to phosphatidylserine 
when it is translocated and exposed in the outer cellular membrane of apoptotic cells [430, 
431]. PI is a vital dye that binds to the nucleic acids of cells that have lost the integrity of 
their cellular membrane [432]. The double staining and the subsequent flow cytometric 
analysis enabled the differentiation of a cell population treated with several glycolytic 
inhibitors in four distinct categories as presented in the following two-dimensional scatter 
plots. In these plots the annexin V fluorescent signal is indicated in the y-axis and the PI 
signal in the x-axis. Annexin V and PI negative cells, in the lower left quadrant, are 
considered intact live cells. Annexin V high and PI low cells, in the upper left quadrant are 
characterised as early apoptotic. The upper right quadrant represents cells in late apoptotic 
stages stained with both Annexin V and PI. And finally the lower right quadrant with cells 
stained only with PI represents necrotic cells [430, 431]. Cells in the upper region (upper left 
and upper right quadrants), stained positive for annexin V, were collectively characterised as 
cells undergoing apoptosis. 
  
For this experiment MCF7 breast cancer cells were used and were treated for 24 and 48 h 
with the nine glycolytic inhibitors described in previous chapters. The concentrations used 
for each compound were based on previously acquired SRB data presented in Chapter 3 
section 3.2. The mechanism of cell death involved in the end point of the sigmoidal 
concentration response curves was investigated. The concentration used for each of the 
compounds was associated with maximal growth inhibition in the SRB assays following a 5-
day treatment and was anticipated to have a significant effect on cell viability even as early 
as 24h. Two time points (24h and 48h) were selected to give a clear picture of the apoptotic 




   
Figures 4.1 & 4.2: Flow cytometric analysis of untreated MCF7 breast cancer cells at 24 and 48h. FL1 (annexin 
V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated annexin V and propidium 
iodide are presented. The percentage of cells in each quadrant is indicated in red (n=1).   
 
Figures 4.1 and 4.2 present the flow cytometric analysis of untreated MCF7 cells at 24 and 
48h respectively. At both time points the majority of cells (75 and 78% respectively) were 
found viable and non-apoptotic, annexin V and PI negative. It is interesting that at 24h 6.7% 
of the cells were classified as early apoptotic (annexin V positive, PI negative) and 15.5% 
late apoptotic (annexin V and PI positive). At 48h the percentage of apoptotic cells was 
lower (7% compared to 22.2%), however increased necrosis was observed (14.7% against 
2.9% at 24h). The untreated controls were used to define the baseline levels of apoptotic and 
necrotic cells at each time point. Untreated samples were collected at 24 and 48h and the 
culture medium was not changed before then.      
 
 
     
Figures 4.3 & 4.4: Flow cytometric analysis of MCF7 breast cancer cells treated with 300μM Phloretin for 24 
and 48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated 
annexin V and propidium iodide are presented. The percentage of cells in each quadrant is indicated in red (n=1).  
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Figures 4.3 and 4.4 show the annexin V versus PI plots of gated MCF7 cells treated with 
300μM Phloretin for 24 and 48h, respectively. It is apparent that the percentage of viable 
cells has decreased compared to the untreated controls and it is similar at both time points at 
59.1 and 54.3% respectively. At 24h the PI positively stained population increased compared 
to the untreated control, reaching 21.3%, indicating increased necrosis. After 48h treatment, 
a marked induction of both early and late apoptosis was noted. Annexin V positive cells 
increased to 43.3% from 7% for the untreated cells. The percentage of necrosis was low; 
consisting of only 2.4% of the whole cell population.   
   
Figures 4.5 & 4.6: Flow cytometric analysis of MCF7 breast cancer cells treated with 300μM Quercetin for 24 
and 48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated 
annexin V and propidium iodide are presented. The percentage of cells in each quadrant is indicated in red (n=1). 
The results of flow cytometric analysis of MCF7 cells treated with 300μM Quercetin for 24 
and 48h are presented in Figures 4.5 and 4.6. The number of live cells is similar to the 
corresponding value of the untreated controls. At 24h a marginal increase of PI positively 
stained, necrotic cells can be observed (from 2.9 to 7.4%). With respect to the 48h time 
point, an induction of both early and late apoptosis was detected. The percentage of cells in 
the upper left quadrant increased from 1.3 to 7.9% while in the upper right quadrant from 5.7 
to 17.2%.                
      
Figures 4.7 & 4.8: Flow cytometric analysis of MCF7 breast cancer cells treated with 30μM STF31 for 24 and 
48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated annexin V 
and propidium iodide are presented. The percentage of cells in each quadrant is indicated in red (n=1). 
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Scatter plots generated through flow cytometric analysis of MCF7 cells treated with 30μM 
STF31 for 24 and 48h are depicted in Figures 4.7 and 4.8. At 24h the proportion of live cells 
was almost unaffected. However an induction of necrotic cell death was seen (from 2.9 to 
19.9%). After a 48h treatment with STF31 MCF7 cells presented a fivefold increase of late 
apoptotic cells, stained positive for both annexin V and PI. It is interesting that the 
percentage of early apoptotic cells remained the same.             
   
Figures 4.9 & 4.10: Flow cytometric analysis of MCF7 breast cancer cells treated with 30μM WZB117 for 24 
and 48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated 
annexin V and propidium iodide are presented. The percentage of cells in each quadrant is indicated in red (n=1). 
Figures 4.9 and 4.10 present the scatter plots of gated MCF7 cells treated with 30μM 
WZB117 for 24 and 48h. Treatment with this particular GLUT1 inhibitor did not affect the 
viability of cancer cells at either of the time points, since live cells at 24h were quantified at 
85% of the measured population, 10% higher than the respective percentage of the untreated 
sample. Nonetheless, a threefold increase of necrotic cells, positively stained only with PI, 
can be observed after 24h treatment. At 48h a modest increase of both early and late 
apoptosis was observed. Annexin V positively stained cells increased from 7% in the control 
to 11%.  
    
Figures 4.11 & 4.12: Flow cytometric analysis of MCF7 breast cancer cells treated with 300μM 3-
bromopyruvate for 24 and 48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with 
FITC-conjugated annexin V and propidium iodide are presented. The percentage of cells in each quadrant is 
indicated in red (n=1). 
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Figures 4.11 and 4.12 reveal that 3BP has a very marked impact on cell viability through the 
apoptotic process. At least 90% of a population of MCF7 cells treated with 300μM 3BP for 
24 or 48h underwent apoptotic cell death (cells stained positive with annexin V). A balanced 
marked induction of both early and late apoptosis was observed. 
 
   
Figures 4.13 & 4.14: Flow cytometric analysis of MCF7 breast cancer cells treated with 30μM 3PO for 24 and 
48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated annexin V 
and propidium iodide are presented. The percentage of cells in each quadrant is indicated in red (n=1). 
The annexin V versus PI two-dimensional scatter plots acquired from the flow cytometric 
analysis of MCF7 cells treated with 3PO for 24 and 48h are depicted in Figures 4.13 and 
4.14. An eightfold increase of cells stained positively for PI, in the lower right quadrant, 
suggesting necrosis, can be observed after treatment with 30μM 3PO for 24h compared to 
the untreated control. On the other hand at 48h the level of necrosis is very limited (2.1%) 
while there is an evident induction of apoptosis. The percentage of cells in early apoptotic 
stages increased eleven times and a twofold increase of late apoptosis was observed as well. 
 
   
Figures 4.15 & 4.16: Flow cytometric analysis of MCF7 breast cancer cells treated with 100mM Dichloroacetate 
for 24 and 48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated 
annexin V and propidium iodide are presented. The percentage of cells in each quadrant is indicated in red (n=1). 
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A 24h treatment with 100mM DCA resulted in increased necrosis. As shown in Figure 4.15 
the percentage of cells in the lower right quadrant increased to 10.5% from 2.9% in the 
untreated control. In Figure 4.16, evidence is provided that treatment with the PDHK1 
inhibitor induces apoptosis at 48h. The percentage of live intact cells was reduced two and a 
half times and a marked increase in apoptosis was observed. Early apoptotic cells, annexin V 
positive, presented a nine fold increase while late apoptotic cells, annexin V and PI positive, 
increased eight fold.   
 
      
Figures 4.17 & 4.18: Flow cytometric analysis of MCF7 breast cancer cells treated with 100mM Oxamic acid for 
24 and 48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated 
annexin V and propidium iodide are presented. The percentage of cells in each quadrant is indicated in red (n=1). 
Plots of gated cells through flow cytometric analysis after a 24 and 48h treatment with 
100mM Oxamic acid are presented in Figures 4.17 and 4.18. At both time points there was a 
modest 5% decline in the number of live cells compared to the respective control sample. 
Nevertheless a sevenfold increase in the proportion of necrotic cells was observed at 24h. 
Regarding the 48h time point the percentage of late apoptotic cells, in the upper right 
quadrant was found to be doubled. 
  
Figures 4.19 & 4.20: Flow cytometric analysis of MCF7 breast cancer cells treated with 300μM NHI-1 for 24 
and 48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated 
annexin V and propidium iodide are presented. The percentage of cells in each quadrant is indicated in red (n=1). 
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Evidence that NHI-1 inhibits cancer cell growth through induction of apoptotic cell death is 
provided in Figures 4.19 and 4.20. Live intact cells are reduced almost by half when treated 
with 300μM NHI-1 for either 24 or 48h compared to the untreated control samples. A large 
increase in apoptotic cells stained positive for annexin V was observed at both time points. 
At 24h a threefold increase of late apoptotic cells was presented. As regards the 48h time 
point the increase of cells in the upper left quadrant was more impressive at the fivefold level 
while a similar threefold increase was presented for late apoptotic cells. 
 
The following charts illustrate the percentage of live, apoptotic and necrotic cell populations 
as quantified after cell cytometric analysis of MCF7 cells treated with the nine glycolytic 
inhibitors. Results are related to the respective populations of an untreated control.  Figure 
4.21 presents the results after a 24h treatment with the indicated inhibitors while in Figure 
4.22 48h treatment’s results are presented. 
 
` 
Figure 4.21: Quantification of percentages of apoptotic, necrotic and live MCF7 cells when treated with 9 
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Figure 4.22: Quantification of percentages of apoptotic, necrotic and live MCF7 cells when treated with 9 
glycolytic inhibitors for 48h compared to an untreated control, as generated through flow cytometric analysis. 
 
 
4.2 The effect of glycolytic inhibitors on cell cycle progression 
 
The cell cycle of eukaryotic cells consists of two separate stages; interphase and mitosis. 
Interphase includes three distinct phases, G1, S and G2 phases. During G1 phase (1
st
 gap) 
cells grow and engage to increased biosynthetic activity. S phase is defined by DNA 
synthesis and cells replicate their chromosomal DNA. G2 phase (2
nd
 gap) prepares cells for 
division and finally during Mitosis (M phase) each cell divides into two genetically identical 
daughter cells. G0 phase describes non proliferative quiescent fully differentiated cells [433]. 
For the purpose of the analysis here G0 and G1 phases, as well as G2 and M phases, are 
described as one phase as they have a uniform DNA content. 
To assess whether treatment with various inhibitors of the glycolytic pathway had an impact 
on cell cycle progression flow cytometric analysis was performed. Propidium iodide (PI) a 
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DNase-free Ribonuclease A enabled DNA specific binding. Through flow cytometry, the 
relative DNA content of samples treated with nine different glycolytic inhibitors for 24h was 
quantified. The histogram plots presented below show gated single cell populations 
according to their cellular DNA content. The PI fluorescent signal was proportional to the 
amount of DNA and separation of cells into three different categories was enabled. Cells 
during G0/G1 phase (P3), prior to DNA synthesis, have one set of paired chromosomes 
(diploid DNA). During S phase (P4) cells replicate their DNA and have variable DNA 
content, increased compared to the diploid chromosomal amount. In  G2/M phase (P5) cells 
have already doubled their DNA content containing two sets of paired chromosomes 
(tetraploid DNA) [433, 434]. For these experiments fixed and permeabilised MCF7 breast 
cancer cells were used. Since great levels of cellular death were previously observed in the 
apoptosis flow cytometry analysis, lower concentrations of the compounds were used here to 
ensure the number of adherent live cells required to run the cell cycle analysis.        
 
        
Figure 4.23: Flow cytometric analysis of cellular DNA content of untreated MCF7 breast cancer cells at 24h. In 
the histogram fluorescence of the DNA bound propidium iodide, indicating the DNA content in X- axis, is plotted 
against the number of cells in the Y-axis. The percentage of cells in each cell cycle phase is demonstrated on the 
right (n=1).  
The DNA content of MCF7 breast cancer cells in exponential growth was analysed through 
flow cytometry. The variation of the fluorescence intensity of PI was used to differentiate 
cells in each phase of the cell cycle. The percentage of cells at the G0/G1 phase (P3) was 
calculated at 36.4% of the total cell population. Cells at the G2/M phase (P5), containing 
twice the amount of DNA of G1 cells, were calculated 34%. Finally 29.6% of the total cell 
population were at the S phase (P4) and had an intermediate amount of DNA between that of 
G1 and G2 cells (Figure 4.23). The cell cycle distribution of the untreated control was used 
as reference to develop an understanding of the mechanism of the antiproliferative action of 










Figure 4.24: Flow cytometric analysis of cellular DNA content of MCF7 breast cancer cells treated with 150μM 
Phloretin for 24h. In the histogram fluorescence of the DNA bound propidium iodide, indicating the DNA content 
in X- axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell cycle phase is 
demonstrated on the right (n=1).  
Figure 4.24 provides evidence that Phloretin inhibits MCF7 cancer cell growth through cell 
cycle arrest in G1 phase. Treatment with 150μM Phloretin for 24h caused an accumulation 
of cells in the G0/G1 phase and inhibited G1-S transition. As shown in the above figure the 
percentage of cells found in the G0/G1 phase almost doubled and a corresponding decrease 
of cells in the S and G2/M phases was observed. Percentage of cells in the S phase decreased 
to 15.1% and in the G2/M phase to 24% compared to 29.6 and 34% respectively in the 
untreated control.   
 
 
Figure 4.25: Flow cytometric analysis of cellular DNA content of MCF7 breast cancer cells treated with 300μM 
Quercetin for 24h. In the histogram fluorescence of the DNA bound Propidium Iodide, indicating the DNA 
content in X- axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell cycle 
phase is demonstrated on the right (n=1).  
The percentage of MCF7 cells treated with 300μM Quercetin for 24h, in each stage of the 
cell cycle is presented in Figure 4.25. Quercetin treatment proved associated with cell cycle 
arrest in the S phase. The proportion of cells in the S phase was found 34.6% compared to 
29.6% in the untreated control while percentage of cells in the G2/M phase remained 
unaffected. In contrast number of cells in the G0/G1 phase decreased from 36.4 to 31%. 














Figure 4.26: Flow cytometric analysis of cellular DNA content of MCF7 breast cancer cells treated with 30μM 
STF31 for 24h. In the histogram fluorescence of the DNA bound propidium iodide, indicating the DNA content 
in X- axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell cycle phase is 
demonstrated on the right (n=1).  
The DNA histogram in Figure 4.26 illustrates the effect of STF31 on cell cycle progression. 
It shows that treatment with 30μM STF31 for 24h restricted cancer cells in the G0/G1 phase 
of the cell cycle. The number of cells in the G0/G1 phase increased by 7% compared to the 




Figure 4.27: Flow cytometric analysis of cellular DNA content of MCF7 breast cancer cells treated with 30μM 
WZB117 for 24h. In the histogram fluorescence of the DNA bound propidium iodide, indicating the DNA 
content in X- axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell cycle 
phase is demonstrated on the right (n=1).  
Figure 4.27 depicts the DNA cell cycle profile of cells treated with 30μM WZB117 for 24h. 
Following WZB117 treatment cells appeared to arrest in the G0/G1 and S phases. The 
percentage of cells in the G0/G1 and S phases increased by 11 and 5% respectively 
compared to the untreated cells. Accordingly a profound decline of cells in the G2/M phase, 
from 34 to 28.2% was detected.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
 














Figure 4.28: Flow cytometric analysis of cellular DNA content of MCF7 breast cancer cells treated with 50μM 
3-bromopyruvate for 24h. In the histogram fluorescence of the DNA bound propidium iodide, indicating the 
DNA content in X- axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell 
cycle phase is demonstrated on the right (n=1). 
The DNA content frequency histogram generated through flow cytometry analysis of MCF7 
cells treated with 50μM 3BP is depicted in Figure 4.28. It can be observed that a 24h hour 
treatment with 3BP resulted in an evident arrest in the G0/G1 and S phases of the cell cycle. 
The proportion of cells in these phases increased 14 and 8% respectively compared to the 
untreated sample. Progression to cell division was strongly inhibited which was 
demonstrated by a 22% reduction of cells in G2/M phase.   
  
Figure 4.29: Flow cytometric analysis of cellular DNA content of MCF7 breast cancer cells treated with 15μM 
3PO for 24h. In the histogram fluorescence of the DNA bound propidium iodide, indicating the DNA content in 
X- axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell cycle phase is 
demonstrated on the right (n=1). 
Figure 4.29 illustrates the quantitation of DNA content of MCF7 cells treated with 15μM 
3PO for 24h. Cells presented a clear arrest in the G1 phase while progression to DNA 
replication and the later stages of the cell cycle were restricted. An accumulation of cells in 
the G0/G1 phase was observed, with the number of cells increased by 43% compared to the 
untreated control. Cell numbers in the S and G2/M phases appeared decreased and were 
calculated at 21.8 and 26.1% respectively compared to 29.6 and 34% that were initially seen 
in controls.   














Figure 4.30: Flow cytometric analysis of cellular DNA content of MCF7 breast cancer cells treated with 100mM 
Dichloroacetate for 24h. In the histogram fluorescence of the DNA bound propidium iodide, indicating the DNA 
content in X- axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell cycle 
phase is demonstrated on the right (n=1). 
Figure 4.30 demonstrates that DCA treatment did not have a remarkable effect on cell cycle 
progression. A 24h treatment with 100mM DCA increased the cell number in the S and 
G2/M phases from 29.6 to 30.9% and from 34 to 35.3% respectively compared to the 




Figure 4.31: Flow cytometric analysis of cellular DNA content of MCF7 breast cancer cells treated with 100mM 
Oxamic acid for 24h. In the histogram fluorescence of the DNA bound propidium iodide, indicating the DNA 
content in X- axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell cycle 
phase is demonstrated on the right (n=1). 
The histogram plot in Figure 4.31 was generated through PI flow cytometric analysis of 
MCF7 cells treated with 100mM Oxamic acid for 24h. It can be observed that treatment with 
the LDH inhibitor induced a cell cycle arrest in G0/G1 and G2/M phases. The proportion of 
cells in these two phases was increased by 20 and 23% respectively while the percentage of 
cells in the DNA replication phase was reduced by half compared to the untreated control.    
 














Figure 4.32: Flow cytometric analysis of cellular DNA content of MCF7 breast cancer cells treated with 150μM 
NHI-1 for 24h. In the histogram fluorescence of the DNA bound propidium iodide, indicating the DNA content in 
X- axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell cycle phase is 
demonstrated on the right (n=1). 
 
The analysis of cell cycle progression with PI DNA staining of MCF7 cells treated with 
150μM NHI-1 for 24h is depicted in Figure 4.32. It can be observed that the anticancer effect 
of the novel LDHA inhibitor can be correlated with an apparent cell cycle arrest in the G1 
phase. Cells in the G1 phase increased by 66% compared to the untreated control while cells 




The following chart illustrates the proportion of cells in the G0/G1, S and G2/M phases of 
the cell cycle as quantified after cell cytometric analysis of MCF7 cells treated with the nine 
glycolytic inhibitors for 24h. Results are related to the respective populations of an untreated 










Figure 4.33: Quantification of percentages of MCF7 cells in the G0/G1, S and G2/M phases of the cell cycle 
when treated with 9 glycolytic inhibitors for 24h compared to an untreated control, as generated through flow 
cytometric analysis. 
4.3 The effect of glycolytic inhibitors on glucose uptake & lactate production 
The next aim of this chapter was to investigate the effect of the selected array of compounds 
as inhibitors of the glycolytic pathway. Glucose is the ‘fuel’ of the glycolytic pathway while 
lactate is its final end product; therefore the effect of the glycolytic inhibitors on glucose 
uptake and lactate production was examined. Taken together, these two measurements 
provide an indication of the activity of the pathway. Two breast cancer cell lines were 
selected for these experiments; MCF7 and HBL100. Breast cancer cells were treated for 24h 
with each of the glycolytic inhibitors and then the culture medium was collected. In these 
samples the concentrations of both glucose and lactate were measured. The following figures 
depict the amount of glucose (in green colour) and the amount of lactate (in red colour) 
measured in the culture medium of the indicated breast cancer cell line when treated with 
each of the glycolytic inhibitors for 24 h. A range of three different concentrations of each of 
the compounds was used; selected by taking into consideration the corresponding IC50 
concentration determined from the SRB assays (Table 3.2, section 3.2). Low concentrations 












compared to an untreated control using one-way ANOVA and the Tukey-Kramer multiple 
comparisons test. 
  
Figures 4.34 & 4.35: Extracellular glucose (in green colour) remaining in the culture medium of MCF7 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 50, 100 or 150μΜ 
Phloretin. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical 
significance indications: * P<0.05, ** P<0.01, *** P<0.001 compared with untreated control (one-way ANOVA 




Figures 4.36 & 4.37: Extracellular glucose (in green colour) remaining in the culture medium of HBL100 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 50, 100 or 150μΜ 
Phloretin. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical 
significance indications: ns not significant P>0.05, ** P<0.01, *** P<0.001 compared with untreated control 
(one-way ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 2 independent 
experiments are presented. 
 
Phloretin has been described as an inhibitor of glucose transmembrane transport [277]. 
However, Phloretin had a differential effect in the two examined breast cancer cell lines. As 
shown in Figures 4.34 and 4.35, Phloretin treatment decreased the amount of glucose 
remaining in the culture medium of MCF7 cells and also increased the production of lactate. 
This is the opposite result expected from an inhibitor targeting the glycolytic pathway. 
Conversely, Phloretin treatment had the anticipated effect on HBL100 cells where increasing 
concentrations of Phloretin caused an increase in the concentration of glucose measured in 
the culture medium after a 24h treatment and a decrease in the production of lactate (Figures 









































































































Figures 4.38 & 4.39: Extracellular glucose (in green colour) remaining in the culture medium of MCF7 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 50, 100 or 150μΜ 
Quercetin. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical 
significance indications: ns not significant P>0.05, *** P<0.001 compared with untreated control (one-way 
ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 2 independent 




Figures 4.40 & 4.41: Extracellular glucose (in green colour) remaining in the culture medium of HBL100 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 50, 100 or 150μΜ 
Quercetin. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical 
significance indications: ns not significant P>0.05, *** P<0.001 compared with untreated control (one-way 
ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 2 independent 
experiments are presented. 
 
Similarly to Phoretin, the two breast cancer cell lines responded differently to the second  
flavonoid Quercetin, which is also reputed to inhibit glucose transport [277]. As shown in 
Figures 4.38 and 4.39, Quercetin caused a reduction in the leftover concentration of glucose 
and had no significant effect on the measurement of lactate in the culture medium of MCF7 
cells. In contrast, HBL100 cells responded as would be anticipated to a glycolytic inhibitor. 
Quercetin treatment resulted in a large increase of the remaining glucose and a concurrent 
depletion of the lactate produced (Figures 4.40 and 4.41). An interesting unexpected 
observation is that 150μM Quercetin seem to have a lesser effect on the glucose and lactate 







































































































Figures 4.42 & 4.43: Extracellular glucose (in green colour) remaining in the culture medium of MCF7 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 0.01, 0.1 or 1μΜ STF31. 
Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical significance 





Figures 4.44 & 4.45: Extracellular glucose (in green colour) remaining in the culture medium of HBL100 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 0.01, 0.1 or 1μΜ STF31. 
Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical significance 
indications: ns not significant P>0.05, * P<0.05, *** P<0.001 compared with untreated control (one-way 
ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 2 independent 
experiments are presented. 
 
 
Figures 4.42 to 4.45 illustrate the effect of the GLUT1 inhibitor STF31 on glucose uptake 
and lactate production of MCF7 and HBL100 cells respectively. STF31 treatment led to 
accumulation of glucose in the culture medium of MCF7 cells coupled with a significant 
reduction in lactate generation. On the other hand HBL100 cells demonstrated an unexpected 
decrease in glucose concentrations while lactate production remained unaffected by STF31 










































































































Figures 4.46 & 4.47: Extracellular glucose (in green colour) remaining in the culture medium of MCF7 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 3, 10 or 30μΜ WZB117. 
Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical significance 
indications: ns not significant P>0.05, ** P<0.01 compared with untreated control (one-way ANOVA followed 






Figures 4.48 & 4.49: Extracellular glucose (in green colour) remaining in the culture medium of HBL100 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 3, 10 or 30μΜ WZB117. 
Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical significance 
indications: ns not significant P>0.05, *** P<0.001 compared with untreated control (one-way ANOVA followed 
by Tukey-Kramer multiple comparisons test). Representative data of 3 independent experiments are presented. 
 
 
Figures 4.46 and 4.48 reveal that the GLUT1 inhibitor WZB117 induced accumulation of 
glucose in the culture medium of both breast cancer cell lines. Even the lowest tested 
concentration of 3μΜ was adequate to cause the maximal observed effect and higher 
concentrations did not cause any additional increase. The effect was more profound on 
HBL100 cells (p<0.001). In contrast no statistically significant differences were detected in 
lactate production after WZB117 treatment in both cell lines (Figures 4.47&4.49).  















































MCF7 - WZB117 - Lactate  
Figure 4.47 


















































Figures 4.50 & 4.51: Extracellular glucose (in green colour) remaining in the culture medium of MCF7 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 10, 20 or 30μΜ 3-
bromopyruvate. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical 
significance indication: *** P<0.001 compared with untreated control (one-way ANOVA followed by Tukey-





Figures 4.52 & 4.53: Extracellular glucose (in green colour) remaining in the culture medium of HBL100 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 10, 20 or 30μΜ 3-
bromopyruvate. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical 
significance indication: *** P<0.001 compared with untreated control (one-way ANOVA followed by Tukey-
Kramer multiple comparisons test). Representative data of 3 independent experiments are presented. 
 
 
As shown in Figures 4.50 to 4.53,  the HKII inhibitor 3BP had a marked impact on glucose 
and lactate measurements in the culture medium of both MCF7 and HBL100 cells. The 
effect was consistent with inhibition of the glycolytic pathway. In both cell lines a large 
increase in glucose combined with a massive reduction in the secreted lactate can be 
observed. The lowest tested concentration of 10μΜ 3BP produced a maximal effect and with 
higher concentrations no additional response could be detected.     














































MCF7 - 3BP - Lactate  
Figure 4.51 





















































Figures 4.54 & 4.55: Extracellular glucose (in green colour) remaining in the culture medium of MCF7 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 1, 2 or 3μΜ 3PO. Mean 
results of 3 replicates are reported and error bars represent standard deviations. Statistical significance indication: 
*** P<0.001 compared with untreated control (one-way ANOVA followed by Tukey-Kramer multiple 





Figures 4.54 & 4.55: Extracellular glucose (in green colour) remaining in the culture medium of HBL100 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 1, 2 or 3μΜ 3PO. Mean 
results of 3 replicates are reported and error bars represent standard deviations. Statistical significance indication: 
*** P<0.001 compared with untreated control (one-way ANOVA followed by Tukey-Kramer multiple 
comparisons test). Representative data of 3 independent experiments are presented. 
 
 
In Figures 4.54 to 4.57, evidence is provided that 3PO effectively blocks the glycolytic 
pathway. Treatment with the PFKFB3 inhibitor resulted in accumulation of glucose, which 
was more notable in HBL100 cells, while lactate production decreased to 50% compared to 
the untreated controls in both cell lines. Interestingly, after treatment with a concentration as 


























MCF7 - 3PO - Glucose 
Figure 4.54 




















MCF7 - 3PO - Lactate 
Figure 4.55 





















HBL100 - 3PO - Glucose 
Figure 4.56 




























Figures 4.58 & 4.59: Extracellular glucose (in green colour) remaining in the culture medium of MCF7 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 10, 20 or 30mΜ 
Dichloroacetate. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical 
significance indications: ns not significant P>0.05, * P<0.05, ** P<0.01, *** P<0.001 compared with untreated 
control (one-way ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 2 




Figures 4.60 & 4.61: Extracellular glucose (in green colour) remaining in the culture medium of HBL100 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 10, 20 or 30mΜ 
Dichloroacetate. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical 
significance indications: ns not significant P>0.05, * P<0.05, ** P<0.01, *** P<0.001 compared with untreated 
control (one-way ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 2 
independent experiments are presented. 
 
 
Figures 4.58 to 4.61 confirm that PDHK1 inhibition suppresses glycolysis. DCA increased 
the concentration of glucose that remained in the culture medium after a 24h treatment in 
both breast cancer cells lines. It is noteworthy that the accumulation of glucose for HBL100 
cells was more significant compared to MCF7. Regarding the results obtained from the 
lactate assay DCA reduced the amount of lactate produced to 30% in both cell lines 









































































































Figures 4.62 & 4.63: Extracellular glucose (in green colour) remaining in the culture medium of MCF7 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 10, 20 or 30mΜ Oxamic 
acid. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical significance 
indications: ns not significant P>0.05, * P<0.05, *** P<0.001 compared with untreated control (one-way 
ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 3 independent 




Figures 4.64 & 4.65: Extracellular glucose (in green colour) remaining in the culture medium of HBL100 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 10, 20 or 30mΜ Oxamic 
acid. Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical significance 
indications: ns not significant P>0.05, * P<0.05, *** P<0.001 compared with untreated control (one-way 
ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 3 independent 
experiments are presented. 
 
 
Figures 4.62 to 4.65 demonstrate that LDH inhibition leads to blockade of the glycolytic 
pathway. A high concentration of 30mM Oxamic acid was required for both breast cancer 
cell lines to induce a statistically significant accumulation of glucose. In contrast it can be 
observed that increasing concentrations of Oxamic acid resulted in decreasing lactate 
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Figures 4.66 & 4.67: Extracellular glucose (in green colour) remaining in the culture medium of MCF7 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 20, 40 or 80μΜ NHI-1. 
Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical significance 
indications: ns not significant P>0.05, *** P<0.001 compared with untreated control (one-way ANOVA followed 




Figures 4.68 & 4.69: Extracellular glucose (in green colour) remaining in the culture medium of HBL100 breast 
cancer cells in parallel with lactate production (in red colour) after a 24h treatment with 20, 40 or 80μΜ NHI-1. 
Mean results of 3 replicates are reported and error bars represent standard deviations. Statistical significance 
indications: * P<0.05, ** P<0.01, *** P<0.001 compared with untreated control (one-way ANOVA followed by 
Tukey-Kramer multiple comparisons test). Representative data of 2 independent experiments are presented. 
 
 
The effects of  NHI-1 on glucose uptake and lactate production on the breast cancer cell lines 
are compared in Figures 4.66 to 4.69. As expected from an inhibitor targeting LDHA, NHI-1 
treatment caused a marked depletion of lactate in the culture medium. Lactate production 
was found decreased to around 40% in both cell lines compared to the untreated controls. 
The effect of NHI-1 treatment on glucose uptake of MCF7 cells was modest. Only the higher 
concentrations of 40 and 80μΜ resulted in a statistically significant increase of the remaining 
glucose in the culture medium. In contrast regarding HBL100 cells, 20μΜ of NHI-1 was 









































































HBL100 - NHI-1 - Glucose 
Figure 4.68 


























4.4 Knockdown of selected glycolytic enzymes 
 
To further elucidate the role of glycolytic enzymes and evaluate them as potential therapeutic 
targets for cancer treatment, gene downregulation was attempted. Two promising targets at 
the top and bottom of the glycolytic pathway, GLUT1 and LDHA, were selected for 
assessment after their inhibitors had been investigated (Chapter 3 section 3.2 growth 
inhibition, Chapter 4 apoptosis induction, cell cycle arrest, inhibition of the glycolytic 
pathway). 
siRNA mediated gene knockdown was utilised to examine the glycolytic targets of interest. 
Four different predesigned siRNA oligos and a pool with a mixture of the four sequences 
were utilised as described in Chapter 2 section 2.8. MCF7 and MDA-MB-231 breast cancer 
cells were used for transfection experiments. An optimisation process was followed to 
identify the optimal conditions achieving high transfection efficiency coupled with minimal 
cellular toxicity. Three controls were used in every experiment; untreated cells, mock cells 
treated only with transfection reagent as well as a negative control transfected with a non-
targeting random sequence. Lysates of transfected samples were collected and efficiency of 
knockdown was assessed at the protein level through Western blotting.  
 
 
4.4.1 GLUT1 knockdown  
 
Efficient GLUT1 knockdown was not achieved in the present study even though a thorough 
optimisation process was followed. Several cell densities of two breast cancer cell lines were 
tried combined with three different volumes of the transfection reagent as recommended by 
the manufacturer. A concentration range (5, 10, 25, 50, 100nM) was used for each of the 
single oligonucleotides and the pool and also transfection duration of 24, 48, 72 and 120h 
was attempted. Unfortunately none of these was successful. A representative result of a 72h 
transfection of MCF7 breast cancer cells is presented below in Figure 4.70. GLUT1 







               
 
                   
                  
 
Figure 4.70: GLUT1 protein expression detected through Western blotting in MCF7 siRNA transfected cells. 
Transfection lasted for 72h and the following siRNA sequences were used: non targeting (25nM), SLC2A1 Pool 
(5, 10, 25, 50, 100nM), SLC2A1 06 (25nM), SLC2A1 07 (25nM), SLC2A1 08 (25nM) and SLC2A1 18 (25nM). 
Expression was compared to mock cells, treated only with transfection reagent. Alpha tubulin was used as a 
loading control. Representative data of 12 independent experiments are presented. 
 
 
4.4.2 LDHA knockdown  
In contrast to GLUT1, significant LDHA knockdown was achieved after targeting with 
oligonucleotides specific to LDHA. Different concentrations of the four siRNA sequences 
and the pool of the four sequences combined were tried under various conditions. Optimal 
conditions allowing high transfection efficiency were identified. A representative Western 
blot from the optimisation process is presented in Figure 4.71. The densitometric analysis of 
a 96h transfection experiment of MCF7 cells is depicted in Figure 4.72. It can be observed 
that transfection with the pool or with two of the sequences as single oligonucleotides 
resulted in significant LDHA knockdown. The two sequences that gave optimal results were 
selected for further experiments. The sequence 06 at 25nM and the sequence 08 at 50nM 
reduced LDHA expression to 19 and 5% respectively compared to mock treated cells.       
 
Similar results were also obtained for MDA-MB-231 breast cancer cells. The respective 
immunoblots and the normalised expression analysis for the triple negative cell line are 
presented in Figures 4.73 and 4.74. These demonstrate that the two selected sequences, after 
a 96h transfection period, reduced LDHA expression to 7 and 9% respectively. 
 












                          
                     
 
Figure 4.71: LDHA protein expression detected through Western blotting in MCF7 siRNA transfected cells. 
Transfection lasted for 96h and the following siRNA sequences were used: non targeting (25nM), LDHA Pool 
(50, 100nM), LDHA 06 (25, 50nM) and LDHA 08 (25, 50nM). Expression was compared to mock cells, treated 
only with transfection reagent. Alpha tubulin was used as a loading control. Representative data of 5 independent 






Figure 4.72: LDHA protein expression detected through Western blotting in MCF7 siRNA transfected cells. 
Transfection lasted for 96h and the following siRNA sequences were used: non targeting (25nM), LDHA Pool 
(50, 100nM), LDHA 06 (25, 50nM) and LDHA 08 (25, 50nM). Expression was compared to mock cells, treated 
only with transfection reagent (percentages shown). Densitometry analysis was conducted using the Odyssey 
Infrared Imaging System software (Licor) and data were normalised to α tubulin expression. 
100% 










Normalised LDHA expression - MCF7 cells 
Figure 4.72 
























4.4.2.1 Effect of LDHA knockdown on LDHB expression 
The effect of LDHA siRNA knockdown on the expression of the other LDH subunit 
(LDHB) was also examined. Figure 4.75 shows LDHB expression in samples transfected 
with LDHA siRNAs. The corresponding densitometry analysis results are presented in 
Figure 4.76.  This indicates that the siRNA effect was specific to the A subunit. It can be 
observed that the same oligonucleotides that reduced LDHA expression to 7% had no effect 























α tubulin  
50kDa 
Figure 4.73: LDHA protein expression 
detected through Western blotting in MDA-
MB-231 siRNA transfected cells. 
Transfection lasted for 96h and the 
following siRNA sequences were used: non 
targeting (25nM), LDHA 06 (25nM) and 
LDHA 08 (50nM). Expression was 
compared to mock cells, treated only with 
transfection reagent. Alpha tubulin was used 
as a loading control. Representative data of 
5 independent experiments are presented. Figure 4.73 
Figure 4.74: LDHA protein expression 
detected through Western blotting in MDA-
MB-231 siRNA transfected cells. 
Transfection lasted for 96h and the 
following siRNA sequences were used: non 
targeting (25nM), LDHA 06 (25nM) and 
LDHA 08 (50nM). Expression was 
compared to mock cells, treated only with 
transfection reagent (percentages shown). 
Densitometry analysis was conducted using 
the Odyssey Infrared Imaging System 
software (Licor) and data were normalised 









           
 
        
 
4.4.2.2 Effect of LDHA knockdown on cell proliferation 
The effect of LDHA knockdown on cell proliferation was examined. MCF7 cells were 
transfected with the 06 and 08 siRNA oligos and incubated for 96h at 21% O2 and 0.5% O2.  
Cancer cell viability was examined by the SRB assay. Measurements were compared to 
mock treated cells using one-way ANOVA and the Tukey-Kramer multiple comparisons 
test.  
Figure 4.77 demonstrates that the two siRNA sequences reduced cell growth to 58 and 40% 
in normoxic conditions compared to mock treated cells. This effect of LDHA knockdown on 
cell proliferation is roughly equivalent to the corresponding effect of 10mM Oxamic acid 
and 10μM NHI-1. The concentration response curves of the two LDH inhibitors were 
generated through a parallel experiment and are presented in Figures 4.79 and 4.80. Cells 
presented slightly less sensitivity to LDHA knockdown when cultured at 0.5% O2 (Figure 
4.78). Under hypoxic conditions cell density was reduced to 73 and 45% of the mock control 
























Figure 4.75: LDHB protein expression 
detected through Western blotting in MDA-
MB-231 cells transfected with LDHA 
siRNAs. Transfection lasted for 96h and the 
following siRNA sequences were used: non 
targeting (25nM), LDHA 06 (25nM) and 
LDHA 08 (50nM). Beta actin was used as a 
loading control. Representative data of 2 
independent experiments are presented. 
Figure 4.76: LDHB protein expression 
detected through Western blotting in MDA-
MB-231 cells transfected with LDHA 
siRNAs. Transfection lasted for 96h and the 
following siRNA sequences were used: non 
targeting (25nM), LDHA 06 (25nM) and 
LDHA 08 (50nM). Densitometry analysis 
was conducted using the Odyssey Infrared 
Imaging System software (Licor) and data 






Figures 4.77 & 4.78: Optical density of MCF7 breast cancer cells transfected with LDHA siRNAs for a 96h 
period at 21 or 0.5%O2. The following siRNA sequences were used: non targeting (25nM), LDHA 06 (25nM) 
and LDHA 08 (50nM). Optical density was determined by an SRB assay. Mean results of 6 replicates are 
reported and error bars represent standard deviations. Growth was compared to mock cells, treated only with 
transfection reagent (percentages shown). Statistical significance indications: *** P<0.001 compared to mock 
treated control (one-way ANOVA followed by Tukey-Kramer multiple comparisons test). Representative data of 
3 independent experiments are presented. 
 
  
Figures 4.79 & 4.80: Concentration response curves of MCF7 breast cancer cells treated with Oxamic acid 
concentrations between 0.2-100mΜ and NHI-1 concentrations between 0.6-300μΜ for 96h. Cell viability was 
determined by an SRB assay. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Values are shown as a percentage of control. A constant 0.3% DMSO concentration was used across 
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4.4.2.3 Effect of LDHA knockdown on lactate production  
The effect of LDHA knockdown on lactate production was examined. MDA-MB-231 cells 
were transfected with the 06 and 08 siRNA sequences for 96h. Immediately after the 
transfection period was terminated, cells were incubated with fresh culture medium for 4h. 
Then the medium was collected and extracellular lactate was measured following the 
protocol described in Chapter 2 section 2.4. Measurements were normalised to the protein 
content to compensate for differences in the cell number and are presented as μg lactate per 
1000 μg/ml of protein. As demonstrated in Figure 4.81 lactate production proved unaffected 
by LDHA knockdown, even though LDHA expression in these specific samples was 
measured at less than 10% compared to expression of mock treated cells. 
 
 
Figure 4.81: Extracellular lactate production in the culture medium of transfected MDA-MB-231 breast cancer 
cells. Measurements were normalised to protein content and are presented as μg lactate per 1000 μg/ml of protein.  
The following siRNA sequences were used: non targeting (25nM), LDHA 06 (25nM) and LDHA 08 (50nM). 
Mean results of 3 replicates are reported and error bars represent standard deviations. Representative data of 7 
independent experiments are presented. 
 
4.5 Discussion 
4.5.1 The glycolytic inhibitors mainly induced apoptosis 
The mechanism of action of the glycolytic inhibitors was examined by flow cytometry. 
MCF7 breast cancer cells were treated with high concentrations of nine glycolytic inhibitors 
for 24 or 48h and double stained with FITC-conjugated annexin V and PI. Flow cytometric 
analysis differentiated the treated cell population in four separate groups; viable intact cells 
(double negative), early apoptotic cells (annexin V positive), late apoptotic cells (double 





































MDA-MB-231 tranfected cells 





Evidence that the mechanism of action of high concentrations of the glycolytic inhibitors 
after a 24h treatment is associated with necrotic cell death was obtained. A notable increase 
of necrotic cells, stained positive for PI, was observed for the vast majority of the 
compounds after 24h of treatment compared to untreated cells. At 24h the proportion of 
untreated necrotic cells was 3% whereas cells treated with 300μM Phloretin for 24h showed 
21% necrosis, 300μM Quercetin for 24h 7%, 30μM STF31 for 24h 20%, 30μM WZB117 for 
24h 9%, 30μM 3PO for 24h 24%, 100mM DCA for 24h 11% and 100mM Oxamic acid for 
24h 20% (Figure 4.57). 
In contrast a 48h treatment with the same high concentrations of the glycolytic inhibitors 
resulted in induction of both early and late apoptosis compared to the untreated control. All 9 
of these inhibitors were shown to induce apoptosis following a 48h treatment of breast 
cancer cells as demonstrated by a pronounced increase of annexin V positive cells. Apoptotic 
untreated cells at 48h were quantified at 7% whereas cells treated with 300μM Phloretin for 
48h showed 43% apoptosis, 300μM Quercetin for 48h 25%, 30μM STF31 for 48h 29%, 
30μM WZB117 for 48h 11%, 300μM 3BP for 48h 92%, 30μM 3PO for 48h 28%, 100mM 
DCA for 48h 58%, 100mM Oxamic acid for 48h 13% and 300μM NHI-1 for 48h 47% 
(Figure 4.58). 
The selected compounds were associated with more than one mode of cell death via different 
signalling routes at different time courses. It seems that they lead to necrosis after a short 
treatment period while longer incubation is associated with apoptotic cell death suggesting 
that apoptosis is not an immediate process following treatment with these compounds. 
Nonetheless great levels of cellular death are in agreement with results obtained by the SRB 
assays in Chapter 3 section 3.2 demonstrating that the same concentrations of these 
inhibitors eliminated breast cancer cellular populations following a 5-day treatment.  
Traditionally, it has been argued that nutrient withdrawal and blocking of the glycolytic 
pathway depletes cellular ATP levels and renders cells unable to engage in an ATP 
demanding death process. Indeed it has been extensively demonstrated that glycolysis 
inhibition leads to necrotic cell death as cells are unable to undergo ATP dependent 
apoptosis [435]. Among the compounds of interest in this study the novel GLUT1 inhibitors, 
STF31 and WZB117, have been associated with necrotic cell death in the literature [312, 
319]. However the concentrations used in these published studies were considerably lower 




Glucose starvation and glycolysis inhibition has also been linked with ROS mediated 
oxidative stress [414, 415]. Apoptotic cell death following treatment with the majority of 
these compounds is in agreement with earlier studies. Phloretin treatment has been 
associated with induction of apoptosis in several tumour types including melanoma, 
hepatocellular carcinoma and breast cancer cell lines [278, 279, 284]. Quercetin has been 
shown repeatedly to induce apoptosis in breast and ovarian cancer cell lines [297-301]. 
Apoptotic cell death of breast cancer cells following 3BP treatment has also been 
documented [330]. DCA and Oxamic acid have also been associated with apoptotic cell 
death in several cancer types [357, 375, 376]. Similarly the novel LDHA inhibitor, NHI-1, 
was reported to cause apoptosis in various cancer cell line models [378]. In this study breast 
cancer cells were consistently found to undergo apoptosis following 3BP and NHI-1 
treatment for either 24 or 48h in line with previous findings [330, 378]. Nevertheless it 
should be highlighted that the concentrations used in this study are high and therefore results 
are not directly comparable.    
An important finding is that the mechanistic response of these breast cancer cells to all nine 
inhibitors was very similar at both time points. This is consistent with a likely shared action 
and targeting of a common pathway. However these data should be interpreted with caution 
as it could conceivably be argued that the high concentrations used may produce off-target 
effects, and therefore cannot be exclusively associated with glycolysis inhibition. The main 
aim of these experiments was to investigate the mechanism of cell death associated with the 
maximal growth inhibitory effect of an array of inhibitors as observed in the SRB assays 
presented in Chapter 3.    
A source of weakness here is that this experiment was only conducted once and there is only 
one set of data suggesting that it should be interpreted with caution. Further work is required 
to explain this shift from necrotic to apoptotic cell death between 24 and 48h of treatment 
with glycolytic inhibitors. ATP measurements, determination of PARP cleavage levels as 
well as expression of pro-apoptotic and necrotic cellular markers would be essential to 
develop a full picture of the antiproliferative mechanism of action of these compounds.   
A growing body of literature associates the growth inhibitory effect of several of these 
compounds with autophagy. Examples include studies demonstrating that 3PO induced an 
autophagic response in HCT-116 colon cancer cells, DCA in colorectal and prostate cancer 
cell lines and Oxamic acid in A549 lung cancer cells as well as in SGC7901 and BGC823 
gastric cancer cells [344, 363, 376, 377]. Autophagy is a regulated degradation process of 




clarified yet. There is evidence suggesting that it promotes survival, tumour growth and 
aggressiveness serving as a protective response to metabolic stress [436, 437]. Combinatorial 
treatment with autophagy inhibitors has been shown to enhance the efficacy of some of these 
agents [344, 377]. It would be interesting to examine the levels of autophagy markers like 
LC3-II following treatment with the array of glycolytic inhibitors and determine the role of 
autophagy in the models of interest here. 
4.5.2 The glycolytic inhibitors mainly caused cell cycle arrest at G0/G1 phase 
An objective of this study was to further assess whether the antiproliferative effect of several 
glycolytic inhibitors could be associated with cell cycle arrest. MCF7 breast cancer cells 
were treated with the panel of nine glycolytic inhibitors for 24h and then fixed and stained 
with PI. Flow cytometric analysis enabled the separation of each population into three 
groups based on the cellular DNA content as this was indicated by variation of the 
fluorescence intensity of PI; cells in the G0/G1 phase, the S phase and the G2/M phase. As 
great levels of cellular death were previously observed in the apoptosis assay lower 
concentrations of the compounds were used here to investigate cell cycle progression.   
The DNA content frequency histograms generated through flow cytometric analysis and 
quantification of cells in the different phases of the cell cycle suggested that the glycolytic 
inhibitors are predominantly associated with cell cycle arrest at the G0/G1 phase. While 36% 
of untreated cells were found at the G0/G1 phase, for cells treated with 150μM Phloretin the 
percentage increased to 61%, 15μM STF31 to 39%, 15μM WZB117 to 41%, 50μM 3BP to 
41%, 15μM 3PO to 52%, 100mM Oxamic acid to 44% and 150μM NHI-1 to 61%. The 
accumulation of cells in the G0/G1 phase and inhibition of the G1-S transition was more 
profound following Phloretin and NHI-1 treatment. It should also be mentioned that Oxamic 
acid induced a concomitant G2/M phase cell cycle arrest, increasing the proportion of cells 
in this phase from 34% in the untreated control to 42%. A different response was observed 
from Quercetin that was associated with cell cycle arrest in the S phase. The number of cells 
in the S phase was increased to 35% compared to 30% in the untreated sample. Following 
DCA treatment no considerable effect in the percentage of cells in the various stages of the 
cell cycle was detected (Figure 4.69).  
In the literature the information regarding the effect of these compounds on cell cycle 
progression is limited. Quercetin was shown to induce G0/G1 cell cycle arrest in breast and 
ovarian cancer cells contradicting the findings of the current study [297, 298]. However a 
more potent sulphated derivative of Quercetin was associated with S phase cell cycle arrest 




WZB117 was previously found to block the cell cycle at the G0/G1 phase in A549 lung 
cancer cells [319]. In contrast 3PO was documented to induce G2/M phase cell cycle arrest 
in Jurkat T cell leukemia cells [343]. A similar effect has also been observed following DCA 
treatment in HCT116 colon cancer cells while G0/G1 arrest was reported for another 
colorectal cancer cell line HT29 and PC3 prostate cancer cells [363]. G2/M phase cell cycle 
arrest has also been observed after Oxamic acid treatment of CNE-1 and CNE-2 
nasopharyngeal carcinoma cells as well as H1395 lung cancer cells. However G0/G1 arrest 
was detected in a different lung cancer cell line, A549, similar to the compound’s effect on 
MCF7 breast cancer cells evidenced here. Nevertheless it should be mentioned that the 
concentrations of the compounds used in this experiment are higher that the concentrations 
used in many of the mentioned studies. Furthermore, the major limitation of this experiment 
is that it was only conducted once and proper statistical analysis unfortunately cannot be 
performed.  
The main finding of this section is that almost every glycolytic inhibitor examined induced 
G0/G1 quiescence in breast cancer cells, inhibiting the transition into the DNA synthesis S 
phase. The major regulator of the G1/S cell cycle checkpoint is the tumour suppressor gene 
retinoblastoma (Rb) that binds and inhibits the transcription factor E2F. Phosphorylation of 
the Rb by CDK complexes (Cyclin D-CDK 4/6 and Cyclin E-CDK 2) dissociates E2F 
enabling gene transcription and DNA replication [438]. Investigation of the pRb and CDK 
levels would further enlighten the cell cycle arrest in breast cancer cells treated with 
glycolytic inhibitors.   
4.5.3 The glycolytic inhibitors blocked the glycolytic pathway 
The experiments in this section provide evidence that the nine glycolytic inhibitors studied 
block the glycolytic pathway. Each of the examined compounds induced accumulation of 
glucose along with decline in the amount of produced lactate in the media of breast cancer 
cells treated for 24h with each agent (Figures 4.34 to 4.69). This is supportive evidence that 
this set of compounds indeed targets the glycolytic pathway.  
Two breast cancer cell lines were used in these experiments. It should be highlighted that at 
least for one of them the anticipated effect consistent with glycolysis inhibition was 
documented for every single compound. Some discrepancy was observed for the GLUT1 
inhibitors as treatment with the two flavonoids, Phloretin and Quercetin, reduced the amount 
of glucose remaining in the culture medium of MCF7 cells and increased lactate production. 
Similarly STF31 treatment had the same unexpected effect on HBL100 cells. As mentioned 




and STF31 impaired glucose uptake and lactate production in renal cell carcinoma cells 
[277, 312]. However it is known that the two flavonoids are associated with a wide range of 
biological effects other than inhibition of glucose transport and STF31 has recently been 
characterised as a NAMPT inhibitor [274, 275, 315]. Regarding WZB117 while a significant 
increase in the remaining glucose in the culture medium of both cell lines was detected, this 
study has been unable to demonstrate any significant effect on the measurement of lactate. 
This contradicts earlier findings from Liu et al who showed that WZB117 treatment 
decreased the amount of produced lactate in A549 non–small cell lung cancer cells even 
after 6h of treatment [319]. The rest of the compounds resulted in a consistent increase in the 
concentration of glucose that remained in the culture medium after a 24h treatment in both 
breast cancer cells lines combined with a decrease in the extracellular lactate levels secreted. 
It should be mentioned that even when the bottom of the pathway was targeted an effect on 
glucose uptake was apparent signifying the tight allosteric regulation of the glycolytic 
enzymes.  
A noteworthy observation is that for the majority of the compounds (including STF31, 
WZB117, 3BP and 3PO) the lowest concentration used induced the maximal observed 
response while higher concentrations did not have any additional effect. This possibly 
indicates that inhibition of each glycolytic enzyme can affect glucose uptake and lactate 
secretion to a certain extent. It was also observed that changes in the levels of glucose and 
lactate were mostly more profound for the ER negative HBL100 breast cancer cell line 
compared to the ER positive MCF7. Interestingly this relatively modest response from 
MCF7 cells did not coincide with resistance to the inhibitors (Table 3.2). However it 
corroborates previous findings suggesting that HBL100 cells demonstrated stronger reliance 
on glucose availability for cell growth as they were not able to proliferate in glucose depleted 
conditions (Table 3.1).  
Another caveat is that it cannot be excluded that a proportion of the observed effect is 
attributed to the antiproliferative effect of the inhibitors. Ideally glucose and lactate 
measurements should be normalised to the cell number. However the concentrations used 
were selected based on the corresponding IC50 concentrations generated from the SRB assays 
following a 5-day treatment (Chapter 3), whereas here incubations lasted only 24h. 
Therefore the anticipated antiproliferative effect from such low concentrations at only 24h is 
minimal. Another possibility to minimise even more the antiproliferative effect of the 
inhibitors could be to examine glucose uptake and lactate production following shorter time 




The present study makes a further contribution to our understanding of the mechanism 
mediating the antiproliferative effect of glycolytic inhibitors in breast cancer cells. Induction 
of apoptosis along with G0/G1 cell cycle arrest are identified as key elements of the action of 
these compounds. However, it is important to bear in mind that inhibition of the glycolytic 
pathway was detected at much lower concentrations compared to the ones used in the flow 
cytometry experiments. It is therefore likely that the enhanced apoptosis and cell cycle arrest 
observed could not be exclusively attributed to inhibition of the glycolytic pathway (since 
this was demonstrated in considerably lower concentrations) and additional off-target effects 
should be taken into consideration. 
4.5.4 Evaluation of glycolytic targets through siRNA knockdown 
The final section of this chapter sought to evaluate further selected glycolytic enzymes as 
anticancer targets using siRNA mediated gene knockdown. Inhibition of multiple molecules 
of the glycolytic pathway using an array of inhibitors was previously investigated in this 
study (Chapter 3). Among the compounds used the novel inhibitors IOM-1190 and NHI-1, 
targeting GLUT1 and LDHA respectively, were identified as valuable pharmacological tool 
compounds and potent cancer cell growth inhibitors. The two targeted glycolytic enzymes, at 
the top and bottom of the glycolytic pathway, were demonstrated to be promising therapeutic 
targets and were selected for further assessment using siRNA mediated gene 
downregulation.  
This study was unable to achieve significant GLUT1 silencing by siRNA despite extensive 
optimisation experiments that took into consideration every suggestion of the manufacturer. 
Different plating cell densities of two breast cancer cell lines were used with a range of 
volumes of the transfection reagent and a dose curve of each of the five siRNAs (four single 
oligos and the pool) while transfection duration ranged from 24 to 120h. Unfortunately 
GLUT1 downregulation was not accomplished. A representative example of the GLUT1 
knockdown experiments is presented in Figure 4.70. 
Since significant LDHA knockdown was achieved, this indicates that optimal transfection 
conditions were successfully identified. This suggests that ineffective GLUT1 
downregulation was not related to transfection efficiency as the protocol was successfully 
optimised and validated, but target related. Nevertheless effective GLUT1 silencing by 
siRNA oligos or shRNA vectors has been previously documented [323, 439, 440]. 
Interestingly in their study Shibuya et al reported that sustained GLUT1 siRNA knockdown 




GLUT1 has a very short half-life, much shorter than the average degradation rate of cellular 
proteins. Sargeant et al calculated GLUT1 protein half-life equal to 19h in 3T3-L1adipocytes 
while another study reported 6h in L6 myotubes [441, 442]. This rapid turnover rate might 
render the assessment of the knockdown at the protein level problematic. Further 
experimentation should ideally examine the mRNA level using PCR as siRNA transfection 
is a direct RNA specific process and short time points for immediate downregulation can be 
investigated. Alternatively CRISPR gene editing technology could be employed to ensure 
precise and efficient GLUT1 knockdown [443].  
Another possible explanation for ineffective knockdown of GLUT1 might be the specificity 
of the antibody used. Because the siRNA manufacturer guarantees GLUT1 specific 
silencing, it is possible that the antibody is not GLUT1 specific and is binding to other 
GLUTs as well. It is known that both MCF7 and MDA-MB-231, the breast cancer cell lines 
used, express other glucose transporters [179, 180]. 
On the other hand LDHA silencing was achieved. All four single siRNA oligonucleotides as 
well as the pool of four combined, accomplished significant LDHA knockdown (Figure 
4.72). The sequences that demonstrated highest target downregulation efficiency were used 
in the experiments that followed in MCF7 and MDA-MB-231 cells.  
The specificity of LDHA silencing with respect to LDHB expression was then investigated. 
Even though the two subunits share a high level of homology selective LDHA protein 
knockdown was documented. LDHA siRNA transfection resulted in a depletion of LDHA 
protein levels (up to 93%) without affecting LDHB expression in MDA-MB-231 cells 
(Figure 4.75). 
The most interesting finding of this section was that LDHA knockdown significantly 
attenuated breast cancer cell proliferation. It was observed that the two siRNA 
oligonucleotides following a 96h transfection period reduced the cell density of MCF7 breast 
cancer cells to 58 and 40% respectively at 21% O2 compared to mock treated cells (Figure 
4.77). The antiproliferative effect of LDHA silencing was comparable to the corresponding 
effect of 10mM Oxamic acid and 10μM NHI-1, the two LDH inhibitors used in this study 
(Figures 4.79&4.80). These findings are consistent with previous studies. Fantin et al 
demonstrated that shRNA mediated LDHA knockdown impaired the proliferation rate of 
breast cancer cells, stimulated mitochondrial oxidative phosphorylation and also suppressed 
their tumorigenic potential in vivo [271]. In line with these Sheng et al reported that 




carcinoma cells, increased ROS production and resulted in apoptotic cell death. Moreover it 
inhibited invasion in vitro and supressed metastasis in an in vivo xenograft model [444]. 
More recently Allison et al documented that LDHA knockdown induced apoptosis in cancer 
cells associated with oxidative stress [445]. 
The effect of LDHA knockdown on cell proliferation was also examined at 0.5% O2. Under 
hypoxic conditions transfection with the two selected siRNA sequences resulted in a 
reduction of the cell number to 73 and 45% respectively compared to mock treated control 
cells (Figure 4.78). It was noted that breast cancer cells were less sensitive to LDHA 
silencing under hypoxic conditions. This is consistent with enhanced sensitivity presented to 
LDH inhibitors at 21% O2 conditions demonstrated in Chapter 6 section 6.1. It is known that 
LDHA, as a verified HIF-1 target, is upregulated in hypoxia [446]. However this finding 
does not support previous research. Fantin et al reported that the effect of LDHA knockdown 
on the proliferation rate of breast cancer cells was greater in hypoxic conditions [271].     
Taken together these findings provide additional evidence that LDHA is a legitimate target 
for anticancer treatment. Suppressing LDHA expression in breast cancer cells in vitro was 
sufficient to significantly impair their proliferation. LDHA is a tumour specific enzyme that 
plays a key role in the glycolytic phenotype of cancer cells. It is responsible for NAD+ 
regeneration which is essential to sustain the glycolytic flux.  Most importantly normal cells 
predominantly rely on mitochondrial respiration for energy generation and LDHA inhibition 
is anticipated to cause minimal toxicity [257, 258].  
Finally an unexpected finding was that LDHA silencing did not affect lactate production. It 
was observed that even though LDHA protein expression was reduced at least by 90% 
compared to mock treated cells following siRNA transfection the lactate levels secreted 
surprisingly remained unaffected (Figure 4.81). This result is difficult to interpret and differs 
from previous findings. In their study Allison et al reported inhibition of the glycolytic 
pathway, indicated by 30% reduced lactate production, following LDHA silencing in 
HCT116 colorectal cancer cells [445]. 
The glycolytic pathway is not the exclusive source of intracellular lactate as it is also 
generated, to a lesser extent, by the catabolism of alanine and other amino acids. 
Nevertheless LDH is the only characterised enzyme that catalyses the reduction of pyruvate 
to lactate [447]. Thus another enzyme cannot be implicated in lactate formation following 
LDHA knockdown. However a possibility might be that in the absence of LDHA increased 




isozymes can catalyse the interconversion of pyruvate to lactate even though each one is 
more efficient in catalysing the reaction in a specific direction [258]. Nevertheless if this was 
the case LDHB would possibly be expected to negate the observed antiproliferative effect. 
Also LDHB protein expression was found to remain unaffected following LDHA silencing. 
Another possible explanation might be that the expression of LDHA in MDA-MB-231 cells 
is so high that even a fraction of the expressed protein can produce the same levels of lactate. 
In line with this it has been demonstrated that MDA-MB-231 triple negative cells have a 
highly glycolytic phenotype and upregulated LDHA levels [423]. Several questions 





















Chapter 5: Combining glycolytic inhibitors with chemotherapy and 
targeted inhibitors 
 
The efficacy of an array of glycolytic inhibitors in attenuating cancer cell proliferation has 
been described in Chapter 3. However their value as monotherapy for breast and ovarian 
cancer treatment is likely to be limited as relatively high concentrations are required to 
achieve the desired antitumour effect. Combination treatment is currently carried out for 
most tumour types and therefore the effects of several glycolytic inhibitors were assessed in 
combination strategies with traditional drugs. There are two primary aims of this section. 
Firstly to attempt to improve the efficacy of currently used therapeutics using glycolytic 
inhibitors and to investigate the possibility of resensitising cancer cells to treatment to which 
they had developed resistance. Secondly, to explore novel combinations of inhibitors that 
could potentially be developed as future treatment strategies. 
A range of co-treatments with two cytotoxic drugs, a monoclonal HER2 antibody and an 
antidiabetic inhibitor of oxidative phosphorylation were conducted. Cisplatin is a platinum-
based chemotherapy drug that causes DNA crosslinking and is widely used for the treatment 
of ovarian cancer [384]. Paclitaxel (Taxol) is a chemotherapy drug that binds to microtubules 
and inhibits tubulin depolymerisation. It is commonly used for the treatment of both breast 
and ovarian cancer [387]. Trastuzumab (Herceptin) is a humanised monoclonal HER2 
antibody. It is mainly used for the treatment of HER2-positive breast cancers [32]. Finally, 
metformin inhibits mitochondrial oxidative phosphorylation and is widely used for the 
treatment of type 2 diabetes. Recently it has attracted great interest as it exhibits 
antiproliferative action [389-392]. 
In these experiments a range of different concentrations of each glycolytic inhibitor were 
used in combination with a constant fixed concentration, around the IC20 or less, of the other 
drug. Both drugs were delivered at the same time and cancer cell proliferation was examined 
by the SRB assay after a 3-day treatment period. Along with each co-treatment, in every 
experiment, single drug concentration response curves of both compounds were performed. 
Data were analysed using the Calcusyn software. Combination Index values (CI) were 
generated for each combination point providing a quantitative evaluation of the combination 
efficacy. A detailed indication of the CI values can be seen in Chapter 2 section 2.2.1. 
Briefly, values lower than 0.8 suggest synergy, values between 0.8 and 1.2 imply additivity 




Three paired cancer cell-line models were used in these experiments. One breast cancer cell 
line pair, the ER positive cell line MCF7 and the triple negative MDA-MB-231 cell line and 
two chemosensitive - chemoresistant ovarian cancer cell line pairs, PEA1-PEA2 and PEO1- 
PEO4, which were previously described in Chapter 2 section 2.1.1. The high HER2 MDA-
MB-361 breast cancer cell line was also used in one set of studies investigating trastuzumab. 
Co-treatments with cisplatin were only conducted in ovarian cancer cell lines, as platinum-
based regimens are first line treatment for ovarian cancer.  
 
Glycolytic Inhibitor Traditional  Drug 
Cell Lines generating 
synergistic combination 
points 










Cisplatin PEA1, PEA2, PEO1, PEO4 
Paclitaxel PEA1, PEA2, PEO1, PEO4 
Oxamic acid 
Metformin all tested 
Cisplatin none 








Metformin MCF7, MDA-MB-231 
Cisplatin none 
 
Table 5.1: Summary of the combination treatments examined in this study. Cell lines for which each 





Table 5.1 summarises the combination treatments that were examined in this study. The last 
column indicates the cell lines for which each particular combination was found to 
successfully produce at least one treatment point that could be characterised as synergistic 
(CI<0.8). The most interesting combinations identified are presented in detail below. 
Representative examples of unfavourable non-synergistic combinations can be seen in the 
Appendix (Figures A1.4 to A1.7).   
5.1 Combinations with cytotoxic drugs – Cisplatin & Paclitaxel 
5.1.1 Cisplatin 
The interaction between cisplatin and several glycolytic inhibitors (Phloretin, STF31, 3PO, 
Oxamic acid, NHI-1, DCA) was examined. Among them 3PO was found able to enhance the 
potency of the cytotoxic agent.   
5.1.1.1 3PO & Cisplatin 
The PFKFB3 inhibitor was able to enhance the effect of cisplatin on two ovarian cancer cell 
line pairs, as shown in Figures 5.1 and 5.2 for the cell lines PEA1 and PEA2 and Figures 5.5 
and 5.6 for PEO1 and PEO4 respectively. The fixed concentration of cisplatin was selected 
for each cell line based on its growth inhibitory effect. For example, in PEA2 cells, 4μΜ of 
cisplatin was required to produce a similar inhibitory effect on cell number to that of 1μΜ 
cisplatin on PEA1 cells.  A synergistic interaction between the two compounds is observed. 
In these graphs, the blue line indicates the concentration response curve of the glycolytic 
inhibitor given alone. The green line demonstrates the effect of a constant concentration of 
cisplatin on cell viability, while in red, the combination curve of a range of 7 different 3PO 
concentrations combined with a fixed concentration of cisplatin is shown. The asterisks on 
the red line indicate synergistic combination points with CI values lower than 0.8. The 
growth inhibition effect of each combination point along with the CI values generated 
through the Calcusyn Software is presented in tables in the Appendix (Tables A1.1&A1.2). 
The most successful combination point for each cell line, the one characterised by the lowest 
CI value, is presented in greater detail in the separate column charts below (Figures 
5.3&5.4).   
The platinum naïve PEA1 line was found slightly more sensitive to the combination of 3PO 
with cisplatin compared to the platinum-resistant line PEA2 as it was characterised by lower 
CI values. As can be seen in Figure 5.3 1.9μΜ 3PO had no growth inhibitory effect on PEA1 
cells; 1μΜ cisplatin reduced the cell number to 89% while the combination of both resulted 




combination a CI value equal to 0.22 was generated which indicates strong synergism. When 
the same 3PO concentration was combined with 4μΜ cisplatin the cell number of PEA2 cells 
was reduced to 52%. The CI value for this combination was 0.5 indicating synergy. The IC50 
values of the combination concentration response curves were roughly fivefold lower 
compared to the respective values of the 3PO curves for both cell lines (Table 5.2). 
The other ovarian cancer cell line pair also proved sensitive to this combination. Figures 5.7 
and 5.8 show that 3.8μΜ 3PO combined with 0.5 or 1μΜ cisplatin generated a synergistic 
combination for PEO1 and PEO4 cells respectively; characterised by a CI value equal to 0.6 
in both cases. The IC50 values of the combination curves were found to be 2.6 and 1.6 times 
lower compared to the single 3PO treatment curves of the two cell lines (Table 5.2). 
   
Figures 5.1 & 5.2: Concentration response curves of PEA1 (5.1) and PEA2 (5.2) ovarian cancer cells treated 
with 3PO concentrations between 0.5-30μΜ alone (blue line) or combined with a constant concentration of 
Cisplatin (red line). Cell viability was determined by an SRB assay after a three day treatment. Mean results of 6 
replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control. 
In green the effect of 1μΜ (PEA1) or 4μΜ (PEA2) Cisplatin on cell viability is presented. Asterisks indicate 
synergistic combination points with Combination Index values lower than 0.8. Representative data of 3 
independent experiments are presented.    
   
Figures 5.3 & 5.4: Effect of 1.9μΜ 3PO, 1μΜ Cisplatin and their combination on cell viability of PEA1 cells 
(5.3) as well as effect of 1.9μΜ 3PO, 4μΜ Cisplatin and their combination on cell viability of PEA2 cells (5.4). 
Mean results of 6 replicates are reported and error bars represent standard deviations. The respective Combination 
Index values generated through Calcusyn are indicated. Statistical significance indications: *** P<0.001 






















3PO Concentration, μM 
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3PO & 1μM Cisplatin 
1μM Cisplatin 
Figure 5.1 



















3PO Concentration, μM 
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3PO & Cisplatin 
Figure 5.3 
























3PO & Cisplatin 
Figure 5.4 





Figures 5.5 & 5.6: Concentration response curves of PEO1 (5.5) and PEO4 (5.6) ovarian cancer cells treated 
with 3PO concentrations between 0.5-30μΜ alone (blue line) or combined with a constant concentration of 
Cisplatin (red line). Cell viability was determined by an SRB assay after a three day treatment. Mean results of 6 
replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control. 
In green the effect of 0.5μΜ (PEO1) or 1μΜ (PEO4) Cisplatin on cell viability is presented. Asterisks indicate 
synergistic combination points with Combination Index values lower than 0.8. Representative data of 3 
independent experiments are presented.      
 
   
Figures 5.7 & 5.8: Effect of 3.8μΜ 3PO, 0.5μΜ Cisplatin and their combination on cell viability of PEO1 cells 
(5.7) as well as effect of 3.8μΜ 3PO, 1μΜ Cisplatin and their combination on cell viability of PEO4 cells (5.8). 
Mean results of 6 replicates are reported and error bars represent standard deviations. The respective Combination 
Index values generated through Calcusyn are indicated. Statistical significance indications: *** P<0.001 
compared to 3PO single treatment (two-tailed P value generated from unpaired t-test). 
 
 






PEA1 PEA2 PEO1 PEO4 
3PO 16.4 25.6 15.5 22.3 
3PO & Cisplatin 3.8 5.1 5.9 13.9 
 
Table 5.2: Summary of the IC50 concentrations generated for two ovarian cancer cell line pairs when treated with 
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3PO & Cisplatin 
Figure 5.7 
























3PO & Cisplatin 
Figure 5.8 





In this study paclitaxel was assessed in combination strategies with STF31, 3PO, Oxamic 
acid and NHI-1. Of these glycolytic inhibitors, 3PO and Oxamic acid were found to enhance 
the potency of paclitaxel.  
 
5.1.2.1 3PO & Paclitaxel 
Figures 5.9 and 5.10 show that the combination of 3PO with paclitaxel was very effective in 
inhibiting growth of the PEA1 and PEA2 cell lines, generating low CI values for all 3PO 
concentrations used. While 1.9μΜ 3PO and 1nM paclitaxel did not affect PEA1 cell number 
when delivered by themselves, their combination caused a 50% reduction in cell number 
(Figures 5.11&5.12). Similarly the same growth inhibition effect was caused by the 
combination of 0.9μΜ 3PO with 2nM paclitaxel in PEA2 cells. The CI values attributed to 
these combinations were 0.1 and 0.3 respectively both characterised as strong synergy. 
Moreover, as shown in Table 5.3 the IC50 values of the combination curves of the two cell 
lines were found at least threefold lower compared to the values of the 3PO single treatment 
curves.  
The efficacy of this combination on the other ovarian cancer cell line pair was different. 
Figure 5.13 shows that for the platinum-sensitive line PEO1 the combination of 3PO with 
paclitaxel generated synergistic CI values for the whole range of 3PO concentrations used. 
As an example, Figure 5.15 demonstrates that while 0.9μΜ 3PO and 2nM paclitaxel reduced 
the percentage of cell number to 95 and 91% respectively, when combined together the 
inhibitory effect reached 47% (CI=0.5). In contrast, for the platinum-resistant line PEO4 the 
CI values generated for the lowest 3PO concentrations revealed additivity and moderate 
antagonism (Figure 5.14). Only a concentration as high as 15μΜ 3PO produced a synergistic 
interaction (CI=0.6, Figure 5.16). The differences between the two cell lines with regards to 
the efficacy of the combination is also reflected in the modification of the IC50 values (Table 
5.3). PEO1 cells increased their sensitivity to the combination of the drugs tenfold compared 
to their sensitivity to 3PO single treatment while a modest twofold reduction in the IC50 
value of the combination curve occurred in PEO4 cells. 
 
The interaction between 3PO and paclitaxel was also examined in breast cancer cell lines but 




   
 
 
Figures 5.9 & 5.10: Concentration response curves of PEA1 (5.9) and PEA2 (5.10) ovarian cancer cells treated 
with 3PO concentrations between 0.5-30μΜ alone (blue line) or combined with a constant concentration of 
Paclitaxel (red line). Cell viability was determined by an SRB assay after a three day treatment. Mean results of 6 
replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control. 
In green the effect of 1nΜ (PEA1) or 2nΜ (PEA2) Paclitaxel on cell viability is presented. Asterisks indicate 
synergistic combination points with Combination Index values lower than 0.8. Representative data of 3 
independent experiments are presented.    
 
 
    
 
 
Figures 5.11 & 5.12: Effect of 1.9μΜ 3PO, 1nΜ Paclitaxel and their combination on cell viability of PEA1 cells 
(5.11)  as well as effect of 0.9μΜ 3PO, 2nΜ Paclitaxel and their combination on cell viability of PEA2 cells 
(5.12). Mean results of 6 replicates are reported and error bars represent standard deviations. The respective 
Combination Index values generated through Calcusyn are indicated. Statistical significance indications: *** 
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Figure 5.9 
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3PO & Paclitaxel 
Figure 5.11 































Figures 5.13 & 514: Concentration response curves of PEO1 (5.13) and PEO4 (5.14) ovarian cancer cells treated 
with 3PO concentrations between 0.5-30μΜ alone (blue line) or combined with 2nΜ Paclitaxel (red line). Cell 
viability was determined by an SRB assay after a three day treatment. Mean results of 6 replicates are reported 
and error bars represent standard deviations. Values are shown as a percentage of control. In green the effect of 
2nΜ Paclitaxel on cell viability is presented. Asterisks indicate synergistic combination points with Combination 
Index values lower than 0.8. Representative data of 3 independent experiments are presented.   
  
   
Figures 5.15 & 5.16: Effect of 0.9μΜ 3PO, 2nΜ Paclitaxel and their combination on cell viability of PEO1 cells 
(5.15) as well as effect of 15μΜ 3PO, 2nΜ Paclitaxel and their combination on cell viability of PEO4 cells 
(5.16). Mean results of 6 replicates are reported and error bars represent standard deviations. The respective 
Combination Index values generated through Calcusyn are indicated. Statistical significance indications: *** 
P<0.001 compared to 3PO single treatment (two-tailed P value generated from unpaired t-test). 
 






PEA1 PEA2 PEO1 PEO4 
3PO 16.4 18.4 15.5 17 
3PO & Paclitaxel 4.3 5.4 1.6 7.9 
 
Table 5.3: Summary of the IC50 concentrations generated for two ovarian cancer cell line pairs when treated with 
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3PO & Paclitaxel 
Figure 5.15 























3PO & Paclitaxel 
Figure 5.16 




5.1.2.2 Oxamic acid & Paclitaxel 
A favourable interaction between Oxamic acid and paclitaxel was identified in the breast 
cancer cell lines. Figures 5.17 and 5.18 illustrate that Oxamic acid enhanced the effect of 
paclitaxel on both MCF7 and MDA-MB-231 cells. Low synergistic CI values were 
generated only for the lower Oxamic acid concentrations used. As shown in Figure 5.19, 
9.4mM Oxamic acid reduced the MCF7 cell number to 76% and 1nM paclitaxel to 93% 
compared to the untreated controls. However when the two drugs were combined the cell 
number was reduced to 49% (CI=0.5). Regarding MDA-MB-231 cells, Figure 5.20 depicts 
that while 4.7mM Oxamic acid and 1nM paclitaxel caused 5 and 10% growth inhibition 
respectively their combination resulted in 63% cell viability (CI=0.4). Both cell lines 
demonstrated a twofold lower IC50 value of the concentration response curves when Oxamic 
acid was combined with a fixed low concentration of paclitaxel compared to the respective 






Figures 5.17 & 5.18: Concentration response curves of MCF7 (5.17) and MDA-MB-231 (5.18) breast cancer 
cells treated with Oxamic acid concentrations between 2.3-150mΜ alone (blue line) or combined with 1nΜ 
Paclitaxel (red line). Cell viability was determined by an SRB assay after a three day treatment. Mean results of 6 
replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control. 
In green the effect of 1nΜ Paclitaxel on cell viability is presented. Asterisks indicate synergis tic combination 
points with Combination Index values lower than 0.8. Representative data of 2 independent experiments are 
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Figures 5.19 & 5.20: Effect of 9.4mΜ Oxamic acid, 1nΜ Paclitaxel and their combination on cell viability of 
MCF7 cells (5.19) as well as effect of 4.7mΜ Oxamic acid, 1nΜ Paclitaxel and their combination on cell 
viability of MDA-MB-231 cells (5.20). Mean results of 6 replicates are reported and error bars represent standard 
deviations. The respective Combination Index values generated through Calcusyn are indicated. Statistical 
significance indications: *** P<0.001 compared to Oxamic acid single treatment (two-tailed P value generated 




Table 5.4: Summary of the IC50 concentrations generated for two breast cancer cell lines when treated with 
Oxamic acid alone or combined with Paclitaxel. 
 
 
5.2 Combinations with targeted therapy – Trastuzumab 
The HER2-high MDA-MB-361 cell line was used for experiments with trastuzumab in this 
study. Figure 5.21 indicates that trastuzumab had an invariable cytostatic effect on MDA-
MB-361 cells; reducing the percentage of cell number to 80% over the whole range of 
concentrations used (0.3-160μg/ml). For that reason the examined combinations could not be 
analysed through Calcusyn, as the software requires a sigmoidal growth inhibition curve 
from both single agents to describe quantitatively a combination and generate CI values. 
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5.19 

























Oxamic acid & Paclitaxel 
Figure  
5.20 


















Trastuzumab Concentration, μg/ml 
Trastuzumab 
Figure 5.21 
IC50 values (mM) MCF7 MDA-MB-231 
Oxamic acid 33.1 49.7 
Oxamic acid & Paclitaxel 12 22.3 
Figure 5.21: Concentration response 
curve of MDA-MB-361 breast cancer 
cells treated with Trastuzumab 
concentrations between 0.31-160μg/ml 
for a three day period. Cell viability was 
determined by an SRB assay. Mean 
results of 6 replicates are reported and 
error bars represent standard deviations. 





5.2.1 Oxamic acid & Trastuzumab 
Figure 5.22 demonstrates that Oxamic acid enhanced the efficacy of trastuzumab on MDA-
MB-361 cells as a growth inhibitor. Oxamic acid was used in combination with four separate 
trastuzumab concentrations. The glycolytic inhibitor had similar effects on the efficacy of 
trastuzumab, even when different concentrations of trastuzumab were examined. As the 
combination of the two agents is more effective than each agent separately their interaction 
is characterised as synergistic. Examples of the synergistic action are depicted in Figures 
5.23 and 5.24. When 1.6 or 12.5mM Oxamic acid, both of which had no effect on cell 
viability were combined with either 10 or 40μg/ml trastuzumab, the cell number was reduced 
to 50%.  
 
Figure 5.22: Concentration response curves of MDA-MB-361 breast cancer cells treated with Oxamic acid 
concentrations between 0.4-200mΜ alone (light blue line) and combined with 10μg/ml (blue line), 20μg/ml (red 
line), 40μg/ml (green line) or 80μg/ml (purple line) Trastuzumab. Cell viability was determined by an SRB assay 
after a three day treatment. Mean results of 6 replicates are reported and error bars represent standard deviations. 
Values are shown as a percentage of control. In yellow the effect of Trastuzumab on cell viability is indicated.  
Representative data of 3 independent experiments are presented.    
  
 
Figures 5.23 & 5.24: Effect of 1.6mΜ Oxamic acid, 10μg/ml Trastuzumab and their combination (5.23) as well 
as of 12.5mΜ Oxamic acid, 40μg/ml Trastuzumab and their combination (5.24) on cell viability of MDA-MB-
361 cells. Mean results of 6 replicates are reported and error bars represent standard deviations. Statistical 
significance indications: *** P<0.001 compared to Oxamic acid single treatment (two-tailed P value generated 
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5.2.2 NHI-1 & Trastuzumab 
 
 
NHI-1 augmented the action of Trastuzumab as a cancer cell proliferation inhibitor. The 
novel LDHA inhibitor was used in combination with four separate trastuzumab 
concentrations (Figure 5.25). The addition of NHI-1 had a greater effect on the lowest 
concentration of trastuzumab (5μg/ml) compared to the higher concentrations of 20 and 
40μg/ml. Interestingly when even lower concentrations were used equal to 0.1 and 0.5μg/ml 
(Figures 5.26 and 5.27) a synergistic interaction was identified. Figures 5.28 and 5.29 show 
that a combination of 1.2 or 37.5μM NHI-1, both of which have no effect on cell viability by 
themselves, with 5 or 0.1μg/ml trastuzumab respectively resulted in a cell number lower than 





Figure 5.25: Concentration response curves of MDA-MB-361 breast cancer cells treated with NHI-1 
concentrations between 0.6-300μΜ alone (light blue line) and combined with 5μg/ml (blue line), 10μg/ml (red 
line), 20μg/ml (green line) or 40μg/ml (purple line) Trastuzumab. Cell viability was determined by an SRB assay 
after a three day treatment. Mean results of 6 replicates are reported and error bars represent standard deviations. 
Values are shown as a percentage of control. In yellow the effect of Trastuzumab on cell viability is indicated. A 
constant 0.3% DMSO concentration was used across the whole curve in all cases. Representative data of 3 
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Figures 5.26 & 5.27: Concentration response curves of MDA-MB-361 breast cancer cells treated with ΝΗΙ-1 
concentrations between 4.7-300μΜ (5.26) and 9.4-600μΜ (5.27) alone (blue line) or combined with 0.1μg/ml 
(5.2.6) and 0.5μg/ml Trastuzumab (red line). Cell viability was determined by an SRB assay after a three day 
treatment. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are 
shown as a percentage of control. In green the effect of Trastuzumab on cell viability is indicated.  Representative 
data of 2 independent experiments are presented.    
 
   
Figures 5.28 & 5.29: Effect of 1.2μΜ NHI-1, 5μg/ml Trastuzumab and their combination (5.28) as well as of 
37.5μΜ NHI-1, 0.1μg/ml Trastuzumab and their combination (5.29) on cell viability of MDA-MB-361 cells. 
Mean results of 6 replicates are reported and error bars represent standard deviations. Statistical significance 
indications: *** P<0.001 compared to NHI-1 single treatment (two-tailed P value generated from unpaired t-test). 
 
5.3 Combinations with an antidiabetic drug – Metformin 
In the present study metformin was assessed in combination strategies with several 
glycolytic inhibitors. Interestingly a synergistic interaction was demonstrated with five of 
these compounds while antagonistic combinations were identified with 3PO and NHI-1.  
Concentration response curves of metformin for the panel of breast and ovarian cancer cell 
lines used in these experiments justifying the range of concentrations used are included in 
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5.3.1 IOM-1190 & Metformin 
The strongest synergistic combination that was identified in the present study was between 
the novel GLUT1 inhibitor IOM-1190 and metformin. Figure 5.30 shows that 1 or 2mM 
metformin enhanced greatly the potency of the GLUT1 inhibitor on MCF7 breast cancer 
cells.  Similarly Figure 5.33 indicates that the effect of IOM-1190 on MDA-MB-231 cells 
was markedly augmented by the addition of 1 or 4mM metformin. The potency of these 
combinations is evident from the CI values. All the values generated for the whole range of 
used concentrations are very low indicating strong synergy. Some examples for MCF7 cells 
are emphasised in Figures 5.31 and 5.32. It is depicted that 0.9μΜ IOM-1190 reduced the 
cell number to 82% and 1 and 2mM metformin to 99 and 94% respectively. When IOM-
1190 was combined with these two metformin concentrations the cell number was reduced to 
41 and 13%.  The CI values describing these combinations are 0.2 and 0.04 indicating strong 
and very strong synergism respectively. Regarding the triple negative cell line similar 
synergistic combinations are presented in Figures 5.34 and 5.35. It is shown that while 
0.5μΜ IOM-1190 reduced the percentage of cell number to 71% and the two metformin 
concentrations used to 99 and 75%, when IOM-1190 was combined with each of metformin 
concentrations cell number was reduced to 31 and 11%. The attributed CI values to these 
combinations were 0.1 and 0.04 respectively indicating very strong synergism. The great 
efficacy of the combinations is also reflected in the very low IC50 values of the combination 
curves (Table 5.5). 
 
 
Figure 5.30: Concentration response curves of MCF7 breast cancer cells treated with IOM-1190 concentrations 
between 0.06-30μΜ alone (blue line) and combined with 1mM (green line) or 2mM Metformin (red line). Cell 
viability was determined by an SRB assay after a three day treatment. Mean results of 6 replicates are reported 
and error bars represent standard deviations. Values are shown as a percentage of control. A constant 0.3% 
DMSO concentration was used across the whole curve in all cases. Asterisks indicate synergistic combination 
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Figures 5.31 & 5.32: Effect of 0.9μΜ IOM-1190, 1mΜ Metformin and their combination (5.31) as well as effect 
of 0.9μΜ IOM-1190, 2mΜ Metformin and their combination (5.32) on cell viability of MCF7 cells. Mean results 
of 6 replicates are reported and error bars represent standard deviations. The respective Combination Index values 
generated through Calcusyn are indicated. Statistical significance indications: *** P<0.001 compared to IOM-
1190 single treatment (two-tailed P value generated from unpaired t-test).   
 
 
Figure 5.33: Concentration response curves of MDA-MB-231 breast cancer cells treated with IOM-1190 
concentrations between 0.06-30μΜ alone (blue line) and combined with 1mM (green line) or 4mM Metformin 
(red line). Cell viability was determined by an SRB assay after a three day treatment. Mean results of 6 replicates 
are reported and error bars represent standard deviations. Values are shown as a percentage of control. A constant 
0.3% DMSO concentration was used across the whole curve in all cases. Asterisks indicate synergistic 
combination points with Combination Index values lower than 0.8 (n=1).    
  
Figures 5.34 & 5.35: Effect of 0.5μΜ IOM-1190, 1mΜ Metformin and their combination (5.34) as well as effect 
of 0.5μΜ IOM-1190, 4mΜ Metformin and their combination (5.35) on cell viability of MDA-MB-231 cells. 
Mean results of 6 replicates are reported and error bars represent standard deviations. The respective Combination 
Index values generated through Calcusyn are indicated. Statistical significance indications: *** P<0.001 
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IOM-1190 & Metformin 
Figure  
5.32 
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IOM-1190 & Metformin 
Figure  
5.34 

























IOM-1190 & Metformin 
Figure  
5.35 











MCF7 12.5 0.8 0.08 
MDA-MB-231 1.9 0.2 <0.06 
 
Table 5.5: Summary of the IC50 concentrations generated for two breast cancer cell lines when treated with IOM-
1190 alone or combined with two different Metformin concentrations. 
 
 
5.3.2 STF31 & Metformin 
 
 
Another effective combination identified was between STF31 and metformin. The effect of 
the GLUT1 inhibitor on both breast and ovarian cancer cell lines was enhanced by 
metformin. Figures 5.36 and 5.37 depict the synergistic action of the two agents on MCF7 
and MDA-MB-231 cells. The lowest CI value presented from MCF7 cells was 0.4 when 
0.9μΜ STF31 was combined with 2mΜ metformin. The single agents reduced the cell 
number to 84 and 85% respectively however when combined the cell number was reduced to 
37% (Figure 5.38). As regards the triple negative cell line Figure 5.39 demonstrates that the 
effect on cell viability of 1.9μΜ STF31 was 78%, of 3mΜ metformin 87% whereas their 
combination produced 37% cell number; giving a synergistic CI value equal to 0.2. 
A synergistic interaction between STF31 and metformin was also observed for the ovarian 
cancer cell line pair PEA1 and PEA2. As shown in Figures 5.40 and 5.41 low CI values were 
generated for both cell lines. Strong synergy at the level of a CI value equal to 0.1 was 
demonstrated for both. Examples of the combination of 0.9μM STF31 with 1mM metformin 
are presented in Figures 5.42 and 5.43. The effect of this concentration of the GLUT1 
inhibitor on the cell number of the platinum naïve cell line was 48%, of metformin 99% 
whilst their combination resulted in cell number reduced to 22%. The respective percentages 
for the platinum resistant line were 93% for STF31, 90% for metformin and 49% for the 
combination. A large shift of the IC50 values of the combination growth inhibition curves, 
compared to the STF31 single treatment curves, was observed for both breast and ovarian 







Figures 5.36 & 5.37: Concentration response curves of MCF7 (5.36) and MDA-MB-231 (5.37) breast cancer 
cells treated with STF31 concentrations between 0.1-7μΜ (MCF7) and 0.5-30μΜ (MDA-MB-231) alone (blue 
line) or combined with a constant concentration of Metformin (red line). Cell viability was determined by an SRB 
assay after a three day treatment. Mean results of 6 replicates are reported and error bars represent standard 
deviations. Values are shown as a percentage of control. In green the effect of 2mM(MCF7) or 3mΜ (MDA-MB-
231) Metformin on cell viability is presented. Asterisks indicate synergistic combination points with Combination 





   
 
 
Figures 5.38 & 5.39: Effect of 0.9μΜ STF31, 2mΜ Metformin and their combination on cell viability of MCF7 
cells (5.38) as well as effect of 1.9μΜ STF31, 3mΜ Metformin and their combination on cell viability of MDA-
MB-231 cells (5.39). Mean results of 6 replicates are reported and error bars represent standard deviations. The 
respective Combination Index values generated through Calcusyn are indicated. Statistical significance 
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STF31 & Metformin 
Figure  
5.38 

























STF31 & Metformin 
Figure  
5.39 





Figures 5.40 & 5.41: Concentration response curves of PEA1 (5.40) and PEA2 (5.41) ovarian cancer cells 
treated with STF31 concentrations between 0.5-30μΜ alone (blue line) or combined with 1mM Metformin (red 
line). Cell viability was determined by an SRB assay after a three day treatment. Mean results of 6 replicates are 
reported and error bars represent standard deviations. Values are shown as a percentage of control. In green the 
effect of 1mM Metformin on cell viability is presented. Asterisks indicate synergistic combination points with 
Combination Index values lower than 0.8. Representative data of 2 independent experiments are presented. 
    
 
   
Figures 5.42 & 5.43: Effect of 0.9μΜ STF31, 1mΜ Metformin and their combination on cell viability of PEA1 
(5.42) and PEA2 cells (5.43). Mean results of 6 replicates are reported and error bars represent standard 
deviations. The respective Combination Index values generated through Calcusyn are indicated. Statistical 
significance indications: *** P<0.001 compared to STF31 single treatment (two-tailed P value generated from 
unpaired t-test). 
 
IC50 values (μM) 
Breast cancer cell 
lines 






STF31 1.9 4.4 0.9 9.4 
STF31 & Metformin 0.5 1.3 0.5 0.9 
 
Table 5.6: Summary of the IC50 concentrations generated for one breast and one ovarian cancer cell line pair 
when treated with STF31 alone or combined with Metformin. 
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STF31 & Metformin 
Figure 5.42 

























STF31 & Metformin 
Figure  
5.43 




5.3.3 Phloretin & Metformin 
An effective interaction between Phloretin and metformin was characterised for PEO1 
ovarian cancer cells and is depicted in Figure 5.44. The combination was not found effective 
for platinum resistant ovarian cancer cell lines nor for breast lines. A synergistic action 
between the two compounds for the platinum sensitive line was observed only for the lower 
Phloretin concentrations examined. An example is presented in Figure 5.45. Even though 
18.8μM of the flavonoid and 3mM metformin did not affect PEO1 cell viability their 
combination appeared to reduce the cell number to 60% (CI=0.4). Furthermore the IC50 







Figure 5.45: Effect of 18.8μΜ Phloretin, 3mΜ Metformin and their combination on cell viability of PEO1 cells. 
Mean results of 6 replicates are reported and error bars represent standard deviations. The respective Combination 
Index value generated through Calcusyn is indicated. Statistical significance indication: *** P<0.001 compared to 
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Phloretin & Metformin 
Figure  
5.45 
CI = 0.4 





Table 5.7: Summary of the IC50 
concentrations generated for one ovarian 
cancer cell line when treated with Phloretin 
alone or combined with Metformin. 
 
Figure 5.44: Concentration response curves of 
PEO1 ovarian cancer cells treated with 
Phloretin concentrations between 9.4-600μΜ 
alone (blue line) or combined with 3mM 
Metformin (red line). Cell viability was 
determined by an SRB assay after a three day 
treatment. Mean results of 6 replicates are 
reported and error bars represent standard 
deviations. Values are shown as a percentage of 
control. In green the effect of 3mM Metformin 
on cell viability is presented. Asterisks indicate 
synergistic combination points with 




5.3.4 Oxamic acid & Metformin 
 
A promising positive interaction between Oxamic acid and metformin was identified and 
found to have universal effectiveness in all cancer cell lines, both breast and ovarian, that 
were examined. Figures 5.46 and 5.47 present a synergistic interaction between the two 
agents in MCF7 and MDA-MB-231 breast cancer cells. Equally low CI values (between 0.3 
and 0.4) were generated for both the ER positive and the triple negative breast cancer cell 
line. According to Figure 5.48, 18.5mM Oxamic acid reduced MCF7 cell number to 70% 
and 2mM metformin to 75% while their combination reached a 68% growth inhibition. 
Regarding MDA-MB-231 cells as shown in Figure 5.49, 37.5mM Oxamic acid caused a 
reduction of the cell number to 62%, 4mM metformin to 85% and their combination to 22%. 
 
Figures 5.50 and 5.51 demonstrate a synergistic interaction between the LDH inhibitor and 
metformin in the first ovarian cancer cell line pair PEA1 and PEA2; while Figures 5.54 and 
5.55 are for PEO1 and PEO4 lines. The combination was very effective for all four cell lines 
producing very low CI values. An interesting observation though is that while the second 
pair of cell lines presented similar sensitivity to the combination; the platinum naïve line 
PEA1 was more sensitive compared to its paired platinum resistant line generating CI values 
even lower than 0.1. The synergistic interaction for this cell line pair is demonstrated in 
Figures 5.53 and 5.54. The combination of 3.1mM Oxamic acid with 1mM metformin 
reduced PEA1 cell number to 18% in contrast to a 10% and 2% growth inhibition presented 
from each compound alone (CI=0.05). Similarly 12.5mM Oxamic acid combined with 1mM 
metformin reduced PEA2 cell number to 48% compared to 81 and 95% when used as single 
agents (CI=0.3). Figures 5.56 and 5.57 depict examples of synergistic action for the other 
ovarian cancer cell line pair. It is shown that 3.1mM of the LDH inhibitor reduced the 
percentage of PEO1 cell number to 92% and 2mM metformin to 94% whereas the 
combination of both resulted in 29% cell viability (CI=0.2). Regarding the platinum resistant 
line PEO4 the combination of 6.3mM Oxamic acid with 2mM metformin caused 75% 
growth inhibition while each of the drugs alone were 19 and 1% respectively (CI=0.1). 
Along with the low CI values generated, the efficacy of the combination of Oxamic acid 
with the widely prescribed antidiabetic drug is also demonstrated from the IC50 values of the 
combination curves, which were much lower compared to the values for Oxamic acid alone 







Figures 5.46 & 547: Concentration response curves of MCF7 (5.46) and MDA-MB-231 (5.47) breast cancer 
cells treated with Oxamic acid concentrations between 2.3-150mΜ alone (blue line) or combined with a constant 
concentration of Metformin (red line). Cell viability was determined by an SRB assay after a three day treatment. 
Mean results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a 
percentage of control. In green the effect of 2mM (MCF7) or 4mΜ (MDA-MB-231) Metformin on cell viability 
is presented. Asterisks indicate synergistic combination points with Combination Index values lower than 0.8.  
Representative data of 2 independent experiments are presented.   
 
  
   
 
 
Figures 5.48 & 5.49: Effect of 18.8mΜ Oxamic acid, 2mΜ Metformin and their combination on cell viability of 
MCF7 cells (5.48) as well as effect of 37.5mΜ Oxamic acid, 4mΜ Metformin and their combination on cell 
viability of MDA-MB-231 cells (5.49). Mean results of 6 replicates are reported and error bars represent standard 
deviations. The respective Combination Index values generated through Calcusyn are indicated.  Statistical 
significance indications: *** P<0.001 compared to Oxamic acid single treatment (two-tailed P value generated 
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Oxamic acid & Metformin 
Figure 5.48 

























Oxamic acid & Metformin 
Figure 5.49 







Figures 5.50 & 5.51: Concentration response curves of PEA1 (5.50) and PEA2 (5.51) ovarian cancer cells 
treated with Oxamic acid concentrations between 1.56-100mΜ alone (blue line) or combined with 1mM 
Metformin (red line). Cell viability was determined by an SRB assay after a three day treatment. Mean results of 
6 replicates are reported and error bars represent standard deviations. Values are shown as a percentage of 
control. In green the effect of 1mM Metformin on cell viability is presented. Asterisks indicate synergistic 
combination points with Combination Index values lower than 0.8. Representative data of 3 independent 
experiments are presented.    
 
 
   
 
 
Figures 5.52 & 5.53: Effect of 3.1mΜ Oxamic acid, 1mΜ Metformin and their combination on cell viability of 
PEA1 cells as well as effect of 12.5mΜ Oxamic acid, 1mΜ Metformin and their combination on cell viability of 
PEA2 cells. Mean results of 6 replicates are reported and error bars represent standard deviations. The respective 
Combination Index values generated through Calcusyn are indicated. Statistical significance indications: *** 
P<0.001 compared to Oxamic acid single treatment (two-tailed P value generated from unpaired t-test). 
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Oxamic acid & Metformin 
Figure 5.52 


























Oxamic acid & Metformin 
Figure 5.53 





Figures 5.54 & 5.55: Concentration response curves of PEO1 (5.54) and PEO4 (5.55) ovarian cancer cells 
treated with Oxamic acid concentrations between 1.56-100mΜ alone (blue line) or combined with a constant 
concentration of Metformin (red line). Cell viability was determined by an SRB assay after a three day treatment. 
Mean results of 6 replicates are reported and error bars represent standard deviations. Values are shown as a 
percentage of control. In green the effect of 2mM (PEO1) or 0.5mΜ (PEO4) Metformin on cell viability is 
presented. Asterisks indicate synergistic combination points with Combination Index values lower than 0.8. 
Representative data of 3 independent experiments are presented.    
 
 
   
Figures 5.56 & 5.57: Effect of 3.1mΜ Oxamic acid, 2mΜ Metformin and their combination on cell viability of 
PEO1 cells as well as effect of 6.3mΜ Oxamic acid, 0.5mΜ Metformin and their combination on cell viability of 
PEO4 cells. Mean results of 6 replicates are reported and error bars represent standard deviations. The respective 
Combination Index values generated through Calcusyn are indicated. Statistical significance indications: *** 




Breast cancer cell lines Ovarian cancer cell line pairs 
MCF7 MDA-MB-231 PEA1 PEA2 PEO1 PEO2 
Oxamic acid 33.1 49.7 18.8 19 14.5 18 
Oxamic acid 
& Metformin 
10.8 12.2 1.7 11.5 2 2.7 
 
Table 5.8: Summary of the IC50 concentrations generated for one breast and two ovarian cancer cell line pairs 
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Oxamic acid & Metformin 
Figure 5.56 


























Oxamic acid & Metformin 
Figure 5.57 




5.3.5 Dichloroacetate & Metformin 
 
Figures 5.58 and 5.59 provide evidence of a synergistic interaction between DCA and 
metformin for MCF7 and MDA-MB-231 cells. The inhibitor of oxidative phosphorylation 
was found to enhance the efficacy of DCA only on breast cancer cell lines. The triple 
negative cell line was found more sensitive to the combination as very low CI values were 
generated suggesting strong synergism. Examples of the synergistic interaction are presented 
in Figures 5.60 and 5.61. Combination of 6.3mΜ DCA with 1mΜ metformin reduced the 
percentage of MCF7 cell number to 45% compared to 69 and 88% cell number that was 
caused from each of them alone (CI=0.4). As for MDA-MB-231 cells 3.1mM DCA did not 
affect the cell number, 3mΜ metformin reduced the cell number to 87% and their 
combination to 57% (CI=0.2). Sensitivity to the combination of the drugs was at least 50% 
higher compared to the use of the PDHK1 inhibitor alone; as this was quantified by an IC50 






Figures 5.58 & 5.59: Concentration response curves of MCF7 (5.58) and MDA-MB-231 (5.59) breast cancer 
cells treated with Dichloroacetate concentrations between 1.56-100mΜ alone (blue line) or combined with a 
constant concentration of Metformin (red line). Cell viability was determined by an SRB assay after a three day 
treatment. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are 
shown as a percentage of control. In green the effect of 1mM (MCF7) or 3mΜ (MDA-MB-231) Metformin on 
cell viability is presented. Asterisks indicate synergistic combination points with Combination Index values lower 
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Figures 5.60 & 5.61: Effect of 6.3mΜ DCA, 1mΜ Metformin and their combination on cell viability of MCF7 
cells (5.60) as well as effect of 3.1mΜ DCA, 3mΜ Metformin and their combination on cell viability of MDA-
MB-231 cells (5.61). Mean results of 6 replicates are reported and error bars represent standard deviations. The 
respective Combination Index values generated through Calcusyn are indicated. Statistical significance 




Table 5.9: Summary of the IC50 concentrations generated for two breast cancer cell lines when treated with 
Dichloroacetate alone or combined with Metformin. 
 
 
The following table summarises the most successful combinations that were identified in this 
study (Table 5.10). These combinations produced promising effects in breast and ovarian 










IOM-1190 Metformin   
STF31 Metformin   
3PO Cisplatin   
3PO Paclitaxel   
Oxamic acid Metformin   
Oxamic acid Trastuzumab   
NHI-1 Trastuzumab   
 























DCA & Metformin 
Figure 5.60 
























DCA & Metformin 
Figure 5.61 
CI = 0.2 
IC50 values (mM) MCF7 MDA-MB-231 
Dichloroacetate 14.9 47.5 




5.4 The effect of STF31 & Metformin combination on induction of apoptosis 
 
The combination of STF31 with metformin was identified as a very successful combination 
on both breast and ovarian cancer cell lines. The mechanism of antiproliferative action of 
this combination was examined through flow cytometric analysis of double stained MDA-
MB-231 cells with FITC-conjugated annexin V and propidium iodide. Figures 5.62 and 5.63 
present the scatter plots of gated cells treated with 4μM STF31, 4mΜ metformin and their 
combination for 24 and 48h. Data illustrates that combination treatment of the two drugs 
inhibited cancer cell growth through induction of apoptotic cell death. Regarding cells 
treated with the combination of STF31 with metformin for 24h the population undergoing 
apoptosis stained positive with annexin V (upper region) was quantified at 8.1%; this 
represented an increase of 100% compared to the respective percentages of cells treated with 
each of the agents alone. After a 48h combination treatment late apoptotic cells, positively 
stained with annexin V and PI (upper right quadrant), reached 14.3% when the same 
population after single treatment with either 4μM STF31 or 4mM metformin was found to be 
4.5 and 7.1% respectively. 
Scatter plots of untreated MDA-MB-231 control cells can be seen in the Appendix (Figures 
A1.8&A1.9).   
 
 












Figure 5.62: Flow cytometric analysis of MDA-MB-231 breast cancer cells treated with 4μM STF31, 4mΜ 
Metformin and their combination for 24h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double 
stained with FITC-conjugated annexin V and propidium iodide are presented. The percentage of cells in each 
















Figure 5.63: Flow cytometric analysis of MDA-MB-231 breast cancer cells treated with 4μM STF31, 4mΜ 
Metformin and their combination for 48h. FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double 
stained with FITC-conjugated annexin V and propidium iodide are presented. The percentage of cells in each 
quadrant is indicated in red (n=1).  
 
Figures 5.64 and 5.65 illustrate the percentage of live, apoptotic and necrotic cell populations 
as quantified after cell cytometric analysis of MDA-MB-231 cells treated with STF31 and 
metformin alone or combined for 24 or 48h.   
 
 
   
 
 
Figures 5.64 & 5.65: Quantification of percentages of apoptotic, necrotic and live MDA-MB-231 cells when 
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To examine whether the combinations of glycolytic inhibitors with metformin had an impact 
on cell cycle progression, compared to their use as single agents, flow cytometric analysis 
was performed. PI fluorescent staining was used to separate MDA-MB-231 cell populations 
in different phases of the cell cycle according to their cellular DNA content. The histogram 
plots presented below illustrate the effect of the combinations of three glycolytic inhibitors, 
IOM-1190, STF31 and Oxamic acid, with metformin on cell cycle progression. Figure 5.66 
demonstrates that combination treatment of IOM-1190 with metformin was associated with 
cell cycle arrest in the G2 phase. The proportion of cells in this phase of the cell cycle was 
found to be 54.2%, doubled compared to the respective percentages of single treated cells. 
Figure 5.67 indicates that combination treatment of MDA-MB-231 cells with STF31 and 
metformin did not have any additional effect on cell cycle progression compared to treatment 
with each of the drugs alone. The distribution of double treated cells in each stage of the cell 
cycle was similar to that of cells treated with them as single agents. Co-treatment of Oxamic 
acid with metformin was associated with cell cycle arrest in G1 phase. As shown in Figure 
5.68 the percentage of co-treated cells found in the G1 phase was 66.4% compared to 57.6 
and 52.85% for cells treated with either Oxamic acid or metformin. A corresponding 
decrease of cells in G2/M phases was observed. 
 
Histogram plots of untreated MDA-MB-231 control cells can be seen in the Appendix 
(Figure A1.10).   
 
 















Figure 5.66 & Table 5.11: Flow cytometric analysis of cellular DNA content of MDA-MB-231 breast cancer 
cells treated with 0.5μM IOM-1190, 4mΜ Metformin and their combination for 24h. In the histograms 
fluorescence of the DNA bound propidium iodide, indicating the DNA content in X-axis, is plotted against the 
number of cells in the Y-axis. The percentage of cells in each cell cycle phase is demonstrated in the 
complementary table (n=1).  












Figure 5.67 & Table 5.12: Flow cytometric analysis of cellular DNA content of MDA-MB-231 breast cancer 
cells treated with 4μM STF31, 4mΜ Metformin and their combination for 24h. In the histograms fluorescence of 
the DNA bound propidium iodide, indicating the DNA content in X-axis, is plotted against the number of cells in 
the Y-axis. The percentage of cells in each cell cycle phase is demonstrated in the complementary table (n=1).  
 











G0/G1 55 52.85 32.6 
S 17.5 21.4 13.2 







G0/G1 55.9 52.85 50.5 
S 18.9 21.4 22.2 













Figure 5.68 & Table 5.13: Flow cytometric analysis of cellular DNA content of MDA-MB-231 breast cancer 
cells treated with 20mM Oxamic acid, 4mΜ Metformin and their combination for 24h. In the histograms 
fluorescence of the DNA bound propidium iodide, indicating the DNA content in X-axis, is plotted against the 
number of cells in the Y-axis. The percentage of cells in each cell cycle phase is demonstrated in the 
complementary table (n=1).  
 
Figures 5.69 to 5.71 illustrate the proportion of cells in the G0/G1, S and G2/M phases of the 
cell cycle as quantified after cell cytometric analysis of MDA-MB-231 cells treated with 
IOM-1190, STF31, Oxamic acid and Metformin alone or combined for 24h. 




Figures 5.69 to 5.71: Quantification of percentages of MDA-MB-231 cells in the G0/G1, S and G2/M phases of 
the cell cycle when treated with IOM-1190, STF31, Oxamic acid and Metformin alone or combined for 24h, as 
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Oxamic acid & 
Metformin 
G0/G1 57.6 52.85 66.4 
S 18.4 21.4 17.2 




5.6 Discussion  
 
Currently, the administration of antitumour therapy generally involves combinatorial 
strategies of several therapeutic agents. Drug combinations aim to augment the therapeutic 
benefit, reduce the adverse effects and delay or ideally hinder resistance [448]. Synergism 
can be defined as an effective drug interaction where one agent enhances the effect of the 
other and the combination of them both is more efficient than each of them individually. In 
contrast antagonism refers to the case where two agents used together are less effective than 
each of them separately with one opposing the other’s action [402].  
The median-drug effect analysis method is a mathematical model commonly used for the 
analysis of the effectiveness of drug interaction studies. It was developed by Chou and 
Talalay and assumes sigmoidal concentration response curves from both single agents and 
their combination [402, 448]. CI values were generated based on this method using the 
Calcusyn Software. In this way each combination point was characterised quantitatively as 
synergistic, additive or antagonistic. However, the mathematical algorithm is unreliable 
when growth inhibition is minimal (around 100% growth) or maximal (almost 0% growth) 
and for that reason edge values near each end point of the sigmoidal curves were excluded 
from every analysis.   
The combinatorial experiments of this study were designed involving simultaneous drug 
exposure and a non-constant concentration ratio. A range of different concentrations with 1:2 
dilution steps of the glycolytic inhibitors were combined with a fixed concentration, around 
the IC20 or less, of the established drug. In this set of experiments the constant concentration 
of the non-glycolytic inhibitor was selected based on its growth inhibition effect. The main 
aim was to use a low clinically relevant concentration (below the IC20 of the single drug 
inhibition curve) that would have roughly the same growth inhibitory effect between each 
cell line pair. Therefore for example a higher concentration of cisplatin was used for the 
platinum resistant PEA2 line compared to the platinum naïve PEA1 line to achieve a 
comparable antiproliferative effect (4μM compared to 1μM – Figures 5.1&5.2).   
The main goal of the current chapter of this thesis was to investigate the efficacy of novel 
combinatorial strategies among glycolytic inhibitors and traditional therapeutics. Among a 
wide range of investigated combinations (Table 5.1) only the ones that proved effective 
generating low CI values and were considered promising for further evaluation have been 




Appendix (Figures A1.4 to A1.7). Nevertheless it should be highlighted that this refers to the 
current experimental design and conditions. It is not unlikely that a different experimental 
setting for example sequential (non-simultaneous) delivery or a different cell line model 
could generate different results.     
 
5.6.1 Glycolytic inhibitors potentiated the antiproliferative effect of cisplatin 
and paclitaxel on breast and ovarian cancer cells 
Resistance to common chemotherapeutic agents has been associated with the deregulated 
reliance of tumours on the glycolytic pathway. It has been suggested that targeting the 
metabolic phenotype of tumours may enhance the efficacy of chemotherapy regimens and 
moreover resensitise tumour cells to treatment to which they had developed resistance [382, 
383]. Possible proposed mechanisms predict glycolysis inhibition reducing cellular ATP 
levels and compromising the activation of resistance pathways or attenuating tumour growth 
promoting induction of apoptosis and hindering the adaptation to chemotherapeutic 
treatment [382, 383].  
The interaction between cisplatin and a range of glycolytic inhibitors was examined in this 
study (Table 5.1). Cisplatin is the most extensively used drug for the treatment of ovarian 
cancer however resistance frequently emerges [385]. A dilution series of certain compounds 
targeting the glycolytic pathway was used in combination with a fixed concentration of the 
platinum analogue. It was observed that the PFKFB3 inhibitor 3PO significantly enhanced 
the anticancer effect of cisplatin in four ovarian cancer cell line models. The platinum naïve 
cell line PEA1 was particularly sensitive to the combination of 3PO with cisplatin generating 
CI values as low as 0.2 indicating strong synergism. For the platinum sensitive line of the 
other pair, PEO1, the combination was also effective, however the lowest synergistic CI 
value observed was in the range of 0.6. Interestingly both platinum resistant lines, PEA2 and 
PEO4, were also responsive to this combination with lowest CI values detected equal to 0.5 
and 0.6 for each cell line respectively (Figures 5.1 to 5.8). This is an important finding 
suggesting that combinatorial treatment of cisplatin with 3PO could reverse the platinum 
resistant phenotype and may be an effective strategy against platinum-resistant ovarian 
tumours. It should be noted that the concentrations of the two drugs that gave the lowest CI 
values are relatively low and potentially achievable in  in vivo experiments.    
Paclitaxel is an anti-mitotic agent extensively used for the treatment of both breast and 




inhibitor and paclitaxel. 3PO combined with paclitaxel presented synergistic anticancer 
action on ovarian cancer cells. Both PEA1 and PEA2 lines of the first ovarian cancer cell 
line pair were very sensitive to this combination. Very low CI values indicating strong 
synergism were generated for both of them. Interestingly this was not the case for the other 
pair. While synergistic CI values were detected for the platinum sensitive PEO1 line its 
paired platinum resistant PEO4 line responded to the combination showing moderate 
antagonism. Synergism was only observed when a high concentration of 3PO equal to 15μM 
was used but this defeats the main purpose of the combination being to use low 
concentrations of the individual agents and cannot be considered promising (Figures 5.9 to 
5.16). Nevertheless the effectiveness of the combination in the other lines including the 
resistant PEA2 line suggests that this combination might have in vivo potential. On searching 
the literature, this research appears to be the first providing direct evidence of a synergistic 
interaction between 3PO and widely used chemotherapeutic cytotoxic agents.  
To date a number of studies have revealed that certain compounds targeting the glycolytic 
metabolism of tumours might improve the therapeutic index of chemotherapeutic cytotoxic 
agents mainly through reduction of the ATP levels selectively in malignant cells [382, 383]. 
Similar to this study’s observations Liu et al reported synergistic antitumour action between 
the GLUT1 inhibitor WZB117 and cisplatin or paclitaxel [319]. Another glucose transport 
inhibitor, the phytochemical Phloretin, has been shown to potentiate the cytotoxic effect of 
daunorubicin promoting apoptosis and also sensitised resistant leukaemia and colon cancer 
cells to the anthracycline exclusively under hypoxic conditions [287]. Nakano et al 
documented that the HKII inhibitor 3BP enhanced the anticancer effects of daunorubicin and 
doxorubicin in leukaemia and myeloma cells both in vitro and in vivo. The glycolytic 
inhibitor diminished the cellular ATP levels which led to inactivation of the ATP-binding 
cassette transporters (ABC) therefore preventing the agent’s efflux from malignant cells 
[449]. Synergistic antitumour activity has also been evidenced among DCA and 5-
fluorouracil in colon cancer cell lines demonstrating elevated apoptotic cell death compared 
to treatment with each agent individually [450].  
An additional effective combination that was described here was that between Oxamic acid 
and paclitaxel. The competitive LDH inhibitor proved able to enhance the potency of the 
taxane on two breast cancer cell lines. Both the ER positive MCF7 line and the triple 
negative MDA-MB-231 line gave synergistic CI values for the lowest Oxamic acid 
concentrations used (Figures 5.17 to 5.20). Nonetheless Oxamic acid required great 




this combination problematic. Research using Oxamic acid as a lead compound to synthesise 
a derivative exhibiting enhanced potency and membrane permeability is currently being 
conducted [368]. However for the potent selective LDHA inhibitor, NHI-1, no synergistic 
inhibitory interaction with paclitaxel was observed under the particular conditions of these 
experiments.  
In their key study Zhou et al linked LDHA expression with resistance to paclitaxel in breast 
tumours. They observed elevated LDHA expression and activity in paclitaxel resistant breast 
cancer cells and demonstrated that LDHA siRNA knockdown or inhibition by Oxamic acid 
significantly enhanced their sensitivity to paclitaxel. The authors suggested that the 
combination of Oxamic acid with paclitaxel could be promising for the treatment of 
paclitaxel resistant mammary malignancy promoting apoptotic cell death [373]. The 
contribution of the current thesis lies in the observation of a synergistic interaction between 
Oxamic acid and paclitaxel in paclitaxel sensitive breast cancer cell lines. It is possible to 
hypothesise that combinatorial treatment of these two agents could delay or even prevent 
development of paclitaxel resistance. This would be of great importance and remains to be 
further investigated.   
 
5.6.2 LDH inhibitors potentiated the antiproliferative effect of trastuzumab on 
breast cancer cells  
Trastuzumab is a recombinant humanised monoclonal antibody against the HER2 receptor. It 
has revolutionised treatment of HER2 positive breast tumours however clinical resistance 
presents a major challenge [32]. In the present study I examined the effect of two LDH 
inhibitors combined with several constant concentrations of trastuzumab on cell growth of 
the HER2 amplified MDA-MB-361 breast cancer cell line. As shown in Figure 5.21 
trastuzumab induced an invariable cytostatic effect on MDA-MB-361 cells reducing their 
cell number by 20%. For this reason it was not possible to analyse the data in the Calcusyn 
software and obtain quantitative CI values since sigmoidal growth inhibition curves from 
both single agents is a requirement of the used algorithm. As shown, the MDA-MB-361 cell 
line is moderately sensitive to trastuzumab treatment and therefore it has been used as a 
model system for the study of trastuzumab resistant disease [451].   
Both LDH inhibitors enhanced the antiproliferative effect of trastuzumab on breast cancer 
cells. Even though quantitative characterisation was not possible it was obvious that in both 




according to the current predominant definition qualifies for synergism [402]. Oxamic acid 
enhanced the efficacy of several different trastuzumab concentrations, ranging from 10 to 
80μg/ml, in a comparable way. In contrast, the novel selective LDHA inhibitor NHI-1 
improved the inhibitory effect of low trastuzumab concentration (5μg/ml) more effectively 
compared to higher concentrations (40μg/ml). Interestingly, NHI-1 markedly increased the 
sensitivity of MDA-MB-361 cells to trastuzumab concentrations as low as 0.1 and 0.5μg/ml, 
(Figures 5.22 to 5.29). Taking into account that MDA-MB-361 cells represent trastuzumab 
resistant breast cancer these findings suggest that combination of LDH inhibitors with 
trastuzumab has the potential to be developed for the treatment of HER2 positive 
trastuzumab resistant breast malignancy.        
Zhao et al were the first to report a synergistic interaction between trastuzumab and Oxamic 
acid. They observed that trastuzumab inhibits the glycolytic metabolism of HER2 positive 
tumours via heat shock factor 1 and LDHA downregulation and associated trastuzumab 
resistance with the elevated dependency of tumours on the glycolytic pathway. They 
demonstrated that Oxamic acid enhanced the antitumour activity of trastuzumab in both 
trastuzumab sensitive and resistant HER2 high breast cancers in vitro as well as in vivo. 
They proposed this combination as a strategy to battle trastuzumab resistance [372].  
The present study confirms previous findings and contributes additional evidence that 
suggests that LDHA inhibition can potentially reverse trastuzumab resistance in HER2 
amplified breast tumours. A favourable interaction between trastuzumab and the selective 
LDHA inhibitor NHI-1 appears not to have been described before. An important noteworthy 
finding is that the concentration of trastuzumab required to augment the NHI-1 effect on 
MDA-MB-361 cellular growth is considerably lower compared to the concentrations used 
for the pyruvate analogue Oxamic acid.  
Zhao et al suggested that inhibition of the glycolytic metabolism of tumours is associated 
with the antitumour mechanism of trastuzumab. Therefore inhibition of the glycolytic 
pathway, broader than LDHA inhibition, could enhance the potency of trastuzumab on 
HER2 positive breast tumours. Additionally to Oxamic acid a synergistic interaction with 
2DG has also been demonstrated [372]. A question arises as to whether inhibition of other 
glycolytic enzymes with more potent ‘next-generation’ compounds may have the same 
impact on trastuzumab efficacy. This remains to be further investigated and has great 





            
5.6.3 Metformin potentiated the antiproliferative effect of glycolytic inhibitors 
on breast and ovarian cancer cells  
Metformin is a biguanide universally prescribed for the treatment of type 2 diabetes mellitus. 
Besides its anti-hyperglycaemic action metformin is known to inhibit the mitochondrial 
respiratory chain complex 1. Reduced ATP synthesis leads to an increased AMP/ATP 
intracellular ratio provoking AMPK activation and mTOR inhibition. In recent years, there 
has been an increasing volume of literature providing evidence of marked antitumour 
activity. Even though diabetic patients have a well substantiated elevated risk for the 
development of cancer a growing body of epidemiologic studies and meta-analyses have 
associated metformin treatment with decreased cancer incidence as well as with improved 
clinical outcome of diabetic cancer patients [389-392, 452, 453].     
Metformin has received considerable critical attention and is currently a major area of 
extensive research and numerous clinical trials in various cancer types as chemoprevention, 
monotherapy or in combination with several chemotherapeutic agents [389-392, 452, 453]. 
Metformin is a very attractive candidate for combinatorial cancer treatment. There are 
several lines of evidence that recognise its antiproliferative properties; there is great 
experience in human administration coupled with a favourable toxicity profile and minimal 
cost. Nevertheless contradictory findings have recently emerged and a number of clinical 
trials have questioned metformin’s antitumour value in non-diabetic patients. Further 
research and large scale clinical trials are required to elucidate the mechanisms and 
substantiate the anticancer efficacy of this biguanide [389, 390, 392, 452, 453]. 
A number of pre-clinical as well as epidemiological studies have revealed that metformin 
potentiates cancer therapeutics [389, 391, 452]. It has been suggested that metformin 
selectively targets cancer stem cells which are resistant to several chemotherapeutics. Hirsch 
et al reported that metformin in concert with doxorubicin was able to eradicate the stem cell 
and non-stem cell cancer cell population in vitro and the combination synergistically 
suppressed tumour growth and prolonged remission in vivo [454]. In a follow-up study 
Iliopoulos et al documented that metformin in combination with paclitaxel or carboplatin 
synergistically inhibited tumour growth and decreased the dosage of doxorubicin required to 
prevent relapse of breast, lung and prostate xenografts [455]. Consistent with the stem cell 
hypothesis, Cufi et al demonstrated that metformin preferentially targeted trastuzumab 




xenograft mouse model [456]. Moreover metformin has been evidenced to enhance the 
cytotoxic effects of cisplatin and paclitaxel on endometrial cancer cells [457, 458]. In 
another study Rattan et al reported that metformin attenuated tumour growth inhibiting 
angiogenesis and lung metastasis and also enhanced the therapeutic efficacy of cisplatin in 
established ovarian tumour xenografts [459]. 
To date far too little attention has been paid to a possible interaction among glycolytic 
inhibitors and the antidiabetic drug. In 2011 Sahra et al were the first to report that 
metformin in combination with 2DG synergistically attenuated prostate cancer cell growth. 
The combinatorial strategy was associated with ATP depletion, p53 dependent apoptotic cell 
death and G2-M cell cycle arrest [460]. A year later an independent research group verified 
the beneficial combination and reported suppressed tumour growth in a breast cancer mouse 
xenograft model [461]. Choi et al documented that DCA-mediated PDH activation enhanced 
metformin cytotoxicity in HeLa cells inducing oxidative stress resulting in cell death  [462]. 
The synergism was further confirmed by Haugrud et al who demonstrated caspase dependent 
apoptotic cell death in breast cancer cells treated with the PDHK1 inhibitor along with 
metformin [463].      
In the present study a synergistic beneficial effect was revealed between metformin and 
several compounds targeting the glycolytic pathway. It was observed that while low 
concentrations of the antidiabetic drug and the glycolytic inhibitors had only marginal effects 
on the growth of breast and ovarian cancer cell lines, in combination they induced a marked 
antitumour effect. The most robust synergistic relationship that was identified was with the 
novel GLUT1 inhibitor IOM-1190. Two separate metformin concentrations were used for 
each of the paired breast cancer cell lines. Metformin was shown to greatly enhance the 
antiproliferative potency of IOM-1190 in both the ER positive and the triple negative breast 
cancer cell lines. The great efficacy of this combination was reflected in very low CI values. 
All CI values generated for the whole range of concentrations used signified either strong or 
even very strong synergism (Figures 5.30 to 5.35).  
Metformin was also found to augment STF31-induced cytotoxicity on both breast and 
ovarian cancer cells. The favourable interaction between the GLUT1 inhibitor and the 
antidiabetic agent was characterised by low synergistic CI values. Interestingly comparing 
the CI values the triple negative and more aggressive MDA-MB-231 line was more sensitive 
to the combination compared to the ER positive and of low invasive potential MCF7 line. 
Furthermore the two paired ovarian cancer cell lines the platinum naïve PEA1 and the 




5.43). The antiproliferative effect of another inhibitor of glucose transport (Phloretin) on the 
PEO1 ovarian cancer cell line was also enhanced by metformin. Low CI values indicating 
synergism were only generated for this platinum sensitive line while the combination was 
not effective on its paired platinum resistant line nor the breast cancer cell lines examined 
(Figures 5.44&5.45).  
An additional beneficial interaction encountered while examining combinatorial treatments 
of glycolytic inhibitors with the most widely prescribed antidiabetic drug was with Oxamic 
acid. Metformin proved able to improve the antiproliferative efficacy of the established 
pyruvate analogue. The combination was effective on every breast and ovarian cancer cell 
line examined in this study giving synergistic CI values. Interestingly the two breast cancer 
cell lines as well as the PEO1 and PEO4 paired ovarian cancer cell lines demonstrated 
comparable sensitivity to Oxamic acid and metformin co-administration as inferred by the 
similar CI values generated. In contrast the combination was considerably more effective on 
the platinum naïve PEA1 cell line compared to its paired platinum resistant line (Figures 
5.46 to 5.57). The last synergistic relationship of metformin identified in this thesis was with 
DCA. The two agents demonstrated a synergistic inhibitory effect on two breast cancer cell 
lines. Interestingly the CI values generated for the triple negative line were remarkably lower 
than the corresponding values of MCF7 cells (Figures 5.58 to 5.61).  The synergistic effect 
on MCF7 cells demonstrated is in agreement with previous findings by Haugrud et al [463].      
A reasonable concern regarding the clinical potential of these preliminary data is the 
relatively high concentrations of metformin used. Indeed the plasma concentration of the 
drug in a diabetic patient does not exceed 15μM [390]. However metformin remains stable, 
is not metabolised and accumulates in the liver, stomach, colon or salivary glands before 
being excreted through the kidneys [390, 464]. It has been reported that metformin does 
accumulate in tissues reaching significantly higher concentrations compared to the blood 
stream [464, 465]. Therefore low millimolar concentrations could be considered achievable 
in vivo and clinically relevant [465]. But this remains to be further evaluated in a clinical 
setting.      
The antiproliferative action of metformin is postulated to be dependent on glucose 
availability. A number of studies have demonstrated that cells could be rescued in a rich 
glucose environment even following treatment with high metformin concentrations [462, 
465]. It should be emphasised that all these experiments were conducted in physiologically 
relevant glucose conditions (5.56mM) differing from the majority of in vitro experiments 




The tumour suppressor gene Liver kinase B1 (LKB1) is associated with metformin mediated 
hepatic gluconeogenesis inhibition. LKB1 is an upstream kinase that phosphorylates and 
activates AMPK leading to mTOR inhibition. This is currently the best characterised 
mechanism of the antiproliferative action of metformin [390, 452, 465]. The triple negative 
MDA-MB-231 breast cancer cell line is known to be LKB1 deficient. Sensitivity of this cell 
line to metformin even though it lacks a functional LKB1 gene corroborates previous 
findings from Zordoky et al [465]. Furthermore it verifies that metformin can also activate 
AMPK via an LKB1 independent mechanism [390, 452, 465]. An interesting observation 
was that in many cases this cell line proved more sensitive to metformin combinations 
compared to the MCF7 line that has a functional LKB1 gene.  
The fact that a comparable synergistic interaction between metformin and several glycolytic 
inhibitors is identified provides an indication that the synergism is indeed a consequence of 
inhibition of glycolysis. It is hypothesised that simultaneous inhibition of two energy 
pathways, mitochondrial oxidative phosphorylation along with the glycolytic pathway 
induces ATP depletion that results in massive cell death. The present study provides 
substantial evidence and suggests that dual inhibition of the two energy pathways might be a 
promising antitumour therapeutic strategy.    
5.6.4 Combinatorial treatment of STF31 and Metformin was associated with 
induction of apoptosis in breast cancer cells  
The molecular mechanism of cellular death induced by the co-treatment of metformin with 
the GLUT1 inhibitor STF31was examined. This is a novel combination that appeared to be 
effective on both breast and ovarian cancer cells. Flow cytometric analysis provided 
evidence that STF31 in combination with metformin promoted apoptotic cell death in MDA-
MB-231 breast cancer cells (Figures 5.62&5.63). Simultaneous inhibition of two energy 
pathways, the glycolytic pathway and oxidative phosphorylation, is expected to lead to 
massive ATP depletion. The current findings link this energy stress with apoptotic cell death.    
The anti-hyperglycaemic agent when used individually has been extensively associated with 
apoptotic cell death. Metformin accumulates in the mitochondria and inhibits the 
mitochondrial respiratory chain complex I. The biguanide impairs mitochondrial respiration 
and induces oxidative stress leading to apoptosis [390, 463, 465]. Zhuang et al demonstrated 
caspase-dependent apoptosis in a number of breast cancer cell lines [466]. Caspase 
dependent apoptosis linked with oxidative damage and mitochondrial depolarisation has also 
been confirmed in glioma cells [467]. Another recent study revealed that metformin 




proteins Mcl-1 and Bcl-2 and increasing the expression of the pro-apoptotic proteins Bim 
and Puma [468]. 
The results of this study are consistent with previous findings indicating apoptosis following 
metformin treatment combined with glycolysis inhibition. Sahra et al reported that the 
combination of 2DG with metformin diminished the intracellular ATP levels and induced p-
53 dependent apoptotic cell death in prostate cancer cells [460].  Moreover, recent evidence 
suggested that DCA augmented the metformin induced oxidative stress and synergistically 
enhanced the induction of caspase-dependent apoptosis in breast cancer cell line models 
[463].   
 
5.6.5 Combinatorial treatments of glycolytic inhibitors and Metformin were 
associated with cell cycle arrest 
In the last section of this chapter the effect of combinations of glycolytic inhibitors with 
metformin on cell cycle progression was investigated. The most successful metformin 
combinations were prioritised for these experiments as metformin is not currently in use as 
an antitumour agent and the novel combinations identified in this study are proposed for 
further evaluation as future treatment strategies. Interestingly the three combinations 
examined had differential effects on the distribution of MDA-MB-231 breast cancer cells in 
each phase of the cell cycle. Co-treatment of the novel GLUT1 inhibitor IOM-1190 with the 
antidiabetic drug was associated with cell cycle arrest in the G2/M phase. The proportion of 
co-treated cells in this phase was double compared to single treated cells with each 
individual inhibitor (Figure 5.66). In contrast the combination of STF31 with metformin did 
not affect cell cycle progression (Figure 5.67). Apoptotic cell death following this co-
treatment was previously demonstrated but was not coupled with cell cycle arrest (section 
5.4). Finally combinational treatment of Oxamic acid with metformin caused an 
accumulation of cells in the G0/G1 phase compared to the controls of cells treated with the 
agents individually (Figure 5.68). 
In the literature metformin treatment of breast cancer cells has been associated with cell 
cycle arrest in the G0/G1 phase linked with cyclin D1 inhibition [469]. However very little is 
known regarding cell cycle arrest following combinatorial treatments of metformin with 
glycolytic inhibitors. The only relevant information identified was that the combination of 
2DG with metformin induced G2/M phase cell cycle arrest in prostate cancer cells according 




The primary aim of this research was to investigate the preclinical efficacy of combinatorial 
treatments among glycolytic inhibitors and traditional cancer therapies. This is the first study 
to explore the effectiveness of a wide range of such combinations in breast and ovarian 
cancer cell line models. Several combinations that synergistically inhibited tumour growth 
were identified and presented in this chapter. Among them the combination of the novel 
GLUT1 inhibitor IOM-1190 and metformin was the most potent one for the breast cancer 
cell lines. Impressively low CI values signifying strong synergism were generated for both 
the ER positive and the triple negative cell line. More importantly the MDA-MB-231 cell 
line, which represents triple negative aggressive breast cancer with limited treatment options,   
was particularly sensitive to this combination. Regarding the ovarian cancer cell lines the 
most promising combinatorial treatment identified was that between 3PO and cisplatin. Low 
CI values indicated a promising strategy to overcome platinum resistance.  
Both IOM-1190 and 3PO are novel specific compounds. They were identified as the most 
potent growth inhibitors among the ones used in this study (Chapter 3). They are both 
believed to have great in vivo potential.  
Further research should be undertaken to validate these promising in vitro pilot data and 
investigate their in vivo therapeutic potential. An in vivo model of triple negative breast 
cancer and one of platinum resistant ovarian cancer is proposed for each of them 
respectively. These models could further assess the mechanism of synergy between these 
agents and hopefully a positive outcome could serve as a translational platform which could 
potentially have a great impact on these subgroups of tumours that currently have very 




























Chapter 6: The effect of varying oxygen levels on sensitivity to 
glycolytic inhibition 
 
6.1 The effect of glycolytic inhibitors on the growth of breast cancer cell lines 
under varying oxygen levels 
 
Hypoxia is a common characteristic of the tumour microenvironment. It is well substantiated 
that adaptation to low oxygen conditions induces high flux through the glycolytic pathway 
and enhanced glycolytic rates [153, 470]. Therefore this study set out to examine the effect 
of varying oxygen levels on sensitivity to glycolysis inhibition. An array of eight glycolytic 
inhibitors was compared under a range of oxygen concentrations. Two representative breast 
cancer cell lines were selected for these experiments; the ER positive MCF7 and the triple 
negative MDA-MB-231 which were adapted in four oxygen concentrations 21, 7, 2 and 
0.5% (cells were cultured in each of the oxygen levels for at least two weeks prior to the 
experiments). Cancer cell proliferation was examined by the SRB assay in each of the 
conditions after a 3 and a 5-day treatment period with the glycolytic inhibitors. The 
concentration response curves generated using SRB assays are presented below. These 
results depict the percentage of cell numbers remaining following treatment with increasing 
concentrations of each of the compounds under the four different oxygen levels. Tables 6.1 




It was observed that breast cancer cells grow more slowly in low oxygen conditions. Table 
6.3 indicates the 3 and 5-day growth fold changes of the untreated MCF7 and MDA-MB-231 
controls in the four different oxygen conditions. For both cell lines, comparable growth at 
the three low oxygen conditions was observed, and this was decreased 40 to 60% compared 
to the respective growth at 21% O2 (with the only exception being the growth of MCF7 cells 
after 3 days that appeared unaffected by hypoxia). It was speculated that the reduced 
proliferation rate presented in hypoxic conditions could play a role in the sensitivity to the 





   
 
   
Figures 6.1 to 6.4: Concentration response curves of MCF7 (6.1 & 6.2) and MDA-MB-231 (6.3 & 6.4) breast 
cancer cells treated with Phloretin concentrations between 0.6-300μΜ under four different oxygen levels (21% - 
7% - 2% - 0.5% O2). Results for a three day treatment are presented on the left while those for a five day 
treatment are shown on the right. Cell viability was determined by an SRB assay. Mean results of 6 replicates are 
reported and error bars represent standard deviations. Values are shown as a percentage of control. A constant 
0.3% DMSO concentration was used across the whole curve in each case (n=1). 
 
Figures 6.1 and 6.2 present the concentration response curves of MCF7 breast cancer cells 
treated with a range of Phloretin concentrations under four different oxygen conditions for 3 
and 5 days respectively. Results for MDA-MB-231 cells are presented in Figures 6.3 and 
6.4. Both cell lines regardless of the duration of treatment responded to Phloretin in a very 
similar way at the three lower oxygen levels. Increased sensitivity can be observed from both 
MCF7 and MDA-MB-231 cells at 21% O2, in parallel with enhanced resistance at 7, 2 and 
0.5% O2. An interesting observation is that Phloretin was found to induce proliferation of 
MCF7 cells (at concentrations up to 150μM) at the three lower O2 levels after 3 days and at 
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Figures 6.5 to 6.8: Concentration response curves of MCF7 (6.5 & 6.6) and MDA-MB-231 (6.7 & 6.8) breast 
cancer cells treated with STF31 concentrations between 0.06-30μΜ under four different oxygen levels (21% - 7% 
- 2% - 0.5% O2). Results for a three day treatment are presented on the left while those for a five day treatment 
are shown on the right. Cell viability was determined by an SRB assay. Mean results of 6 replicates are reported 
and error bars represent standard deviations. Values are shown as a percentage of control. A constant 0.3% 
DMSO concentration was used across the whole curve in each case (n=1). 
The above figures indicate the effect of the oxygen level on breast cancer cell sensitivity to 
STF31. Figures 6.5 and 6.7 show that both MCF7 and MDA-MB-231 cells were very 
sensitive to this GLUT1 inhibitor at 21% O2 after 3 days of treatment. The triple negative 
cell line presented a fourfold increase in the IC50 value at 7% O2 and even greater resistance 
at the lower oxygen conditions. Regarding MCF7 cells, a similar pattern of increased 
resistance at the three lower oxygen levels can be observed. Figure 6.6 indicates that the 
oxygen concentration did not have a great influence on the antiproliferative effect of STF31 
after 5 days of treatment; the four generated IC50 values were comparable. In contrast Figure 
6.8 demonstrates that MDA-MB-231 cells were more sensitive to the inhibitor at 21% O2 
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Figures 6.9 to 6.12: Concentration response curves of MCF7 (6.9 & 6.10) and MDA-MB-231 (6.11 & 6.12) 
breast cancer cells treated with WZB117 concentrations between 0.06-30μΜ under four different oxygen levels 
(21% - 7% - 2% - 0.5% O2). Results for a three day treatment are presented on the left while those for a five day 
treatment are shown on the right. Cell viability was determined by an SRB assay. Mean results of 6 replicates are 
reported and error bars represent standard deviations. Values are shown as a percentage of control. A constant 
0.3% Ethanol concentration was used across the whole curve in each case (n=1). 
 
Figures 6.9 to 6.12 illustrate the effect of WZB117 on cell viability of two breast cancer cell 
lines under four different oxygenation conditions. Evidence is provided of enhanced activity 
of this GLUT1 inhibitor under normoxic conditions after either 3 or 5 days of treatment. 
Both MCF7 and MDA-MB-231 cells were found to be very sensitive to the compound at 
21% O2 while increased resistance was observed in the presence of lower oxygen. Under 
hypoxic conditions, 2 and 0.5% O2, even the highest concentrations of WZB117 that were 
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Figures 6.13 to 6.16: Concentration response curves of MCF7 (6.13 & 6.14) and MDA-MB-231 (6.15 & 6.16) 
breast cancer cells treated with 3-bromopyruvate concentrations between 0.6-300μΜ under four different oxygen 
levels (21% - 7% - 2% - 0.5% O2). Results for a three day treatment are presented on the left while those for a 
five day treatment are shown on the right. Cell viability was determined by an SRB assay. Mean results of 6 
replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control  
(n=1).  
 
The preceding figures (6.13 to 6.16) demonstrate that 3BP is only effective in attenuating 
breast cancer cell proliferation under normoxic conditions. An interesting observation is that 
varying the oxygen concentration between 7, 2 and 0.5% did not affect the efficacy of the 
HKII inhibitor. Both cell lines responded in an almost identical way to these lower oxygen 
levels. For MCF7 cells a reduction of cell number up to 40% was observed after treatment 
with 300μΜ 3BP in low oxygen conditions while in contrast MDA-MB-231 cells were 
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Figures 6.17 to 6.20: Concentration response curves of MCF7 (6.17 & 6.18) and MDA-MB-231 (6.19 & 6.20) 
breast cancer cells treated with 3PO concentrations between 0.06-30μΜ under four different oxygen levels (21% 
- 7% - 2% - 0.5% O2). Results for a three day treatment are presented on the left while those for a five day 
treatment are shown on the right. Cell viability was determined by an SRB assay. Mean results of 6 replicates are 
reported and error bars represent standard deviations. Values are shown as a percentage of control. A constant 
0.3% DMSO concentration was used across the whole curve in each case (n=1). 
 
In the above graphs, evidence is provided that 3PO is more effective in inhibiting breast 
cancer cell proliferation when oxygen availability is at 21%, while variation of the oxygen 
concentration between 7, 2 and 0.5% did not alter the sensitivity to the compound. Figures 
6.17 and 6.18 show that MCF7 cells demonstrated a twofold and a threefold increase of their 
IC50 value under low oxygen conditions compared to 21% O2 after a 3 and a 5-day treatment 
with the PFKFB3 inhibitor respectively. For MDA-MB-231 cells the difference in sensitivity 
was even more profound. Triple negative cells increased their IC50 value 26 times when 
treated with the inhibitor for 3 days in low oxygen conditions and up to sevenfold following 
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Figures 6.21 to 6.24: Concentration response curves of MCF7 (6.21 & 6.22) and MDA-MB-231 (6.23 & 6.24) 
breast cancer cells treated with Dichloroacetate concentrations between 0.4-100mΜ under four different oxygen 
levels (21% - 7% - 2% - 0.5% O2). Results for a three day treatment are presented on the left while those for a 
five day treatment are shown on the right. Cell viability was determined by an SRB assay. Mean results of 6 
replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control 
(n=1). 
 
The above figures indicate that DCA is effective in inhibiting breast cancer cell proliferation 
over the whole range of oxygen levels examined. Figures 6.21 and 6.23 show that MCF7 and 
MDA-MB-231 cells presented increased sensitivity to the PDHK1 inhibitor at 21% O2 when 
treated for 3 days. Both cell lines were found to be more resistant to treatment at low oxygen 
conditions (7-2 and 0.5%) presenting a tenfold increase in their IC50 values. In contrast, as 
demonstrated in Figures 6.22 and 6.24 both breast cancer cell lines responded similarly to a 
5-day treatment irrespective of oxygen availability. Little variation was detected in their IC50 
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Figures 6.25 to 6.28: Concentration response curves of MCF7 (6.25 & 6.26) and MDA-MB-231 (6.27 & 6.28) 
breast cancer cells treated with Oxamic acid concentrations between 0.4-100mΜ under four different oxygen 
levels (21% - 7% - 2% - 0.5% O2). Results for a three day treatment are presented on the left while those for a 
five day treatment are shown on the right. Cell viability was determined by an SRB assay. Mean results of 6 
replicates are reported and error bars represent standard deviations. Values are shown as a percentage of control 
(n=1). 
Both breast cancer cell lines were found sensitive to Oxamic acid in all examined conditions. 
Figure 6.25 demonstrates that the lower the oxygen level, the greater the resistance (higher 
the IC50 value) after a 3-day treatment of MCF7 cells. In contrast, Figure 6.26 illustrates that 
after 5 days of treatment MCF7 cells presented increased sensitivity at 21% O2, but variation 
of the oxygen level between 7 and 0.5% did not affect the potency of the LDH inhibitor. 
MDA-MB-231 cells presented increased sensitivity at 21% O2 (Figures 6.27 and 6.28) 
although response in the three lower oxygen levels was almost identical at both 3 and 5-day 
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Figures 6.29 to 6.32: Concentration response curves of MCF7 (6.29 & 6.30) and MDA-MB-231 (6.31 & 6.32) 
breast cancer cells treated with NHI-1 concentrations between 0.6-300μΜ under four different oxygen levels 
(21% - 7% - 2% - 0.5% O2). Results for a three day treatment are presented on the left while those for a five day 
treatment are shown on the right. Cell viability was determined by an SRB assay. Mean results of 6 replicates are 
reported and error bars represent standard deviations. Values are shown as a percentage of control. A constant 
0.3% DMSO concentration was used across the whole curve in each case (n=1). 
The above figures examine the effect of oxygen availability on the efficacy of NHI-1 as a 
breast cancer growth inhibitor. Figures 6.29 and 6.31 show that after 3 days of treatment 
both breast cancer cell lines were very sensitive to the novel LDHA inhibitor at 21% O2 
whereas resistance was presented at the three low oxygen conditions. This was demonstrated 
by the increase of the respective IC50 values up to 7 and 70 times higher for MCF7 and 
MDA-MB-231 cells respectively. The same pattern of increased sensitivity at 21% O2 was 
followed in the 5-day treatment results as well that are shown in Figures 6.30 and 6.32 
however the differences were not as great. Both cell lines became more resistant to the 
compound presenting a twofold increase in their IC50 values. It is interesting that while both 
cell lines at 7 and 2% O2 increase their resistance at 0.5% O2 their IC50 values presented a 
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MCF7 – 3 days MCF7 – 5 days 
21% O2 7% O2 2% O2 0.5% O2 21% O2 7% O2 2% O2 0.5% O2 
Phloretin (μΜ) 49.7 294.4 >300 >300 90 295.2 >300 >300 
STF31 (μΜ) 1.7 N/A N/A N/A 1.3 2.3 1.4 1.6 
WZB117 (μΜ) 5 N/A >30 >30 2.3 16.4 >30 >30 
BP (μΜ) 5.8 >300 >300 >300 62.7 >300 N/A >300 
3PO (μΜ) 1.7 7.2 3.6 4.4 1.3 3.8 3.5 3.7 
DCA (mM) 3.3 45.5 38.4 30.1 13 18.9 19.6 12.6 
Oxamic (mM) 24.3 52.8 66.6 82.3 10.4 39.4 47.1 49.5 
NHI-1 (μΜ) 24.2 178 174.4 185.5 61.8 80 150.1 111.5 
 
 
Table 6.1: Summary of the IC50 concentrations generated for MCF7 breast cancer cells when treated with 8 
glycolytic inhibitors under four different oxygen levels (21% - 7% - 2% - 0.5% O2) for 3 or 5 days. N/A stands 





MDA-MB-231 – 3 days MDA-MB-231 – 5 days 
21% O2 7% O2 2% O2 0.5% O2 21% O2 7% O2 2% O2 0.5% O2 
Phloretin (μΜ) 28.3 >300 >300 >300 69.6 289.1 >300 >300 
STF31 (μΜ) 0.99 4.3 N/A 25.6 1.2 1.8 2.4 2.2 
WZB117 (μΜ) 14.7 N/A N/A >30 4.1 N/A >30 N/A 
BP (μΜ) N/A >300 N/A N/A 39 >300 N/A >300 
3PO (μΜ) 0.47 12.3 11.3 12.2 1.5 11.2 8.6 12.9 
DCA (mM) 5.7 61.5 55.9 58.8 23.3 38.9 37 31.1 
Oxamic (mM) 30.3 83.4 93.3 >100 6.9 60.4 66.2 74 
NHI-1 (μΜ) 3.7 229 266 260.5 93.6 190.1 227.6 174.1 
 
 
Table 6.2: Summary of the IC50 concentrations generated for MDA-MB-231 breast cancer cells when treated 
with 8 glycolytic inhibitors under four different oxygen levels (21% - 7% - 2% - 0.5% O2) for 3 or 5 days. N/A 











Table 6.3: Summary of growth fold change presented from MCF7 and MDA-MB-231control breast cancer cells 










Table 6.4: Pearson correlation of sensitivity of  two breast cancer cell lines to eight glycolytic inhibitors when 
treated for a five day period under four different oxygen levels (21% - 7% - 2% - 0.5% O2) with their growth fold 
change in each of the conditions. Correlation coefficient (r) and Pearson two-tailed P-values are presented. 
 
  
It was speculated that a reduced growth rate could contribute to increased resistance to the 
glycolytic inhibitors at low oxygen conditions. Therefore the fold growth of the cell lines in 
each of the conditions was correlated with sensitivity to the inhibitors. Correlation 
coefficient and Pearson P-values are presented in Table 6.4. A statistically significant inverse 
correlation is demonstrated between an increased proliferation rate at conditions of high 
oxygen availability and increased sensitivity to the glycolytic inhibitors, as indicated by a 
low IC50 value. When 5-day treatment data were taken into consideration all the growth rate-
Control growth 
fold change  
MCF7 MDA-MB-231 
3 days 5 days 3 days 5 days 
21% O2 4.1 16.3 5 15.7 
7% O2 3.5 10.7 3.3 7.9 
2% O2 5.1 9 3 5.6 
0.5% O2 4.1 10.8 3 6.7 
5-day IC50 values – fold growth 
Pearson correlation 
r two-tailed P value 
Phloretin -0.8871 0.0033 
STF31 -0.9136 0.0297 
WZB117 -0.7568 0.0015 
3-bromopyruvate -0.8860 0.0034 
3PO -0.8197 0.0127 
Dichloroacetate -0.6883 0.0591 
Oxamic acid -0.9718 < 0.0001 




inhibitor potency associations were statistically significant (P<0.05) with the only exemption 
being the DCA correlation (P=0.0591) and this was nearly of borderline significance. Based 
on these associations it appears that the low proliferation rate of breast cancer cells grown in 
hypoxic conditions is significantly correlated with decreased efficacy of the glycolytic 
inhibitors (high IC50 values).    
However while greater resistance to the majority of glycolytic inhibitors in hypoxic 
conditions was observed following a 3-day treatment compared to 5 days low oxygen 
availability had a minimal impact on the proliferation of MCF7 cells. Thus at this time point 
the observed resistance at low oxygen conditions does not appear to correlate with a lower 
proliferation rate. 
  
6.2 Protein expression of glycolytic targets under varying oxygen levels 
In an attempt to gain a better understanding of how glycolysis inhibition is affected by 
oxygen availability the protein expression of the glycolytic targets of interest was examined 
in hypoxic conditions. It was hypothesised that relative resistance to glycolytic inhibitors in a 
low oxygen environment could be associated with upregulation of the targeted glycolytic 
enzymes. To investigate this further the protein expression of the glycolytic targets was 
examined in MCF7 and MDA-MB-231 cells under varying oxygen levels. The following 
figures (Figures 6.33 to 6.52) show the Western blot results for GLUT1, HKII, PFKFB3, 
PDHK1 and LDHA protein expression in whole lysates collected from cells cultured at 7%, 
2% and 0.5% O2 for a time course of 24, 48 or 72 hours. The expression was compared to 
the 21% O2 control lysate. Data were normalised to α tubulin expression. Quantitative 
densitometric analysis of the immunoblots was performed and is presented below. 
 Glucose Transporter 1 
In the following figures the effect of the oxygen level on GLUT1 protein expression is 
examined. Figures 6.33 and 6.34 present the immunoblots showing the transporter’s 
expression in MCF7 and MDA-MB-231 cells cultured in 7, 2 and 0.5% O2 for three 
different time points of 24, 48 and 72h. In Figures 6.35 and 6.36 the corresponding 
densitometric results are shown. GLUT1 expression in hypoxic conditions was found to be 
similar to the 21% O2 controls for both cell lines. Variation of the oxygen level in the 
examined conditions did not have a marked effect on expression of the transporter and no 
upregulation was detected. Rather, GLUT1 expression decreased by 30% at 0.5% O2 
















Figures 6.33 & 6.34: GLUT1 protein expression detected through Western blotting in MCF7 and MDA-MB-231 
breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% and 
0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Alpha tubulin was 
used as a loading control (n=1).   
 
 
   
Figures 6.35 & 6.36: GLUT1 protein expression detected through Western blotting in MCF7 and MDA-MB-231 
breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% and 
0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Densitometry analysis 











































Figures 6.37 & 6.38: HKII protein expression detected through Western blotting in MCF7 and MDA-MB-231 
breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% and 
0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Alpha tubulin was 
used as a loading control (n=1).   
   
Figures 6.39 & 6.40: HKII protein expression detected through Western blotting in MCF7 and MDA-MB-231 
breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% and 
0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Densitometry analysis 
was conducted using the Odyssey Infrared Imaging System software (Licor) and data were normalised to α 
tubulin expression. 
In Figures 6.37 and 6.38 the Western blot results of HKII expression of MCF7 and MDA-
MB-231 breast cancer cells under varying oxygen concentrations are presented. Figures 6.39 
and 6.40 show the densitometric analysis of the same blots. HKII expression of MCF7 cells 
at 7 and 2% O2 was very comparable to that of the 21% O2 control. However a gradual 
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upregulation was detected in MDA-MB-231 cells with expression of the enzyme being 
comparable between the four oxygen levels. The lowest expression was seen at 7% O2 after 












Figures 6.41 & 6.42: PFKFB3 protein expression detected through Western blotting in MCF7 and MDA-MB-
231 breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% 
and 0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Alpha tubulin was 
used as a loading control (n=1).   
 
   
Figures 6.43 & 6.44: PFKFB3 protein expression detected through Western blotting in MCF7 and MDA-MB-
231 breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% 
and 0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Densitometry 
analysis was conducted using the Odyssey Infrared Imaging System software (Licor) and data were normalised to 



































The effect of the oxygen level on PFKFB3 expression of two breast cancer cell lines was 
examined and the Western blots are presented in Figures 6.41 and 6.42. As can be seen from 
the densitometric analysis in Figures 6.43 and 6.44, both cell lines presented a threefold 
increase in PFKFB3 expression in low oxygen conditions at 72h. Regarding MCF7 cells, an 
upregulation compared to the control was observed under all 3 oxygen conditions, with 
highest expression at both 7 and 0.5% O2 after 72h. A similar induction was demonstrated in 
MDA-MB-231 cells. An interesting observation was that under each condition, expression 
increased with time with a peak at 2% O2 after 72h. 
 















Figures 6.45 & 6.46: PDHK1 protein expression detected through Western blotting in MCF7 and MDA-MB-231 
breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% and 
0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Alphatubulin was 

















   
Figures 6.47 & 6.48: PDHK1 protein expression detected through Western blotting in MCF7 and MDA-MB-231 
breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% and 
0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Densitometry analysis 
was conducted using the Odyssey Infrared Imaging System software (Licor) and data were normalised to α 
tubulin expression. 
 
The immunoblots in Figures 6.45 and 6.46 indicate PDHK1 expression of two breast cancer 
cell lines under four different oxygen conditions. As can be seen from the densitometric 
analysis displayed in Figures 6.47 and 6.48 a large induction was observed for both cell lines 
when oxygen availability was reduced. For MCF7 cells, PDHK1 expression was very low at 
21, 7 and 2% O2 but increased substantially at 0.5% O2. A threefold increase was observed at 
24 and 48h while a maximal fivefold induction was seen after 72h. In MDA-MB-231 cells, 
PDHK1 expression peaked at 0.5% O2 after 48h (threefold increase compared to the 
normoxic control).  
 
 Lactate Dehydrogenase A 
 
The following Figures 6.49 and 6.50 present the Western blot results examining LDHA 
expression in the breast cancer cell lines under a range of oxygen concentrations. Based on 
the normalised results acquired from densitometric analysis, oxygen had a differential effect 
on LDHA expression in the two cell lines. Figure 6.51 shows that LDHA expression of 
MCF7 cells was low at 21, 7 and 2% O2 but was elevated at 0.5% O2. The highest twofold 
increase was observed after 24h and interestingly a 20 and 40% decline was noticed at 48 
and 72h respectively. Regarding MDA-MB-231 cells, Figure 6.52 shows that no LDHA 
upregulation was seen in hypoxic conditions. Expression was actually reduced by half at 7% 






































Figures 6.49 & 6.50: LDHA protein expression detected through Western blotting in MCF7 and MDA-MB-231 
breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% and 
0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Alpha tubulin was 
used as a loading control (n=1).   
 
 
   
Figures 6.51 & 6.52: LDHA protein expression detected through Western blotting in MCF7 and MDA-MB-231 
breast cancer cells under four different oxygen levels. Lysates were collected from cells cultured at 7%, 2% and 
0.5% O2 for 24, 48 and 72 hours and expression was compared to a 21% O2 control lysate. Densitometry analysis 









































6.3 The antiproliferative effect of the novel GLUT1 inhibitor IOM-1190 under 
hypoxic conditions 
 
The effect of the oxygen level on sensitivity to the novel GLUT1 inhibitor was next 
examined. Sensitivity of breast cancer cells to IOM-1190 was compared under three different 
oxygenation conditions; normoxic cells cultured and treated at 21% O2, acute hypoxic cells 
treated at 21% O2, placed in the hypoxic chamber immediately after treatment and incubated 
at 0.5% O2 for a 3-day period (not being preadapted to hypoxic conditions) and chronic 
hypoxic cells which were fully adapted to 0.5% O2 conditions for 10 weeks before being 
treated with the inhibitor (inside the hypoxic chamber). MCF7 and MDA-MB-231 breast 
cancer cells were used for these experiments. Cancer cell proliferation was examined by the 
SRB assay in each of the conditions after a 3-day treatment period. The generated 
concentration response curves of MCF7 cells are presented in Figure 6.53 and for MDA-
MB-231 cells in Figure 6.54. The corresponding IC50 values are shown in Table 6.5. 
 
 
From the figures below it is apparent that the effect of the oxygen level on sensitivity to 
IOM-1190 was greater in MCF7 cells. The most striking observation was that both cell lines 
presented greater sensitivity to the inhibitor in acute hypoxic conditions. A fortyfold 
decrease was demonstrated from MCF7 cells in their IC50 value between cells that were 
treated at 21% O2 and those that were incubated at 0.5% O2 during treatment without 
preadaptation in low oxygen conditions. Comparatively MDA-MB-231 cells presented a 
fourfold decrease in their IC50 values in these conditions. Interestingly the response to IOM-
1190 of chronically adapted cells in hypoxia was different between the two cell lines. MCF7 
cells were more resistant compared to acute hypoxic cells but still more sensitive compared 
to normoxic cells. Their IC50 value was eightfold lower compared to 21% O2 conditions. In 
contrast the MDA-MB-231 cells became more resistant in chronic hypoxic conditions 








Figures 6.53 & 6.54: Concentration response curves of MCF7 and MDA-MB-231 breast cancer cells treated 
with IOM-1190 concentrations between 0.06-30μΜ under three different conditions (normoxic, acute and chronic 
hypoxic). Cell viability was determined by an SRB assay after a three day treatment. Mean results of 6 replicates 
are reported and error bars represent standard deviations. Values are shown as a percentage of control. A constant 










MCF7 12.5 0.31 1.6 
MDA-MB-231 1.9 0.43 3.5 
 
Table 6.5: Summary of the IC50 concentrations generated for two breast cancer cell lines after a three day 





















































6.3.1 The effect of the combination of IOM-1190 with metformin under hypoxic 
conditions  
 
The most robust synergist combination identified in Chapter 5 was between IOM-1190 and 
metformin (section 5.3.1). The effect of this combination on MCF7 and MDA-MB-231 
breast cancer cells was therefore examined under hypoxic conditions. Chronic hypoxic cells 
adapted in hypoxic conditions for 10 weeks before co-treatment were used. These cells were 
treated with a range of concentrations of the GLUT1 inhibitor along with a constant 
concentration of metformin for 3 days. Cancer cell proliferation was assessed through SRB 
assays and the generated curves are presented in Figures 6.55 and 6.56 while the 
corresponding IC50 values can be seen in Table 6.6. 
 
The combination was not effective under hypoxic conditions for both cell lines. The IOM-
1190 single treatment curve was almost identical to the combination curves and remained 
unaffected from the addition of a constant metformin concentration either low (1mM for 
both cell lines) or higher (2mM for MCF7 cells). The only exception was the combination of 
IOM-1190 with 4mM metformin in MDA-MB-231 cells. MDA-MB-231 cells presented 
fivefold more sensitivity to this combination compared to single treatment with the 
glycolytic inhibitor (based on the IC50 values).      
 
  
Figures 6.55 & 6.56: Concentration response curves of MCF7 and MDA-MB-231 breast cancer cells treated 
with IOM-1190 concentrations between 0.06-30μΜ alone (blue line) and combined with 1mM (green line) or 
2/4mM Metformin (red line) at 0.5% O2. Cell viability was determined by an SRB assay after a three day 
treatment. Mean results of 6 replicates are reported and error bars represent standard deviations. Values are 
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IOM-1190 Concentration, μΜ 
MDA-MB-231 IOM-1190 & 
Metformin 0.5%O2  
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MCF7 1.6 N/A 2.1 
MDA-MB-231 3.5 2.2 0.72 
 
Table 6.6: Summary of the IC50 concentrations generated for two breast cancer cell lines when treated with IOM-
1190 alone or combined with two different Metformin concentrations at 0.5% O2. N/A stands for not achieved in 
the range of used concentrations. 
It was concluded that this combination, although potent in normoxic conditions generating 
CI values lower than 0.1, was not effective in hypoxic conditions. However the effect of 
metformin as single treatment on breast cancer cells at 0.5% O2 provides an explanation, 
since a concentration range of metformin up to 64mM had no effect on viability of either 
breast cancer cell line under these hypoxic conditions (Figures 6.57&6.58). (The equivalent 
effect of metformin under normoxia is presented in the Appendix Figure A1.1). 
         
Figures 6.57& 6.58: Concentration response curves of MCF7 and MDA-MB-231 breast cancer cells treated with 
Metformin concentrations between 0.13-64mΜ at 0.5% O2. Cell viability was determined by an SRB assay after 
a three day treatment. Mean results of 6 replicates are reported and error bars represent standard deviations. 
Values are shown as a percentage of control (n=1). 
 
6.4 Analysis of the glycolytic pathway in hypoxia using transcriptomic data 
The primary aim of this section was to elucidate further the role of glycolytic induction in 
hypoxic breast cancer and develop a better understanding of the observed resistance to the 
majority of glycolytic inhibitors (section 6.1) in hypoxia. A collaborative gene expression 
Illumina BeadChip analysis was undertaken with two colleagues, James Meehan and Ed 
Jarman, and separate analysis was incorporated in the three independent projects. Dr Arran 
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Breast cancer cells (MCF7, MCF7-HER2, MDA-MB-231 and HBL100) were cultured in 
four distinct experimental conditions: normoxia (21% O2), acute hypoxia (0.5% O2 for 24h), 
chronic hypoxia (0.5% O2 for 10 weeks) and treatment with CoCl2, a hypoxia mimetic agent 
that chemically induces HIF-1. Approximately 3x10
6
 pelleted cells were collected and total 
RNA was extracted. The RNA was then reverse transcribed, amplified and biotinylated. 
Labelled RNA was hybridised to whole genome HumanHT-12 v4 Illumina BeadChips and 
arrays were scanned on the Illumina iScan. Raw gene expression files were processed, 
filtered and normalised as described in Chapter 2, section 2.10. 
 
 
6.4.1 Differentially expressed genes between hypoxic and normoxic breast 
cancer cells  
Gene expression profiles were obtained for breast cancer cells cultured in normoxia and 
hypoxia. Differentially expressed genes between chronic hypoxic and normoxic breast 
cancer cells were identified with the use of rank products (FDR cut-off P value 0.05). 
Functional enrichment analysis of differentially expressed genes was conducted using 
DAVID Bioinformatics Resources 6.7. Gene Ontology (GO) analysis was then performed 
and clusters of GO terms reflecting mutually modulated genes in three breast cancer cell 
lines between hypoxic and normoxic conditions were summarised and visualised using 
Revigo. The Revigo server applies a clustering algorithm in a list of GO terms and based on 
the concept of GO term semantic similarity, reduces functional redundancies and visualises 
representative clusters of GO terms [471].  
The Venn diagrams presented below indicate the genes that were commonly deregulated in 
all three cell lines in the selected conditions. 30 genes were consistently downregulated and 
20 were upregulated when comparing breast cancer cells in long term hypoxia and normoxia 
(Figures 6.59&6.61 left). The commonly deregulated genes are listed in tables in the 
Appendix (Tables A2.1&A2.2). Two dimensional scatterplots of GO terms reflecting 
mutually modulated genes in all three MCF7, MDA-MB-231 and HBL100 breast cancer cell 
lines were generated (Figures 6.59&6.61 right). These plots present the GO terms in a two 
dimensional scale by applying multidimensional scaling to a matrix of their semantic 
similarities [471]. Circle colour indicates the P value and their size reflects the frequency of 




GO terms in rectangles while superclusters, illustrated in different colours, associate related 
terms (Figures 6.60&6.62). The size of the rectangles reflects the P value.   
 
Comparison of differentially expressed genes between culture at 0.5% O2 for 10 weeks and 
normoxia revealed that 30 genes were commonly downregulated in three breast cancer cell 
lines while 20 were upregulated. The functional categories of genes downregulated in breast 
cancer cells following long term adaptation in hypoxia were mainly associated with nuclear 
division, mitotic cell cycle, mitotic M phase, chromosome localisation and translation 
(Figures 6.59&6.60). Genes upregulated in breast cancer cells chronically adapted in 
hypoxia were assigned to two main categories - the glycolytic process and response to 
hypoxia. Along with glucose metabolism the upregulated genes were involved in hexose and 
fructose metabolism, alcohol and carbohydrate catabolism (Figures 6.61&6.62).        




Figure 6.59:  Gene Ontology analysis of downregulated genes in breast cancer cells under chronic hypoxia. The 
Venn diagram (on the left) indicates the number of downregulated genes in each cell line. The yellow circle 
highlights the number of genes mutually modulated in all three breast cancer cell lines. The Revigo scatterplot 
(on the right) visualises representative clusters of gene functional categories in accord with their semantic 
similarity. The colour of the circles indicates the P value and their size reflects the frequency of the respective 








Figure 6.60: Revigo Tree map generated by Gene Ontology analysis of mutually downregulated genes in three 
breast cancer cell lines under chronic hypoxia. Each rectangle illustrates a representative cluster of Gene 
Ontology terms. Superclusters of each colour depict joined clusters of related terms. The size of the rectangles 
indicates the P value (the larger the rectangle the lower the P value). The lilac unnamed rectangle represents 





Figure 6.61:  Gene Ontology analysis of upregulated genes in breast cancer cells under chronic hypoxia. The 
Venn diagram (on the left) indicates the number of downregulated genes in each cell line. The yellow circle 
highlights the number of genes mutually modulated in all three breast cancer cell lines. The Revigo scatterplot 
(on the right) visualises representative clusters of gene functional categories in accord with their semantic 
similarity. The colour of the circles indicates the P value and their size reflects the frequency of the respective 








Figure 6.62: Revigo Tree map generated by Gene Ontology analysis of mutually upregulated genes in three 
breast cancer cell lines under chronic hypoxia. Each rectangle illustrates a representative cluster of Gene 
Ontology terms. Superclusters of each colour depict joined clusters of related terms. The size of the rectangles 
indicates the P value (the larger the rectangle the lower the P value). The beige unnamed rectangle represents 
residual genes that do not fit the clusters.    
 
6.4.2 Modulation of the glycolytic pathway in chronic hypoxic breast cancer 
cells  
Having established that the glycolytic process was commonly upregulated in hypoxic breast 
cancer cells attention was next focused on the glycolytic genes. The expression profiles of 
the genes implicated in the glycolytic pathway of four breast cancer cell lines between 
chronic hypoxic and normoxic conditions were compared. The genes are presented in a table 
in the Appendix (Table A2.3). Hierarchical clustering was performed using log2 fold change 
values and the following heatmap (Figure 6.63) summarises the differences in the expression 
patterns of MCF7, MCF7-HER2, MDA-MB-231 and HBL100 cells. Genes were clustered 
using average linkage and Euclidean distance metric.  
The changes in expression after 10 weeks incubation in hypoxia as depicted in the heatmap 
verify that the glycolytic genes are upregulated in this condition. GLUT1 (SLC2A1), HKII 
and PFKFB3 were strongly upregulated following long term hypoxia in all four cell lines as 
indicated by the bright red colour. These three genes were clustered together in the same 
branch of the dendrogram. LDHA and PDHK1 were similarly modulated and were 
positioned in a separate branch. These genes demonstrated lower log2 gene expression fold 
changes as illustrated by darker red colours.  
The only genes that presented signs of significant downregulation (bright green colouration 





cells were two isozymes of phosphoglucomutase (PGM). This enzyme catalyses the 
upstream transfer of a phosphate group and the interconversion of glucose-1-phosphate and 
glucose-6-phosphate [472]. Indeed this is virtually the sole glycolytic gene that has not been 
described as a HIF-1 or c-Myc target [113, 473].    
 
Figure 6.63: Heatmap visualisation of hierarchical clustering of glycolytic genes. The log2 fold change values of 
four breast cancer cell lines between chronic hypoxic and normoxic conditions were used. Red and green colours 
indicate relatively high and low log2 gene expression fold changes respectively. Average linkage clustering was 
performed and genes were ordered by Euclidean distance. List of glycolytic genes is presented on the right and 
genes of particular interest are highlighted.    
 
6.4.3 Modulation of selected glycolytic enzymes in breast cancer cells under 
varying conditions of hypoxia  
The final objective of this experiment was to evaluate the effect of hypoxia on the mRNA 
expression of the five glycolytic enzymes of particular interest to this study. Transcriptome 
levels of these enzymes in MCF7, MDA-MB-231 and HBL100 cells were assessed under 
chronic hypoxic and acute hypoxic conditions as well as following chemical induction of 
HIF-1 mediated responses via treatment with CoCl2 and were compared to normoxic levels. 
mRNA data were determined using gene expression profiling as described in Chapter 2, 




Figures 6.64 to 6.66: Log2 transformed SLC2A1 (GLUT1) mRNA levels in MCF7, MDA-MB-231 and HBL100 breast cancer cells cultured in normoxia (21% O2), chronic hypoxia 
(0.5% O2 for 10 weeks), acute hypoxia (0.5% O2 for 24h) or treated with CoCl2. Three replicate values are reported and error bars represent standard deviations. Statistical significance 
indications: * P<0.05, ** P<0.01 compared with the normoxic control (one-way ANOVA followed by Dunnett’s multiple comparisons test).  
 
The above figures (Figures 6.64 to 6.66) present the effect of varying conditions of hypoxia on GLUT1 expression in three breast cancer cell lines. 
GLUT1 was upregulated in every condition in all three cell lines (though only certain values were statistically significant). However the upregulation 
was greater in HBL100 cells and especially under chronic hypoxic conditions. In contrast in MDA-MB-231 cells the upregulation was statistically 
significant only following short term 24h incubation at 0.5% O2. MCF7 cells demonstrated a similar induction across the examined conditions but the 
up-regulation did not reach significance.  
 


































































Figures 6.67 to 6.69: Log2 transformed HKII mRNA levels in MCF7, MDA-MB-231 and HBL100 breast cancer cells cultured in normoxia (21% O2), chronic hypoxia (0.5% O2 for 10 
weeks), acute hypoxia (0.5% O2 for 24h) or treated with CoCl2. Three replicate values are reported and error bars represent standard deviations. Statistical significance indications: * 
P<0.05, ** P<0.01, *** P<0.001 compared with the normoxic control (one-way ANOVA followed by Dunnett’s multiple comparisons test).  
 
Figures 6.67 to 6.69 demonstrate the transcript levels of HKII in three breast cancer cell lines across several conditions of hypoxia. The upregulated 
levels of this target were comparable between acute and chronic hypoxic conditions in MCF7 and MDA-MB-231 cells. An interesting observation is 
that the hypoxia-mimetic agent CoCl2 resulted in significantly higher HKII mRNA levels in these two cell lines. In contrast treatment with CoCl2 did not 
significantly increase HKII expression in HBL100 cells suggesting that the upregulation observed in 0.5% O2 conditions is only partially attributed to 
HIF-1 stabilisation in these cells. Statistically significant induction of this enzyme in HBL100 cells was only observed following long term incubation 
in low oxygen conditions.      























































Figures 6.70 to 6.72: Log2 transformed PFKFB3 mRNA levels in MCF7, MDA-MB-231 and HBL100 breast cancer cells cultured in normoxia (21% O2), chronic hypoxia (0.5% O2 for 
10 weeks), acute hypoxia (0.5% O2 for 24h) or treated with CoCl2. Three replicate values are reported and error bars represent standard deviations. Statistical significance indications: 
*** P<0.001, ****P<0.0001 compared with the normoxic control (one-way ANOVA followed by Dunnett’s multiple comparisons test).  
 
 
Figures 6.70 to 6.72 depict the response of PFKFB3 mRNA expression in MCF7, MDA-MB-231 and HBL100 cells respectively to variable conditions 
of hypoxia. The first two cell lines presented a marked induction of this target in hypoxic conditions. PFKFB3 expression was comparable in MCF7 
cells across the examined conditions while higher mRNA levels following CoCl2 treatment compared to low oxygenation were observed in MDA-MB-
231 cells. In contrast no statistically significant changes in PFKFB3 expression were detected in HBL100 cells. Interestingly expression was unchanged 



































































Figures 6.73 to 6.75: Log2 transformed PDHK1 mRNA levels in MCF7, MDA-MB-231 and HBL100 breast cancer cells cultured in normoxia (21% O2), chronic hypoxia (0.5% O2 for 
10 weeks), acute hypoxia (0.5% O2 for 24h) or treated with CoCl2. Three replicate values are reported and error bars represent standard deviations. Statistical significance indications: * 
P<0.05, ** P<0.01, *** P<0.001, ****P<0.0001 compared with the normoxic control (one-way ANOVA followed by Dunnett’s multiple comparisons test).  
 
 
Results acquired from PDHKI gene expression analysis are shown in Figures 6.73 to 6.75. MCF7 cells demonstrated a modest induction when cultured 
in a low oxygen environment whereas statistically significant upregulation was only observed following treatment with CoCl2. On the contrary MDA-
MB-231 and HBL100 cells significantly upregulated PDHK1 expression in hypoxic conditions or conditions mimicking hypoxia. Both cell lines 
demonstrated comparable levels of this target across the three examined conditions. 































































Figures 6.76 to 6.78: Log2 transformed LDHA mRNA levels in MCF7, MDA-MB-231 and HBL100 breast cancer cells cultured in normoxia (21% O2), chronic hypoxia (0.5% O2 for 
10 weeks), acute hypoxia (0.5% O2 for 24h) or treated with CoCl2. Three replicate values are reported and error bars represent standard deviations. Statistical significance indications: * 
P<0.05, ** P<0.01, *** P<0.001 compared with the normoxic control (one-way ANOVA followed by Dunnett’s multiple comparisons test).  
 
 
Figures 6.76 to 6.78 provide evidence that breast cancer cells upregulate LDHA expression in hypoxia. MCF7 and HBL100 cells exhibited significantly 




























































6.5 Discussion  
 
6.5.1 Breast cancer cells demonstrated increased sensitivity to glycolysis 
inhibition in high oxygen conditions 
Hypoxia is a well substantiated prevalent characteristic of the tumour microenvironment. 
Solid tumours grow uncontrollably and outreach the diffusion distance of oxygen. Oxygen 
deficiency commonly arises as a result of the unrestricted tumour growth and the chaotic 
architecture of the tumour microvasculature. Hypoxia has important implications as it has 
been extensively associated with an aggressive phenotype, adverse clinical outcome and 
resistance to radiation therapy and several cytotoxic agents [142, 143, 474]. Previous 
research has established that advanced solid tumours frequently exhibit heterogeneously 
distributed hypoxic and anoxic areas. A number of studies have reported remarkable 
variability in the oxygenation status among individual tumours as well as within the same 
lesion [142-144]. In their major study Helmlinger et al employed high-resolution microscopy 
techniques to measure the oxygen tension in vivo in colon cancer xenograft models. They 
revealed pronounced gradients and heterogeneously distributed patterns with distinct 
variability in the oxygen pressure. Hypoxic regions (<5mmHg) were detected at a distance of 
70-80μm from the nearest blood vessel wall while anoxic regions (0-0.5mmHg) at a distance 
greater than 150μm [475]. With regard to breast malignancies, Vaupel et al demonstrated 
differentially oxygenated populations within individual breast tumours and documented that 
at least 40% of examined breast carcinomas contained hypoxic tissue regions with O2 
tensions ranging from 0 to 2.5mmHg. The median oxygen level of 16 normal breast tissue 
samples was calculated at 8.6% O2, while the respective value of 15 breast tumours was 4% 
[145]. 
The HIF family of transcription factors plays a leading role in cellular homeostasis and the 
adaptation of cancer cells in the hypoxic tumour microenvironment, particularly HIF-1. HIF-
1 activation, either because of low oxygen tensions or through aberrant oncogenic signalling, 
is known to promote the glycolytic phenotype and suppress mitochondrial oxidative 
phosphorylation. The glycolytic enzymes of particular interest to this study, along with 
PDHK1, are known to be HIF-1 inducible [151, 446, 474]. Based on previous research 
supporting variability in the oxygenation of breast tumours and metabolic dependency on 
oxygen availability, this study set out to determine the efficacy of glycolysis inhibition in 
differing oxygen conditions. The effect of the panel of glycolytic inhibitors was assessed 




experiments and were treated with eight glycolytic inhibitors under four oxygen conditions, 
21%, 7%, 2% and 0.5% O2, for an either 3 or 5-day period.  
The four different oxygenation levels were deliberately selected based on the HIF-1α 
activation status. As discussed in the introduction HIF-1 is the major regulator of cellular 
response to low oxygen tensions (Chapter 1, section 1.3.1). Jiang et al documented that HIF-
1α protein levels increase exponentially in HeLa cells mainly when oxygen availability 
becomes lower than 6%. Thus the selected 7% O2 condition aims to reflect an environment 
prior to HIF-1α activation. In the same study half maximal HIF-1α protein levels and HIF-1-
DNA binding activity was observed at 2% while the maximal response occurred at 0.5% O2 
[476].      
It is necessary to clarify that normoxia here denotes 21% O2 conditions (150mmHg), the 
oxygen concentration in ambient air. The majority of in vitro cancer research experiments 
are currently conducted in this aerobic environment. Nevertheless these conditions are not 
physiologically relevant and the term ‘normoxia’ does not imply normal oxygen availability 
in mammalian tissue which is averaged between 2 and 9% O2 [474].   
The most important finding of this experiment was that breast cancer cells presented 
enhanced sensitivity to all eight glycolytic inhibitors in 21% O2 conditions, compared to the 
three lower oxygen levels. Enhanced sensitivity in normoxia was consistent for both breast 
cancer cell lines and was confirmed at both time points examined. Higher IC50 values in 
hypoxia suggested increased resistance to the inhibitors in these conditions. Nevertheless, 
both cell lines were susceptible to glycolysis inhibition over the whole range of oxygen 
levels tested validating the strategy as effective anticancer treatment in the gradient of 
hypoxia observed in solid tumours. Modulation of the activity of the eight compounds 
targeted against multiple points of the glycolytic pathway was comparable across the varying 
levels of oxygen. This could be considered an indication of a shared mechanism of action 
and inhibition of a common pathway.  
The most striking observation was the notable difference in the efficacy of the inhibitors 
between 21 and 7% O2. Both cell lines markedly increased their IC50 values between 21 and 
7% O2 regardless of the duration of treatment. Breast cancer cells were found to be 
considerably more resistant to the whole panel of glycolytic inhibitors at 7% O2 compared to 
21% O2 conditions. The respective IC50 values increased from 1.5 fold (MDA-MB-231 cells 
treated with STF31 for 5 days – Figure 6.8) up to 62 times (MDA-MB-231 cells treated with 




seemed to have a relatively minimal effect on the sensitivity to the glycolytic inhibitors. 
Interestingly, the response of the breast cancer cells to the majority of the compounds in the 
three lower oxygen levels was comparable at both time points. However, in some cases cells 
enhanced their resistance increasing further their IC50 values (MCF7 cells treated with 
Oxamic acid for 3 days – Figure 6.25) or became slightly more sensitive demonstrating a 
modest decrease in their IC50 values (MCF7 and MDA-MB-231 treated with DCA – Figures 
6.21 to 6.24). Taken together, breast cancer cells were found to be considerably more 
sensitive to the eight glycolytic inhibitors at 21% O2 compared to any of the lower oxygen 
levels examined following a 3-day or a 5-day treatment period (Tables 6.1&6.2).  
One unanticipated observation was that Phloretin actually enhanced the growth of MCF7 
breast cancer cells following a 3-day treatment under the three low oxygen conditions as 
well as following a 5-day treatment at 7% O2. Growth reached 160 and 180% compared to 
the untreated controls in each time point respectively (Figures 6.1&6.2). Taking into account 
that this effect was specific to the ER positive line this could possibly be attributed to the 
oestrogenic nature of this phytochemical. As discussed in the introduction (Chapter 1 section 
1.5.1.1) these substances have been associated with a wide range of pharmacological 
responses. Several flavonoids possess oestrogenic activity as they resemble 17β-oestradiol 
and have the ability to interact directly and competitively bind the ER receptors [275, 477]. 
Phloretin has been described as a natural nonsteroidal oestrogen [478]. It has previously been 
reported that genistein, another flavonoid, induces proliferation of MCF7 breast cancer cells 
when used in low concentrations in an ER dependent way while it demonstrates 
antiproliferative action in high concentrations [275, 479]. However dependency of the effect 
on the oxygen availability has never been described and furthermore stimulation of cancer 
cell growth by Phloretin has not been reported. Further work needs to be undertaken to 
clarify this interesting observation.  
This study has demonstrated amplified sensitivity to inhibition of the glycolytic pathway in 
normoxia. This outcome seems counter-intuitive as it is contrary to the notion of increased 
dependency on glycolysis under hypoxic conditions. In the absence of oxygen, cells rely 
primarily on the catabolism of glucose for the production of energy. Furthermore, it is now 
well established that HIF-1 induces the expression of glycolytic enzymes, promotes the 
glycolytic phenotype and suppresses mitochondrial oxidative phosphorylation as an adaptive 
response to support tumour growth in the hostile hypoxic tumour microenvironment [146, 
446]. Hence mechanistically it would be anticipated that increased reliance on glycolysis 




even in the presence of ample oxygen is in agreement with the seminal theory of Warburg 
[87].  
An important factor that could possibly be related to the observed resistance to the inhibitors 
in hypoxia is the growth rate. Cells grow more slowly in low oxygen tensions and this may 
have influenced the response to the compounds. Significant associations between the 
potency of the inhibitors under the varying levels of oxygen and the proliferation rate in the 
corresponding conditions were revealed (Table 6.4). One conceivable explanation is that 
faster growing cells under high oxygen tensions are highly dependent on glycolysis for the 
production of energy and the metabolic intermediates required for the biosynthesis of 
macromolecules, and for that reason are more susceptible to glycolytic inhibitors. Greater 
resistance to glycolysis inhibition by slow growing cancer cells is in agreement with results 
presented in Chapter 3 section 3.3 demonstrating a correlation between response to certain 
glycolytic inhibitors and the proliferation rate across an extended panel of breast and ovarian 
cancer cell lines (Figures 3.39&3.40).  
In the literature there has been little agreement on the efficacy of glycolysis inhibition in 
hypoxia in several cancer cell line models. Research in the field has generated disparate 
results. Although a number of studies demonstrated minimal changes in the potency of 
selected glycolytic inhibitors under normoxic and hypoxic conditions, some studies 
suggested enhanced activity in hypoxia while others showed the opposite. According to Cao 
et al Phloretin was equally effective in normoxia and hypoxia against SW620 colon cancer 
cells and K562 leukaemia cells [287]. In line with this Xiao et al reported that 3BP had a 
comparable effect on pancreatic cancer cells in normoxic and hypoxic conditions [480]. In 
contrast three independent studies demonstrated enhanced 3BP activity in hypoxic 
conditions using lymphoma and colon cancer cell lines, hepatocellular as well as pancreatic 
cancer cells [331, 481, 482]. Similarly increased sensitivity of A549 lung cancer cells to 
WZB117 in hypoxia has been evidenced by Liu et al [319]. Furthermore Liu et al developed 
anaerobic osteosarcoma cell model systems that exhibited hypersensitivity to 2-DG and 
Oxamic acid [483, 484]. Likewise Granchi et al documented that NHI-1 was particularly 
potent against various cancer cell line models in a low oxygen environment [378, 379]. 
However, in agreement with the findings of the present study, Anderson et al reported that 
DCA was more potent in attenuating the proliferation of HeLa and PANC-1 cells in 
normoxic conditions. Accordingly, Shahrzad et al confirmed that colorectal cancer cells 
were more susceptible to PDHK1 inhibition under normoxia both in vitro and in vivo [485]. 




inhibitor DMA and the V-ATPase inhibitor bafilomycin A1) under low oxygen availability 
has been recently demonstrated (James Meehan, personal communication, paper under 
review). Even though the concept of amplified sensitivity to glycolysis inhibition in hypoxia 
has been challenged there has been no detailed study investigating the effect of multiple 
inhibitors of the glycolytic pathway within a wide range of hypoxia.       
This study offers valuable insights into the sensitivity to glycolysis inhibition under 
physiological levels of hypoxia. This is the first study to examine the effect of a series of 
glycolytic inhibitors on breast cancer cells in varying oxygenation levels in contrast to the 
previous research on the subject that has been mostly restricted to 21% O2 conditions which 
are undoubtedly less relevant to the tumour microenvironment. Relative resistance of breast 
cancer cells in hypoxic conditions was consistently demonstrated for all eight of these 
inhibitors and may have implications for their use as antitumour agents. This important 
finding will be further investigated in this chapter.   
 
6.5.2 Resistance of breast cancer cells to glycolysis inhibition in hypoxia was 
associated with target overexpression 
The aim of this section was to interpret the observed resistance of breast cancer cells to 
glycolysis inhibition in varying levels of hypoxia. It was assessed whether the expression of 
the targeted glycolytic enzymes could have an impact on the efficacy of the inhibitors. The 
protein expression of the glycolytic targets of interest were evaluated by Western blotting in 
MCF7 and MDA-MB-231 cells cultured in a range of hypoxia levels (7, 2 and 0.5% O2) for 
varying periods of time (24, 48 and 72h). The expression was compared to a 21% O2 control.   
This study has been unable to demonstrate GLUT1 protein upregulation in either of the 
breast cancer cell lines under the examined conditions (Figures 6.35&6.36). HKII and 
LDHA were upregulated compared to the normoxic control only in MCF7 cells at 0.5% O2. 
Peak HKII expression was observed following 72h incubation at 0.5% O2 while maximal 
LDHA expression as early as 24h (Figures 6.39&6.51). The most profound effect of oxygen 
depletion was on PDHK1 expression. Both breast cancer cell lines demonstrated a marked 
induction of this target. MCF7 cells exhibited a fivefold increase at 0.5% O2 and MDA-MB-
231 cells a threefold increase in the same conditions (Figures 6.47&6.48). Furthermore 
PFKFB3 expression was also increased in both cell lines. Both MCF7 and MDA-MB-231 
cells had increased expression of this enzyme (up to threefold) when grown at 7 and 2% O2 




An interesting observation was that the modulation of the targets in the triple negative basal 
B breast cancer cell line (MDA-MB-231) was less profound compared to the ER positive 
luminal A line (MCF7). Two of the targets were upregulated only in MCF7 cells while 
PDHK1 upregulation was greater in this cell line. A possible explanation for that could be 
that MDA-MB-231 cells harbouring an oncogenic K-Ras are highly glycolytic suggesting 
that the expression of the glycolytic enzymes is already elevated in normoxia and further 
induction in hypoxic conditions is modest. In agreement with this, Gaglio et al documented 
upregulation of several glycolytic enzymes in MDA-MB-231 cells compared to normal 
breast tissue [423].                                                        
This experiment examined the hypothesis that elevated expression of the targeted glycolytic 
enzymes could lead to increased resistance to glycolytic inhibitors in a low oxygen 
environment. Mechanistically it can conceivably be assumed that increased expression of an 
enzyme is likely to require increased amount of an inhibitor to be targeted. HIF-1α mediated 
upregulation of the glycolytic targets in hypoxia is well characterised [151, 446]. The 
glycolytic enzymes as verified HIF-1 targets are upregulated in hypoxic conditions however 
the majority of research in the field has only focused on mRNA expression levels. No study 
has been identified examining the modulation of protein expression levels of several 
glycolytic enzymes under a range of oxygen levels in breast cancer cells. 
A limitation in this experiment is that it was only conducted once and so detailed statistical 
analysis is not feasible. An additional limitation lies in the absence of HIF-1 data. Ideally the 
expression of the glycolytic enzymes should be associated with the expression of the major 
hypoxia response regulator. Evaluation of the HIF-1 levels in the same lysates was 
attempted. However due to complications in the antibody optimisation process and because 
of stability issues of the protein reliable data were not acquired.  
Further support for the concept of reduced sensitivity to glycolytic inhibitors in hypoxia 
mediated by elevated expression of the respective targets was provided by the findings of 
Maher et al. In their study the authors used several in vitro models (chemical restriction of 
oxidative phosphorylation, HIF-1 downregulation and HIF-1 deficient cells) and indicated 
that HIF-1 confers resistance to 2-DG. They suggested that HIF-1 activation upregulates the 
expression of the glycolytic enzymes reducing the sensitivity to glycolytic inhibitors as 
higher concentrations are required to block the pathway and induce the same antitumour 
effect. Corroborating the findings of the present study elevated resistance to 2-DG was 
associated with HKII upregulation [486]. The same mechanism of resistance has also been 




methotrexate in leukemia cells has been attributed to target gene amplification (dihydrofolate 
reductase) [487]. 
According to these data, it can be inferred that relative resistance to glycolysis inhibition in 
hypoxia can at least to some extent be attributed to upregulation of the targeted glycolytic 
enzymes. These findings enhance our understanding of the effect of oxygen availability on 
the glycolytic pathway and sensitivity to its inhibition and provide new insights into the 
interpretation of the impaired potency of glycolytic inhibitors in hypoxic conditions.  
6.5.3 Breast cancer cells demonstrated enhanced sensitivity to the novel 
GLUT1 inhibitor IOM-1190 in low oxygen conditions 
In chapter 3 the novel GLUT1 inhibitor IOM-1190 was identified as a potent inhibitor of 
breast cancer cell proliferation. In this section the effect of this inhibitor was assessed in 
hypoxic conditions. IOM-1190 was compared against MCF7 and MDA-MB-231 cells at 
0.5% O2 in two distinct situations. Acute hypoxic cells were incubated at 0.5% O2 for 3 days 
during treatment while chronically hypoxic cells were perfectly preadapted to the oxygen 
level for 10 weeks prior to treatment. These conditions were selected to mirror the tumour 
microenvironment. It is known that the abnormal tumour vasculature gives rise to 
heterogeneously distributed alternating normoxic, hypoxic, anoxic necrotic and re-
oxygenated areas [146]. Consequently acute hypoxic along with chronically hypoxic cells 
are a common feature of solid malignancies.  
The single most important observation to emerge from these data is that breast cancer cells 
presented enhanced sensitivity to IOM-1190 in hypoxic conditions. Interestingly both breast 
cancer cell lines exhibited a marked reduction in their IC50 values between normoxic and 
acute hypoxic conditions that reached the fortyfold level in MCF7 cells. Long term 
adaptation in hypoxic conditions made breast cancer cells less sensitive to treatment with the 
GLUT1 inhibitor. However MCF7 cells were still eightfold more sensitive compared to 21% 
O2 conditions while in contrast MDA-MB-231 cells presented a modest increase in their IC50 
value compared to normoxic conditions (Figures 6.53&6.54 and Table 6.5).  
Enhanced sensitivity to IOM-1190 in hypoxia is contrary to the findings with the majority of 
the other eight compounds tested (Tables 6.1&6.2). However these results corroborate the 
notion of elevated sensitivity to glycolysis inhibition stemming from increased dependency 
on the pathway under hypoxic conditions. Moreover, they are consistent with earlier studies 
demonstrating that a number of glycolytic inhibitors, including WZB117, 3BP, Oxamic acid 




The glycolytic inhibitors have been evaluated in combination strategies with established 
chemotherapeutic and targeted agents. Several synergistic interactions were identified and 
are presented in Chapter 5. Robust synergy was revealed between IOM-1190 and the 
antidiabetic drug metformin as shown in section 5.3.1. Here this combination was assessed 
in hypoxic conditions. It was demonstrated that metformin did not enhance the 
antiproliferative effect of the GLUT1 inhibitor on chronically hypoxic breast cancer cells 
(Figures 6.53&6.54) suggesting that the interaction between the two compounds is less 
favourable in these conditions. However a high concentration of metformin (4mM) 
significantly augmented the action of IOM-1190 against MDA-MB-231 cells.  
While IOM-1190 as a single agent is highly potent in hypoxic conditions, metformin did not 
affect breast cancer cell proliferation in a low oxygen environment, even over a broad range 
of concentrations (Figures 6.57&6.58). However, an inhibitor of mitochondrial oxidative 
phosphorylation is unlikely to have any influence in oxygen depleted conditions, if cells are 
not reliant on mitochondrial respiration. Nonetheless literature has recently emerged that 
offers contradictory findings. In agreement with the findings of the present study Garofalo et 
al documented that Ewing sarcoma cells were less sensitive to metformin in hypoxia either 
as single treatment or in combination with vincristine both in vitro and in vivo. They claimed 
that the limited efficacy was associated with impediment to AMPK activation and 
subsequent mTOR inhibition [488]. Along the same line Griss et al reported that metformin 
impaired the proliferation of osteosarcoma cells exclusively in aerobic conditions. The 
authors argued that the antiproliferative effect of metformin is not related to the activation of 
AMPK. The antitumour effect of the antidiabetic agent was attributed to impairment of the 
anabolic growth of tumour cells due to deficiency of mitochondrial metabolic intermediates 
(particularly for lipid biosynthesis). It was suggested that cells not reliant on mitochondria to 
replenish their biosynthetic precursors develop resistance to the biguanide. This includes 
hypoxic cells engaged in a reductive glutamine metabolism [489]. On the other hand Safari 
et al indicated that metformin was more effective against hypoxic than normoxic MCF7 
breast cancer cells [490]. In agreement with this Wheaton et al associated the antitumour 
effect of the antidiabetic agent with inhibition of the mitochondrial respiratory chain 
complex I. They demonstrated that metformin inhibits HIF-1 activation and suggested that 
low glucose or oxygen availability augments the action of metformin [491].   
One important result to emerge from these data is that the novel GLUT1 inhibitor exhibited 
significant antiproliferative action in hypoxic conditions. Cells chronically adapted in 




treatment including radiation therapy and several chemotherapeutic agents [142]. The 
observation that both ER positive and triple negative ‘resistant’ hypoxic breast cancer cells 
demonstrated amplified sensitivity to IOM-1190 in low concentrations is of great 
importance. The novel GLUT1 inhibitor is identified here as a potent cancer cell 
proliferation inhibitor. Evidence is provided that this compound has potential therapeutic 
value and could play a role in the future cancer therapy. However further studies need to be 
carried out in order to evaluate its efficacy in in vivo systems. Furthermore the combination 
of IOM-1190 and metformin needs further evaluation and may prove useful in the treatment 
of triple negative tumours. Although metformin did not increase the effectiveness of IOM-
1190 as a single treatment in chronically hypoxic cells, the combination may be more 
effective in the range of oxygenation levels found in the microenvironment of solid tumours. 
IOM-1190 along with metformin is highly potent under high oxygen levels, while the 
GLUT1 inhibitor is effective by itself in low oxygen conditions.    
 
6.5.4 Upregulation of the glycolytic pathway in breast cancer cells under 
hypoxia at the transcriptomic level  
A genome-wide transcriptomic analysis on breast cancer cells under short term (24h) and 
long term (10 week) hypoxia as well as in conditions of chemically induced hypoxia (by 
CoCl2 treatment) was undertaken. Illumina BeadChip analysis was conducted to evaluate the 
transcriptome changes between these conditions. The aim of this experiment was to 
determine the response of breast cancer cells to hypoxia and investigate the modulation of 
the glycolytic pathway in these conditions. To further explore the previously observed 
resistance to glycolysis inhibition in a low oxygen environment, the transcript levels of 
selected glycolytic enzymes were assessed.    
It has been long appreciated that hypoxia has extensive effects on gene expression and 
enhances the glycolytic pathway. Adaptation to the hostile hypoxic microenvironment 
dictates high flux through the glycolytic pathway and enhanced glycolytic rates [153, 470]. 
However, the transcriptional response to oxygen deprivation is specific for each cell type 
[492]. It has been suggested that HIF-1 targets vary between cell types and are dependent on 
the expression profile of the α subunit as well as the severity of hypoxia [146, 492]. 
Therefore this study set out to investigate the control of the glycolytic enzymes expression in 




Prolonged exposure to 0.5% O2 had a great impact on gene expression in breast cancer cells. 
By comparing cells in chronic hypoxia with those in normoxia, a number of differentially 
expressed genes were identified; this indicates that substantial changes are induced at the 
transcriptomic level in hypoxic breast cancer cells. The gene expression profile in hypoxic 
breast cancer cells and the hypoxia-mediated transcriptional changes were studied. Genes 
that were consistently deregulated in three breast cancer cell lines (MCF7, MDA-MB-231 
and HBL100) following 10 week incubation at 0.5% O2 were established. Enrichment test 
and functional annotation GO analysis were performed to identify the gene functional 
categories among the differentially expressed genes and explore the key biological processes 
affected in chronic hypoxia. Transcriptional changes induced by long term adaptation in 
hypoxia are summarised in Figures 6.59 and 6.61. The Revigo server implementing a simple 
clustering procedure enabled the representation of clusters of semantically similar GO terms 
[471].  
Functional analysis of the data revealed that genes commonly upregulated in chronic 
hypoxia in three breast cancer cell lines were associated with the glycolytic process and 
response to hypoxia (Figures 6.61&6.62). This finding provides evidence that the glycolytic 
pathway was strongly upregulated in hypoxic breast cancer cells despite the inherent 
differences among the cell lines. Similar data were generated in a recent study conducted by 
Sanzey et al in glioblastoma cells [493]. However, long term incubation at 0.5% O2 led to the 
downregulation of transcripts involved in multiple pathways regulating primarily the mitotic 
cell cycle and nuclear division (Figures 6.59&6.60). This result is in agreement with the 
classic study by Hochachka et al where the authors argued that primary mechanisms 
contributing to cellular hypoxia tolerance include suppression of biosynthetic pathways (and 
subsequently mitosis) in order to diminish energy demand [494].    
Further analysis was carried out to investigate hypoxia driven transcriptional changes on the 
glycolytic pathway. The log2 fold change expression values of the glycolytic genes 
calculated between chronic hypoxic and normoxic conditions in four breast cancer cell lines 
(MCF7, MCF7-HER2, MDA-MB-231 and HBL100) were used for hierarchical clustering. 
The generated heatmap shows that the genes involved in the glycolytic pathway were 
collectively upregulated under hypoxia (Figure 6.63). These results demonstrate that 
glycolysis is a major pathway mediating the response of breast cancer cells to oxygen 
deprivation. GLUT3 and ENO2 (enolase 2) formed a separate branch and were strongly 
induced by hypoxia. PGK1 (phosphoglycerate kinase 1), GPI (glucose-6-phosphate 




bisphosphate C) and PFKFB3 were clustered together and demonstrated significant 
upregulation. The remaining glycolytic genes (including LDHA and PDHK1) were also 
upregulated however they were characterised by lower log2 gene expression fold changes. 
The transcription factor HIF-1 orchestrates the cellular response to low oxygen availability. 
In hypoxia HIF-1 binds to hypoxia-response elements of hypoxia-sensitive genes and 
induces their transcriptional activation as an adaptive response to the hostile low oxygen 
tumour microenvironment. The HIF-1 responsive transcriptome is predominantly involved in 
angiogenesis, erythropoiesis and glucose metabolism [150, 153, 470]. Therefore increased 
mRNA expression of glycolytic genes in hypoxia stems primarily from stabilisation of HIF-
1α. Virtually all the genes implicated in the glycolytic pathway are considered HIF-1 
inducible [118, 473]. In their key study Iyer et al documented that HIF-1 activates the 
transcription of genes implicated in the glycolytic pathway. The authors demonstrated that 
HIF-1α was essential for their expression in embryonic stem cells and characterised the 
pathway as ‘‘a remarkable example of coordinate transcriptional regulation’’ [495]. 
Functional hypoxia-response elements in the promoters of several glycolytic genes have 
been characterised [470, 496, 497]. 
However, according to the Warburg effect many tumours preferentially rely on the glycolytic 
pathway irrespective of oxygen availability [87]. Analysis of NIH gene expression libraries 
show that at least 70% of human cancer cases worldwide exhibit inherent upregulation of 
glycolytic enzymes [498].       
Gene expression changes occurring upon hypoxia were finally assessed in glycolytic 
enzymes of particular interest to this study. Comparison of hypoxia responses at the level of 
transcription between chronic and acute hypoxic cells as well as following treatment with 
CoCl2 was carried out. Three of the breast cancer cell lines that have been included in the 
growth inhibition studies were used in this analysis (MCF7, MDA-MB-231 and HBL100).  
CoCl2 is a hypoxia mimetic agent that chemically induces HIF-1. Transition metals like 
cobalt mimic the effect of oxygen deprivation and stabilise HIF-1α. It has been evidenced 
that CoCl2 inhibits prolyl hydroxylases (through iron substitution) that hydroxylate HIF-1α 
provoking its degradation and leads to the accumulation of active transcription factor 
complexes within the cell nucleus [154, 499]. However it has also been suggested that CoCl2 
inhibits the interaction between hydroxylated HIF-1α and pVHL and prevents its 
ubiquitination and degradation [500]. CoCl2 treatment was used in this study to mirror the 




in normoxia. Therefore it was possible to develop an understanding of the contribution of 
HIF-1 to the induction of the glycolytic enzymes in hypoxia. (Oxygen regulation of HIF-1α 
is discussed in Chapter 1 section 1.3.1) 
The present study confirms previous findings and contributes additional evidence to a 
growing body of literature investigating the impact of oxygen concentration on the 
expression of glycolytic enzymes in breast cancer. The GLUT isoforms prevalent in breast 
cancer cells under low oxygen availability were GLUT1 and GLUT3. Both transporters 
demonstrated a marked induction in chronic hypoxic conditions in the examined cell lines 
(Figure 6.63). These isoforms have high affinity for glucose to ensure high glycolytic flux 
[501]. In a previous study Takagi et al reported GLUT1 mRNA in cultured bovine retinal 
endothelial cells increased ninefold after 12h at 0.5% O2  [502].  Sorensen et al demonstrated 
a prompt induction (evident as early as 1h) of GLUT1 and LDHA expression in anoxia using 
cervix squamous cell carcinoma cells. Upregulation reached twelvefold after 6h and fivefold 
after 3h for the two genes respectively while maximal response was reported at 0.01% O2 
[503]. Minchenko et al documented HIF-1 mediated significant upregulation of PFKFB3 in 
several cancer cell lines. Furthermore in line with the observation of the present study that 
treatment with CoCl2 failed to induce PFKFB3 mRNA expression in HBL100 cells (Figure 
6.72), the authors reported a similar finding for HeLa cells [504]. PDHK1 has also been 
verified as a HIF-1 target and at least a fourfold mRNA upregulation has been demonstrated 
in hypoxic P493-6 Burkitt’s lymphoma cells [161]. 
The most important finding of this analysis was that the glycolytic targets of interest were 
significantly induced in hypoxic conditions in all three breast cancer cell lines examined. 
Response between acute and chronic hypoxic conditions was primarily comparable 
suggesting that the glycolytic pathway is rapidly upregulated upon exposure to 0.5% O2 and 
remains consistently activated following long term incubation. This is contrary to the 
acknowledged regulation of HIF-1α as the levels of this subunit get promptly induced upon 
exposure in a low oxygen environment but in chronic hypoxia, accumulation decreases [146, 
505]. This has been described as a protective mechanism against necrosis mediated by 
activation of prolyl hydroxylases that cause HIF-1α degradation [505]. Another major 
difference is that HIF-1α expression is regulated by oxygen availability mainly at the post-
translational level through inhibition of protein degradation whereas mRNA transcription is 
ubiquitous and constant [470]. Upregulation of the glycolytic enzymes is consistent with the 
hypothesis that increased expression of the glycolytic targets may lead to enhanced 




treatment with the hypoxia mimetic agent corroborated that the upregulation of the 
glycolytic genes is mainly attributable to the activation of HIF-1 as CoCl2 induced 
comparable effects to actual hypoxia. 
Expression of the glycolytic enzymes was consistently a level of magnitude higher in MDA-
MB-231 compared to MCF7 cells in normoxia. This corroborates previous findings from 
Gaglio et al that MDA-MB-231 cells, harbouring an oncogenic K-Ras, exhibit enhanced 
glycolytic activity and upregulation of several glycolytic enzymes [423]. Furthermore this 
finding further supports the view of a prevalent glycolytic phenotype in triple negative 
tumours [424, 506]. 
The protein levels of these targets have previously been assessed in MCF7 and MDA-MB-
231 breast cancer cells under varying oxygenation levels through Western blotting (section 
6.2). One of the examined conditions was incubation at 0.5% O2 for 24h. This matches 
exactly the acute hypoxic conditions of this experiment. Therefore a direct comparison 
between mRNA and protein levels was enabled. HKII, PFKFB3 and PDHK1 upregulation 
was mirrored at both the mRNA and protein levels in both cell lines (Figures 6.39, 
6.40&6.67,6.68 for HKII, Figures 6.43, 6.44&6.70, 6.71 for PFKFB3, Figures 6.47, 
6.48&6.73, 6.74 for PDHK1). Although PFKFB3 mRNA expression in MCF7 cells was 
significantly induced at the P<0.0001 level while the effect of oxygen deprivation on the 
protein level was only marginal. Furthermore an apparent disconnect between mRNA and 
protein levels was observed for LDHA expression in MDA-MB-231 cells (Figures 
6.52&6.77). Significant upregulation was demonstrated at the mRNA level whereas no effect 
was detected in protein expression. A similar disparity was also noticed as regards GLUT1 
expression as this study failed to identify hypoxia mediated protein induction of this enzyme 
in either cell line (Figures 6.35&6.36).        
The correlation between mRNA and protein expression levels is not always straightforward. 
Increased gene transcription does not always predict increased levels or enhanced activity of 
the protein product [507]. Nonetheless induction of glycolytic enzymes in low oxygen 
conditions at both the mRNA and protein levels as a result of HIF-1 activation has been 
substantiated [153].  
In a very recent study Smith et al investigated the metabolic profile of colon cancer 3-D 
spheroid models cultured in severe hypoxia. Significant induction of the glycolytic flux was 
demonstrated following short term 16h exposure to 0.1% O2 by a radioactivity assay. The 




and GLUT3) and enhanced enzymatic activity of PFK1. Nevertheless increased mRNA 
expression of key glycolytic enzymes, including HKII, PK and LDHA, was not reflected in 
protein expression and metabolic capacity in line with observations of the present study. The 
authors attributed reduced enzymatic levels to impaired protein synthesis in these conditions. 
Furthermore it was argued that their reduced expression serves the purpose to divert 
metabolic intermediates from biosynthetic pathways and diminish anabolic growth [508].        
This study validates glycolysis as a major pathway mediating the response of breast cancer 
cells to an oxygen depleted environment. The present study enhances our understanding of 





















Chapter 7: Evaluation of glycolytic targets in ovarian tumours 
 
7.1 Expression of selected glycolytic enzymes in ovarian tumours 
To date much uncertainty still exists about the metabolism of ovarian tumours. Therefore the 
role of glycolysis in ovarian cancer was thoroughly investigated in this study by examining 
the level of protein expression of selected glycolytic enzymes in a series of clinical ovarian 
cancer samples. Expression of four glycolytic targets was assessed with in situ staining in 
469 ovarian tumours using Automated Quantitative Analysis (AQUA). The objective of this 
experiment was to quantitatively evaluate the expression of glycolytic enzymes and associate 
expression with several clinicopathological parameters, as well as with survival outcome. 
Thus, the aim was to enhance our understanding of the role of the glycolytic pathway in 
ovarian carcinogenesis and reveal subtypes of tumours that might benefit from targeted 
inhibition of the glycolytic enzymes.  
Tissue Microarrays (TMAs), constructed of formalin fixed, paraffin embedded samples of 
each of 469 ovarian tumours in triplicate, were obtained from the Division of Pathology 
Laboratories, Western General Hospital, University of Edinburgh. Details of patient 
characteristics of this cohort (summarised in the Appendix Table A3) and the procedure of 
TMA construction have been previously published [509, 510]. They are all primary ovarian 
tumours obtained from patients treated in the Edinburgh Cancer Centre the period between 
1991 and 2006. Samples were collected prior to treatment. Antibodies targeting glycolytic 
markers of interest -GLUT1, HKII, PKM2 and LDHA- were optimised and a standard three 
label immunofluorescent protocol as described in Chapter 2 section 2.9 was followed. DAPI 
counterstain was used to identify the nuclei, pan-cytokeratin to visualise the epithelium and 
Cy-5 tyramide for target detection. AQUA analysis was employed as an automated scoring 
method to access the target’s expression generating a quantitative score for each histospot. 
High resolution monochromatic images of each TMA core were obtained and analysed by 
the AQUA software. The Cy-5 fluorescent signal intensity of the target antigen was 
quantified in each image pixel. A score was attributed in each core based on the average Cy-
5 signal within the epithelial tumour mask, as this was identified from the cytokeratin stain. 
For the four targets of interest, expression in the cytoplasmic compartment was assessed. 
Damaged cores or cores containing imaging errors as well as those consisting of less than 
5% epithelium were excluded from further analysis. After filtering the data only the samples 
that had at least two replicate values were used. Average expression values from either two 




Representative immunofluorescence images showing the expression of four glycolytic 
targets in TMA cores of ovarian cancers obtained from the AQUA image analysis software 
are presented below. Figure 7.1 presents representative examples of GLUT1 fluorescent 
staining. GLUT1 showed membranous as well as cytoplasmic localisation. In Figures 7.2, 
7.3 and 7.4 images of HKII, PKM2 and LDHA expression are presented respectively. These 




   
   
 
 
Figure 7.1: Representative immunofluorescence images showing GLUT1 expression in TMA cores of ovarian 
cancers. Blue colour visualises DAPI nuclear counterstain, green colour cytokeratin tumour mask and red colour 
GLUT1 staining. Quantified GLUT1 expression in the cytoplasmic compartment of each core is indicated. 
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Figure 7.2: Representative immunofluorescence images showing HKII expression in TMA cores of ovarian 
cancers. Blue colour visualises DAPI nuclear counterstain, green colour cytokeratin tumour mask and red colour 
HKII staining. Quantified HKII expression in the cytoplasmic compartment of each core is indicated. 
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Figure 7.3: Representative immunofluorescence images showing PKM2 expression in TMA cores of ovarian 
cancers. Blue colour visualises DAPI nuclear counterstain, green colour cytokeratin tumour mask and red colour 
PKM2 staining. Quantified PKM2 expression in the cytoplasmic compartment of each core is indicated. 
LDHA 
   
   
Figure 7.4: Representative immunofluorescence images showing LDHA expression in TMA cores of ovarian 
cancers. Blue colour visualises DAPI nuclear counterstain, green colour cytokeratin tumour mask and red colour 
LDHA staining. Quantified LDHA expression in the cytoplasmic compartment of each core is indicated. 
In Figure 7.5 the expression of the four glycolytic targets is compared in one individual 
ovarian cancer case. Immunofluorescence images showing expression of the four glycolytic 
enzymes in TMA cores of a particular patient are presented. High expression of all four 
markers consistent with a glycolytic phenotype can be observed. 
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Figure 7.5: Immunofluorescence images showing expression of four glycolytic enzymes in TMA cores of an 
individual ovarian cancer patient. Blue colour visualises DAPI nuclear counterstain, green colour cytokeratin 
tumour mask and red colour staining of the target protein. Quantified target expression in the cytoplasmic 
compartment of each core is indicated. 
 
The initial question addressed by this experiment was whether differential expression of 
glycolytic enzymes in ovarian tumours could be associated with discrete clinicopathological 
characteristics. The expression of each of the glycolytic markers was therefore compared 
across the different pathological stages and histological subtypes of ovarian tumours. 
 
7.2 Association of the expression of glycolytic enzymes with ovarian cancer 
progression    
The relationship between the level of expression of the four glycolytic enzymes and the 
pathological stage of ovarian cancer was examined and is presented below. Table 7.1 shows 













Interestingly lower LDHA expression was associated with increasing tumour stage. LDHA 
expression was significantly higher in stage I tumours compared to stage III and IV (Figure 
7.9). In contrast no statistically significant change in the expression of GLUT1, HKII and 
PKM2 across the different tumour stages was observed.  (Figures 7.6 to 7.8). 
Tumour stage GLUT1 HKII PKM2 LDHA 
I 28 36 33 29 
II 39 42 37 30 
III 183 211 202 157 
IV 54 63 58 48 
Unknown 10 14 10 8 
TOTAL 314 366 340 272 
 
Table 7.1: Number of ovarian cancer patients of different tumour stages that gave adequate AQUA data for each 
of the four glycolytic markers. 
   
 










Figures 7.6 to 7.9: Expression of four glycolytic enzymes correlated with different stages of ovarian cancer. 
Statistical significance indication: * P<0.05 (one-way ANOVA followed by Tukey's multiple comparisons test). 































































7.3 Association of the expression of glycolytic enzymes with ovarian cancer 
histological subtype  
The expression of the four glycolytic enzymes was compared across the different 
histological types of ovarian tumours. Table 7.2 shows the number of patients of each 
subtype that were included in the analysis for each of the markers.  
GLUT1 appeared to be similarly expressed in all different histotypes (Figure 7.10). The 
analysis revealed that LDHA expression was heterogeneous between histological subtypes; 
significantly increased expression was demonstrated in clear cell tumours (Figure 7.13). The 
same trend was also observed for PKM2, but was not significant (Figure 7.12). In contrast 















Figures 7.10 to 7.13: Expression of four glycolytic enzymes correlated with different histological subtypes of 
ovarian cancer. Statistical significance indications: * P<0.05, ** P<0.01, *** P<0.001 (one-way ANOVA 





*** * ** * 
Figure 7.13 Tumour Histotype 

























































Tumour Histotype GLUT1 HKII PKM2 LDHA 
Adenocarcinoma 11 11 11 8 
Serous 168 200 182 143 
Endometrioid 63 74 71 61 
Clear cell 16 20 18 11 
Mucinous 8 10 10 8 
Mixed 48 51 48 41 
TOTAL 314 366 340 272 
 
Table 7.2: Number of ovarian cancer patients of different histotypes that gave adequate AQUA data for each of 
the four glycolytic markers. 
7.4 Correlation of the expression of glycolytic enzymes with other markers 
The expression of the four glycolytic enzymes was then correlated with expression of several 
other molecular markers. These data were already available for the same cohort from 
previous independent projects that had used the same TMAs in the past [509]. Spearman 
nonparametric correlation was performed and the following correlation heatmaps were 
generated using TMA Navigator. Positive rho correlation values are displayed in bright 
yellow colours while negative rho values are displayed in dark blue colours.  For this 
analysis all data had been log transformed, mean-centred and quantile-normalised to 
compensate for differences in the staining of different markers.      
Figure 7.14 presents a heatmap correlating the expression of the four examined glycolytic 
enzymes. The expression of the four targets across the ovarian cancers gave positive rho 
correlation values when compared to each other. Based on the dendrogram, it can be 
concluded that LDHA expression appeared more closely correlated to PKM2 expression; 











Figure 7.14 Figure 7.14: Heatmap correlating the 
expression of four glycolytic 
enzymes in a cohort of 469 ovarian 
cancers. Positive Spearman rho 
correlation values are displayed in 
bright yellow colours while negative 
Spearman rho correlation values in 
dark blue colours. The heatmap was 




Spearman correlation network analysis was conducted to further interpret the relationship 
between the glycolytic markers and evaluate their significance. The Spearman correlation 
coefficient was calculated for each pair of markers and statistical significance was 
determined using the Algorithm AS89 [511]. Spearman's correlation P-values were adjusted 
for multiple hypothesis testing according to Benjamini-Yekutieli FDR correction. The P-
value significance threshold was set at 0.01. The Spearman correlation network of the 
expression of four glycolytic enzymes is presented in Figure 7.15. Significant relationships 
(FDR P <0.01) are drawn as lines that connect pairs of markers. Thickness of connection 
lines reflects significance. Positive significant relationships are displayed in grey colour. The 
colour of each marker indicates the number of significant connections. High number of 
significant connections is displayed in yellow colour while low in blue. Significant 




































Table 7.3: Spearman correlation of the expression of four glycolytic enzymes in a cohort of 469 ovarian cancers. 
Spearman rho correlation values (top value) along with the respective adjusted P value (bottom value) of 
statistically significant correlations thresholded at FDR P value <0.01 are summarised. 
Figure 7.15: Spearman correlation 
network of the expression of four 
glycolytic enzymes in a cohort of 469 
ovarian cancers. Statistically significant 
correlations thresholded at FDR P value 
<0.01 are presented. High number of 
significant connections is displayed in 
bright yellow colours while low in dark 
blue colours. Positive relationships are 
indicated in grey while negative in red. 
Thickness of connection lines reflects 
significance (the adjusted P value). The 








A large dataset detailing the expression of important oncogenic markers in the same ovarian 
cancer patient cohort was available and already published elsewhere [509]. The heatmap in 
Figure 7.15 shows the correlation of the expression of the four glycolytic enzymes with the 
expression of proliferation (Ki67, histone H3), apoptosis (caspase 3), cell cycle (RB), DNA 
damage response (H2AX, BRCA1, p53) and various signalling markers (ER, ERK, STAT3, 
AKT, NFκB). The four glycolytic markers appeared clustered together giving positive rho 
correlation values when compared to each other. GLUT1 expression was more closely 
correlated to HKII expression while PKM2 to LDHA. Regarding the relationship with the 
expression of the other non-glycolytic markers the most distinct positive correlations were 
observed with AKT, BRCA1 and ERβ2 while the most apparent negative correlations were 














Figure 7.15: Heatmap correlating the expression of four glycolytic enzymes with the expression of various 
proliferation, apoptosis and signalling markers previously examined in the same cohort of 469 ovarian cancers. 
Data of the expression of the oncogenic markers were obtained from Faratian et al [509]. Positive Spearman rho 
correlation values are displayed in bright yellow colours while negative Spearman rho correlation values in dark 





The relationship with this set of markers was further interpreted and their significance was 
evaluated. Spearman's correlation P-values were adjusted for multiple hypothesis testing by 
Benjamini-Yekutieli FDR correction. The P-value significance threshold was set at 0.01. The 
significant correlations (FDR P <0.01) detected for each of the glycolytic markers are 
summarised in Table 7.4. The previously described correlations among them were not 





Spearman rho adjusted P value 
GLUT1 - - - 
HKII 
BRCA1 0.44 3.4e-7 
ERβ2 c 0.44 3.6e-7 
ERβ2 n 0.42 0.0000012 
WNT1 0.37 0.000040 
pAKT 0.33 0.00049 
PKM2 
Caspase 3 -0.35 0.00021 
Snail -0.34 0.00030 
ERβ1 n -0.33 0.00042 
LDHA 
ERβ1 n -0.38 0.000023 
Snail -0.35 0.00013 
ERβ1 c -0.35 0.00013 
 
Table 7.4: Spearman correlation of the expression of four glycolytic enzymes with the expression of various 
proliferation, apoptosis and signalling markers previously examined in the same cohort of 469 ovarian cancers. 
Spearman rho correlation values along with the respective adjusted P value of statistically significant correlations 
thresholded at FDR P value <0.01 are summarised. (n and c indicate nuclear and cytoplasmic expression). 
 
7.5 Association of the expression of glycolytic enzymes with clinical outcome 
The expression of the four glycolytic targets was assessed for association between the 
behaviour of tumours and the survival outcome of the ovarian cancer patients. Overall 
survival data calculated from the day of initial surgical diagnosis until the date of death by 
ovarian cancer were used.  Patients who discontinued medical supervision or died from a 
different cause were censored. No association was found between the expression of the 
markers and the clinical outcome of the total patient cohort. Therefore, whether the 
expression of the targets in separate histopathological subtypes could be associated with the 




The following figures present the survival analysis of endometrioid ovarian cancer patients. 
Optimised cut-off values, dividing the target expression into either low, moderate or high; 
were generated in X-Tile and enabled the association to be made between protein expression 
and the clinical outcome. Miller–Siegmund P-value correction was applied. Based on these 
cut-off points Kaplan-Meier survival curves were created. Figures 7.19 and 7.18 show that 
low LDHA and low PKM2 expression were correlated with improved survival of 
endometrioid ovarian cancer patients. The corresponding P values determined through the 
Log-Rank survival analysis test were 0.0038 and 0.0006 respectively. The same trend was 














Figures 7.16 to 7.19: Kaplan-Meier survival curves showing relationship between the expression of four 
glycolytic enzymes and overall survival of endometrioid ovarian cancer patients. Statistical significance was 
determined using the Log-Rank survival analysis test and optimised cut-off values were generated in X-Tile.  
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7.6 Discussion  
Little attention to date has been paid on the glycolytic pathway in ovarian tumours as a target 
for new therapies. This chapter sought to identify the subtypes of ovarian tumours in which 
inhibition of glycolysis might be a beneficial strategy. The expression of four glycolytic 
enzymes was examined in clinical ovarian tumours with in situ immunofluorescent staining 
and quantitated automatically. Two upstream targets, GLUT1 and HKII, as well as two 
downstream targets, PKM2 and LDHA, were selected. No previous study has reported the 
expression of multiple glycolytic enzymes in ovarian tumours.  
AQUA is a novel technology that enables accurate, efficient and reproducible assessment of 
biomarker expression in hundreds of tissue sections. Traditional widely used IHC techniques 
involve the subjective semi-quantitation interpretation of staining intensity characterised ‘by 
eye’ on a scoring system as weak, moderate or strong. In contrast AQUA provides an 
opportunity to automatically quantitate the protein expression of biomarkers in TMA cores. 
Mathematical algorithms generate a score of immunofluorescence intensity for each 
histospot. This is based on the average Cy-5 fluorescent signal intensity of the target antigen 
in a subcellular compartment of choice within the epithelial tumour mask, as this was 
defined by Cy-3 cytokeratin staining [512, 513]. For the targets of interest here the 
cytoplasmic compartment was selected.   
The expression of the glycolytic enzymes varied considerably across the ovarian tumours. 
Representative immunofluorescence images exhibiting a wide range of quantitated 
expression of each of the targets are presented in Figures 7.1 to 7.4. An example 
demonstrating variable expression of each of the enzymes in the same cancer is shown in 
Figure 7.5. Prior to further analysis data were filtered and expression values from either two 
or three replicate cores were averaged. However, lost TMA cores and absence of at least two 
replicate values resulted in some missing data. 
The initial step of the analysis of this dataset was to associate the expression of the glycolytic 
enzymes with tumour progression and the histopathological subtype. The relationship 
between these discrete variables and target expression was investigated by comparing the 
mean expression level in each subgroup by one-way ANOVA. Statistical significance was 
determined by Tukey's multiple comparisons test.   
Correlation of the level of expression of the four glycolytic enzymes with the pathological 
stage of the disease revealed interesting associations. Significantly higher LDHA expression 




targets, no statistically significant change in their expression across the different tumour 
stages was detected (Figures 7.6 to 7.9). 
The expression of the glycolytic enzymes was also compared across the different ovarian 
cancer histological types. The analysis revealed that GLUT1 expression was comparable 
among the different histotypes. In contrast the other three markers were differentially 
expressed. Significantly higher LDHA expression was detected in clear cell carcinomas. 
Similarly higher PKM2 expression was also observed in clear cell tumours. However this 
histotype was significantly associated with lower HKII expression (Figures 7.10 to 7.13). 
The existing literature has repeatedly reported a possible role for GLUT1 in ovarian 
carcinogenesis. Several studies have demonstrated gradually elevated GLUT1 expression 
from healthy ovarian epithelium to benign and borderline tumours to malignant ovarian 
adenocarcinomas and the transporter has been suggested as a potential marker of ovarian 
malignancy [189, 191, 192]. Increased GLUT1 expression in advanced stage ovarian 
tumours has also been reported [193]. In line with these findings a trend was also observed 
here but it did not reach significance. Moreover a number of studies have documented 
elevated GLUT1 expression in serous adenocarcinomas [189, 193-195]. In contrast to earlier 
findings however the present study indicated comparable GLUT1 expression among the 
different ovarian cancer histological types. The findings of this research seem to be 
consistent with data published by Rudlowski et al which found no significant association 
between GLUT1 expression and disease progression or histotype following IHC of 78 
invasive ovarian tumour samples [192]. The mitochondrial-bound HKII is the predominant 
isoform expressed in many tumours [206]. A graduation in elevated HKII expression from 
benign and borderline tissues to malignant tumours has been noted in ovarian cancer [219]. 
Jin et al documented increased HKII expression in serous carcinomas compared to non-
serous tumours while in contrast another study reported that HKII expression was correlated 
with neither the tumour stage nor the histotype [218, 219]. Decreased HKII expression in 
clear cell carcinomas as observed here has not previously been described. Elevated LDHA 
and PKM2 expression (although not significantly in the second case) in clear cell tumours is 
consistent with recent findings indicating that these cancers are highly dependent on the 
glycolytic pathway. The transcription factor HNF1β, frequently overexpressed in this 
histotype, suppresses oxidative phosphorylation and promotes glycolytic metabolism. The 
glycolytic phenotype of clear cell carcinomas has been described as a protective mechanism 
against oxidative stress and has been linked with chemoresistance [514]. Confirmation of 




and is of great importance as it may have therapeutic significance in future treatment of these 
highly resistant tumours. The observed discrepancy with the upstream glycolytic targets, 
GLUT1 and HKII, might be an indication that additional GLUT or HK isoforms might be 
involved. Nevertheless, a weakness of this analysis was the relatively small sample size of 
clear cell cancers (18 patients were included for PKM2 and 11 for LDHA – Table 7.2).  
Further work is required to investigate the role of other GLUTs in ovarian carcinogenesis. 
Although a few studies have highlighted the importance of GLUT1 in ovarian cancer much 
less is known about the role of other GLUTs and contradictory findings have been generated. 
In their study Rudlowski et al reported weak GLUT3 expression in ovarian tumours while 
GLUT2 and GLUT4 were not detected [192]. In contrast Tsukioka et al demonstrated strong 
GLUT3 and GLUT4 expression when examining 154 ovarian tumour samples using IHC 
[193].           
The expression of the four glycolytic enzymes across the ovarian cancers was correlated. 
Positive rho correlation values indicated a positive relationship consistent with activation of 
a single pathway. The expression of the two downstream enzymes PKM2 and LDHA 
appeared more closely related to each other while in contrast HKII expression was the least 
related to the expression of the other three markers (Figure 7.14). 
A large dataset of the expression of several oncogenic markers in the same ovarian cancer 
patient cohort was available from preceding independent research projects [509]. The 
expression of the four glycolytic enzymes was compared with the expression of a series of 
oncogenic biomarkers including proliferation (Ki67, histone H3), apoptosis (caspase 3), cell 
cycle (RB), DNA damage response (H2AX, BRCA1, P53) and signalling markers (ER, 
ERK, STAT3, AKT, NFκB). In the heatmap correlating the expression of all these proteins, 
the most apparent observation was that the four glycolytic enzymes clustered together and 
were characterised by a relatively strong positive relationship as anticipated of enzymes 
belonging to the same pathway. Interestingly the upstream targets, GLUT1 and HKII, as well 
as the downstream ones, PKM2 and LDHA, appeared closely related to each other. From the 
dendrogram it can be observed that the four enzymes formed a separate branch quite distant 
from the other markers (Figure 7.15). Regarding the non-glycolytic markers a positive 
correlation between GLUT1 and ki-67 has been previously described and was further 
verified here. Semman et al correlated high GLUT1 expression with high ki-67 levels 
following IHC evaluation in 213 primary ovarian tumours correlating the glycolytic 




The most significant positive correlations revealed in the present study were among HKII 
and the DNA damage response related tumour suppressor gene BRCA1, the oestrogen 
receptor β splice variant 2 ERβ2, the regulator of the oncogenic Wnt signalling pathway 
WNT1 and the effector of the PI3K pathway AKT. A tight relationship between signalling 
cell survival and metabolic pathways has previously been described. AKT is known to 
stimulate glycolysis and has been shown to regulate HKII activity and mitochondrial 
association [515]. Interestingly it has been demonstrated that AKT directly phosphorylates 
HKII (in an Akt consensus sequence) enhancing the mitochondrial binding of the glycolytic 
target. The interaction between the two kinases has been associated with a protective anti-
apoptotic survival mechanism [515, 516]. The tumour suppressor gene BRCA1 is known to 
downregulate AKT oncogenic activity [517]. This interaction has been linked with the effect 
of BRCA1 on cancer cell metabolism. A recent study reported that BRCA1 suppresses 
glycolysis and promotes mitochondrial oxidative phosphorylation in breast cancer cells. 
Contradicting the strong positive correlation between BRCA1 and HKII observed in this 
study the authors presented that the expression of key glycolytic enzymes (including HKII) 
was significantly downregulated in wild type BRCA1 breast tumours [518].     
The most significant negative correlations detected were between PKM2 and LDHA and the 
apoptosis marker caspase 3, the transcriptional repressor Snail and the oestrogen receptor β 
splice variant 1 ERβ1 (Table 7.4). The observed negative association between the glycolytic 
enzymes PKM2 and LDHA and Snail contradicts the current state of knowledge. The 
epithelial–mesenchymal transition inducer and regulator of multiple signalling pathways has 
been shown to promote the glycolytic metabolism of tumours. In their key study Dong et al 
provided evidence that Snail directly represses fructose-1,6-bisphosphatase expression by 
promoter methylation in basal-like breast tumours (this enzyme catalyses the conversion of 
fructose-1,6-bisphosphate to fructose 6-phosphate in gluconeogenesis). Loss of fructose-1,6-
bisphosphatase induced glycolytic metabolism, activated tetrameric PKM2 and suppressed 
mitochondrial respiration and ROS production. The Snail-mediated glycolytic 
reprogramming was suggested to enhance tumourigenesis and invasiveness in these tumours  
[519]. Along similar lines Tao et al documented that downregulation of Snail suppressed 
prostate cancer cell growth and glucose metabolism and lowered PKM2 as well as HIF-1α 
(major regulator of the expression of glycolytic enzymes in hypoxia) expression [520]. 
Negative association between PKM2 and caspase 3 expression is in line with recent findings 
by Stetak et al. In their study the authors documented that in response to apoptotic agents 
PKM2 translocates to the nucleus and induces caspase independent cell death [521]. On the 




Crohn's disease argued that upregulated PKM2 correlated with increased caspase 3 
expression. The authors showed that high levels of PKM2 and active caspase 3 co-localised 
in intestinal epithelial cells [522]. Oestrogen and ERs are major cellular regulators and have 
been reported to regulate glucose homeostasis, enhance glucose uptake and promote 
glycolysis [523-525]. It has been demonstrated that estradiol stimulates glucose consumption 
and lactate production in MCF7 breast cancer cells while glycolysis was suppressed by 
tamoxifen [526]. Investigation of the estradiol effect on rat brain and mouse neuroblastoma 
cells revealed that hormonal treatment induced the activity of the glycolytic enzymes HK, 
PFK and PK [527]. Furthermore enolase β and PKM2 have been characterised as oestrogen 
regulated enzymes in a bone proteome study while glucose metabolism was found to be 
suppressed by oophorectomy [528]. Previous research is in agreement with the currently 
detected robust correlation between HKII and ERβ2 expression in the examined cohort of 
ovarian tumours but does not support the finding of a significantly negative association 
between ERβ1 and the glycolytic targets PKM2 and LDHA.  
An interesting observation is that the upstream glycolytic targets demonstrated only positive 
significant associations while in contrast the downstream targets negative. This research has 
gone some way towards enhancing our knowledge of the interaction between the glycolytic 
metabolism and oncogenic signalling pathways in ovarian cancer. Several significant 
associations between the expression of glycolytic enzymes and key oncogenic molecular 
markers were revealed. However, further investigation is required for the interpretation and 
evaluation of their potential significance.     
Finally the relationship between the expression of the enzymes and the clinical outcome of 
ovarian cancer patients was investigated. Levels of expression of the glycolytic enzymes did 
not associate with the survival outcome. GLUT1 has been proposed as a marker of adverse 
prognosis in ovarian cancer [195]. However this study has been unable to demonstrate an 
association between increased GLUT1 expression and poor survival outcome as has 
previously been reported. Cantuaria et al associated GLUT1 overexpression with poor 
disease free survival rate in 89 advanced stage ovarian carcinomas [190]. Semaan et al 
demonstrated that high GLUT1 expression had a negative impact on the overall survival of 
213 ovarian cancer patients [194]. Cho et al consistently reported a reverse statistically 
significant relationship among overall survival of 50 patients and high GLUT1 expression 
[195]. On the other hand Rudlowski et al failed to identify any evidence of an association 
between GLUT1 expression and disease clinical outcome [192]. Much less information is 




IHC in 111 ovarian tumours and documented that high HKII was correlated with 
chemoresistance and disease recurrence as well as decreased progression free survival [218]. 
In agreement with our data Hjerpe et al were unable to demonstrate an association between 
PKM2 expression and disease free or overall survival of 54 ovarian cancer patients [529]. 
LDHA overexpression has been reported in several tumour types and has been frequently 
associated with poor survival [259, 262]. Nevertheless LDHA expression in ovarian tumours 
had never been reported before.     
To explore the associations with the clinical outcome further the histopathological subtypes 
were examined separately. Indeed low PKM2 and LDHA expression appeared significantly 
correlated with improved survival of endometrioid ovarian cancer patients. Low PKM2 and 
LDHA expression was proportional to decreased relative risk of death in patients with this 
tumour histotype. A similar association was also observed for GLUT1 expression but it did 
not reach significance.  
Endometrioid and clear cell tumours have similar pathology associated with the endometrial 
epithelium as they both arise from endometrioid cysts [51, 61]. It has been suggested that the 
carcinogenic process associated with this microenvironment selects for a highly glycolytic 
phenotype as a survival mechanism against ROS production which contributes to an 
aggressive resistant behaviour. This hypothesis has recently been proposed for clear cell 
carcinomas based on the upregulation of HNF1β [514]. However due to the shared site of 
origin it is possible that endometrioid tumours favour the same metabolic pathway (i.e. 
glycolysis). In this case, the observed correlation of enhanced GLUT1, PKM2 and LDHA 
expression with poor clinical outcome would be in line with the association of glycolytic 
metabolism with cell survival and chemoresistance as suggested for clear cell tumours. 
Further support that endometrioid tumours favour a glycolytic phenotype was obtained in 
Chapter 3, where TOV112D endometrioid ovarian cancer cells demonstrated enhanced 
sensitivity to an array of glycolytic inhibitors. They were identified as the most sensitive 
cells to 7 out of 9 compounds compared to 3 other non-endometrioid ovarian cancer cell 
lines (Chapter 3.3).               
The discrepancy with previous studies may be related to the nature of the disease. As 
discussed in the introduction ovarian cancer is a highly heterogeneous disease and the 
diversity of findings might be attributed to the great disease heterogeneity and population 
variability [78]. Other possible explanations could be related to the specificity of the used 




various studies. That being said, this present study is the first to report expression using an 
automated quantitative technique for the detection of glycolytic enzymes in ovarian tumours.    
To the best of my knowledge this is the first study evaluating the expression of a series of 
glycolytic enzymes in a large cohort of ovarian tumours. Taken together, the results of this 
research show that the glycolytic pathway plays a significant role in epithelial ovarian 
tumours. This is corroborated by previous research indicating enhanced tracer FDG uptake 
by ovarian cancers [530, 531], and by a study from Anderson et al that used a murine model 
of progressive ovarian cancer to demonstrate that along with progression of ovarian cancer, 
the glycolytic phenotype increasingly prevails and oxidative phosphorylation is repressed 
[532].   
Most importantly, evidence is provided for the first time of an association among glycolytic 
metabolism and endometrium related tumours. Inhibition of the glycolytic pathway, 
specifically LDHA, is proposed as a promising strategy for the treatment of resistant clear 
cell cancers and furthermore PKM2 and LDHA are identified as prognostic markers of 
adverse survival in endometrioid cancers. These findings could possibly have therapeutic 
implication however further research in experimental and clinical settings is essential to 

































Chapter 8: Concluding Discussion 
 
Despite important advances in diagnosis and treatment, breast and ovarian cancers still 
present major health care concerns. Significant challenges remain to be faced (including 
adverse effects of widely used treatment modalities, clinical resistance and poor survival 
rates of certain tumour types) and there is an urgent need for more efficient targeted 
treatments. This project examined the hypothesis that the differential metabolism of glucose 
by cancer cells, in comparison to normal cells, could offer a possible therapeutic target for 
new drugs in these cancer types. Therefore this study aimed to investigate the role of aerobic 
glycolysis in breast and ovarian cancer cells and identify a therapeutically exploitable 
glycolytic target or a translatable combinatorial strategy for the development of novel cancer 
drug therapies. 
The data obtained provided further evidence that the glycolytic pathway is a potential target 
for breast and ovarian cancer treatment. Initially, strong reliance on glucose availability for 
cancer cell proliferation was established and further work confirmed that breast and ovarian 
cancer cell proliferative growth is dependent on the glycolytic pathway. Ten compounds 
targeting key enzymes of the glycolytic pathway were selected for investigation in this study 
and were compared against a panel of breast and ovarian cancer cell line models. Each of 
these inhibitors blocked the glycolytic pathway and attenuated breast and ovarian cancer cell 
proliferation in a concentration-dependent manner. The antiproliferative effects of the 
compounds were demonstrated to be associated with induction of apoptosis along with 
G0/G1 cell cycle arrest in selected cancer cell lines. 
Hypoxia is a well substantiated common characteristic of the tumour microenvironment. 
Therefore the effects of the selected glycolytic inhibitors were assessed under a range of 
oxygen conditions. Interestingly, and in contrast to the notion of enhanced dependency on 
glycolysis in hypoxia, cancer cells presented increased sensitivity to glycolytic inhibitors at 
21% O2 conditions relative to lower O2 conditions. Nevertheless, breast cancer cells were 
found to be susceptible to glycolysis inhibition over a wide range of oxygen levels, including 
the physiologically relevant low oxygen conditions found in solid tumours. Moreover, 
dependency on the glycolytic pathway even in the presence of oxygen sufficiency, 
corroborates Warburg’s theory [87]. The relative lack of sensitivity to the glycolytic 
inhibitors in hypoxia was associated with slow proliferation rates as well as overexpression 
of the targeted glycolytic enzymes as demonstrated at both protein and mRNA levels. The 




by Western blotting. Furthermore genome-wide transcriptomic analysis identified glycolysis 
as a major pathway mediating the response of breast cancer cells to oxygen deprivation.  
Based on these findings, the glycolytic pathway is proposed as a potential target for breast 
and ovarian cancer treatment. All compounds tested, inhibiting major enzymes of the 
glycolytic pathway, proved effective at inhibiting cancer cell proliferation, even under 
varying levels of hypoxia. However, all these compounds do not have the same potential for 
further development as antitumour agents. Established inhibitors including Phloretin, 
Quercetin, 3BP, DCA and Oxamic acid served as reference compounds and enabled 
comparative inhibition of the whole pathway. However it is well substantiated that they 
affect more than one target and they required high concentrations to exert antitumour 
activity. These concentrations would likely be associated with high systemic toxicity. Even 
among “next generation” inhibitors that demonstrated promising anticancer activity at low 
concentrations specificity issues do exist, for example STF31 targeting NAMPT [315-317]. 
The most promising glycolytic targets identified in this study were GLUT1 and LDHA at the 
very top and bottom of the glycolytic pathway, as well as the intermediate regulator 
PFKFB3. LDHA seems an ideal candidate as its inhibition is anticipated to cause minimal 
adverse effects in normal tissue [257, 258]. In this study, evaluation of this target by siRNA 
knockdown demonstrated that suppressing LDHA expression was sufficient to significantly 
impair breast cancer cell proliferation. However NHI-1 had low potency, even though it has 
been characterised as a specific LDHA inhibitor and proved a valuable tool compound in this 
research. Further research using NHI-1 as a lead molecule to synthesise a derivative 
exhibiting enhanced potency and efficacy would be useful. PFKFB3 is a critical enzyme that 
plays a key role in the glycolytic phenotype of tumours promoting the high glycolytic rate by 
regulating F2,6BP the allosteric activator of PFK1 [221, 222]. 3PO was identified here as a 
potent inhibitor of breast and ovarian cancer cell proliferation and is believed to have 
potential as an antitumour agent. Similar antiproliferative action against several 
adenocarcinoma and haematological cell lines was also documented in the identification 
study of the compound conducted by Clem and colleagues. Additional evidence supporting 
the potential of PFKFB3 inhibition as an antitumour strategy was provided in the referred 
study as 3PO treatment suppressed the tumourigenic growth of established leukaemia, lung 
and breast adenocarcinomas in vivo [343]. PFK15, a recently developed 3PO derivative, 
demonstrated 100 fold enhanced potency against the enzymatic activity of recombinant 
PFKFB3 compared to the parent compound. The authors reported that PFK15 attenuated 




However the effect of the optimised derivative compound on breast and ovarian cancer 
remains to be investigated. 
Glucose transport is the first key rate-limiting step controlling the metabolism of glucose 
[176]. The novel GLUT1 inhibitor IOM-1190 demonstrated antitumour activity in a low 
concentration range and was characterised as a very potent cancer cell growth inhibitor in 
this study. Importantly, resistant cancer cells, including the triple negative breast cancer cell 
line MDA-MB-231 and the platinum resistant PEO4 ovarian cancer cell line were sensitive 
to IOM-1190 treatment. Furthermore, the compound was highly effective against hypoxic 
cancer cells, in contrast to the other anti-glycolytic molecules tested. Both IOM-1190 and 
3PO exhibited very promising antiproliferative action supporting their potential for 
continued in vivo evaluation and appear to hold promise for development as antitumour 
agents.  
Targeting the glycolytic pathway for cancer treatment requires some caution as the 
glycolytic enzymes are not tumour specific and are ubiquitously expressed. However normal 
cells are expected to exhibit metabolic plasticity and be able to better tolerate inhibition of 
the glycolytic pathway. Ample oxygen availability combined with intact mitochondrial 
function enables energy generation through mitochondrial respiration using alternative 
energy substrates such as fatty acids and amino acids [94, 100]. Preclinical evidence that 
antiglycolytic agents are well tolerated derives from studies documenting that several of 
these compounds, including WZB117 and 3PO, were associated with minimal adverse 
effects in xenograft models [319, 343, 349]. Preferential reliance on glycolysis has been 
acknowledged as a hallmark of tumourigenesis and has been described as a ‘vulnerable 
Achilles’ heel’ providing an opportunity to target cancer cells [90, 92]. Metabolic 
reconfiguration and lost cellular homeostasis renders cancer cells highly susceptible to 
inhibition of the glycolytic pathway which is anticipated to deplete their energy supply, 
severely disrupting their proliferation rate and eventually lead to apoptosis [100, 103]. 
Nonetheless a logical concern raised regards tissues intrinsically engaging a glycolytic 
metabolism. A few tissues, most importantly the brain, but also the testes and retina, are 
known to use glucose as their primary energy source [533-535]. Further research is required 
to establish the safety profile for glycolytic inhibitors. One way to avoid neurological 
toxicity would be to use molecules unable to cross the blood-brain barrier [100]. However 
this would compromise effectiveness against brain metastases. An additional limitation is 
that the majority of tool molecules currently available for inhibiting the glycolytic enzymes 




concentrations [100]. Targeting the metabolic phenotype of tumours even though it presents 
an exciting and promising anticancer strategy is still in its infancy and further progress is 
required to translate it to the clinic. Future research should concentrate on the identification 
of molecules exhibiting enhanced specificity and potency. 
Despite glycolysis inhibition being a promising antitumour strategy its value as monotherapy 
has been questioned [105]. Therefore the glycolytic inhibitors were assessed in combination 
strategies with established chemotherapeutic and targeted agents. Multiple co-treatments 
were investigated and indeed several synergistic combinations characterised by low 
combination index values were revealed. Two distinct goals were achieved in this study. 
Firstly, to improve the efficacy of currently used chemotherapeutics using a glycolytic 
inhibitor and resensitise resistant cancer cells to treatment, and secondly, to identify a novel 
combination of inhibitors with potential to be developed as a future anticancer strategy. The 
PFKFB3 inhibitor, 3PO, enhanced the cytotoxic effect of cisplatin against both platinum 
sensitive and platinum resistant ovarian cancer cells. This combination suggested a 
promising approach to overcome platinum resistance and future work should evaluate it in a 
relevant in vivo model. Moreover, combination of IOM-1190 with the antidiabetic agent 
metformin demonstrated a robust synergistic antiproliferative effect on breast cancer cells. 
MDA-MB-231 triple negative highly aggressive breast cancer cells exhibited enhanced 
sensitivity to this combination. This combination is anticipated to hold possible promise for 
the treatment of triple negative breast cancer disease and future research should focus on 
determining its efficacy in vivo. Both combinatorial strategies presented preclinical efficacy 
in subgroups of tumours. Such novel approaches are important and may have potential for 
continued development. Nevertheless, these results are exploratory pilot data and future 
work should focus on evaluating these combinations to assess their therapeutic index in in 
vivo and clinical models. 
This research focused on two malignancies, breast and ovarian cancer. Interestingly, breast 
and ovarian cancer cell line models exhibited comparable sensitivity to glycolysis inhibition. 
Metabolism of breast tumours has been extensively studied in the past. It has been shown 
that triple negative tumours depend on a highly glycolytic Warburg metabolism while in 
contrast ER positive breast cancers primarily demonstrate a reverse Warburg phenotype 
[506]. This is a symbiotic metabolic model in which cancer cells induce a glycolytic 
metabolism in the neighbouring fibroblastic stroma and they rely on the secreted lactate and 
pyruvate to fuel their mitochondrial TCA cycle [536]. The glycolytic phenotype of triple 




proliferation [506]. A number of studies have documented significantly enhanced tracer 
FDG uptake compared to other breast cancer subtypes [424, 537, 538]. Thus triple negative 
breast tumours seem an ideal candidate cancer type for future research on glycolysis 
inhibition. This could possibly have important therapeutic implications as these tumours lack 
specific treatment options [428].  
In contrast, relatively few studies have considered the metabolism of ovarian tumours. This 
study sought to investigate the glycolytic phenotype of ovarian cancer. The expression of 
several glycolytic markers was examined across a large cohort of ovarian tumours by 
AQUA. The role of the glycolytic profile in ovarian cancer was explored. Results suggested 
that inhibition of the glycolytic pathway, specifically LDHA, could be a promising strategy 
for the treatment of clear cell cancers. PKM2 and LDHA were identified as prognostic 
markers of adverse survival in patients with endometrioid carcinomas. The findings of the 
present study, for the first time, suggest a significant role for glycolytic metabolism in 
endometrium related tumours. Further experimental investigations however are needed to 
verify this association. Future studies should focus on therapeutically exploiting the 
glycolytic phenotype of clear cell ovarian tumours. This is of paramount importance as these 
tumours exhibit chemoresistance and are associated with adverse clinical outcome [52, 54]. 
A natural progression of this work would be to validate these preliminary preclinical data, by 
assessing the efficacy of the most promising glycolytic inhibitors and identifying the 
combinatorial strategies that inhibit growth and invasion of 3-D spheroid culture models, 
which mimic more closely the tumour microenvironment. Future in vivo studies should focus 
on the subtypes of breast and ovarian cancers identified as more susceptible to inhibition of 
the glycolytic pathway. The effect of IOM-1190 as monotherapy and in combination with 
metformin should be evaluated in xenograft models of triple negative breast tumours. 
Additionally further research should determine the efficacy of the optimised derivative of 
3PO, PFK15 (characterised by enhanced potency and improved pharmacokinetic properties) 
as a single agent or combined with cisplatin against xenograft models of platinum resistant 
clear cell ovarian tumours. 
In recent years, there has been renewed interest in the dysregulated metabolic pathways 
characterising malignant transformation and tumour metabolism has emerged as a promising 
strategy for selective tumour targeting [272, 539-541]. In addition to the glycolytic 
phenotype of tumours, the well-known Warburg effect, alterations in several metabolic 
pathways supporting the high proliferative demands of tumours have been characterised 




essential for ribonucleotide synthesis and NADPH generation, as well as the serine and 
glycine metabolic pathway which plays an important role in nucleotide, amino acid and 
lipids synthesis and redox homeostasis [540, 543-545]. A number of inhibitors targeting the 
altered metabolic pathways in tumours are currently under development or undergoing 
clinical trials [105, 272]. In their key study Folger et al developed a genome-wide cancer 
metabolic model and identified a wide range of metabolic enzymes essential for the 
proliferation of cancer cell lines. 52 of these targets, the majority of them novel, were 
predicted to have cytostatic antitumour action. Synergistic combinations of synthetic lethal 
metabolic targets were proposed as a tumour-selective approach. The pentose phosphate 
pathway along with pyruvate metabolism was identified as an attractive target in synthetic 
lethal strategies [546].  
Overall it should be highlighted that the glycolytic phenotype of tumours studied in the 
present study is only one aspect of the aberrant metabolism of tumours that potentially can 
offer an opportunity of selective tumour targeting. Furthermore targeting tumour metabolism 
for cancer treatment is far from a novel therapeutic strategy. Antimetabolites including 
nucleoside analogues (e.g. 5‑fluorouracil and gemcitabine) and antifolate agents 
(pemetrexed) as well as L-asparaginase (for the treatment of acute lymphoblastic leukaemia) 
all have unique metabolic targets and are widely and effectively used in the clinic [272]. 
However the principal challenge to exploit the altered expression of tumour specific enzyme 
isoforms and the dependency of tumours on particular metabolic pathways to achieve 
selectivity remains to be translated into clinical practice [272, 540]. In recent years 
pharmaceutical industry has shown an increased interest demonstrating enhanced 
commercial activity and investment around cancer metabolism supporting the therapeutic 
potential in this field. The pipeline of several pharmaceutical companies is focused on the 
discovery and development of novel small molecules disrupting cancer cell metabolism. 
Examples include the GLUT1 inhibitor IOM-1190 (IOmet Pharma), the IDH1 and IDH2 
mutant inhibitors AG-120, AG-221 and AG-881 (Agios in collaboration with Celgene), the 
glutaminase inhibitor CB-839 (Calithera BioSciences) as well as the arginase inhibitor CB-
1158 (Calithera BioSciences) [141, 324, 547, 548].          
The present study contributes further to our understanding of the role of glycolytic 
metabolism in breast and ovarian cancer. The metabolic reconfiguration of tumours is 
indicated as a promising anticancer target. Inhibition of the glycolytic pathway is suggested 
as a potential strategy for future assessment especially against triple negative breast and clear 






















Appendix 1: Supplementary figures of Chapter 5 
The following tables correspond to the drug interaction studies presented in Chapter 5. The 
specific concentrations of each pair of compounds that were used in the combination 
experiments are indicated along with the growth inhibition effect (fraction affected) of each 
combination point and the respective CI values as they were generated through the Calcusyn 











0.9 1 0.094 1.339 
1.9 1 0.509 0.22 
3.8 1 0.505 0.351 
7.5 1 0.546 0.566 
15 1 0.782 0.716 






0.9 4 0.158 - 
1.9 4 0.476 0.457 
3.8 4 0.463 0.553 
7.5 4 0.502 0.716 
15 4 0.687 0.923 






0.9 0.5 0.096 1.662 
1.9 0.5 0.176 1.098 
3.8 0.5 0.430 0.568 
7.5 0.5 0.507 0.757 
15 0.5 0.839 0.434 






0.9 1 - - 
1.9 1 0.197 0.626 
3.8 1 0.244 0.602 
7.5 1 0.275 0.763 
15 1 0.353 1.054 






0.9 0.001 0.125 - 
1.9 0.001 0.526 0.125 
3.8 0.001 0.517 0.253 
7.5 0.001 0.490 0.524 
15 0.001 0.699 0.794 






0.9 0.002 0.515 0.262 
1.9 0.002 0.496 0.327 
3.8 0.002 0.499 0.415 
7.5 0.002 0.532 0.535 
15 0.002 0.613 0.657 






0.9 0.002 0.534 0.542 
1.9 0.002 0.542 0.602 
3.8 0.002 0.581 0.669 
7.5 0.002 0.670 0.712 
15 0.002 0.885 0.444 






0.9 0.002 0.370 1.077 
1.9 0.002 0.399 1.044 
3.8 0.002 0.356 1.617 
7.5 0.002 0.428 1.458 























4,700 0.001 0.280 0.607 
9,400 0.001 0.512 0.457 
18,800 0.001 0.557 0.656 
37,500 0.001 0.653 0.814 
75,000 0.001 0.756 0.943 
MDA-MB-231 (Figure 5.18) Table  A1.10 





4,600 0.001 0.369 0.363 
9,400 0.001 0.430 0.436 
18,800 0.001 0.334 1.02 
37,500 0.001 0.523 0.94 
75,000 0.001 0.680 1.002 





Fa CI Metformin  
(μΜ) 
Fa CI 
0.1 1000 0.310 0.421 2000 0.660 0.147 
0.2 1000 0.306 0.46 2000 0.744 0.094 
0.5 1000 0.308 0.512 2000 0.852 0.044 
0.9 1000 0.589 0.152 2000 0.866 0.042 
1.9 1000 0.607 0.184 2000 0.865 0.05 
3.8 1000 0.668 0.196 2000 0.857 0.069 
7.5 1000 0.728 0.224 2000 0.879 0.078 
15 1000 0.811 0.218 2000 0.890 0.109 





Fa CI Metformin  
(μΜ) 
Fa CI 
0.1 1000 0.513 0.167 4000 0.754 0.121 
0.2 1000 0.495 0.246 4000 0.861 0.051 
0.5 1000 0.687 0.108 4000 0.888 0.04 
0.9 1000 0.739 0.116 4000 0.895 0.043 
1.9 1000 0.788 0.13 4000 0.898 0.054 
3.8 1000 0.845 0.128 4000 0.918 0.056 
7.5 1000 0.859 0.202 4000 0.926 0.077 
30 1000 0.904 0.377 4000 0.927 0.243 






0.2 2000 0.426 0.485 
0.4 2000 0.374 0.721 
0.9 2000 0.633 0.39 
1.8 2000 0.707 0.568 
3.5 2000 0.773 0.951 






0.9 3000 0.343 0.36 
1.9 3000 0.634 0.182 
3.8 3000 0.707 0.251 
7.5 3000 0.681 0.522 
15 3000 0.722 0.882 






0.9 1000 0.775 0.101 
1.9 1000 0.817 0.138 
3.8 1000 0.829 0.236 
7.5 1000 0.835 0.431 
15 1000 0.818 0.957 






0.9 1000 0.510 0.11 
1.9 1000 0.697 0.147 
3.8 1000 0.727 0.276 
7.5 1000 0.727 0.549 













Tables A1.1 to A1.25: Concentration range of a glycolytic inhibitor that was combined with a constant 
concentration of a chemotherapy or targeted inhibitor for the treatment of the referred breast or ovarian cancer 
cell line. The growth inhibition effect of each combination point (fraction affected) along with the respective 
combination index value generated through Calcusyn are presented. In brackets the figure of Chapter 5 that each 
combination is depicted is indicated.   






18.8 3000 0.396 0.351 
37.5 3000 0.394 0.448 
75 3000 0.298 0.701 
150 3000 0.567 0.884 
300 3000 0.914 1.002 
MCF7 (Figure 5.46)       Table  A1.18 





4.7 2 0.236 1.903 
9.4 2 0.428 0.825 
18.8 2 0.683 0.388 
37.5 2 0.777 0.414 
75 2 0.846 0.493 






4.7 4 0.390 0.467 
9.4 4 0.357 0.73 
18.8 4 0.569 0.483 
37.5 4 0.783 0.336 
75 4 0.865 0.382 
PEA1 (Figure 5.50)       Table  A1.20 





3.1 1 0.821 0.052 
6.3 1 0.882 0.055 
12.5 1 0.895 0.085 
25 1 0.862 0.211 
50 1 0.895 0.303 
PEA2 (Figure 5.51)       Table  A1.21 





3.1 1 0.203 0.352 
6.3 1 0.364 0.273 
12.5 1 0.519 0.272 
25 1 0.658 0.305 
50 1 0.847 0.235 
PEO1 (Figure 5.54)       Table  A1.22 





3.1 2 0.713 0.154 
6.3 2 0.742 0.205 
12.5 2 0.819 0.24 
25 2 0.770 0.539 
50 2 0.845 0.702 






3.1 0.5 0.573 0.123 
6.3 0.5 0.747 0.11 
12.5 0.5 0.737 0.217 
25 0.5 0.751 0.392 
50 0.5 0.788 0.627 






3.1 1 0.291 0.938 
6.3 1 0.555 0.448 
12.5 1 0.630 0.603 
25 1 0.685 0.903 
50 1 0.890 0.4 






3.1 3 0.426 0.203 
6.3 3 0.419 0.292 
12.5 3 0.460 0.405 
25 3 0.471 0.689 




The following figures correspond to the metformin drug interaction studies presented in 
Chapter 5 section 5.3. Concentration response curves of metformin single treatments for a 
panel of three paired breast and ovarian cancer cell lines are presented here as reference.  
 
Figures A1.1 to A1.3: Concentration response curves of three paired breast and ovarian cancer cell lines (MCF7 
and MDA-MB-231, PEA1 and PEA2, PEO1 and PEO4) treated with metformin concentrations between 0.8-
50mΜ for a three day period. Cell viability was determined by an SRB assay. Averaged results of 6 replicates are 
reported and error bars represent standard deviations. Values are shown as a percentage of control. 
Below some examples of unfavourable non-synergistic combinations that were encountered 
in this study are presented. The combinations of Phloretin, Oxamic acid and NHI-1 with 
cisplatin as well as 3PO with metformin gave rise to high CI values (>1) indicating an 
antagonistic relationship.   
  
Figures A1.4 & A1.5: Concentration response curves of PEO1 ovarian cancer cells treated with Phloretin 
concentrations between 9.4-600μΜ alone (blue line) or combined with 0.5μM Cisplatin (red line) on the left 
(A1.4) as well as concentration response curves of PEA1 ovarian cancer cells treated with 3PO concentrations 
between 0.5-30μΜ alone (blue line) or combined with 0.5mM Metformin (red line) on the right (A1.5). Cell 
viability was determined by an SRB assay after a 3 day treatment. Averaged results of 6 replicates are reported 
and error bars represent standard deviations. Values are shown as a percentage of control. In green the effect of 



















































































Phloretin Concentration, μM 
PEO1 - Phloretin & 0.5μM 
Cisplatin 
Phloretin
Phloretin & 0.5μM Cisplatin 




















3PO Concentration, μM 
PEA1 - 3PO & 0.5mM 
Metformin 
3PO
3PO & 0.5mM Metformin
0.5mM Metformin
Figure A1.5 





Figures A1.6 & A1.7: Concentration response curves of PEO1 ovarian cancer cells treated with Oxamic acid 
concentrations between 1.6-100mΜ alone (blue line) or combined with 0.5μM Cisplatin (red line) on the left 
(A1.6) as well as treated with NHI-1 concentrations between 4.7-300μΜ alone (blue line) or combined with 
0.5μM Cisplatin (red line) on the right (A1.7). Cell viability was determined by an SRB assay after a 3 day 
treatment. Averaged results of 6 replicates are reported and error bars represent standard deviations. Values are 
shown as a percentage of control. In green the effect of 0.5μM Cisplatin on cell viability is indicated.  
 
The following figures correspond to the flow cytometric analysis of induction of apoptosis of 
the drug interaction studies presented in Chapter 5 section 5.4. They are the controls of 
untreated MDA-MB-231 cells at 24 and 48h respectively related to the examination of 
apoptosis of STF31 and metformin co-treated cells in Figures 5.62 and 5.63. 
 
Figures A1.8 & A1.9: Flow cytometric analysis of untreated MDA-MB-231 breast cancer cells at 24 and 48h. 
FL1 (annexin V) versus FL2 (PI) scatter plots of gated cells double stained with FITC-conjugated annexin V and 
propidium iodide are presented. The percentage of cells in each quadrant is indicated in red. 
 
Figure A1.10 corresponds to the flow cytometric cell cycle analysis of the drug interaction 
studies presented in Chapter 5 section 5.5. It is the control of untreated MDA-MB-231 cells 
related to the examination of cell cycle progression of cells treated with three glycolytic 




















Oxamic acid Concentration, mM 
PEO1 - Oxamic acid & 0.5μM 
Cisplatin 
Oxamic acid
Oxamic acid & 0.5μM 
Cisplatin 




















NHI-1 Concentration, μM 
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Figure A1.10: Flow cytometric analysis of cellular DNA content of untreated MDA-MB-231 breast cancer cells 
at 24h. In the histogram fluorescence of the DNA bound propidium iodide, indicating the DNA content in X- 
axis, is plotted against the number of cells in the Y-axis. The percentage of cells in each cell cycle phase is 









Appendix 2: Supplementary tables of Chapter 6 
 
ENSM Gene ID Gene Symbol DAVID Gene Name 
ENSG00000003436 TFPI tissue factor pathway inhibitor 
ENSG00000006747 SCIN scinderin  
ENSG00000087586 AURKA aurora kinase A 
ENSG00000088325 TPX2 TPX2, microtubule nucleation factor 
ENSG00000089009 RPL6 ribosomal protein L6 
ENSG00000090889 KIF4A kinesin family member 4A 
ENSG00000101447 FAM83D family with sequence similarity 83 member D  
ENSG00000112984 KIF20A kinesin  family member 20A 
ENSG00000124802 EEF1E1 eukaryotic translation elongation factor 1 epsilon 1 
ENSG00000126787 DLGAP5 DLG associated protein 5 
ENSG00000131747 TOP2A topoisomerase (DNA) II alpha  
ENSG00000138778 CENPE centromere protein E 
ENSG00000145220 LYAR Ly1 antibody reactive 
ENSG00000145386 CCNA2 cyclin 2 
ENSG00000147224 PRPS1 phosphoribosyl pyrophosphate synthetase 1 
ENSG00000148459 PDSS1 prenyl (decaprenyl) diphosphate synthase, subunit 1 
ENSG00000154719 MRPL39 mitochondrial ribosomal protein L39 
ENSG00000156802 ATAD2 ATPase family, AAA domain containing 2 
ENSG00000163170 BOLA3 bolA family member 3 
ENSG00000163319 MRPS18C mitochondrial ribosomal protein S18C 
ENSG00000165264 NDUFB6 NADH:ubiquinone oxidoreductase subunit B6 
ENSG00000165672 PRDX3 peroxiredoxin 3 
ENSG00000171863 RPS7 ribosomal protein S7 
ENSG00000172172 MRPL13 mitochondrial ribosomal protein L13 
ENSG00000183527 PSMG1 proteasome assembly chaperone 1 
ENSG00000214810 CYCSP55 cytochrome c, somatic pseudogene 55 
ENSG00000233966 UBE2SP1 ubiquitin conjugating enzyme E2 S pseudogene 1 
ENSG00000235001 EIF4A1P2 
eukaryotic translation initiation factor 4A1 
pseudogene 2 
ENSG00000238249 HMGN2P17 
high mobility group nucleosomal binding domain 2 
pseudogene 17 
ENSG00000242616 GNG10 G protein subunit gamma 10 
 
 
Table A2.1: Genes mutually downregulated in three breast cancer cell lines (MCF7, MDA-MB-231, HBL100) 






ENSM Gene ID Gene Symbol DAVID Gene Name 
ENSG00000059804 SLC2A3 solute carrier family 2 member 3 
ENSG00000100906 NFKBIA NFKB inhibitor alpha 
ENSG00000104419 NDRG1 N-myc downstream regulated 1 
ENSG00000105220 GPI glucose-6-phosphate isomerase 
ENSG00000107159 CA9 carbonic anhydrase 9 
ENSG00000109107 ALDOC aldolase, fructose-bisphosphate C 




ENSG00000115548 KDM3A lysine demethylase 3A 
ENSG00000122884 P4HA1 prolyl 4-hydroxylase subunit alpha 1 
ENSG00000124145 SDC4 syndecan 4 
ENSG00000134107 BHLHE40 basic helix-loop-helix family member e40 
ENSG00000138166 DUSP5 dual specificity phosphatase 5 
ENSG00000143847 PPFIA4 PTPRF interacting protein alpha 4 
ENSG00000145901 TNIP1 TNFAIP3 interacting protein 1 
ENSG00000164463 CREBRF CREB3 regulatory factor 
ENSG00000167702 KIFC2 kinesin family member C2 
ENSG00000168209 DDIT4 DNA damage inducible transcript 4 
ENSG00000176171 BNIP3 BCL2 interacting protein 3 
ENSG00000186352 ANKRD37 ankyrin repeat domain 37 
 
 
Table A2.2: Genes mutually upregulated in three breast cancer cell lines (MCF7, MDA-MB-231, HBL100) 













ENSM Gene ID Gene Symbol DAVID Gene Name 
ENSG00000149925 ALDOA aldolase A, fructose-bisphosphate 
ENSG00000136872 ALDOB aldolase B, fructose-bisphosphate 
ENSG00000109107 ALDOC aldolase C, fructose-bisphosphate 
ENSG00000172331 BPGM 2,3-bisphosphoglycerate mutase 
ENSG00000074800 ENO1 enolase 1 (alpha) 
ENSG00000111674 ENO2 enolase 2 (gamma, neuronal) 
ENSG00000108515 ENO3 enolase 3 (beta, muscle) 
ENSG00000143891 GALM galactose mutarotase (aldose 1-epimerase) 
ENSG00000106633 GCK glucokinase (hexokinase 4) 
ENSG00000105220 GPI glucose phosphate isomerase 
ENSG00000159399 HK2 hexokinase 2 pseudogene; hexokinase 2 
ENSG00000134333 LDHA lactate dehydrogenase A 
ENSG00000152256 PDK1 pyruvate dehydrogenase kinase, isozyme 1 
ENSG00000005882 PDK2 pyruvate dehydrogenase kinase, isozyme 2 
ENSG00000067992 PDK3 pyruvate dehydrogenase kinase, isozyme 3 
ENSG00000004799 PDK4 pyruvate dehydrogenase kinase, isozyme 4 
ENSG00000172840 PDP2 
pyruvate dehydrogenase phosphatase catalytic 
subunit 2 
ENSG00000090857 PDPR 





ENSG00000141959 PFKL phosphofructokinase, liver 
ENSG00000102144 PGK1 phosphoglycerate kinase 1 
ENSG00000170950 PGK2 phosphoglycerate kinase 2 
ENSG00000079739 PGM1 phosphoglucomutase 1 
ENSG00000169299 PGM2 phosphoglucomutase 2 
ENSG00000013375 PGM3 phosphoglucomutase 3 
ENSG00000143627 PKLR pyruvate kinase, liver and RBC 
ENSG00000117394 SLC2A1 
solute carrier family 2 (facilitated glucose 
transporter), member 1 
ENSG00000059804 SLC2A3 
solute carrier family 2 (facilitated glucose 
transporter), member 3 
ENSG00000111669 TPI1 TPI1 pseudogene; triosephosphate isomerase 1 
 
 
Table A2.3: Probes of interest in this study indicating genes involved in the glycolytic pathway and its 





Appendix 3: Supplementary table of Chapter 7 
 





1 III ADENO 29.20 1 
2 III ENDO 20.87 1 
3 IV Serous PAP 1.23 1 
4 IV ENDO 20.03 1 
5 III Serous PAP 20.10 1 
6 I ENDO 207.07 0 
7 I ENDO 87.27 1 
8 III Serous PAP 15.10 1 
9 IV Serous PAP 10.97 1 
10 III CLEAR CELL 5.47 1 
11 III Serous PAP 47.87 1 
12 III Serous PAP 10.07 1 
13 III Serous PAP 178.00 0 
14 III ENDO 20.70 1 
15 I Serous PAP 169.43 1 
16 I Serous PAP 149.30 1 
17 III Serous PAP 16.43 1 
18 III Serous PAP 29.23 1 
19 III ENDO 211.90 0 
20 III Serous PAP 44.37 1 
21 III Serous PAP 7.03 1 
22 IV Serous PAP 33.47 1 
23 III Serous PAP 21.70 1 
24 I Serous PAP 29.63 1 
25 III ENDO 35.83 1 
26 III Serous PAP 14.27 1 
27 II Serous PAP 6.60 1 
28 IV MIXED 7.57 1 
29 III Serous PAP 76.50 1 
30 III Serous PAP 19.07 1 
31 III ENDO 39.40 1 
32 III ENDO 69.13 1 
33 III ENDO 25.10 1 
34 III ENDO 31.93 1 
35 III Serous PAP 10.60 1 
36 I CLEAR CELL 158.40 0 
37 III ENDO 50.40 1 
38 III Serous PAP 21.47 1 




40 III Serous PAP 39.17 1 
41 II ENDO 30.57 1 
42 III Serous PAP 13.40 1 
43 III Serous PAP 23.30 1 
44 III ENDO 23.20 1 
45 III Serous PAP 12.93 1 
46 III ENDO 51.03 1 
47 III Serous PAP 37.33 1 
48 III Serous PAP 18.53 1 
49 III Serous PAP 15.40 1 
50 III Serous PAP 5.37 1 
51 III ADENO 12.03 1 
52 IV CLEAR CELL 34.30 1 
53 III MUCINOUS 48.67 1 
54 IV ENDO 2.30 1 
55 III Serous PAP 11.90 1 
56 IV Serous PAP 15.00 1 
57 III ENDO 8.27 1 
58 II MUCINOUS 145.13 0 
59 III Serous PAP 16.83 1 
60 IV ENDO 11.57 1 
61 IV ADENO 20.33 1 
62 III Serous PAP 149.37 0 
63 III Serous PAP 5.57 1 
64 III Serous PAP 105.50 1 
65 III Serous PAP 24.00 1 
66 II CLEAR CELL 158.07 0 
67 III Serous PAP 33.73 1 
68 III Serous PAP 11.90 1 
69 III Serous PAP 124.10 1 
70 III ENDO 152.47 0 
71 I MIXED 143.80 0 
72 IV Serous PAP 9.90 1 
73 III Serous PAP 45.30 1 
74 II ENDO 156.63 0 
75 III Serous PAP 41.50 1 
76 III Serous PAP 43.47 1 
77 III Serous PAP 45.00 1 
78 III Serous PAP 13.07 1 
79 IV Serous PAP 19.83 1 
80 II MUCINOUS 5.83 1 
81 III Serous PAP 11.57 1 
82 III Serous PAP 25.17 1 




84 III Serous PAP 8.83 1 
85 III Serous PAP 50.93 1 
86 IV Serous PAP 1.90 1 
87 III Serous PAP 70.47 1 
88 IV Serous PAP 18.67 1 
89 III Serous PAP 46.00 1 
90 III Serous PAP 15.00 1 
91 III ENDO 65.83 1 
92 III MUCINOUS 21.40 1 
93 I MUCINOUS 133.03 0 
94 I ENDO 137.73 0 
95 IV Serous PAP 49.73 1 
96 unknown ENDO 138.67 0 
97 III Serous PAP 20.00 1 
98 III Serous PAP 25.03 1 
99 IV ENDO 9.67 1 
100 III Serous PAP 6.47 1 
101 III MUCINOUS 138.57 0 
102 III ENDO 7.87 1 
103 I ENDO 23.03 1 
104 III ADENO 97.87 1 
105 III MIXED 19.63 1 
106 III CLEAR CELL 31.60 1 
107 III MIXED 144.20 0 
108 I ENDO 136.60 0 
109 IV Serous PAP 7.57 1 
110 I CLEAR CELL 132.37 0 
111 IV Serous PAP 53.67 1 
112 II MIXED 78.10 1 
113 III Serous PAP 10.43 1 
114 III Serous PAP 2.53 1 
115 III Serous PAP 65.53 1 
116 IV Serous PAP 79.27 1 
117 III Serous PAP 20.80 1 
118 II Serous PAP 133.00 0 
119 III ADENO 13.03 1 
120 I Serous PAP 14.83 1 
121 IV Serous PAP 7.67 1 
122 III Serous PAP 132.07 0 
123 III ENDO 37.07 1 
124 III Serous PAP 34.67 1 
125 III MIXED 10.40 1 
126 III Serous PAP 89.93 1 




128 III Serous PAP 80.83 1 
129 III ENDO 8.90 1 
130 III ENDO 6.47 1 
131 II ENDO 74.67 1 
132 III Serous PAP 12.13 1 
133 IV Serous PAP 18.03 1 
134 III ENDO 48.40 1 
135 III Serous PAP 10.40 1 
136 III ADENO 13.23 1 
137 III Serous PAP 78.97 1 
138 III Serous PAP 59.63 1 
139 IV Serous PAP 13.93 1 
140 I ADENO 44.70 1 
141 IV MIXED 30.47 1 
142 IV Serous PAP 13.20 1 
143 III Serous PAP 16.67 1 
144 IV Serous PAP 30.27 1 
145 I ENDO 105.13 1 
146 III ADENO 7.10 1 
147 IV Serous PAP 37.40 1 
148 II ENDO 55.37 1 
149 I MIXED 117.27 0 
150 II MIXED 10.13 1 
151 III Serous PAP 12.07 1 
152 III Serous PAP 53.63 1 
153 III Serous PAP 29.03 1 
154 III Serous PAP 48.37 1 
155 III MIXED 71.40 1 
156 III Serous PAP 41.00 1 
157 III ENDO 34.57 1 
158 I Serous PAP 121.80 0 
159 III ENDO 23.57 1 
160 III Serous PAP 12.17 1 
161 III Serous PAP 18.73 1 
162 III Serous PAP 12.43 1 
163 III ENDO 111.23 0 
164 III Serous PAP 13.67 1 
165 II Serous PAP 40.00 1 
166 IV Serous PAP 15.30 1 
167 IV Serous PAP 8.17 1 
168 III Serous PAP 11.83 1 
169 III ENDO 114.03 1 
170 III Serous PAP 108.50 0 




172 II ENDO 109.27 0 
173 IV ENDO 18.80 1 
174 IV Serous PAP 12.50 1 
175 III MIXED 46.23 1 
176 IV MIXED 12.27 1 
177 I Serous PAP 104.83 1 
178 III MIXED 34.77 1 
179 III Serous PAP 65.07 1 
180 II ENDO 64.03 1 
181 I MIXED 80.27 1 
182 III MIXED 28.53 1 
183 II Serous PAP 63.63 1 
184 III ENDO 114.57 0 
185 III Serous PAP 3.67 1 
186 IV ENDO 15.47 1 
187 III Serous PAP 94.87 1 
188 II CLEAR CELL 78.63 1 
189 III MUCINOUS 20.93 1 
190 III Serous PAP 16.20 1 
191 unknown CLEAR CELL 46.30 1 
192 I ADENO 44.73 1 
193 III Serous PAP 50.77 1 
194 II MIXED 10.33 1 
195 I MUCINOUS 30.43 1 
196 IV Serous PAP 104.90 0 
197 IV MIXED 9.40 1 
198 III Serous PAP 1.80 1 
199 III Serous PAP 50.07 1 
200 III Serous PAP 104.10 0 
201 III MIXED 8.83 1 
202 III Serous PAP 11.70 1 
203 I ENDO 104.77 0 
204 I ENDO 108.83 0 
205 III Serous PAP 110.00 0 
206 IV Serous PAP 29.33 1 
207 I ENDO 106.70 0 
208 II MIXED 112.00 0 
209 I Serous PAP 55.07 1 
210 III ENDO 9.40 1 
211 IV Serous PAP 5.07 1 
212 III MIXED 36.57 1 
213 II ENDO 114.77 0 
214 III ENDO 99.20 1 




216 III ADENO 2.27 1 
217 III ENDO 80.53 1 
218 II ENDO 96.20 0 
219 III Serous PAP 13.10 1 
220 unknown MIXED 14.83 1 
221 III Serous PAP 34.53 1 
222 I ENDO 100.40 0 
223 III Serous PAP 12.93 1 
224 III Serous PAP 5.27 1 
225 III Serous PAP 41.37 1 
226 III Serous PAP 56.93 1 
227 I CLEAR CELL 73.20 1 
228 I ENDO 101.03 0 
229 III Serous PAP 25.63 1 
230 IV Serous PAP 31.57 1 
231 II ENDO 7.30 1 
232 II Serous PAP 5.50 1 
233 IV Serous PAP 56.50 1 
234 III Serous PAP 97.37 0 
235 I ENDO 119.10 0 
236 IV Serous PAP 31.53 1 
237 IV Serous PAP 35.40 1 
238 III Serous PAP 18.63 1 
239 III Serous PAP 27.50 1 
240 unknown ENDO 96.10 0 
241 II MIXED 76.20 1 
242 unknown ENDO 98.60 0 
243 I MIXED 23.00 1 
244 II Serous PAP 47.10 1 
245 III MIXED 7.50 1 
246 III Serous PAP 10.73 1 
247 III Serous PAP 37.50 1 
248 III ENDO 39.37 1 
249 III MIXED 100.37 0 
250 III Serous PAP 93.07 1 
251 III ENDO 45.07 1 
252 II Serous PAP 97.37 0 
253 III Serous PAP 32.40 1 
254 II MUCINOUS 96.67 0 
255 II MIXED 24.17 1 
256 IV ENDO 30.03 1 
257 IV Serous PAP 49.80 1 
258 III Serous PAP 44.63 1 




260 III Serous PAP 47.27 1 
261 III Serous PAP 44.23 1 
262 III Serous PAP 46.67 1 
263 I ENDO 35.13 1 
264 III Serous PAP 12.63 1 
265 II ENDO 57.90 1 
266 IV Serous PAP 14.87 1 
267 III Serous PAP 8.73 1 
268 III Serous PAP 97.23 0 
269 unknown Serous PAP 12.73 1 
270 III Serous PAP 9.20 1 
271 III Serous PAP 29.73 1 
272 I CLEAR CELL 43.83 1 
273 III ENDO 44.73 1 
274 III Serous PAP 35.83 1 
275 II ENDO 9.27 1 
276 I MUCINOUS 90.13 0 
277 II CLEAR CELL 71.17 1 
278 III CLEAR CELL 26.17 1 
279 III Serous PAP 27.00 1 
280 IV Serous PAP 77.93 0 
281 III MIXED 51.13 1 
282 unknown Serous PAP 14.30 1 
283 I MUCINOUS 75.83 0 
284 III Serous PAP 44.37 1 
285 III Serous PAP 46.03 1 
286 III ENDO 55.60 1 
287 III CLEAR CELL 7.37 1 
288 III ENDO 90.53 0 
289 IV Serous PAP 21.07 1 
290 III Serous PAP 87.90 0 
291 III Serous PAP 29.00 1 
292 III Serous PAP 78.60 0 
293 IV MIXED 1.37 1 
294 III Serous PAP 48.23 1 
295 III Serous PAP 5.60 1 
296 IV Serous PAP 31.37 1 
297 III MIXED 83.03 0 
298 IV ENDO 41.30 1 
299 III MIXED 46.87 1 
300 III Serous PAP 22.63 1 
301 III Serous PAP 31.10 1 
302 III Serous PAP 41.47 1 




304 III MIXED 38.10 1 
305 III Serous PAP 15.53 1 
306 III MIXED 75.77 1 
307 III Serous PAP 81.00 1 
308 III ENDO 15.33 1 
309 III Serous PAP 11.73 1 
310 III ENDO 82.27 0 
311 III Serous PAP 42.37 1 
312 III MIXED 20.03 1 
313 II Serous PAP 72.50 0 
314 III Serous PAP 31.33 1 
315 III ENDO 34.43 1 
316 III Serous PAP 51.53 1 
317 II CLEAR CELL 42.20 1 
318 III Serous PAP 27.60 0 
319 III Serous PAP 73.97 0 
320 III Serous PAP 14.33 1 
321 IV Serous PAP 4.07 1 
322 III Serous PAP 21.83 1 
323 IV Serous PAP 20.97 1 
324 IV Serous PAP 20.57 1 
325 III Serous PAP 28.20 1 
326 IV Serous PAP 8.40 1 
327 III Serous PAP 52.77 1 
328 II Serous PAP 73.23 0 
329 II ENDO 64.97 0 
330 III MIXED 33.27 1 
331 III Serous PAP 41.00 1 
332 III Serous PAP 71.77 0 
333 III Serous PAP 13.37 1 
334 III Serous PAP 67.77 1 
335 III MIXED 42.10 1 
336 III Serous PAP 34.27 1 
337 unknown ENDO 71.53 0 
338 I CLEAR CELL 29.63 1 
339 III ADENO 17.83 1 
340 III Serous PAP 8.93 1 
341 III Serous PAP 66.57 0 
342 III Serous PAP 19.37 1 
343 IV Serous PAP 27.83 1 
344 III MIXED 31.10 1 
345 IV Serous PAP 14.63 1 
346 III Serous PAP 31.77 1 




348 II CLEAR CELL 59.00 0 
349 III Serous PAP 68.43 0 
350 I ENDO 73.67 0 
351 III Serous PAP 30.33 1 
352 II Serous PAP 57.17 0 
353 IV ENDO 48.07 0 
354 IV Serous PAP 49.63 1 
355 III Serous PAP 59.07 0 
356 III Serous PAP 17.00 1 
357 III Serous PAP 56.43 0 
358 III Serous PAP 23.10 1 
359 II Serous PAP 50.77 0 
360 IV MIXED 16.93 1 
361 III ENDO 58.43 0 
362 unknown Serous PAP 54.80 0 
363 III Serous PAP 3.30 1 
364 II ENDO 59.30 0 
365 III MIXED 22.73 1 
366 II ENDO 56.20 0 
367 III MIXED 10.00 1 
368 IV MIXED 59.30 0 
369 unknown Serous PAP 33.80 1 
370 III Serous PAP 30.10 1 
371 III Serous PAP 56.77 0 
372 III Serous PAP 3.83 1 
373 I MIXED 55.60 0 
374 unknown MIXED 8.53 1 
375 unknown CLEAR CELL 52.30 0 
376 IV ENDO 7.97 1 
377 III MIXED 24.23 1 
378 II MIXED 45.23 0 
379 II ENDO 48.07 0 
380 I ENDO 56.73 0 
381 IV MIXED 52.60 0 
382 III Serous PAP 37.87 1 
383 I ENDO 41.57 0 
384 IV Serous PAP 23.30 1 
385 III Serous PAP 24.50 1 
386 II ENDO 48.60 0 
387 III ENDO 53.73 0 
388 IV Serous PAP 18.00 1 
389 II ENDO 46.40 0 
390 II MIXED 51.77 0 




392 IV MIXED 16.03 1 
393 IV Serous PAP 20.10 1 
394 IV Serous PAP 47.50 1 
395 III Serous PAP 47.10 0 
396 II CLEAR CELL 28.70 1 
397 III Serous PAP 49.87 0 
398 III Serous PAP 34.47 1 
399 IV Serous PAP 53.47 0 
400 III Serous PAP 17.93 1 
401 I ENDO 34.30 1 
402 III Serous PAP 21.50 1 
403 I ENDO 44.57 0 
404 IV Serous PAP 48.57 0 
405 III Serous PAP 21.30 1 
406 III MIXED 19.63 1 
407 III Serous PAP 41.30 1 
408 III Serous PAP 25.87 1 
409 III Serous PAP 14.63 1 
410 III MIXED 19.83 1 
411 II MIXED 45.57 0 
412 III Serous PAP 36.73 1 
413 I MIXED 38.77 0 
414 II MIXED 43.17 0 
415 III Serous PAP 44.77 0 
416 IV MIXED 30.20 1 
417 II CLEAR CELL 46.70 0 
418 III Serous PAP 11.90 1 
419 III MUCINOUS 5.30 1 
420 III MIXED 18.63 1 
421 III Serous PAP 11.20 1 
422 unknown Serous PAP 9.17 1 
423 III CLEAR CELL 16.50 1 
424 unknown MIXED 14.13 1 
425 III Serous PAP 22.00 1 
426 unknown ADENO 26.87 1 
427 IV ENDO 41.53 0 
428 III Serous PAP 41.23 0 
429 III MIXED 41.03 0 
430 IV Serous PAP 9.07 1 
431 IV Serous PAP 41.80 0 
432 III Serous PAP 30.93 1 
433 II ENDO 37.53 0 
434 I Serous PAP 13.07 1 




436 IV Serous PAP 5.17 1 
437 III MIXED 22.00 1 
438 IV Serous PAP 36.37 0 
439 I MUCINOUS 39.20 0 
440 II MIXED 29.70 1 
441 III Serous PAP 21.37 1 
442 III Serous PAP 33.23 0 
443 III Serous PAP 26.07 1 
444 III Serous PAP 25.93 1 
445 III MUCINOUS 28.93 1 
446 unknown MIXED 35.77 0 
447 III MIXED 36.00 0 
448 II CLEAR CELL 26.10 0 
449 III Serous PAP 13.60 1 
450 III Serous PAP 29.30 0 
451 I CLEAR CELL 35.40 0 
452 I ENDO 32.63 0 
453 II ENDO 20.00 1 
454 IV Serous PAP 19.20 1 
455 unknown ENDO 33.33 0 
456 I Serous PAP 32.20 0 
457 IV Serous PAP 19.50 1 
458 III Serous PAP 34.03 0 
459 III Serous PAP 35.23 0 
460 III Serous PAP 14.07 1 
461 IV Serous PAP 32.73 1 
462 III Serous PAP 30.63 0 
463 unknown Serous PAP 27.63 1 
464 III Serous PAP 43.90 0 
465 III Serous PAP 27.93 1 
466 III Serous PAP 29.30 0 
467 II CLEAR CELL 29.83 0 
468 II Serous PAP 32.23 0 
469 III Serous PAP unknown unknown 
 
Table A3: Patient characteristics (tumour stage, histotype and survival data) of the cohort of 469 ovarian 
tumours used in the Tissue Microarrays of Chapter 7. ADENO stands for Adenocarcinoma, Serous PAP for 
Serous and ENDO for Endometrioid. Event described is death, 0 indicates no event (censored patients) and 1 
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